<SEC-DOCUMENT>0001558370-21-007157.txt : 20210514
<SEC-HEADER>0001558370-21-007157.hdr.sgml : 20210514
<ACCEPTANCE-DATETIME>20210514070446
ACCESSION NUMBER:		0001558370-21-007157
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210514
DATE AS OF CHANGE:		20210514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		21921912

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20210331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/14/2021 11:03:59 AM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: e5974d14-dca3-482d-9308-7a5c4e1a2083 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:plx="http://www.protalix.com/20210331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityCentralIndexKey" id="Tc_ebGjDoarPEWjA7aoaQm4Lg_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:CurrentFiscalYearEndDate" id="Tc_l4SZtZLsmUKCc8rlAGHR_A_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:DocumentFiscalYearFocus" id="Tc_0Lb3D1SL9kKA9kXqYb4LeQ_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_NThTlAdS1kqHaFx23GttaQ_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:AmendmentFlag" id="Narr_5a6h5I4JiU2cNVAJesCY-Q">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_fH-eFiWWTEWpXTsknvvImw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Nq3l1ggiG0WOrAXIuoXDsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RxigFEmVwUiEby_y9qE_KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DYn_82moD0GzQs7ZYeZtGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_56UcNId1aEWoJb4G10-Hmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Aa-Gbn7sR0WZ75YVpvDG2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bHkBYaLN-UGbRFDu8vTV9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__AQFGosJOEe3MtGAAmI2-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OwK6mWRUSEeU9FfVEMERyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_10T57iIY90SjOzgIZg1NUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bTggB3rqcE2CubUqXx-z4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Klv4TOV3SE-4-xc-l4SQKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ei_SgWNXwUO3DGpZNp_vXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_6pKW20bscE2Ku3nHfNM7Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_NTsUlyVWH0iAhOuc-JATrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_DpyYY9nDa0Cy_n2dtTOfHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_AVEnMunZKE2ZyjoOzJX63A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_8WJteDHFv0uHhDDSYCX3ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_HgUCN56GCUCbhH5dRyjtRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_rsuCkhAchUKfvtMJQ7Jdkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-PP3WwL7Ek624e-6Fj9uCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ThxKgBuf2UK2nF6qftr2kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-29</xbrli:startDate><xbrli:endDate>2021-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_TQRiEj4vMkeo1dXynWjINA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2021_To_2_17_2021_u_XK6e7UVESYlSBODfH83Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-17</xbrli:startDate><xbrli:endDate>2021-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_e7hdGudACk2S__aUdhpOSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Kv2xZBEDnEuhBJxoFSUWfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tflQqgNDrUGhPnHhxKjf9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_IWN34CGSq02efTOZFIDwQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BaH8L0w5DEycxituHyiDNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_BMaSMHlJfkSwlgEYxqWOuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_n58i0vokQU6Bu9njK42qFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_5NM-tGWaUkyvfqzfREuJnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_2fSRYl5U6ki6zEDhNxZMXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_tJnyJJMrvk64LWQ_LMBvfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_W7bSf7UauU2UcKXEjO21YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2021_Y55Ar_XSM0Cn4NkSAnOr_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_iGxYDoGsbk6P98GCsK8Y4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_5TDbx3U0ik6qCFvcE8CLmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_gqv2DN3kKEGHFA_c0gXKWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_1WvGJ0fXT0ubQS8uTighiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_MeqgCdhT4kqsQK5qJtNerQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QgHea-r4HEW3mtx9OaLcmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NxPZGRi_0kq-YVHiOyngKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_cUvfdjvwYEa9IMFmcOD8nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_j3-U2lgv9kaYDYpnq-Cz7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1dyrNNFEr0ipVKxmpMMfoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_d3BrXmiZ10eL6A392JU9mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7aJC2MSBhke9XBhPUx6xiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_1_2020_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_G_tb6sGRnk6B27_FVPjvUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_2Iwh_PZxMUuR2b_zQIjxjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember__7guBnYaGk-PHQNjbXG97Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_1sBE3oSTM0etPlYlt5LcuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_IZDIDKW0ckix5UQLj_kyyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r-lq86-0tUWqJBQNVq0i8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_ora0XsBMfkOq7xYpZZOFwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SarcomedUsaInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-10</xbrli:startDate><xbrli:endDate>2021-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIaRfShWUKuo071QwzGrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_r3AHKZ-r30CFs0FZk9Nlzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_14_2021_To_5_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_CVQTExGFqUyzhQ6JuwB5tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-14</xbrli:startDate><xbrli:endDate>2021-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iMSRRkNGFEqFLRRG3ATJ0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B8rfirlHo0-scc7zqwmU3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wEgmk_bQ70CSJwv5vY46ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_UZb52YP5Gkqo2veFUnlg_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2021_70AbjOnoG0OAleWM0jsOrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_crDxDnAv7EmGAesWUEmcsw"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9eREpW5XdUutlzAa5vvOEA_6_6" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Yw3wcWFGSka907xn6Lv1ww_6_3" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_kwZ3nUllNkCVml5Vz2VX0w_7_6" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_8ccmMdc2oEWK500X1xRitw_7_3" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_5uK2XgY1IECIvVfIJ88JiA_8_6" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Q_UVBociTUSy8YM3pVGE5w_8_3" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><b style="font-weight:bold;">fFFAS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_95eda0d5_8d82_463a_b9d3_428d6b682abf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:DocumentType" id="Narr_kHxRnx6fYk6-3QCiVeoHpA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:DocumentQuarterlyReport" id="Narr_ei4wgWyxe067UkSgbedr3Q"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:DocumentPeriodEndDate" id="Narr_xIr894sPlU2chju0BmNTYg"><b style="font-size:8pt;font-weight:bold;">March&#160;31, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:DocumentTransitionReport" id="Narr_iKTN4tn6X02QJK7jPgtMKA"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityFileNumber" id="Narr_TyM_H7InSUCkpMcF5SfLHw"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityRegistrantName" id="Narr_1k6YhTvjm0aiGq_A7fUPcw"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_ney5UICISkyz4s2VvV7moA_1_1"></a><a id="Tc_LnzubeNZGkypTXeo3pCMhA_2_0"></a><a id="Tc_tikSHgVkUkKMwKQM6otDJQ_2_1"></a><a id="Tc_SHGTj9Kz3EaLS8xy0FLjDA_4_0"></a><a id="Tc_LyZh1dcWDk2wukY3QVtiqA_5_0"></a><a id="Tc_do2CId2L3kiyaW05wMNnwQ_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_UApuCiyAcU249rnlySCkKg_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityTaxIdentificationNumber" id="Narr__fjBPbnj0Umk1bSbXJbfHQ"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityAddressAddressLine1" id="Narr_4WXmgMo9ykKLHehN09R2Cg"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityAddressAddressLine2" id="Narr_CqD1m3s71Eu290vsMbiVHg"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityAddressCityOrTown" id="Narr_91bcYlD0-USctkTlHCGaZw"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityAddressStateOrProvince" id="Narr_hmJQV6UOFU2mEA862l7Bng"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityAddressPostalZipCode" id="Tc_-6S10Jjr6UaZZ_CSvLpGkw_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:CityAreaCode" id="Narr_vAPNsUsfXkmLbjdnz_JPTA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">(201)</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">-</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:LocalPhoneNumber" id="Narr_Cbv4_l7Mnk-kANZ2opqbLQ"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_MTrGXyItT0Wp_aVRfDtoSw_1_0"></a><a id="Tc_5eqs4khc60iSZD4MDVCoCA_1_2"></a><a id="Tc_7ZQyxTG0WkmsjxAD8Yquaw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:Security12bTitle" id="Tc_SEotxD6BfU-c8d_tSfI1rA_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:TradingSymbol" id="Tc_VoWD1VSh-02aRBcB7RK5Rg_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:SecurityExchangeName" id="Tc_udRF2SUBLUyHvP3gLu5zbw_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityCurrentReportingStatus" id="Narr_nT8VZlMug0GjxaI59XGPzQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityInteractiveDataCurrent" id="Narr_fTICM7dlgU2k8IOJ42zVLg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_yFdc2W4vt0WcaJl4-s9yFg_1_0"></a><a id="Tc_Xy53mTOxSUaGewHKIUendw_1_1"></a><a id="Tc_nFMCRf-2RUeexXmbAsOl9Q_1_2"></a><a id="Tc_A5_6izKi90GxnSBy9kol-Q_1_3"></a><a id="Tc_iQkOtYB6hUacSTNdyySSdg_2_1"></a><a id="Tc_FNf9UAj2LEOKDinBlicE-w_2_2"></a><a id="Tc_VUTUEJS3k0WhZ5OsrUWRWg_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityFilerCategory" id="Tc_ApZyONRcukiGGaMjt7tsyw_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntitySmallBusiness" id="Tc_HI2t4jaVBUq7vfkioyfcWw_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityEmergingGrowthCompany" id="Tc_RHuSRUZMFEuXzhvWavSAxA_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="dei:EntityShellCompany" id="Narr_jol2JdyjWUCDbzHg1RiCbw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On May&#160;10, 2021, approximately <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_5_10_2021_70AbjOnoG0OAleWM0jsOrQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_ctjqavY3IEqwQ7uZCDEZ3g">45,382,831</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ca812b1b_617e_4274_8dde_577dcf1a0c06"></a></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of March&#160;31, 2021 and December&#160;31, 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Changes in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Stockholders&#8217; equity (</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Capital Deficiency) (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2021 and 2020</span></a></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2021 and 2020</span></a></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">52</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">55</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_3aae51b8_2efb_4879_a380_f0153560fa49"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_C7GrApG0iUKoERP61WZYCg_1_2"></a><a id="Tc_tLyZlZCry0aULlhH5lEX3A_1_5"></a><a id="Tc_h46rEG9dD0ilIyebTj3NvQ_3_0"></a><a id="Tc_P9b2tYQxWUaQ17AjlzDvEQ_5_0"></a><a id="Tc_zWZvBNC5p02tKtvnbGE4vQ_6_0"></a><a id="Tc_0rbVP8Hd4EyQhuPqxulawQ_6_2"></a><a id="Tc_9SjsolNe30GpBaMxljlujw_6_5"></a><a id="Tc_HL1ro7uaM0mH3O64XClqrg_7_0"></a><a id="Tc_Ee1E2VYKEk6IgmGRjDR7hA_8_0"></a><a id="Tc_HFmAR8Fi8E28ATwWQ9u1vg_9_0"></a><a id="Tc_yRvtCVxlHEaGrxXV7I7nrQ_10_0"></a><a id="Tc_TvGdQlQSGkWvVbkP0dtPRw_11_0"></a><a id="Tc_rAeKx0ng2ECDUB6v2BqgjQ_11_2"></a><a id="Tc_YimlSplcJE-gFw9g6ziiuQ_11_5"></a><a id="Tc_AjWNRRQfzUW8lYe4fRmtXg_13_0"></a><a id="Tc_bAA0ON1pRUi_51LHIGfKcg_14_0"></a><a id="Tc_2RE1cPM8EUals_u3-Nydag_14_2"></a><a id="Tc_2w7fq912CUKjEYSfmQ1uDw_14_5"></a><a id="Tc_ZWDN8RK7Z0OurJMQSilMGw_15_0"></a><a id="Tc_cIZY8JL72kGMVnB0ii9ySA_16_0"></a><a id="Tc_2h32sJ8EikuQVTMpj2RwHA_17_0"></a><a id="Tc_TFyetGBfpUqm5PNIKdYNHg_17_2"></a><a id="Tc_uwvQ9w_2mkS-ET4r56eXng_17_5"></a><a id="Tc_ncgNnMiWgk64lPsUuYGH6A_19_0"></a><a id="Tc__pgYovL4j0yeKUr2CLzjbw_21_0"></a><a id="Tc_kJ5KfI98OkmAjTA_J31Gyg_22_0"></a><a id="Tc_hodOi5WEiEeFgCktQksdDg_23_0"></a><a id="Tc_OOBVufFcdEuc2xQ0623jKw_23_2"></a><a id="Tc_FoqN3CQIP0S7EwMfmiCaww_23_5"></a><a id="Tc_scUc-FmFg0m91l2isIKrLQ_24_0"></a><a id="Tc_IiyM38S9bk-8A-MMMINaxQ_25_0"></a><a id="Tc_p_YvKsud7EKJXiTKiLiHGQ_26_0"></a><a id="Tc_DFYOx3arWEu2N5kKlcXohg_27_0"></a><a id="Tc_PlEtmiUm0kilI1Cy1E4AjA_28_0"></a><a id="Tc_z_VLVw_m-kmrSak-3jqBoA_29_0"></a><a id="Tc_iJNh1lJ40kyriXVFoJD_aA_29_2"></a><a id="Tc_mNQL2Wd8pEqrA6Eb9FluCw_29_5"></a><a id="Tc_Na9mpJ2kPUW3gu0KqFk0HA_31_0"></a><a id="Tc_ZoWrHNeMfE2Bb_9wDpoytA_32_0"></a><a id="Tc_WJxbiIIRXEOz1U2Q9W8FkA_33_0"></a><a id="Tc_V1hHbjUR_UWCMQcJW6sBCA_34_0"></a><a id="Tc_aj4Z8jICwU2bp02Yi1eHyw_35_0"></a><a id="Tc_EZFheJrdvEOK6EptfhKQSA_36_0"></a><a id="Tc_0mU0MQk7JkKnOVy81tncqw_36_2"></a><a id="Tc_e46TlwoiQE6peIfohzs0lw_36_5"></a><a id="Tc_sUxUvUQaL02q1JDRkyQAuA_37_0"></a><a id="Tc_jG7PcjbPSUef8Z6yGupuTg_37_2"></a><a id="Tc_vyyhhDFYfEWn_7UVqwklKA_37_5"></a><a id="Tc_0zNn0Gd8QEGDfr3io_d--Q_39_0"></a><a id="Tc_7h9TkjLA7kaqVBeST9PE1A_40_0"></a><a id="Tc_NzmZqqgL4UeMgChdmWWPSw_40_2"></a><a id="Tc_Yi0UKjYLRUeAbTkZrkHWmg_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_WlwpyyxntUWSu4kjCRmoTQ_6_3">19,830</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_4IFg4eQFMEWe7cc5sPqAAQ_6_6">18,265</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_m_RwQojYjEezyPFM3byMfg_7_3">50,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_P1vFqcsCi0CjQUiQxZaKiw_7_6">20,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_Okv2JAh7k0uufY5gy_lh-A_8_3">4,599</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_35lbIvr7NUKebXXOc1wE1g_8_6">2,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_R8589l7-hUyzcUyZDgomSw_9_3">1,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_l-DEfSzJz0iNB7kLo2ySbQ_9_6">2,096</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_8_dah6NzaESUD8O2TIdMIQ_10_3">13,915</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc__EwjItM3FEaseFzKUBh7YQ_10_6">13,082</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_AubjmjTi2U6Zc__fe1yPZA_11_3">90,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_7MHj9RDlTEukbx0sQRYT4Q_11_6">55,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_rGivOtytLkWhkzyGuXtSEA_14_3">1,776</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_LHY2kphP2USiDqF0dGGhUw_14_6">1,799</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_OZeMA5zjGUq7COMsfJlCtA_15_3">4,828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_EaRp8Bui8EaFmSene_0Vrw_15_6">4,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_7KTiZutid0uuxyH73mkcQA_16_3">5,490</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_qdb82AufZE6_a8M8kJLBqQ_16_6">5,567</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_bCLbhtn1kEmhTxpqFs5gzQ_17_3">102,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_2wJdV0vRC0CaVtRJhbRaJw_17_6">67,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (NET OF CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_JLfCkO2OCkesrrvWJC8cUg_23_3">6,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_3rR_JMgxbUOlChcP2tbX7w_23_6">7,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_3De_hTlbXUeyLsD_b34v9g_24_3">15,167</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_Z-UWcVavC0yDhaaMX80hHw_24_6">13,926</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_n7d1tn9rH02PaHO-xAdC6A_25_3">1,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_O_XVeiMrXUyP5ulC11E4FA_25_6">1,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_Hjb01ds2M0eYe-Ga05Fbfw_26_3">2,560</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_aO3iL-L9IUyNdJvTHamqng_26_6">5,394</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_Oen0kqqTf0Owv3A26nf6xg_27_3">55,372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_weM3Z0Ej8ki5Tp2oEuITLQ_27_6">54,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Promissory note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_nMdg1UBFOUatqvkMucVH3w_28_6">4,086</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_YEEZT8G2wki49BazeNx35Q_29_3">80,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_ScRYOkwtcUCOXharWtzitA_29_6">86,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_8ymusNhIxkuJVepDkQgHLQ_32_3">858</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_5UW__SZB1kWIuUAKTjJPnQ_32_6">1,716</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_mAS6-MSPzk-HDhbvyS5Z_g_33_3">2,224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_t0tC8vv4ZUSwk57nzf5P4g_33_6">2,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_ppKFI8y5Q0CVTozFaVX_Zg_34_3">4,319</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_mFz2xdoH5k6SsHvUcmcZhw_34_6">4,467</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_K3nzXGuCh0-u41L3n2Urnw_35_3">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_How34sYzrUqKygL783qGtQ_35_6">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_vJxeW2FlAU2W8-xrfmoP4g_36_3">7,427</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_8KnuhwLXA0y0wGOp7yhaPQ_36_6">8,497</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Z_4NTylUpUOnGPLIK65AIQ_37_3">88,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_obhJUjBudkmN-6qmAEZiDw_37_6">94,971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rXlcWb01Qkep6nCL_LDLyg_39_3">14,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_hWCy1TkhjUyzYWXaAYgV_Q_39_6">27,037</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities and stockholders&#8217; equity (net of capital deficiency)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_8foOhYF_2kCtP_Zunlr7uA_40_3">102,792</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_vbLGitI-6UidENf24GoP7w_40_6">67,934</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_23a73f13_b26e_4f4c_b9e1_4a4408f46bce"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_dvtjWCXWTUCVhD_mEqOmmQ_1_2"></a><a id="Tc_HHTxx2QDC0iJTiUrnnjvkg_2_2"></a><a id="Tc_Rm96L-5dnU-uiHKO7Y2FuA_2_5"></a><a id="Tc_7UCft9yiCE2C8UinfTfCng_3_0"></a><a id="Tc_8Yi-weNRPkKDtg32KFNz2Q_3_2"></a><a id="Tc_4QRCKGpU1E-pE2RIYZZa0g_3_5"></a><a id="Tc_HQyPEAn2v0eE6ErTXxS4Jw_4_0"></a><a id="Tc_oZ03GyooAkOVxVyVxAVx1Q_5_0"></a><a id="Tc_AdIGreuYOEWbPB4mq_dgfw_6_0"></a><a id="Tc_PWlAef6kC0qXDClDSqI9lg_7_0"></a><a id="Tc_S7WpxSQUGky2eAQzFyeatw_8_0"></a><a id="Tc__eLr38Fqgk2yeNvbdAPNHw_9_0"></a><a id="Tc_yM2DA1oau0GlSeKQCWQjTg_10_0"></a><a id="Tc_0qkfIk0E9kG_G6IRr-8NPA_11_0"></a><a id="Tc_QD6vWD_h9kmbksA3l120cw_12_0"></a><a id="Tc_lsc7_WHYjkuPefDb-t87Pw_13_0"></a><a id="Tc_8UC_ly0l4kylj5doDfAlzQ_14_0"></a><a id="Tc_Ec27IcgSYE-6eGRoJ4SNkA_14_2"></a><a id="Tc_LtiRg2IA1kyYj2RezUQJpg_14_5"></a><a id="Tc_goIBHRzD1Um8GASkJLvKkg_15_0"></a><a id="Tc_g6Styha6zkWUkLG9BbCFRg_15_2"></a><a id="Tc_obX3GYXqzk6SsGqzllplDA_15_5"></a><a id="Tc_5rNfQPteO0mNOVfN4V-l6w_16_0"></a><a id="Tc_yvWuXwbGTUGdgPfNieh6Bw_17_0"></a><a id="Tc_7nkkuWtCzECEQ8S-IKMqRg_18_0"></a><a id="Tc_FkIF0v9iF0S9l0FzhLjgvA_18_2"></a><a id="Tc_w556RcrgEUOY0dDuTpObPA_18_5"></a><a id="Tc_cIKRLdisa0WaLSVtXuioiQ_19_0"></a><a id="Tc_vVujCfRy70q9Jn66q-Lv2g_19_2"></a><a id="Tc_L-b2Q7xalEuS0uDfStzIhg_19_5"></a><a id="Tc_-VEBMchZcEih62zQK2T1SQ_20_0"></a><a id="Tc_Boj9AK71IUmNhd2C0YQpQQ_20_2"></a><a id="Tc_kXAiuSOcjEC3CSw_xzZdrQ_20_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_NTsUlyVWH0iAhOuc-JATrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_a8uhjyl09EyZI7WwcNSnyA_3_3">4,511</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_rsuCkhAchUKfvtMJQ7Jdkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-7XW_hEdPE6kJKrIPm3Niw_3_6">5,031</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_DpyYY9nDa0Cy_n2dtTOfHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_qhbYG12GaU2_PlGjnSnNQw_4_3">6,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-PP3WwL7Ek624e-6Fj9uCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Q_8CIv3wHEScwETU1DiOoQ_4_6">16,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_6e91kn1dG0SaEMiDdXmahA_5_3">11,320</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_6NpKs5vB1k2ZNMOWfuhVOA_5_6">21,646</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD (1)</b></p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_Yw3wcWFGSka907xn6Lv1ww_6_3">4,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_9eREpW5XdUutlzAa5vvOEA_6_6">3,426</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES, NET (2)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_8ccmMdc2oEWK500X1xRitw_7_3">7,122</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_kwZ3nUllNkCVml5Vz2VX0w_7_6">10,340</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)</b></p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_Q_UVBociTUSy8YM3pVGE5w_8_3">3,138</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_5uK2XgY1IECIvVfIJ88JiA_8_6">3,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_DbirLCIa702BjrTB8zbydQ_9_3">3,705</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_mqdQGfi690q0Y41vZxpi4g_9_6">4,693</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_2TKsIFkmfUuHEsbVA7SwpA_10_3">2,156</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_20Lqenp3tEmtiAYaTeL6sg_10_6">3,229</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_5golq-VLhUKYEJVb-yKsoA_11_3">335</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_7mQz5Gb2VUKOxrB6g-xfPw_11_6">203</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES &#8211; NET</b></p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_TO1qPDpyJ0u9mPHFf8wIsw_12_3">1,821</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_Jz-FMKRoYUqJZaL_OspNsg_12_6">3,026</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OTHER INCOME</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="Tc_0EbBoayEI0W6Z_tfrW74vQ_13_3">51</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCOME (LOSS) FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jFed7Q0NVU-fysb_S2_U6Q_14_3">5,475</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_EC0yoXSPL0WP2KyhIugaTA_14_6">1,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EARNINGS (LOSS) PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_YaHYOdfOp02G3scxHqpGJQ_15_3">0.14</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="Tc_4BNp9lUVskq1OM78luI9cw_15_6">0.10</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING EARNINGS (LOSS) PER SHARE &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_GHB6DjV5C02taLWMQjYE2w_17_3">39,933,972</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_3AtXLRA3eUOvS4KdvCRBIA_17_6">17,381,074</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></ix:footnote></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_MeqgCdhT4kqsQK5qJtNerQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_IgU0Y4t8V02W0ChT0ALkKg_18_3">109</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_8530ca94_6c84_4f48_984f_7cc5a2959400"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_1WvGJ0fXT0ubQS8uTighiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_OAvKXxtjBEGZ8u-rDFe07w_19_3">210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NxPZGRi_0kq-YVHiOyngKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_y06kepjqc0CTrj6cT5dqIg_19_6">78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></ix:footnote></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_gqv2DN3kKEGHFA_c0gXKWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_xwW2kiFrj0-ZgIK6YzR4Gw_20_3">497</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QgHea-r4HEW3mtx9OaLcmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_sm6nG-JqH0G0CesHR9i7SQ_20_6">353</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e2c2d562_5401_4cf2_ada4_cb0c68fed21e"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_OZrdjTyMYESqnDG3HPOv8g_1_7"></a><a id="Tc_FRCSK4XFUEGPygogAiDapA_2_2"></a><a id="Tc_C1WuIXTlN0SCXQqupg1GMg_2_4"></a><a id="Tc_ZBccOyv6F0SaZZcqJMbikA_2_7"></a><a id="Tc_A52lqh5yake8k5B_OXOQ6A_2_10"></a><a id="Tc_NmqUWyQHukqhQ7zirJrjbw_3_2"></a><a id="Tc_MCSXuWXXrEmzUMERGiIZeg_3_4"></a><a id="Tc_wvb43s6QBUWZJrrk060bHQ_3_7"></a><a id="Tc_AeiCV4EXnkWPbbnt9R5dkw_3_10"></a><a id="Tc_Ebag0bLOYUau4kh4C3zV-w_3_13"></a><a id="Tc_5xEd4V17L0OZPFBUdMGgIQ_4_2"></a><a id="Tc_A0BlWHakmU2-CQ1BAiG5QA_5_2"></a><a id="Tc_FycMLqHFEkyt2iMp2hHtpA_5_4"></a><a id="Tc_eK4SkqJBXEiexd62TjifrA_6_0"></a><a id="Tc_Eo5Idh46okeQdejZRUvy0w_6_4"></a><a id="Tc_GU8SmjBVsUabpvRNkioVqQ_6_7"></a><a id="Tc_IRuXOSljs0uoZ8faR9YvRw_6_10"></a><a id="Tc_CGZ6UWO3Q0OkCWbCAeiVHw_6_13"></a><a id="Tc_5NrgulFpDEiDDC-aQ4R1nw_7_0"></a><a id="Tc_3rlCqUkyn0iPitLoHtlSxQ_8_0"></a><a id="Tc_r5n6dw0kgE2hY-4BpAAUjw_9_0"></a><a id="Tc_mFbgAAXRxEKniGIVQ9RzrQ_10_0"></a><a id="Tc_ZQLfVBVDM0a3LAkSU3r9yw_11_0"></a><a id="Tc_Tq1PC-bZokymk5BJJGWCDg_12_0"></a><a id="Tc_OpPUViPiaEqDESAdz4jCaA_12_4"></a><a id="Tc_GIlOrs0XD0eJKZDNUNqxNw_12_7"></a><a id="Tc_BKPaSKrhpEyGtKadJm04-w_12_10"></a><a id="Tc_uVfnq7dT2kGZ2a-rUYTE8A_12_13"></a><a id="Tc_i2lv2iGcTkaq8RJgP3NySg_13_0"></a><a id="Tc_W-isuNU2lk2Q_ffqykmohg_13_4"></a><a id="Tc_yM5I5If9wk2UcTU949OjHQ_13_7"></a><a id="Tc_V0-bXR2ZxUmDG_DH4rRdag_13_10"></a><a id="Tc_qxcb2gLRR0OFbBU1drUcXQ_13_13"></a><a id="Tc_zmU2hb8hjEOL1ZrNtd0NdQ_14_0"></a><a id="Tc_EpbQq8ZUfEGucHNdQMA5TA_15_0"></a><a id="Tc_M0vaDdZGG02F5BO5L7CIqw_16_0"></a><a id="Tc_YhHDb3C1lk6pUlLKcDBuqw_17_0"></a><a id="Tc_4jodvB5cPUmUOyeDnvD95Q_18_0"></a><a id="Tc_s9AUj5hA-ka1rvK8d3XVVg_19_0"></a><a id="Tc_EnDbzOHtCEGIP0fB1Z8cIA_20_0"></a><a id="Tc_D7SUw6xNjUKiU7jh-_hBbg_20_4"></a><a id="Tc_US_AqSZxcUucGG90uvlliw_20_7"></a><a id="Tc_UfB5Qk-HrUC5HQGHPvvyAQ_20_10"></a><a id="Tc_oa6KPV1_yUWu7pYfKhZ4Vg_20_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ei_SgWNXwUO3DGpZNp_vXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_aguZ4qGbNUeFZnqMBcg_eg_6_2">14,838,213</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ei_SgWNXwUO3DGpZNp_vXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_B_nYyXrpL0KQKysw0m5vWg_6_5">15</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OwK6mWRUSEeU9FfVEMERyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3-OS3InHfUW1Z1gNoOidDg_6_8">270,492</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__AQFGosJOEe3MtGAAmI2-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gK08wUOKqEm6vKQ8YAge0g_6_11">340,829</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2019_5TDbx3U0ik6qCFvcE8CLmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_4X2AIvhymUGEjpaYm15G3g_6_14">70,322</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended March&#160;31,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock and warrants, net of issuance cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIaRfShWUKuo071QwzGrg" decimals="INF" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" scale="0" id="Tc_iCBDbDyf30qZbg68LwlsHA_8_2">17,604,423</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIaRfShWUKuo071QwzGrg" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_sbRCu5xwV0mklo65l4_XTg_8_5">18</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B8rfirlHo0-scc7zqwmU3A" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_2NckslJqdUyooQ6X5O365g_8_8">41,325</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_hbV37Wn2U0ukRCUfirs8JQ_8_14">41,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Note receivable from issuance of common stock and warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B8rfirlHo0-scc7zqwmU3A" decimals="-3" format="ixt:numdotdecimal" name="plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" scale="3" id="Tc_B0hVb940lkWpMx3ocST2zA_9_8">4,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" scale="3" id="Tc_Y46VBuAWrU63IM7iO2MhnA_9_14">4,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B8rfirlHo0-scc7zqwmU3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_bZCu3iDki0eAOTArtETSgg_10_8">431</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_vMK7qVV7fEaFTkae-0lx5g_10_14">431</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net income for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tflQqgNDrUGhPnHhxKjf9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_YHQvzluX9Eu6CUh7cpVeog_11_11">1,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_Tz8wzTnoUUWhuUSM5Xym0w_11_14">1,667</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Klv4TOV3SE-4-xc-l4SQKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_awBTyJ9d6UaDqHlQrm5PAg_12_2">32,442,636</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Klv4TOV3SE-4-xc-l4SQKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_L66y5Dd3HUeWLWRJIsiHwg_12_5">33</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bHkBYaLN-UGbRFDu8vTV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_vr4bb5skMEyeUltwng1VLA_12_8">308,248</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Aa-Gbn7sR0WZ75YVpvDG2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5n3RYBMSPUGQEX20erjdgQ_12_11">339,162</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2020_iGxYDoGsbk6P98GCsK8Y4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_GDTov4v7tky2AoUhaS000g_12_14">30,881</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bTggB3rqcE2CubUqXx-z4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_DvKqjgP5Ek6KwhJ7oHYahg_13_2">34,765,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bTggB3rqcE2CubUqXx-z4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_IwDqvlrzKkq2XWO7YxmyvQ_13_5">35</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_56UcNId1aEWoJb4G10-Hmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jJ7B96U7l0Wnb_fQfEJZsw_13_8">320,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DYn_82moD0GzQs7ZYeZtGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_JMLYn6Tbj0apOwIiEZyU3g_13_11">347,352</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_M4KIs5zdG0KbkjMsXXr2jg_13_14">27,037</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended March&#160;31,&#160;2021:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1dyrNNFEr0ipVKxmpMMfoA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_YA06EQEv3UyU7Zozm-ckLg_15_2">8,749,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1dyrNNFEr0ipVKxmpMMfoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_qFmJmLTMekaCrFXUFlpeKQ_15_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7aJC2MSBhke9XBhPUx6xiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_VlvVUMz9rESLk0UJNMVfFg_15_8">37,616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_L2kC_5iqgEqh11cB9auHSw_15_14">37,625</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1dyrNNFEr0ipVKxmpMMfoA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_z6lp43I1PkKN1f6RB1PijQ_16_2">1,867,552</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1dyrNNFEr0ipVKxmpMMfoA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_5pus0Mr3zUyE8DHxX9f2Mw_16_5">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7aJC2MSBhke9XBhPUx6xiQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_SPiQwcCkkkujS_6qy4hl7w_16_8">8,573</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_gSyLt6q5R0S7T_xmKXZlAA_16_14">8,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7aJC2MSBhke9XBhPUx6xiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_aNwp6DQvX0asYrnFV5UApQ_17_8">510</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_L8SXqNBTlEGAXwppw0jl0A_17_14">510</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7aJC2MSBhke9XBhPUx6xiQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_mBYYP165RUCk-QFFB3qZww_18_8">306</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_d3VPJCETdkSD8IeD9mT-Jw_18_14">306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Kv2xZBEDnEuhBJxoFSUWfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FKDkCGXaXUGgVASxiiTAQw_19_11">5,475</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_0UuddWohi0yxQsIeuBsEig_19_14">5,475</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_10T57iIY90SjOzgIZg1NUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_OfP6nAECrE-SSnVpwy-89w_20_2">45,382,831</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_10T57iIY90SjOzgIZg1NUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_OJU3-5Kos0auiqcZv71AGw_20_5">46</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RxigFEmVwUiEby_y9qE_KQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Qbt5XKj2OUWTuc8qZWFt1A_20_8">367,285</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Nq3l1ggiG0WOrAXIuoXDsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_CnoKGWZcvEq2WLqfNISryQ_20_11">352,827</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fVPI2VQrqke-stMhs1KS8g_20_14">14,504</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA" contextRef="As_Of_3_31_2020_iGxYDoGsbk6P98GCsK8Y4A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_JpdetSnbDkKhLAqKNSS4KA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_R3YY3Su13kO8BBzJIr6i_A">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of March&#160;31, 2021 and 2020 - <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="As_Of_3_31_2020_iGxYDoGsbk6P98GCsK8Y4A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_DBYJwJuPzEOPOoNi6ruT8Q"><ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_CkZ7UrucOUuZnqozMh_uqQ">120,000,000</ix:nonFraction></ix:nonFraction> shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_894606c5_4cc6_4bc9_aa30_c04c7abb3057"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_xEleTOY-J0qRkwha0jIZHw_1_2"></a><a id="Tc_2P3G4pslOUWmpkEmWW7Lpw_2_2"></a><a id="Tc_ZZ4VEqqLn0OQc00zzA0E7g_2_5"></a><a id="Tc_eRxpOT_yu0CvwJUnx4uX0Q_3_0"></a><a id="Tc_uifYIkZx5EeJsx70xR3SmA_4_0"></a><a id="Tc_8snuyAezGEO04xGpSnNgBw_4_2"></a><a id="Tc_eYW7L1pOc0umyIx8r6IX-A_4_5"></a><a id="Tc_jIE3t92JaEyzwdvrhqnshw_5_0"></a><a id="Tc_vxMW3YWEW0StwNrMOMJ1iA_6_0"></a><a id="Tc_s5GzBu3DGUqtCpZPdyBZmw_7_0"></a><a id="Tc_EvBJuv2IJUCOCHdqg3oyWg_8_0"></a><a id="Tc_z2j9AArPO0m2K5Wdub-qjg_9_0"></a><a id="Tc_AC18sLI0ZUSozukrjSw2ag_10_0"></a><a id="Tc_48pPkSCN_EyHBWo0tg9Iiw_11_0"></a><a id="Tc_g8oWRfoXVUag0wIdl3idmg_12_0"></a><a id="Tc_EJZFMOtoxEaTil-QpfR19g_13_0"></a><a id="Tc_SMSxUInmHk6l9Bx1vJISTw_14_0"></a><a id="Tc_QrUeGXbYH0667OGlqKCijA_15_0"></a><a id="Tc_B4FEZBoY-ES1-L3PEaYUEQ_16_0"></a><a id="Tc_ocWL1O7-n0afxgMEQ3Jvgg_17_0"></a><a id="Tc_yJrfGDMZmkeznD9YtHjSJQ_18_0"></a><a id="Tc_tGJPWmSjgEyVgk_pJJ56aA_19_0"></a><a id="Tc_ZUkWNOP66kyK2pGKzdULIg_20_0"></a><a id="Tc_yZ4sUhWKPEK_bquifW9H5A_20_2"></a><a id="Tc_b9iFGGlV6ESkjXYB1-Tv7g_20_5"></a><a id="Tc_xFD3RD4wXUOrtjVqGBRZHg_22_0"></a><a id="Tc_29WKxYyBOUC1txNvZzmiTg_23_0"></a><a id="Tc_K60TattPsk2DcfaDDlnlrA_23_2"></a><a id="Tc_ZRrqbhxNFUy1pKU_B4r_rA_23_5"></a><a id="Tc_Ccz2BQt08kO6M4C5-KgiUA_24_0"></a><a id="Tc_Xt5OHr9WDUax7e1LmjS8EA_25_0"></a><a id="Tc_gqZkKntCKUK_BVA_UoSzIg_26_0"></a><a id="Tc_7Z7JrGRS8UqW8YbgpSyfVg_27_0"></a><a id="Tc_jyfD7xqAS0-tE-LDXMwmDg_28_0"></a><a id="Tc_m9JjXUmsvkmlKlHwl-OT7A_29_0"></a><a id="Tc_NmpBJ2bYgESWxG11hOnVXw_29_2"></a><a id="Tc_YSHIV1c0ZEa6ueVCwA25Cw_29_5"></a><a id="Tc_-oBNMiYxuk2OMgiiVCv22A_31_0"></a><a id="Tc_10KvV41t10mdEa9xifZT3Q_32_0"></a><a id="Tc_z7ETPJbACkaU3OpYGqaUgg_32_2"></a><a id="Tc_TBri6TBa-kqpvi-Unhb_8A_33_0"></a><a id="Tc_p7nFrjemrkmEuAPCcm27Mw_33_5"></a><a id="Tc_KEXraYn-2UKNAnnzyKaOEw_34_0"></a><a id="Tc_wPi0JXsh1kmGED6B7k1FOQ_35_0"></a><a id="Tc_uxVDGbJNJESgCUpH10eQRg_35_2"></a><a id="Tc_Twe01fs5UUuLxLroOW7v5Q_35_5"></a><a id="Tc_wRN-iRTIXUSoSM6EdsXCbQ_36_0"></a><a id="Tc_rj_lY_rOT0K12LjpFHZwyg_36_2"></a><a id="Tc_agPwGXWBZ02fPys_Jxx64A_36_5"></a><a id="Tc_AbLfx7UUvEeB275TYaZaoQ_37_0"></a><a id="Tc__DJtvQ52ykqQupJ3fOXXtw_38_0"></a><a id="Tc_mzDzsyYB6EypYeFfoOQaIQ_39_0"></a><a id="Tc_QkTIZXepDUids1fpWy4BwQ_39_2"></a><a id="Tc_FH2S5hhK_0eqPf-AVe__sA_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8-LI__dbLUKGptZ1injQGw_4_3">5,475</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_Ry1l1RJ5aEmY58sL4WQENg_4_6">1,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net income (loss) to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_0qoAaVqDLkCIu7rPMrKchw_6_3">816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_9JjXSwRGVE68U0Koofx3bg_6_6">431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_5mMBlkbCgEOoQabMJqC0fg_7_3">286</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_hI1kfNzz3UuvEMEorfcXnA_7_6">376</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_eSFOTVOVH0GeTSNJrtDP1w_8_3">168</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_hc5kj90oGkGijGpT4p8GpA_8_6">241</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_T7TxR4Lku0WncM3afOuBfQ_9_3">42</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_U4A1dJEWF0Od91_OAZJdYg_9_6">44</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_xxRINiuKbkCuyTMnGxDwuA_10_3">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_PArJAO0Vf0qfYfPFhAnZ-g_10_6">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on sale of fixed assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_srt4T6WFu0mpbV6jwCop6Q_11_3">51</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_v8YXTjQvfEOPn6xeKmR2kw_12_3">945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_dsIBgVlmpEOHeyW87lfeZw_12_6">820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in contracts liability (including non-current portion)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_59lXlZjScUGHQxjD0UyH_w_14_3">3,692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_twFSUvoVeUygoa33Z0PPDg_14_6">7,171</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts receivable and other assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_bhEunQHSMkqP5bnBVrgLkQ_15_3">2,282</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_zUxcZyeZ8kyFbnq6NeDsAg_15_6">4,091</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_wkkE1uB6Rkq_ZO2rqZ-iAw_16_3">42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_uAE0I0FR50CyWXds00VCKw_16_6">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in inventories</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_fkEKI9pjv0Wog5wxcuHz9Q_17_3">833</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_MlAODJXNKUS1yUoXnlj3lA_17_6">1,333</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_VeaYqrINpEGIbNUFV6F_5A_18_3">575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_94QyWxfm4UGpMFsvNLPEdQ_18_6">2,611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in other long term liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_9VgLrCeQ8EmK_8CJSz9-yA_19_3">25</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_idAAarv6A0iOurXAJ-GL_Q_19_6">299</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_5OofKwnxfkeXqxkeDf5YNg_20_3">9,834</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_zDGWyO3AeE-VoiHeFg_RDw_20_6">7,117</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of bank deposits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_VWdcu9ONlU2OzRRrtXgVdw_23_3">37,835</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_V-ckcPLW0EizM_EJGQr02A_23_6">35,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_GFU_i6PXTkyNMjtURWoB6g_24_3">7,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_f3wV2hJuw0GAwQDszxEUfg_25_3">386</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_epyQAjT4vkOpUFDQE8cyJw_25_6">66</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_nqvBomnZQ0q5dySjJFMTiw_26_3">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decrease in restricted deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" sign="-" scale="3" id="Tc_ucUdkU1wwkmZHd_OsPMDHg_27_3">12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" sign="-" scale="3" id="Tc_g3N7C9fMW0K_2iz2aXZp7w_27_6">22</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_y8rmLVlnREecNRcEZNoY3A_28_3">28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_DGMPTU7r0U6HviTovfBtYA_28_6">35</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_erbcjpPIfEe1NgjYXktvig_29_3">30,684</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_-ic8Tweho0Ke_UHJ48zXLw_29_6">35,079</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net payment for promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_ytHP4vth8EK4kRCxEQcJOg_32_3">4,086</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock and warrants, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_QCuAru6PUES0aAgWr-ov-g_33_3">37,625</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_rDm8TS9dCEWcEwy--V-kpg_33_6">38,607</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_D7UZcRG29UumL_PfuNyUhA_34_3">8,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_7s2_rDPJ4USgtF9RfOPERw_35_3">42,114</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_UsMqrdogdE2EHBstjijNVw_35_6">38,607</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_heydiMhfVEubP-36aw7oVw_36_3">31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_DvCFdmC14UCwxhAYRPBajQ_36_6">37</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_bnvMuebMg0u85jKPm4Egfg_37_3">1,565</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_9Vuloj2L2UCZT79Ht5o7Bg_37_6">3,626</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_pkFNNL8Y3k-cmM80KW4MMQ_38_3">18,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2019_5TDbx3U0ik6qCFvcE8CLmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_oc_Dq5CEB0yL6vMfGHxHkQ_38_6">17,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_3kPRqR4ALUiXx44R5FToDA_39_3">19,830</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2020_iGxYDoGsbk6P98GCsK8Y4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_C_CKSf0qsUGdacNB8iKZhw_39_6">14,166</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_hXzOPw-95EixnDI8jXJWLQ_1_2"></a><a id="Tc_jeNY6GFQREqiBuitwZo9Eg_2_2"></a><a id="Tc_YbhL0ShHFUmwjmACD-iBGA_2_5"></a><a id="Tc_axgN4Zzm40abCwR3aDAU3w_3_0"></a><a id="Tc_BdFlCpC1NEWKvO8tafogyQ_4_0"></a><a id="Tc_QP5TDLoZ7Ee3GxWuz3mh_g_4_2"></a><a id="Tc_20XjgDXsI0qmsdl-4oi_2g_4_5"></a><a id="Tc_WMFfASwGQU6waplLeUJ9fw_5_0"></a><a id="Tc_AkMNhSQS8kKHO1Wik74Fhg_5_2"></a><a id="Tc_1XwIQSaeCk-WtQc3iGpmeA_5_5"></a><a id="Tc__SoL4RjyU0OOoSUK9T9yqw_6_0"></a><a id="Tc_ayKePkXAyES5YqMm9BMKqA_6_5"></a><a id="Tc_3NmTqtKsw0Ch6rlYvPm6ug_8_0"></a><a id="Tc_NPkyfZv2VES1XLvxaQImvg_9_0"></a><a id="Tc_X_FJgcw6ek6fc5hQg8JO9w_9_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_T0ZBPvGhC0a4pxNqWmgv8A_4_3">202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_um3cdFsCmEiRlwCWT6CIrA_4_6">147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_LL1X4iSns0q4RXEY67WNqA_5_3">122</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_NLGt0RY72UuYVIk82jatYA_5_6">233</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Note receivable from issuance of common stock and warrants, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="-3" format="ixt:numdotdecimal" name="plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_DHRq2LSXDU603GT1wq-nUA_6_6">2,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_mGGzNEpWwESwRZy039SSiQ_9_3">136</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_uenhpmNZS06iZS1X55iY8g" continuedAt="Tb_uenhpmNZS06iZS1X55iY8g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_zZYghbVqPEKXGEI2AQ5jrg" continuedAt="Tb_zZYghbVqPEKXGEI2AQ5jrg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder. A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The FDA also indicated in its BLA filing communication letter that it did not plan to hold an advisory committee meeting to discuss the application. On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that they received a Complete Response Letter (CRL) from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In the CRL, the FDA noted that an inspection of Protalix&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve the BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease, or COVID-19, the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>), a therapy used to treat Fabry patients, was recently converted to full approval which must be addressed in the context of any potential resubmission seeking accelerated approval of PRX-102. The Company intends to work collaboratively with the FDA to identify the most expeditious pathway to approval, including accelerated approval. Protalix remains confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. The Company intends to request a Type-A meeting with the FDA, and will provide further updates on next steps after this meeting; however, the Company cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which is subject to an exclusive worldwide license agreement with SarcoMed USA, Inc. (&#8220;SarcoMed&#8221;) for use in the treatment</span><span style="color:#000000;direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uenhpmNZS06iZS1X55iY8g_cont1" continuedAt="Tb_uenhpmNZS06iZS1X55iY8g_cont2"><ix:continuation id="Tb_zZYghbVqPEKXGEI2AQ5jrg_cont1" continuedAt="Tb_zZYghbVqPEKXGEI2AQ5jrg_cont2"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;10, 2021, the Company entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. Under the terms of the agreement, SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, and the clinical research and development of such candidates. The Company is entitled to an initial cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_ora0XsBMfkOq7xYpZZOFwQ" decimals="-5" format="ixt:numdotdecimal" name="plx:LicenseAgreementInitialCashPayment" scale="6" id="Narr_eoujTyHuk0ai4tP7rQH_wg">3.5</ix:nonFraction>&#160;million, subject to certain conditions, and to additional regulatory and commercial milestone payments and tiered royalties on net sales of products that are commercialized under the license agreement. In addition to the foregoing, the parties agreed to commence negotiation of clinical and commercial supply agreements for alidornase alfa. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within <ix:nonNumeric contextRef="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_ora0XsBMfkOq7xYpZZOFwQ" format="ixt-sec:durwordsen" name="plx:TermToSignSupplyAgreement" id="Narr_aU0tKn4iy0Ocm5fOD3qbFw">60 days</ix:nonNumeric> of the execution of the license agreement, and SarcoMed has the right to terminate the license agreement if the parties do not successfully do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="Duration_2_17_2021_To_2_17_2021_u_XK6e7UVESYlSBODfH83Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Y73LSETzfEmQhsm73I9NAw">8,749,999</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA" contextRef="As_Of_2_17_2021_Y55Ar_XSM0Cn4NkSAnOr_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ADb2dJMxhkSaEuitVtZ0FQ">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), in an underwritten public offering raising gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_2_17_2021_To_2_17_2021_u_XK6e7UVESYlSBODfH83Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_Rx5wdpKAlUWhHY7b7beIrw">40.2</ix:nonFraction>&#160;million at a price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA" contextRef="As_Of_2_17_2021_Y55Ar_XSM0Cn4NkSAnOr_g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_IdKGoB1M6UyhDMw3DtOEVA">4.60</ix:nonFraction> per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities, Inc. (&#8220;BofA Securities&#8221;) acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March 29, 2021, the Company made a payment of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ThxKgBuf2UK2nF6qftr2kw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="Narr_L5SCL7RC7U6eDGAWA1AWMQ">4.0</ix:nonFraction>&#160;million to Pfizer Inc. (&#8220;Pfizer&#8221;) satisfying the outstanding promissory note payable to Pfizer in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;1, 2020, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;) with BofA Securities as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of Common Stock having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_G_tb6sGRnk6B27_FVPjvUg" decimals="-6" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_BHpMLKHvdE-IwiNOfAH3pQ">30.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). During 2021 to date, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_d3BrXmiZ10eL6A392JU9mw" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Narr_6J6gVV_ulUq01nMz0kIrKg">1,867,552</ix:nonFraction> ATM Shares for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_d3BrXmiZ10eL6A392JU9mw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_tX-8c0QgIEWXfArAGMOKTQ">8.8</ix:nonFraction> million. As of the issuance date of the financial statements, the Company has the right to raise an additional $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_fH-eFiWWTEWpXTsknvvImw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_Z3_4D32fyk246Pv69FhbLQ">16.2</ix:nonFraction>&#160;million of capital under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_j3-U2lgv9kaYDYpnq-Cz7Q" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNonCreditablePaymentReceivable" scale="6" id="Narr_XmXQu5LlOkm-EnzBkhDr9Q"><ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_cUvfdjvwYEa9IMFmcOD8nQ" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNonCreditablePaymentReceivable" scale="6" id="Narr_tbeNPUWVokeqBLfLYnaPlg">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_UZb52YP5Gkqo2veFUnlg_w" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_h8WrgVi1l0CXwkDM4BP92Q">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs, capped at $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_UZb52YP5Gkqo2veFUnlg_w" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_r5DzFpZVJUWLJyZYzMFdww">10.0</ix:nonFraction>&#160;million per year, and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_UZb52YP5Gkqo2veFUnlg_w" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_Be_mbKGdm0OYi55yPi6Pxg">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wEgmk_bQ70CSJwv5vY46ow" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_w_SXIiR6XUe0z1hi_aXP5g">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wEgmk_bQ70CSJwv5vY46ow" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_gfMxvWH8R0eTG9kPHpWt4A">7.5</ix:nonFraction>&#160;million per year, and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wEgmk_bQ70CSJwv5vY46ow" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_FrBsfrmJjkeMtkr5msDTcQ">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_1sBE3oSTM0etPlYlt5LcuA" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_07OCTqmJvkSCF3lMmhSWTw">15</ix:nonFraction>% </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uenhpmNZS06iZS1X55iY8g_cont2" continuedAt="Tb_uenhpmNZS06iZS1X55iY8g_cont3"><ix:continuation id="Tb_zZYghbVqPEKXGEI2AQ5jrg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">to <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r-lq86-0tUWqJBQNVq0i8A" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_-7YBa8uutEKqb8CblfMwIg">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember__7guBnYaGk-PHQNjbXG97Q" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_QENQEU-Z00aVaTJ_7mYjKA">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_IZDIDKW0ckix5UQLj_kyyw" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_AdpAhfw3ZkmlNHrkH479mQ">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Subsequent to March&#160;31, 2021, the Company signed a binding term sheet with Chiesi, pursuant to which the parties reached certain agreements including a $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_5_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iMSRRkNGFEqFLRRG3ATJ0A" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_TjsL5Qu_30C3fo6QsJPcyA">10.0</ix:nonFraction>&#160;million payment by Chiesi prior to June&#160;30, 2021 in exchange for the reduction of a longer-term regulatory milestone payment set forth in the Chiesi EX-US Agreement by $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_5_14_2021_To_5_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_CVQTExGFqUyzhQ6JuwB5tA" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" sign="-" scale="6" id="Narr_I03SwUDs_EiAtu2vQXNlFQ">25.0</ix:nonFraction>&#160;million. All other regulatory and commercial milestone payments remain unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_r3AHKZ-r30CFs0FZk9Nlzw" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_GlxBkwX1s0qp7822fXWCgQ">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and bank deposits as of March&#160;31, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. The Company expects that such cash and cash equivalents and bank deposits will be sufficient to satisfy the full payment of the principal amount of the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_tJnyJJMrvk64LWQ_LMBvfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_NaCDZUyy8028lrE8n2bLcA">7.50</ix:nonFraction>% convertible secured promissory notes due November&#160;15, 2021 equal to $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_tJnyJJMrvk64LWQ_LMBvfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_iJvVeJWG7kyyhcXhcApcbw">57.9</ix:nonFraction>&#160;million, unless the notes are refinanced, restructured or converted before that date.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_k-fJEYi7R022IRugBXWjYg" continuedAt="Tb_k-fJEYi7R022IRugBXWjYg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uenhpmNZS06iZS1X55iY8g_cont3" continuedAt="Tb_uenhpmNZS06iZS1X55iY8g_cont4"><ix:continuation id="Tb_k-fJEYi7R022IRugBXWjYg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_5h4nwhWkr0CWTsMqdmgfzg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_BK11l2OxAkeunAHLzlQXqw">10,694,517</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A" contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_qYYHr_fyUEqRJ1FsWDehCQ">26,769,693</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding convertible notes and outstanding warrants for the three months ended March&#160;31, 2020 and 2021, respectively, because their effect would be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_mTYiF7M0WEWzyJm2N6OD9w" continuedAt="Tb_mTYiF7M0WEWzyJm2N6OD9w_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_agreement_crDxDnAv7EmGAesWUEmcsw" contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_2Iwh_PZxMUuR2b_zQIjxjQ" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_SdZ52QL26UGzSyxrBWpE7Q">two</ix:nonFraction> performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uenhpmNZS06iZS1X55iY8g_cont4"><ix:continuation id="Tb_mTYiF7M0WEWzyJm2N6OD9w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="Tc_WfeSiLXS0USc5H4ZWQBhww_1_2"></a><a id="Tc__ow_QX18UEOwyCIvIbSgmw_1_5"></a><a id="Tc_9Hs8FUe1lkeLM_0uSc43ng_2_0"></a><a id="Tc_s6kB7daDekaVxjGcdgqLVw_2_2"></a><a id="Tc_uKFxf1KOuU-eB1rPilcOsA_2_5"></a><a id="Tc__WmxtFaVKE6VEQLot8_uWA_3_0"></a><a id="Tc_yBugOz3Sx0WA_SWS-5tGPw_3_2"></a><a id="Tc_c2DsI0wHukiHH1V7n5h5Bw_3_5"></a><a id="Tc_X0SCCO8voEieWXjUz8TuDw_4_0"></a><a id="Tc_bVUZ_DSdQ0qL5x6Qf8PNKg_5_0"></a><a id="Tc_AnJmMOLCGkKcX4Z9wIgqng_6_0"></a><a id="Tc_mJltClahXECJYo3w2_okLA_6_2"></a><a id="Tc_2EOmTmXp4EqGKzqnO9qDJw_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_RarTieQF1UmwL1Gl5svbXA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2021 and December&#160;31, 2020 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_Sb9lvx-djESTY6gLXy7deg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_jnHZ1VxQ40mPdngjB-P57w_3_3">3,427</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_AW94Ka6FuUWcTt0gRZu4mw_3_6">3,347</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_qXW69xTIjk60Edw78-295A_4_3">2,273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_3dYDfxO3-UKWPiISbK7nQw_4_6">2,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_LU7T-gFvAkayN4-UkHjExw_5_3">8,215</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_E18-TrxgNUqP2FjEV6F2Sw_5_6">6,848</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_YGGFY4S7Q0eDj4FI7NkSbA_6_3">13,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_yqxfbxSRUEKyjQ5uiGVkPw_6_6">13,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_J0iN26XDfkqDJVwmC3YmLA" continuedAt="Tb_J0iN26XDfkqDJVwmC3YmLA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_7fbH8FQsiE6VFbyBaExXMA_1_2"></a><a id="Tc_22U7h9X9H0C-yH5AnrTb3Q_2_0"></a><a id="Tc_zw7lXVHmy0qZmHOj2RldJA_3_0"></a><a id="Tc_DeUHziO18EmsQF65Y7B2RQ_4_0"></a><a id="Tc_VVoiF-TKJU-LneIzGMnEHg_4_3"></a><a id="Tc_FbOR1l91HkmL2F4042E8qQ_5_0"></a><a id="Tc_1qrAjZr8uEeQ6SmRlcqh9w_5_3"></a><a id="Tc_c-H9WZ4uMUebKBSf-isjYA_6_0"></a><a id="Tc_2xbIAX4GLkqYeMpVrA4cgQ_6_3"></a><ix:continuation id="Tb_J0iN26XDfkqDJVwmC3YmLA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of March&#160;31, 2021, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_W7bSf7UauU2UcKXEjO21YA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_kOBR_ID1fkSB59_1TBCz5w">57.9</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_W7bSf7UauU2UcKXEjO21YA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_-cLhT1rtoUGgFGlAGb9SqA">7.50</ix:nonFraction>% 2021 Notes as of March&#160;31, 2021 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_W7bSf7UauU2UcKXEjO21YA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_xf5wSgTXk02inRXTuVhlSg">59.8</ix:nonFraction>&#160;million based on a Level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of March&#160;31, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_IWN34CGSq02efTOZFIDwQA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_o1cceICqbUikI0McrcBVEQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BaH8L0w5DEycxituHyiDNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_hIlPSWEd_0Cm4HphrRveQA_2_2">4.46</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_5NM-tGWaUkyvfqzfREuJnw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_4YHBSKRwpEaGjHKtoWMg8A_3_2">0.63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_BMaSMHlJfkSwlgEYxqWOuQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_9NpYIut4h0ac63VAxMiMDw_4_2">0.05</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_n58i0vokQU6Bu9njK42qFQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_1LeHojCKeU2nSSsWFd3dTw_5_2">71.89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_2fSRYl5U6ki6zEDhNxZMXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_yB1ddKomn0qxwCNUGwgyig_6_2">11.54</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_9-pzJeb--kiZCOJKcL2bDg_1_2"></a><a id="Tc_dnBMfvX_nkCEmfXWSM0fiQ_2_0"></a><a id="Tc_Gf8mI7i1i0CFoc3SEpkP2Q_2_2"></a><a id="Tc_surnBlDwokuFf_h_dJxqzw_2_5"></a><a id="Tc_YjS-DzeUFU-2kqrseWR70w_3_0"></a><a id="Tc_o_ignotZm0278NrYt0VMKA_3_2"></a><a id="Tc_tK-rSreJcEyfwQyhpyoCMg_3_5"></a><a id="Tc_xywMYJJBY02TMtTh3HGfcA_4_0"></a><a id="Tc_-BZMkIK14Euii4jTi9Skyw_4_2"></a><a id="Tc_QC_rXp80rUmMNU5d1rPbUQ_4_3"></a><a id="Tc_b8w6ljPnmUK-_Zg2yO4uwQ_4_5"></a><a id="Tc_gHA_oN2ju0SganIOdDeM-Q_5_0"></a><a id="Tc_k91grpielka-J95wiuUbzw_5_2"></a><a id="Tc_2EeoEqyCOk6fzqXUX6RRBA_5_5"></a><a id="Tc_Q97EnVyYGUm0N1n3ZZ283Q_6_0"></a><a id="Tc_TcWyrajV4USR5VsfFt4C3A_6_2"></a><a id="Tc_g0SLkzDwp0SMs9PKhIuVxA_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="plx:RevenueDisclosureTextBlock" id="Tb_zJPyiGZZ4keHe_b3fT4kig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_iFQipl3vMkCC9ALeeGsmdQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_6pKW20bscE2Ku3nHfNM7Zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Gi22Jnw3Ak-QoRKPiJ78og_3_3">4,511</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_8WJteDHFv0uHhDDSYCX3ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_g383-SA-P02_ZItfqfp-8Q_3_6">2,016</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_HgUCN56GCUCbhH5dRyjtRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Zyi1QV-2yUS76VKBmjdBvw_4_6">3,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_NTsUlyVWH0iAhOuc-JATrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_lXVn9FFPhUGbTkj52_afAA_5_3">4,511</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_rsuCkhAchUKfvtMJQ7Jdkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_XBx6EmV85E-VnuV4UuCnaw_5_6">5,031</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_DpyYY9nDa0Cy_n2dtTOfHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_MDAvrTvFIkSqtbUv5N6Jbw_6_3">6,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-PP3WwL7Ek624e-6Fj9uCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_GIN6mGN0HkaOptT3TEWUAw_6_6">16,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 36pt;">During the three months ended March&#160;31, 2020, the Company recorded revenue in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_AVEnMunZKE2ZyjoOzJX63A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="Narr_Av5MJOJEaESQLuYS2-7RSg">6.7</ix:nonFraction>&#160;million following a change in estimate of the total costs expected to be incurred in connection with the Chiesi Agreements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ" name="us-gaap:DebtDisclosureTextBlock" id="Tb_arfQEJc2aUK7k1d07ARIsQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; PROMISSORY NOTE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In September 2020, the Company amended the outstanding $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_e7hdGudACk2S__aUdhpOSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="6" id="Narr_cceJuf1sXkafC1y7KBZajQ">4.3</ix:nonFraction>&#160;million promissory note payable to Pfizer by November 2020 to extend the maturity date to the earlier of (a) January&#160;31, 2022 and (b) the date that the Company receives any milestone payment from Chiesi, if at all, subject to certain conditions and exceptions. The amendment also required that the Company make a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_TQRiEj4vMkeo1dXynWjINA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="Narr_LtFZ9MD5qUSr7XpGRRScxA">430,000</ix:nonFraction> to Pfizer. The payment was creditable against the principal amount of the note, in whole or in part, if the Company was to satisfy the note in full on or prior to September&#160;30, 2021, depending on the date the note is satisfied. On March&#160;29, 2021, the Company made a payment of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ" contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ThxKgBuf2UK2nF6qftr2kw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="Narr_4yGUsBH1JE27QNn9puAKVw">4.0</ix:nonFraction>&#160;million to Pfizer satisfying the note in full.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_25f57c16_e30a_46e2_ae65_67d1543cb70b"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS<br />AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2020. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors including those set forth under &#8220;Risk Factors&#8221; in this Quarterly Report on Form</i>&#160;<i style="font-style:italic;">10-Q.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to the timing and progress of the preparation of an updated BLA addressing the CRL;</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the timing, progress and likelihood of final approval by the FDA of a resubmitted BLA for PRX-102 and, if approved, whether the use of PRX-102 will be commercially successful;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA, the European Medicines Agency, or EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file for any of our product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to make required payments under our outstanding convertible notes or any other indebtedness as they come due and our ability to obtain additional financing and raise capital as necessary should the regulatory approval process become more extended;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the COVID-19 outbreak, which may adversely impact our business, preclinical studies and clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic alternatives;</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>our dependence on performance by third-party providers of services and supplies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the impact of development of competing therapies and/or technologies by other companies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to our supply of drug product to Pfizer;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to the compliance by Fiocruz, an arm of the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors, collaborative partners, licensees and clinical trial sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we amended the Chiesi Agreements in order to provide us with near-term capital. Chiesi agreed to make a $10.0&#160;million milestone payment to us before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We also agreed to negotiate certain manufacturing related matters.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On April&#160;28, 2021, we, together Chiesi, announced the receipt from the FDA of a CRL in response to the PRX-102 BLA.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 4.5pt 10pt 0pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;23, 2021, we, together with Chiesi, announced positive topline results from our phase&#160;III <i style="font-style:italic;">BRIGHT </i>clinical trial of PRX-102 for the treatment of Fabry disease, or the <i style="font-style:italic;">BRIGHT</i> study, designed to evaluate the safety, efficacy and pharmacokinetics of PRX-102 treatment, 2&#160;mg/kg every four&#160;weeks, in up to 30&#160;patients with Fabry disease previously treated with a commercially available ERT (agalsidase alfa &#8211; Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or agalsidase beta &#8211; Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>).</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 4.3pt 0pt 0pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;18, 2021, we announced the closing of a public offering of our common stock raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering.</div><div style="margin-top:10pt;"></div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 4.5pt 0pt 0pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;11, 2021, we announced an exclusive worldwide license agreement with SarcoMed for PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.</div><div style="margin-top:10pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">We continue to actively advance all our clinical programs. We are in close contact with our principal investigators and clinical sites and our clinical research organizations, which are primarily located in the United States and Europe, and to date, our clinical trials have not been materially adversely affected by COVID-19. In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March&#160;18, 2020, we and our contract research organizations have made certain adjustments to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial integrity during the pandemic and generally, and we may need to make further adjustments in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:14pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:207.26pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In response to the local spread of COVID-19 at the end of March 2020, and with local directives issued in response thereof, we restructured the work day within our facilities to consist of two shifts thereby reducing the number of employees present in the facilities at any time and facilitating their ability to practice social distancing. Employees that were able to work from home were instructed to do so. Such efforts resulted in minor delays in the performance of administrative activities outside of the clinical programs.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In June 2020, after local directives allowed more flexibility with respect to social interactions, we returned to a regular work day. Since then, as the pandemic&#8217;s effect locally continued to change, and local Israeli directives continued to evolve to address the changing effects, we returned temporarily to the two-shift work day schedule and to again encourage employees that are able to work from home to do so for parts of September 2020. Our facility currently operates on a regular schedule with adherence to local guidelines.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We will continue to evaluate the impact of the COVID-19 pandemic on our business as we learn more and the impact of COVID-19 on our industry becomes more clear. We intend to continuously assess the impact of COVID-19 on our trials, expected timelines and costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"><img src="plx-20210331x10q005.jpg" alt="Graphic" style="display:inline-block;height:207.26pt;width:540pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:234.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell in Suspension Expression System for Therapeutic Proteins Development and Industrial Production: Executive Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20210331x10q006.jpg" alt="Graphic" style="display:inline-block;height:233.28pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;"><img src="plx-20210331x10q007.jpg" alt="Graphic" style="display:inline-block;height:164.64pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:540pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">PRX-102 is our lead product candidate and we expect it to be the primary subject of our development efforts in the short-term. It <span style="letter-spacing:-0.15pt;">is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme,<span style="letter-spacing:-0.15pt;"> under development for the treatment of Fabry disease. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, in blood vessel walls throughout their body. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> increases with time and, as a result, Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> accumulates, primarily in the blood and in the blood vessel walls. The accumulation leads to a narrowing of the blood vessels, which in turn leads to decreased blood flow and tissue nourishment. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males. The global market for Fabry disease is forecasted to be approximately $1.9&#160;billion in 2021 (Global Data) and to continue to grow at a CAGR of approximately 9.5% (Global Data).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:14pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. As discussed above, on April&#160;28, 2021, we, together with Chiesi, announced the receipt of a CRL from the FDA regarding the BLA.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The BLA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II clinical trial of PRX-102, including the related extension study succeeding our phase I/II clinical trial, interim clinical data from our phase III <i style="font-style:italic;">BRIDGE</i> switch-over study and safety data from our on-going clinical studies of PRX-102 in patients receiving 1&#160;mg/kg every other week.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In the CRL, the FDA noted that an inspection of Protalix&#8217;s manufacturing facility in Carmiel, Israel, including a subsequent assessment of any related FDA findings, is required before the FDA can approve the BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to COVID-19, the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme, a therapy used to treat Fabry patients, was recently converted to full approval which must be addressed in the context of any potential resubmission seeking accelerated approval of PRX-102. Protalix intends to work collaboratively with the agency to identify the most expeditious pathway to approval, including accelerated approval. We remain confident that we will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. We intend to request a Type-A meeting with the FDA, and will provide further updates on next steps after the meeting; however, we cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In December 2017, the European Commission granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease. Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> qualifies Chiesi for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation is maintained at the time <span style="font-family:'Times-Roman';">PRX-102</span> is approved for marketing in the European Union, if at all, we expect that <span style="font-family:'Times-Roman';">PRX-102</span> will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In January 2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase<span style="letter-spacing:-0.15pt;">&#160;</span>III clinical program of PRX-102 for the treatment of Fabry disease includes three individual studies; the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies. Enrollment has been completed in all three studies. In 2015, we completed a phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial of PRX-102. Patients that completed the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial were offered the opportunity to continue PRX-102 treatment as part of a long-term extension study. In the phase&#160;III clinical program, we are studying two alternative doses and regimens for PRX-102; 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every four weeks, which has the potential to lower treatment burden versus existing treatments and potentially provide a better quality of life for a subset of Fabry patients. Final results from the <i style="font-style:italic;">BRIDGE</i> study were released in December 2020 and topline results from the <i style="font-style:italic;">BRIGHT</i> study were released in February 2021. We expect to announce interim data from the <i style="font-style:italic;">BALANCE </i>study by the end of the first half of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February 2020, we, together with Chiesi, announced an agreement with the FDA for the Initial Pediatric Study Plan (iPSP) for PRX-102. The joint announcement was made after completion of discussions with the FDA and receipt of confirmation from the FDA </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">in an official &#8220;Agreement Letter&#8221; which outlines an agreed-upon approach to evaluate the safety and efficacy of PRX-102 in pediatric Fabry patients in a clinical trial to be performed by Chiesi with our collaborative efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background-color:#ffffff;">The </span><i style="font-style:italic;">BALANCE</i> s<span style="background-color:#ffffff;">tudy is a 24</span>-<span style="background-color:#ffffff;">month, randomized, double blind, active control study of PRX</span>-<span style="background-color:#ffffff;">102 in Fabry patients with impaired renal function. We have completed enrollment of 78 patients in the trial, which is </span>designed to evaluate the safety and efficacy of PRX-102 compared to agalsidase beta (Fabrazyme) on renal function in Fabry patients with progressing kidney disease previously treated with Fabrazyme infused once every two weeks. <span style="background-color:#ffffff;">Patients previously treated with </span>Fabrazyme <span style="background-color:#ffffff;">for approximately one year and on a stable dose for at least six months were screened and then randomized on a 2:1 ratio to 1</span><span style="letter-spacing:-0.15pt;">&#160;</span><span style="background-color:#ffffff;">mg/kg of PRX-102 or 1</span><span style="letter-spacing:-0.15pt;">&#160;</span><span style="background-color:#ffffff;">mg/kg of </span>Fabrazyme<span style="background-color:#ffffff;">. Randomization is being stratified by urinary protein to creatinine ratio (UPCR) of &lt;</span>&#160;<span style="background-color:#ffffff;">or</span>&#160;<span style="background-color:#ffffff;">&#8805;</span>&#160;<span style="background-color:#ffffff;">1</span>&#160;<span style="background-color:#ffffff;">g/g by spot urine sample. The study was designed such that no more than 50% of the patients enrolled in the study would be female. Approximately 40% of the enrolled patients were female.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The primary endpoint for the <i style="font-style:italic;">BALANCE</i> study is the comparison in the annualized rate of decline of eGFR slope between Fabrazyme and PRX-102. eGFR is considered a reliable and accepted test to measure the level of kidney function and stage of kidney disease. Additional parameters being evaluated include: cardiac assessment, Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients during therapy), pain, quality of life, immunogenicity, Fabry clinical events and pharmacokinetic and other parameters. The study also evaluates the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We intend to conduct an interim analysis when the last patient reaches 12&#160;months of treatment to test for non-inferiority to support anticipated regulatory filings with the EMA. Patients enrolled in the <i style="font-style:italic;">BALANCE</i> study will continue to be treated for a total of 24&#160;months, at which point the data will be analyzed to test for superiority. If the anticipated BLA filing results in an approval from the FDA under the Accelerated Approval pathway, this analysis will also be used to support converting the accelerated approval into a full approval. We anticipate announcing interim results from our <i style="font-style:italic;">BALANCE</i> study in the first half of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background-color:#ffffff;">The </span><i style="font-style:italic;">BRIDGE</i> study was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of pegunigalsidase alfa, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients. The trial, which is was completed in December 2019, enrolled patients then being treated with agalsidase alfa, marketed by Takeda Pharmaceutical Company Limited (formerly Shire&#160;Plc) as Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, for at least two years and on a stable dose for at least six months. Patients were screened and evaluated over three months while continuing Replagal treatment. Following the screening period, each patient was enrolled and switched from Replagal treatment to receive intravenous (IV)&#160;infusions of PRX-102 1&#160;mg/kg every two weeks for 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.4pt 10pt 0pt;">Final results of the data generated in the study showed substantial improvement in renal function as measured by mean annualized estimated Glomerular Filtration Rate, or eGFR, slope in both male and female patients who were switched from agalsidase alfa to PRX-102. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102.<span style="font-size:12pt;"> </span>In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 24.75pt 10pt 0pt;">PRX-102 was well-tolerated in the study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of treatment <span style="letter-spacing:-2.9pt;"> </span>emergent adverse events were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate treatment emergent adverse events were nasopharyngitis, headache and dyspnea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 8.05pt 10pt 0pt;">An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent antidrug antibodies over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.15;margin:0pt 5.2pt 10pt 0pt;">Baseline characteristics of the 20 patients that completed the study, ranging from ages 28 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in males, and 86.14&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> were<span style="vertical-align:super;"> </span>51.81&#160;nM and 13.81&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed of 19.55&#160;nM (32.35%) in males and 4.57&#160;nM (29.81%) in females.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data from the interim analysis of the <i style="font-style:italic;">BRIDGE</i> study, which were first announced in February 2020, were used to support the PRX-102 BLA filing with the FDA, and we anticipate that the final analysis will be used to support a Marketing Authorization Application, or MAA, with the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background-color:#ffffff;">The </span>phase&#160;III <i style="font-style:italic;">BRIGHT </i>clinical trial of PRX-102 for the treatment of Fabry disease, or the<i style="background-color:#ffffff;font-style:italic;"> </i><i style="font-style:italic;">BRIGHT</i> study, was a 12-month, open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of PRX-102 via IV infusions of 2&#160;mg/kg administered every 4 weeks. The trial, which was completed in June 2020, enrolled up to 30 patients with Fabry disease previously treated with a commercially available ERT (Fabrazyme or Replagal), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with stable kidney disease. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV&#160;infusions every 2 weeks to 2&#160;mg/kg of PRX-102 every 4 weeks for 12&#160;months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the 4-week dosing regimen as measured by eGFR and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><a id="_Hlk64553510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We announced topline results in February 2021. The topline results indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was found to be well tolerated among treated patients, and stable clinical presentation was maintained in adult Fabry patients. No new patients developed treatment-induced anti-drug antibodies, or ADA, following the switch to PRX-102 treatment.</p><a id="_Hlk64641068"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study enrolled 24&#160;adult males and 6&#160;adult females. The most common Fabry disease symptoms were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. All 30&#160;patients received at least one dose of PRX-102, and 29 patients (mean [SD] age was 40.5&#160;[11.3]&#160;years, ranging from 19 to 58&#160;years) completed the 12-month study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the study, while one patient was switched to PRX-102 1&#160;mg/kg every two weeks per protocol. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following screening, patients were enrolled and switched from their then current ERT to IV&#160;infusions of 2&#160;mg/kg of PRX-102 every four weeks for 52 weeks (a total of 14&#160;infusions). First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures showed plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change of 3.01&#160;nM from baseline (19.36&#160;nM) to Week&#160;52 (22.23&#160;nM). Mean absolute change of eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or BPI, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week&#160;52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.<span style="background-color:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, substantially all of the patients who completed the study opted, with the advice of the treating physician, to continue treatment under the 4-week dosing regimen in a long-term extension study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Impact on PRX-102 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. In a minimal amount of cases, patients that completed a trial were not able to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">be transferred into an extension study due to the pandemic restrictions, and, accordingly, the main trial was prolonged for the patients to permit the continuation of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;I/II clinical trial of PRX-102, which we completed in 2015, was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult Fabry patients. Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. A majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805;&#160;50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to Month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Results show that Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGRF levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed anti-drug antibodies (ADA), of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix Ltd. has received $50.0&#160;million in upfront payments and was entitled to development cost reimbursements of up to $45.0&#160;million, up to more than $1.0&#160;billion in potential milestone payments and tiered royalties of 15% - 35% (ex-US) and 15% - 40% (US). To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the two Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, subject to a maximum of $7.5&#160;million per year. Protalix Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi is also required to make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we amended the Chiesi Agreements in order to provide us with near-term capital. Chiesi agreed to make a $10.0&#160;million milestone payment to us before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSD, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen, liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1 in 400 to 1 in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease is a $1.5&#160;billion global annual therapeutic market that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of our Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil (marketed as BioManguinhos alfataliglicerase) through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH. In 2020, we generated $8.0&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alidornase Alfa (PRX-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Alidornase alfa is our chemically-modified plant cell expressed recombinant human DNase I, administered via inhalation. Recombinant human DNase I enzymatically cleaves DNA but its activity is inhibited by actin, which is present in the blood and other target organs. PRX-110 is designed to be less susceptible to actin inhibition and have higher affinity to DNA, thus enhancing enzymatic activity. In-vitro studies have shown PRX-110 to have a highly improved catalytic efficiency and affinity to DNA, compared to dornase alfa (Pulmozyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, currently the only commercially available DNase therapy), even more so in the presence of actin.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On February&#160;10, 2021, we entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment<span style="direction:rtl;"> </span>of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;21, 2020, the FDA granted Orphan Drug Designation for alidornase alfa for the treatment of Sarcoidosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRX-115</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated uricase (urate Oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of refractory gout. Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. Gout is caused by factors that elevate serum uric acid, or sUA, levels, which may include diet or genetic predisposition and environmental factors leading to hyperuricemia and tissue deposition of monosodium urate crystals, tophi, in joints and soft tissues, causing acute and chronic inflammation, and is characterized by recurrent flares. Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with metabolic syndrome, and may contribute to myocardial infarction, type 2 diabetes mellitus, chronic kidney disease, or CKD, and premature mortality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently available urate-lowering therapies, or ULTs, can be effective in treating gout. Refractory gout patients are those whom, despite treatment with existing ULTs, have high flare frequency, consistent tophi, and the inability to maintain therapeutic goals of urate levels. An estimated approximately 2% of the gout population is considered to have chronic refractory disease and are in in need of other therapeutic options. One option may be a therapeutic use of the uricase enzyme which converts uric acid to allantoin, which is easily eliminated through urine. The uricase enzyme does not exist naturally in humans. To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for treatment of chronic gout refractory to conventional therapy (no longer approved in the European Union) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis, induce strong immunogenic reactions and have other major side-effects. We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of refractory gout which we are designing to have an improved half-life, reduced immunogenicity and potentially longer term efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of March&#160;31, 2021, we hold a broad portfolio of over 90 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 35 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Scientific Presentations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="letter-spacing:-0.1pt;">On February&#160;1, 2021, Prof. Ales Linhart, M.D., Charles University, Praha, Czech Republic, a principal investigator in our pegunigalsidase alfa phase&#160;III clinical trials, delivered an oral presentation entitled &#8220;Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study,&#8221; describing the final results of the </span><i style="font-style:italic;letter-spacing:-0.1pt;">BRIDGE </i><span style="letter-spacing:-0.1pt;">study. The presentation was delivered at the 17th Annual WORLD</span><i style="font-style:italic;letter-spacing:-0.1pt;">Symposium</i><span style="letter-spacing:-0.1pt;">&#8482;, </span>a research conference dedicated to lysosomal diseases held virtually February&#160;8-12, 2021. Dr. Linhart also made a poster presentation on the same date and on the same topic at the conference<span style="letter-spacing:-0.1pt;">.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development. As disclosed above, we have entered into an exclusive license agreement with SarcoMed relating to the treatment<span style="direction:rtl;"> </span>of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our financial condition, liquidity, or results of operations will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $4.5&#160;million during the three months ended March&#160;31, 2021 a decrease of $0.5&#160;million, or 10%, compared to revenues of $5.0&#160;million for three months ended March&#160;31, 2020. The decrease of $3.0&#160;million in sales to Brazil was partially offset by an increase of $2.5&#160;million in sales to Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $6.8&#160;million for the three months ended March&#160;31, 2021, a decrease of $9.8&#160;million, or 59%, compared to revenues from license and R&amp;D services of $16.6&#160;million for the three months ended March&#160;31, 2020. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The decrease resulted primarily from revenues for the three months ended March&#160;31, 2020 recognized in connection with an updated costs estimation throughout the trials until completion, made in 2020, in the amount of $6.7&#160;million and from revenues recognized in connection with the progress of our clinical trials that have been completed during 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $4.8&#160;million for the three months ended March&#160;31, 2021, an increase of $1.4&#160;million, or 41%, from cost of goods sold of $3.4&#160;million for the three months ended March&#160;31, 2020. The increase in cost of goods sold was primarily the result of higher manufacturing costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses were $7.1&#160;million for the three months ended March&#160;31, 2021, a decrease of $3.2&#160;million, or 31%, compared to $10.3&#160;million of research and development expenses for the three months ended March&#160;31, 2020. The decrease is primarily due to the completion of two out of the three phase&#160;III clinical trials of PRX-102 and reduced costs related to the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates<span style="font-family:'Times-Roman';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $3.1&#160;million for the three months ended March&#160;31, 2021, a decrease of $0.1&#160;million, or 3%, compared to $3.2&#160;million for the three months ended March&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses net were $1.8&#160;million for the three months ended March&#160;31, 2021, a decrease of $1.2&#160;million, or 40%, compared to financial expenses net of $3.0&#160;million for the three months ended March&#160;31, 2020. <span style="background-color:#ffffff;">The decrease resulted primarily from a decrease in expenses related to our outstanding convertible notes equal to $1.3</span>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash balances and bank deposits. At March&#160;31, 2021, we had $19.8&#160;million in cash and cash equivalents and $50.6&#160;million in short-term bank deposits. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the three months ended March&#160;31, 2021, we raised gross proceeds equal to approximately $8.8&#160;million from sales of common stock under our ATM program through the sale of 1,867,552 shares of our common stock. In addition, we raised gross proceeds of approximately $40.2&#160;million from a public offering of our common stock before deducting the underwriting discount and estimated expenses of the offering. In connection with the offering, we issued 8,749,999 shares of our common stock at a purchase price per share of $4.60.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and bank deposits as of March&#160;31, 2021 are sufficient to satisfy our capital needs for at least 12 months from the date that these financial statements are issued. In addition, as of March&#160;31, 2021, we have outstanding 2021 Notes amounting to $57.9&#160;million which are due on November 15, 2021, unless the notes are refinanced, restructured or converted before that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $9.8&#160;million for the three months ended March&#160;31, 2021. In response to the COVID-19 pandemic, a higher number of subjects in our ongoing clinical trials opted for home care treatments over in-site treatments which resulted in an immaterial amount of additional expenses. The net loss for the three months ended March&#160;31, 2021 of $5.5&#160;million was increased by a $3.7&#160;million decrease in contracts liability, a $2.3&#160;million increase in accounts receivable and other assets and a $0.8&#160;million increase in inventories, partially offset by an increase of $0.6&#160;million in accounts payable and accruals, $0.9&#160;million amortization of debt issuance costs and debt discount and $0.8&#160;million in share-based compensation. Net cash used in investing activities for the three months ended March&#160;31, 2021 was $30.7&#160;million and consisted primarily of an increase in bank deposits. Net cash provided by financing activities was $42.1&#160;million resulting from the sale of common stock under our ATM program and from our public offering of common stock, net of the promissory note payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $7.1&#160;million for the three months ended March&#160;31, 2020. The net income for the three months ended March&#160;31, 2020 of $1.7&#160;million decreased by a $7.2&#160;million decrease in contracts liability, a $4.1&#160;million increase in account receivable and other assets and a $1.3&#160;million increase in inventories, and was increased by an increase of $2.6&#160;million in accounts payable and accruals, and by $0.8&#160;million amortization of debt issuance costs and debt discount. Net cash used in investing activities for the three months ended March&#160;31, 2020 was $35.0&#160;million and consisted primarily of an increase in bank deposits. Net cash provided by financing activities was $38.6&#160;million resulting from our issuance of common stock and warrants on March&#160;18, 2020.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Future Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As a result of our significant research and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses from our continuing operations since our inception. Our outstanding <span style="font-family:'28mugxoulnobhnx';">2021 Notes are </span>secured by a perfected lien on all of our assets<span style="font-family:'28mugxoulnobhnx';">. Under the terms of the indenture governing the 2021 Notes, we are required to maintain a minimum cash balance of at least $7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to continue to incur significant expenditures in the near future as we increase our research and developments efforts with respect to our product candidates given the receipt of the CRL from the FDA discussed above, we expect to incur additional expenses in connection with any resubmission. We cannot anticipate the costs or the timing of the occurrence of such costs. As well, to the extent we need to obtain additional financing in connection with this process or with any additional clinical testing that may be required, it may be more difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patents and fees for service providers in connection with our research and development efforts and (v)&#160;payment of principal and interest on our outstanding convertible promissory notes and other debt. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our efforts, combined with those of Chiesi, to file for resubmission with the FDA and to commercialize PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the progress and results of our clinical trials, particularly the PRX-102 </span><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">BALANCE </i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements and under our agreement with SarcoMed. In addition, our ATM program provides us with a quick and efficient manner to raise capital through the sale of shares of our common stock. To date, we have the right to raise an additional $16.2&#160;million of capital through sales of our common stock through the ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material effect on our results of operations during the three months ended March&#160;31, 2021 and March&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of March&#160;31, 2021 and March&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_51501b2d_9a26_4945_8dc3_e280beccd74b"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the dollar. Most of our revenues and approximately 52% of our expenses and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 43% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S. dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.268</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.504</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.442</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.334</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.565</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.215</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6a12a9c2_ad97_4d21_9c1c_a9d83503cb42"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended March&#160;31, 2021 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_77580b69_b719_43de_b7c7_5be5926ee18f"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not involved in any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_73ddf748_4904_4bdf_86e9_429ddd310cf7"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">You should carefully consider the following information about the risks described below, together with the other information contained in this Quarterly Report and in our other public filings in evaluating our business. The risk factors set forth below that are marked with an asterisk (*) did not appear as separate risk factors in, or contain changes to the similarly titled risk factor included in, Item 1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. If any of these risks occur, the value of our common stock could decline. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the COVID-19 Pandemic</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease, may adversely affect our business, results of operations and financial condition.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In December 2019, a novel strain of coronavirus, COVID-19, was identified in Wuhan, China. The virus has spread globally. To date, our clinical trials have not been adversely affected by COVID-19, although certain practices we have adopted in our offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The spread of an infectious disease, including COVID-19, may result in the inability of our suppliers to deliver components or raw materials on a timely basis. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the spread of an infectious disease, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials. Such events may result in a period of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. While the extent of the impact of the current COVID-19 pandemic on our business and financial results depends on future developments that are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others, a continued and prolonged public health crisis such as the COVID-19 pandemic may adversely affect <span style="background-color:#ffffff;">our business, results of operations and financial </span>condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Travel restrictions related to the COVID-19 pandemic have delayed FDA and other regulatory authority inspections of our facilities required for approvals and there is no certainty with respect to the timing of such inspections.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;white-space:pre-wrap;">We are subject to inspection by the FDA and comparable foreign regulatory authorities to determine our compliance with applicable regulatory requirements, as are our suppliers, contract manufacturers, and contract testing laboratories. The FDA had advised us that it requires an inspection of our manufacturing facility and the facility of a third party in Europe that performs fill and finish processes for PRX-102 as part of the FDA&#8217;s review of the BLA application, which inspections have not yet been scheduled due to the FDA&#8217;s travel restrictions resulting from the COVID-19 pandemic.  As previously disclosed, in the recently issued CRL, the FDA noted that an inspection of our manufacturing facility in Israel is required before the FDA can approve the BLA. Due to travel restrictions as a result of the pandemic, the FDA was unable to conduct the required inspection during the review cycle. Also, with respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug and Cosmetic Act in lieu of a pre-licensing meeting. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions and is actively working to define an approach for scheduling outstanding inspections. We cannot predict when such inspections will take place. Once such inspections are able to be conducted, if the facilities are not in substantial compliance with cGMP, there may be adverse consequences to the approval process. Delays in the approval process or our inability to obtain approval for any reason for any drug candidate may have a material adverse effect upon our business, results of operations and financial condition.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Clinical Trials and Regulatory Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would have a material adverse effect on our business, results of operations and financial condition.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We need FDA approval to commercialize our drug candidates in the United States, EMA approval to commercialize our drug candidates in the European Union and approvals from other foreign regulators to commercialize our drug candidates elsewhere. In order to obtain FDA approval of any of our drug candidates, we must submit to the FDA a BLA or an NDA demonstrating that the drug candidate is safe and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials. In the European Union, we must submit an MAA to the EMA. Satisfaction of the regulatory requirements of the FDA, EMA and other foreign regulatory authorities typically takes many years, depends upon the type, complexity and novelty of the drug candidate and requires substantial resources for research, development and testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary findings or other comparable authorities for such clinical trials. Further, even if favorable testing data is generated by the clinical trials of a drug candidate, the applicable regulatory authority may not accept or approve a marketing application we file for the drug candidate or may require us to conduct additional clinical testing or perform post-marketing studies which would cause us to incur additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Failure to obtain approval of the FDA, EMA or comparable foreign authorities of any of our drug candidates in a timely manner, if at all, will severely undermine our business, financial condition and results of operation by reducing our potential marketable products and our ability to generate corresponding product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">In light of our receipt of a CRL from the FDA regarding our BLA for PRX-102, the U.S. regulatory requirements and timing for PRX-102 approval are uncertain; we are substantially dependent on receipt of regulatory approvals for PRX-102, our most advanced product candidate.*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;11, 2020, we, together with Chiesi, announced that the FDA had accepted the BLA for PRX-102, and granted Priority Review designation for PRX-102 for the proposed treatment of adult patients with Fabry disease. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. However, in the CRL, the FDA noted that agalsidase beta (Fabrazyme), a therapy used to treat Fabry patients, was recently converted to full approval which must be addressed in the context of any potential resubmission seeking accelerated approval of PRX-102. We intend to work collaboratively with the agency to identify the most expeditious pathway to approval, including accelerated approval. We remain confident that we will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. We, together with Chiesi, intend to request a Type-A meeting with the FDA. There can be no guarantee that the FDA will grant this request or, if granted, that this meeting will be held promptly. Furthermore, we cannot predict the outcome of any interactions with the FDA nor can we guarantee when, or if, we will be successful in receiving regulatory approval for PRX-102. The regulatory requirements and timing for approval are uncertain at this time. If we do not obtain approval for PRX-102 or are delayed in obtaining such approval, it would have a material and adverse effect on our operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA may request additional data or impose other conditions in connection with a resubmission or approval. We cannot assure you that the FDA will eventually approve PRX-102 on a resubmission. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we may incur significant additional expenditures in order to obtain or maintain FDA approval. Any approval of the BLA may also be subject to post-marketing commitments or requirements, and we may need to develop and/or improve certain antibody or additional assays as post-marketing requirements or commitments. Even if we comply with all the requests of regulatory authorities, the FDA and other authorities may ultimately reject the BLA or any other marketing application that we file for a product candidate in the future, if any, or we might not obtain regulatory clearance in a timely manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also cannot assure you that the results of our ongoing <i style="font-style:italic;">BALANCE</i> study will demonstrate that our product candidates are safe and effective for their intended uses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The Fast Track designation for pegunigalsidase alfa for the treatment of Fabry disease may not lead to a faster development or regulatory review or approval process or increase the likelihood that pegunigalsidase alfa will receive regulatory approval for the treatment of Fabry disease.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA has granted Fast Track designation to pegunigalsidase alfa for the treatment of Fabry disease. As noted above, there can be no assurance that pegunigalsidase alfa will receive regulatory approval for the treatment of Fabry disease and following the receipt of the CRL timing for resubmission and the regulatory review process is uncertain. Despite the designation, we may not experience a faster development process, review or approval compared to applications considered for approval under conventional FDA procedures. In addition, the FDA is entitled to withdraw the Fast Track designation of a drug candidate at any time. Any failure to realize the benefits of Fast Track designation may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are subject to extensive governmental regulation including the requirements of the FDA and other comparable regulatory authorities before our drug candidates may be marketed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Both before and after marketing approval of our drug candidates, if at all, we, our drug candidates, our suppliers, our contract manufacturers and our contract testing laboratories are subject to extensive regulation by the FDA and comparable foreign regulatory authorities. Failure to comply with applicable requirements of the FDA or comparable foreign regulatory authorities could result in, among other things, any of the following actions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">warning letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">fines and other monetary penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">unanticipated expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays in the FDA&#8217;s or other foreign regulatory authorities&#8217; approving, or the refusal of any regulatory authority to approve, any drug candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">product recall or seizure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">interruption of manufacturing or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">operating restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">injunctions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">criminal prosecutions.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to the approval requirements, other numerous and pervasive regulatory requirements apply, both before and after approval, to us, our drug candidates, our suppliers, contract manufacturers, and contract testing laboratories. These include requirements related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">quality control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">advertising;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">promotion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">distribution;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">export;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">reporting to the FDA certain adverse experiences associated with use of the drug candidate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">obtaining additional approvals for certain modifications to the drug candidate or its labeling or claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also are subject to inspection by the FDA and comparable foreign regulatory authorities, to determine our compliance with regulatory requirements, as are our suppliers, contract manufacturers, and contract testing laboratories, and there can be no assurance that the FDA, or any other comparable foreign regulatory authority, will not identify compliance issues that may disrupt production or distribution, or require substantial resources to correct. We may be required to make modifications to our manufacturing operations in response to these inspections which may require significant resources and may have a material adverse effect upon our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The approval process for any drug candidate may also be delayed by changes in government regulation, future legislation or administrative action or changes in policy of the FDA and comparable foreign authorities that occur prior to or during their respective regulatory reviews of such drug candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Delays in obtaining regulatory approvals with respect to any drug candidate will materially and adversely affect our prospects, business, results of operations and financial condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Delays in obtaining regulatory approvals with respect to any drug candidate may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delay commercialization of, and our ability to derive product revenues from, such drug candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delay any regulatory-related milestone payments payable under outstanding collaboration agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">require us to perform costly procedures with respect to such drug candidate; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">otherwise diminish any competitive advantages that we may have with respect to such drug candidate.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Delays in the approval process for any drug candidate will have a material adverse effect upon our prospects, business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Clinical trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs, which may have a material adverse effect on our business, results of operations and financial condition.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Preliminary and initial results from a clinical trial do not necessarily predict final results, and failure can occur at any stage of the trial. We may encounter problems that cause us to abandon or repeat preclinical studies or clinical trials. The clinical trial process is also time-consuming. Other than taliglucerase alfa, all of our other drug candidates, including pegunigalsidase alfa, are in the clinical, preclinical or research stages. Our clinical program for pegunigalsidase alfa is in the middle of phase&#160;III, but generally, clinical programs take at least several&#160;<span style="white-space:pre-wrap;">years to complete.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given the receipt of the CRL, we may be required, in connection with a resubmission to the FDA, to conduct additional clinical trials or undertake additional studies, which may require additional time and resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Failure or delay in the commencement or completion of our clinical trials may be caused by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">slower than expected rates of patient recruitment, particularly with respect to trials of rare diseases such as Fabry disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">determination of dosing issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">unforeseen safety issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">lack of effectiveness during clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">disagreement by applicable regulatory bodies over our trial protocols, the interpretation of data from preclinical studies or clinical trials or conduct and control of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">determination that the patient population participating in a clinical trial may not be sufficiently broad or representative to assess efficacy and safety for our target population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">inability to monitor patients adequately during or after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">lack of sufficient funding to finance the clinical trials.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure or delay in commencement or completion of any clinical trials of pegunigalsidase alfa or our other product candidates will have a material adverse effect on our business, results of operations and financial condition. In addition, we or the FDA or other regulatory authorities may suspend any clinical trial at any time if it appears that we are exposing participants in the trial to unacceptable safety or health risks or if the FDA or such other regulatory authorities, as applicable, find deficiencies in our IND submissions or the conduct of the trial. Any suspension of a clinical trial may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If the results of our clinical trials do not support our claims relating to a drug candidate, or if serious side effects are identified, the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether, which will significantly impair our ability to generate product revenues.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of our clinical trials with respect to any drug candidate might not support our claims of safety or efficacy, the results of our clinical trials may fail to conclusively show superiority over other commercially available treatments for the same or similar indications, the effects of our drug candidates may not be the desired effects or may include undesirable side effects or the drug candidates may have other unexpected characteristics. Data obtained from tests are susceptible to varying interpretations which may delay, limit or prevent regulatory approval. The clinical trial process may fail to demonstrate that our drug candidates are safe for humans and effective for indicated uses. In addition, our clinical trials, may involve specific and small patient populations. Results of early clinical trials conducted on a small patient population may not be indicative of future results. Adverse or inconclusive results may cause us to abandon a drug candidate and may delay development of other drug candidates. Any delay in, or termination of, our clinical trials will delay the filing of NDAs and BLAs with the FDA, or other filings with other foreign regulatory authorities, and, ultimately, significantly impair our ability to commercialize our drug candidates and generate product revenues which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interim, topline or preliminary data from clinical trials that we announce or publish may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may publicly disclose interim, topline or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data. The results and related findings and conclusions are subject to change following a full analysis of all data related to the particular trial. We also may make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, any interim, topline or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different than the preliminary data we previously publish. As a result, any topline data should be viewed with caution until final data are available. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more data becomes available. Further, regulatory agencies may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses, or may interpret or ascribe different weight to the data, which may impact the value of the clinical trial and may affect the particular clinical program and the approvability or commercialization of the particular product candidate and our business in general. If regulatory authorities disagree with the conclusions we reach, we may not be able to obtain approval for and commercialize our product candidates, which will have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may find it difficult to enroll patients in our clinical trials, or patients may discontinue their participation in our clinical trials, which could cause significant delays in the completion of such trials or may negatively impact the results of these studies and extend the timeline for completion of our development programs or cause us to abandon one or more clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Some of the diseases or disorders that our drug candidates are intended to treat are relatively rare and we expect only a subset of the patients with these diseases to be eligible for our clinical trials. Our clinical trials generally mandate that a patient cannot be involved in another clinical trial for the same indication. Therefore, subjects that participate in ongoing clinical trials for products that are competitive with our drug candidates are not available for our clinical trials. An inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, patients that enroll in our clinical trials may discontinue their participation at any time during the study as a result of a number of factors, including withdrawing their consent, experiencing adverse clinical events, which may or may not be judged related to our drug candidates under evaluation, or due to planned or actual pregnancies. The discontinuation of patients in any one of our studies may delay the completion of the study or cause the results from the study not to be positive or to not support a filing for regulatory approval of the applicable drug candidate. Any failure to enroll a sufficient number of patients in our clinical trials in a timely manner, if at all, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Because our clinical trials depend upon third-party researchers, the results of our clinical trials and such research activities are subject to delays and other risks which are, to a certain extent, beyond our control, which could impair our clinical development programs and our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We depend upon independent investigators and collaborators, such as universities and medical institutions, to conduct our preclinical and clinical trials. These collaborators are not our employees, and we cannot control the amount or timing of resources that they devote to our clinical development programs. The investigators may not assign as great a priority to our clinical development programs or pursue them as diligently as we would if we were undertaking such programs directly. If outside collaborators fail to devote sufficient time and resources to our clinical development programs, or if their performance is substandard, the approval of anticipated NDAs, BLAs and other marketing applications, and our introduction of new drugs, if any, may be delayed which could impair our clinical development programs and would have a material adverse effect on our business, results of operations and financial condition. Our collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators also assist our competitors, our competitive position could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have only limited experience in regulatory affairs, and some of our drug candidates may be based on new technologies. These factors may affect our ability or the time we require to obtain necessary regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have only limited experience in filing and prosecuting the applications necessary to gain regulatory approvals for medical devices and drug candidates. Moreover, some of the drug candidates that are likely to result from our development programs may be based on new technologies that have not been extensively tested in humans. The regulatory requirements governing these types of drug candidates may be less well defined or more rigorous than for conventional products. As a result, we may experience a longer regulatory process in connection with obtaining regulatory approvals of any products that we develop, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Orphan drug designation may not ensure that we will enjoy market exclusivity in any jurisdiction. If any of our other competitors are able to obtain orphan drug exclusivity for any products that are competitive with our products, we may be precluded from selling or obtaining approval of our competing products by the applicable regulatory authorities for a significant period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the United States, the European Union and other countries, a drug may be designated as having orphan drug status, subject to certain conditions. There can be no assurance that a drug candidate that receives orphan drug designation will receive orphan drug marketing exclusivity and more than one drug can have orphan designation for the same indication. In addition, the orphan drug designation granted to pegunigalsidase alfa by the EMA does not affect Fabry disease treatments that preexist the approval of pegunigalsidase alfa, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign regulations regarding orphan drugs are similar to those in the United States but there are several differences. For example, the exclusivity period in the European Union is generally 10&#160;years. From time to time, we may apply to the FDA or any comparable foreign regulatory authority for orphan drug designation for any one or more of our drug candidates. Other than pegunigalsidase alfa which was granted orphan drug designation by the EMA, none of our drug candidates have been designated as an orphan drug and there is no guarantee that the FDA or any other regulatory authority will grant such designation in the future. In addition, neither </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">orphan drug designation nor orphan drug exclusivity prevents competitors from developing or marketing different drugs for the relevant indication. Even if we obtain orphan drug exclusivity for one or more indications for one of our drug candidates, we may not be able to maintain the exclusivity. For example, if a competitive product that is the same drug or biologic as one of our drug candidates is shown to be clinically superior to the drug candidate, any orphan drug exclusivity granted to the drug candidate will not block the approval of the competitive product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If any drug receives orphan drug exclusivity in any jurisdiction for the same indication of any of our drug candidates, we may be prevented from attaining a similar designation with respect to our drug candidate or from marketing the drug candidate in the jurisdiction during the applicable exclusivity period, which will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have a limited operating history which may limit the ability of investors to make an informed investment decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Taliglucerase alfa is our only commercial product. The successful commercialization of our other drug candidates will require us to perform a variety of functions, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">continuing to perform preclinical development and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">participating in regulatory approval processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">formulating and manufacturing products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">conducting sales and marketing activities.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our operations have been limited to organizing and staffing our company, acquiring, developing and securing our proprietary technology and undertaking, through third parties, preclinical trials and clinical trials of our principal drug candidates. These operations provide a limited basis for investors to assess our ability to commercialize our drug candidates and whether to invest in our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We currently depend heavily on the success of pegunigalsidase alfa. Any failure to commercialize pegunigalsidase alfa, or the experience of significant delays in doing so, will have a material adverse effect on our business, results of operations and financial condition.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are investing a significant portion of our efforts and financial resources in the development of pegunigalsidase alfa and our ability to generate significant product revenues in the future, will depend heavily on the successful development and commercialization of pegunigalsidase alfa. The successful commercialization of pegunigalsidase alfa will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">successful completion of our ongoing studies of pegunigalsidase alfa;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Chiesi&#8217;s efforts under the Chiesi Agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">identifying a path for resubmission to, and ultimately obtaining marketing approvals from, the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">obtaining marketing approvals from the EMA and other foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">maintaining the cGMP compliance of our manufacturing facility or establishing manufacturing arrangements with third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the successful inspection of our facilities by the FDA and other foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">raising additional capital, if necessary, in order to fund any additional clinical trials required in connection with the resubmission to the FDA or to continue to fund our operations in light of an extended regulatory pathway during which time period we cannot expect to receive additional milestone payments under the Chiesi Agreements;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Chiesi&#8217;s development of successful sales and marketing organizations for pegunigalsidase alfa;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the availability of reimbursement to patients from healthcare payors for pegunigalsidase alfa, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a continued acceptable safety and efficacy profile of pegunigalsidase alfa following approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">other risks described in these Risk Factors.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure to commercialize pegunigalsidase alfa or the experience of significant delays in doing so will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any failure by us to supply drug substance to Pfizer may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Amended Pfizer Agreement, we have agreed, for the first 10-year period after the execution of the agreement, to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. As part of that obligation, we agreed to substantial financial penalties in case we fail to comply with the supply commitments, or are delayed in doing so. The amounts of the penalties depend on when any such failure occurs and for how long it persists, if at all, and other considerations. Any failure to comply with the supply commitments under the Amended Pfizer Agreement may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our strategy, in certain cases, is to enter into collaboration agreements with third parties to leverage our ProCellEx system to develop product candidates. Failure to enter into such agreements, or non-compliance by us or our collaborators with such agreements, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our strategy, in certain cases, is to enter into arrangements with pharmaceutical companies to leverage our ProCellEx system to develop additional product candidates. Under these arrangements, we may grant to our partners rights to license and commercialize pharmaceutical products developed under the applicable agreements, as we have done with Elelyso and pegunigalsidase alfa, and more recently, with alidornase alfa. Our partners may control key decisions relating to the development of the products and we may depend on our partners&#8217; expertise and dedication of sufficient resources to develop and commercialize our product candidates. The rights of our partners limit our flexibility in considering alternatives for the commercialization of our product candidates. If we or any of our current or future partners breach or terminate the agreements that make up such arrangements, our partners otherwise fail to conduct their obligations under such arrangements in a timely manner, there is a dispute about their obligations or if either party terminates the applicable agreement or elects not to continue the arrangement, we may not enjoy the benefits of the agreements or receive a sufficient amount of royalty or milestone payments from them, if any, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are unable to develop and commercialize our product candidates, our business will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our strategy is to develop and commercialize a portfolio of new products in addition to taliglucerase alfa. We seek to do so through our internal research programs and strategic collaborations for the development of new products. Research programs to identify new product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a product candidate is not capable of being produced in commercial quantities at an acceptable cost, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a product candidate may not be accepted by patients, the medical community or third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">competitors may develop alternatives that render our product candidates obsolete;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the research methodology used may not be successful in identifying potential product candidates; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory approval.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure to develop or commercialize any of our other product candidates may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The manufacture of our products is an exacting and complex process, and any manufacturing problems encountered by us or certain of our suppliers may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA and foreign regulators require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance with cGMP or similar requirements that the FDA or foreign regulators establish. We or certain of our materials suppliers may face manufacturing or quality control problems causing product production and shipment delays or a situation where we or the supplier may not be able to maintain compliance with the FDA&#8217;s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing. To date, our current facility has passed audits by the FDA and a number of other regulatory authorities but remains subject to audit by other foreign regulatory authorities. There can be no assurance that we will be able to comply with FDA or foreign regulatory manufacturing requirements for our current facility or any facility we may establish in the future, and the failure to so comply will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on third parties for final processing of taliglucerase alfa, pegunigalsidase alfa and our other product candidates, which exposes us to a number of risks that may delay development, regulatory approval and commercialization of taliglucerase alfa and our other product candidates or result in higher product costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have no experience in the final filling and freeze drying steps of the drug manufacturing process. We rely on third parties in the United States and Europe to perform fill and finish activities for taliglucerase alfa and pegunigalsidase alfa, and have engaged other parties for our other product candidates. We may be unable to identify manufacturers and/or replacement manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA and other regulatory authorities, as applicable, must approve any manufacturer and/or replacement manufacturer, including us, and we or any such third party manufacturer might be unable to formulate and manufacture our drug products in the volume and of the quality required to meet our clinical and commercial needs. If we engage any contract manufacturers, such manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical or commercial needs. In addition, contract manufacturers are subject to the rules&#160;and regulations of the FDA and comparable foreign regulatory authorities and face the risk that any of those authorities may find that they are not in compliance with applicable regulations. Each of these risks, if realized, could delay our clinical trials, the approval, if any, of our potential drug candidates by the FDA and other regulatory authorities, or the commercialization of our drug candidates or could result in higher product costs or otherwise deprive us of potential product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Developments by competitors may render our products or technologies obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private research organizations. Our drug candidates will have to compete with existing therapies and therapies under development by our competitors. Our commercial opportunities may be reduced or eliminated if our competitors develop and market products that are less expensive, more effective or safer than our drug products. Other companies have drug candidates in various stages of preclinical or clinical development to treat diseases for which we are also seeking to develop drug products. Some of these potential competing drugs are further advanced in development than our drug candidates and may be commercialized earlier. See Business&#160;&#8211; Competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Most of our competitors, either alone or together with their collaborative partners, operate larger research and development programs, staff and facilities and have substantially greater financial resources than we do, as well as significantly greater experience in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">developing drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">undertaking preclinical testing and human clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">obtaining marketing approvals from the FDA and other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">formulating and manufacturing drugs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">launching, marketing and selling drugs.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These organizations also compete with us to attract qualified personnel, acquisitions and joint ventures candidates and for other collaborations. Activities of our competitors may impose unanticipated costs on our business or adversely affect the market for our drug products which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we in-license drug candidates, we may delay or otherwise adversely affect the development of our existing drug candidates, which may negatively impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to our own internally developed drug candidates, we proactively seek opportunities to in-license and advance other drug candidates that are strategic and have value-creating potential to take advantage of our development know-how and technology. In-licensing additional drug candidates may significantly increase our capital requirements, and place a strain on the time of our existing personnel, which may delay or otherwise adversely affect the development of our existing drug candidates or cause us to re-prioritize our drug pipeline if we do not have the necessary capital resources to develop all of our drug candidates, which may have a material adverse impact on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are unable to manage future growth successfully there could be a material adverse impact on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability on the part of our management to manage growth could delay the execution of our business plans or disrupt our operations. If we are unable to manage our growth effectively, we may not use our resources in an efficient manner, which may delay the development of our drug candidates and materially and adversely impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we acquire companies, products or technologies, we may face integration risks and costs associated with those acquisitions that could negatively impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If we are presented with appropriate opportunities, we may acquire or make investments in complementary companies, products or technologies. If we acquire companies or technologies, we will face risks, uncertainties and disruptions associated with the integration process, including difficulties in the integration of the operations of an acquired company, integration of acquired technology with our products, diversion of our management&#8217;s attention from other business concerns, the potential loss of key employees or customers of the acquired business and impairment charges if future acquisitions are not as successful as we originally anticipate. In addition, our operating results may suffer because of acquisition-related costs or amortization expenses or charges relating to acquired intangible assets. Any failure to successfully integrate other companies, products or technologies that we may acquire may have a material adverse effect on our business and results of operations. Furthermore, we may have to incur debt or issue equity securities to pay for any additional future acquisitions or investments, the issuance of which could be dilutive to our existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We depend upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are highly dependent upon the principal members of our management team, especially our President and Chief Executive Officer, Dror Bashan, as well as the Chairman of our Board of Directors, Zeev Bronfeld, our other directors, consultants and collaborating scientists. Many of these people have been involved with us for many years and have played integral roles in our progress, and we believe that they will continue to provide value to us. A loss of any of these personnel may have a material adverse effect on aspects of our business, clinical development and regulatory programs. We have employment agreements with Mr.&#160;Bashan and our other executive officers that may be terminated by us or the applicable officer at any time with varying notice periods of 60 to 180&#160;days. The loss of any of these persons&#8217; services may adversely affect our ability to develop and market our products and obtain necessary regulatory approvals. Further, we do not maintain key-man life insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also depend in part on the continued service of our key scientific personnel and our ability to identify, hire and retain additional personnel. We experience intense competition for qualified personnel, and the existence of non-competition agreements between prospective employees and their former employers may prevent us from hiring those individuals or subject us to suit from their former employers. While we attempt to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely to have greater resources and more experience than we have, making it difficult for us to compete successfully for key personnel.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our collaborations with outside scientists and consultants may be subject to restriction and change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We work with medical experts, biologists, chemists and other scientists at academic and other institutions, and consultants who assist us in our research, development, regulatory and commercial efforts, including the members of our scientific advisory board. These scientists and consultants have provided, and we expect that they will continue to provide, valuable advice regarding our programs. These scientists and consultants are not our employees, may have other commitments that would limit their future availability to us and typically will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, we will be unable to prevent them from establishing competing businesses or developing competing products. For example, if a key scientist acting as a principal investigator in any of our clinical trials identifies a potential product or compound that is more scientifically interesting to his or her professional or academic interests, his or her availability to remain involved in our clinical trials could be restricted or eliminated, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Under current U.S. and Israeli law, we may not be able to enforce employees&#8217; covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into non-competition agreements with substantially all of our employees. These agreements prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors for a limited period. Under current U.S. and Israeli law, we may be unable to enforce these agreements against most of our employees and it may be difficult for us to restrict our competitors from gaining the expertise our former employees gained while working for us. If we cannot enforce our employees&#8217; non-compete agreements, we may be unable to prevent our competitors from benefiting from the expertise of our former employees, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. While our assessment of our internal control over financial reporting resulted in our conclusion that as of December 31, 2020, our internal control over financial reporting was effective, we cannot predict the outcome of our testing or any subsequent testing by our auditor in future periods. Any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information and affect our reputation, which could have an adverse effect on the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management is required to assess the effectiveness of our internal controls and procedures and disclose changes in these controls on an annual basis. However, for as long as we are a non accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our internal computer systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Despite the implementation of security measures, our internal computer systems and those of our present and future contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. Although to our knowledge we have not experienced any material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. We have </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">a cybersecurity insurance policy to protect us from such risks. However, to the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability despite our insurance policy, and the further development and commercialization of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We could be subject to securities class action litigation.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Securities class action litigation is often brought against a company following a period of volatility or decline in the market price of its securities. As with pharmaceutical companies generally, our company has experienced significant stock price volatility in recent years. If we become subject to such litigation, we will face substantial costs and a diversion of management&#8217;s attention and resources, which could have a material adverse affect on our business, results of operation and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If product liability claims are brought against us, it may result in reduced demand for our products and product candidates or damages that exceed our insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The clinical testing, marketing and use of our products and product candidates exposes us to product liability claims if the use or misuse of those products or product candidates cause injury or disease, or results in adverse effects. Use of our products or product candidates, whether in clinical trials or post approval, could result in product liability claims. We presently carry clinical trial liability insurance with coverages of up to $10.0&#160;million per occurrence and $10.0&#160;million in the aggregate, an amount we consider reasonable and customary. However, this insurance coverage includes various deductibles, limitations and exclusions from coverage, and in any event might not fully cover any potential claims. We may need to obtain additional clinical trial liability coverage prior to initiating additional clinical trials. We expect to obtain product liability insurance coverage before commercialization of our product candidates; however, such insurance is expensive and insurance companies may not issue this type of insurance when we need it. We may not be able to obtain adequate insurance in the future at an acceptable cost. Any product liability claim, even one that was not in excess of our insurance coverage or one that is meritless and/or unsuccessful, may adversely affect our cash available for other purposes, such as research and development, which may have a material adverse effect on our business, results of operations and financial condition. Product liability claims, even if without merit, may result in reduced demand for our products, if approved, or result in adverse market reactions, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our products, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Increasing healthcare expenditures have been the subject of considerable public attention in the United States. Both private and government entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would result in changes in the U.S. healthcare system are continuously introduced or proposed in the U.S. Congress and in some state legislatures within the United States, including reductions in the pricing of prescription products and changes in the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products. Legislation and regulations that reduce reimbursement for our product candidates could adversely impact how much or under what circumstances healthcare providers will prescribe or administer our product candidates, if approved. This could materially and adversely impact our business by reducing our ability to generate revenue, raise capital, obtain additional collaborators and market our products, if approved. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact product sales, upon approval, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Governments outside the United States tend to impose strict price controls and reimbursement approval policies, which may adversely affect our prospects for generating revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In some countries, particularly European Union member states, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time (six to 12&#160;months or longer) after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries with respect to any product candidate that achieves regulatory approval, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. Any unavailability or limitation on the reimbursement of our products upon approval, if at all, or the determination of unsatisfactory reimbursement prices, may have a material adverse effect on our business, results of operations and financial condition. Further, if we achieve regulatory approval of any product, we must successfully negotiate product pricing for such product in individual countries. As a result, the pricing of our product candidates, if approved, in different countries may vary widely, thus creating the potential for third-party trade in our products in an attempt to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">exploit price differences between countries. This third-party trade of our products could undermine our sales in markets with higher prices which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our ability to utilize net operating loss carryforwards may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our net operating losses, or NOLs, as of December&#160;31, 2020, are equal to approximately $231.4&#160;million, of which approximately $30.9&#160;million may be restricted under Section&#160;382 of the Internal Revenue Code, or the IRC. IRC Section&#160;382 applies whenever a corporation with NOLs experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post-change&#160;year that may be offset by a pre-change NOL may not exceed the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate. Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, we considered all available evidence, including past operating results, the most recent projections for taxable income and prudent and feasible tax planning strategies. We reassess our valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly. Any ownership change (including as a result of conversion of our outstanding convertible notes into shares of our common stock), or any other limitation on our utilization of NOLs, could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our corporate structure may create U.S. federal income tax inefficiencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#160;Ltd. is our wholly-owned subsidiary and thus a controlled foreign corporation of our company for U.S. federal income tax purposes. This organizational structure may create inefficiencies, as certain types of income and investments of Protalix&#160;Ltd. that otherwise would not be currently taxable under general U.S. federal income tax principles may become taxable. These inefficiencies may require us to use more of our NOLs than we otherwise might and may result in a tax liability without a corresponding distribution from our subsidiary which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are a holding company with no operations of our own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a holding company with no operations of our own. Accordingly, our ability to conduct our operations, service any debt that we may incur in the future and pay dividends, if any, is dependent upon the earnings from the business conducted by Protalix&#160;Ltd. The distribution of those earnings or advances or other distributions of funds by our subsidiary to us, as well as our receipt of such funds, are contingent upon the earnings of Protalix&#160;Ltd. and are subject to various business considerations and U.S. and Israeli law. If Protalix&#160;Ltd. is unable to make sufficient distributions or advances to us, or if there are limitations on our ability to receive such distributions or advances, we may not have the cash resources necessary to conduct our corporate operations or service our debt which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to our Financial Condition and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Servicing our debt and settling conversion requests may require a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt. Furthermore, restrictive covenants governing our indebtedness may restrict our ability to raise additional capital.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We currently have outstanding $57.9&#160;million aggregate principal amount of our 2021 Notes which are secured with a perfected lien on all of our assets. Under the terms of the indenture governing the 2021 Notes, we are required to maintain a minimum cash balance of at least $7.5&#160;million. Our ability to make payments with respect to the 2021 Notes and to satisfy any other debt obligations depends on our future operating performance and our ability to generate significant cash flow in the future, which will be affected by prevailing economic conditions and financial, business, competitive, legislative and regulatory factors as well as other factors affecting our company and industry, many of which are beyond our control. If, when required, we are unable to comply with the terms of the 2021 Notes, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. In addition, certain terms of the 2021 regarding the security interest or future indebtedness may restrict us from adopting any of these alternatives. We may be unable to obtain amendments and waivers of such restrictions. If there is a default of such notes, the note holders could, among other things, elect to declare all amounts owed immediately due and payable, which could cause all or a large portion of our available cash flow to be used to pay such amounts and thereby reduce the amount of cash available to pursue our business plans or force us into bankruptcy or liquidation, or, with respect to our indebtedness that is secured, result in the foreclosure on the assets that secure the debt, which would force us to relinquish rights to assets that we may believe are critical to our business. Any default on our debt will have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our significant level of indebtedness could adversely affect our business, results of operations and financial condition and prevent us from fulfilling our obligations under our convertible notes and our other indebtedness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our 2021 Notes represent a significant amount of indebtedness with substantial debt service requirements. We may also incur additional indebtedness to meet future financing needs. Our substantial indebtedness could have material adverse effects on our business, results of operations and financial condition. For example, it could:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">make it more difficult for us to satisfy our financial obligations, including with respect to the convertible notes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">result in an event of default under our outstanding convertible notes if we fail to comply with the financial and other restrictive covenants contained in agreements governing any future indebtedness, which event of default could result in all of our debt becoming immediately due and payable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">increase our vulnerability to general adverse economic, industry and competitive conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">reduce the availability of our cash flow to fund working capital, capital expenditures, acquisitions and other general corporate purposes because we will be required to dedicate a substantial portion of our cash flow from operations to the payment of principal and interest on our indebtedness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">limit our flexibility in planning for, or reacting to, and increasing our vulnerability to changes in our business, the industry in which we operate and the general economy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">prevent us from raising funds necessary to purchase convertible notes surrendered to us by holders upon a fundamental change (as described in the indenture governing the notes), which failure would result in an event of default with respect to the convertible notes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">place us at a competitive disadvantage compared to our competitors that have less indebtedness or are less highly leveraged and that, therefore, may be able to take advantage of opportunities that our debt levels or leverage prevent us from exploiting; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">limit our ability to obtain additional financing.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Each of these factors may have a material and adverse effect on our business, results of operations and financial condition and our ability to meet our payment obligations under the convertible notes and our other indebtedness. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any conversion of our outstanding convertible notes into common stock will dilute the ownership interest of our existing stockholders, including holders who had previously converted their notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The conversion of some or all of our convertible notes into shares of our common stock will dilute the ownership interests of our existing stockholders. Any sales in the public market of our common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of our outstanding convertible notes may encourage short selling by market participants because the conversion of convertible notes could depress the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The fundamental change purchase feature of our outstanding convertible notes may delay or prevent an otherwise beneficial attempt to take over our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The terms of our outstanding convertible notes require us to offer to purchase the notes for cash in the event of a fundamental change. A non-stock takeover of our company may trigger the requirement that we purchase the notes. This feature may have the effect of delaying or preventing a takeover of our company that would otherwise be beneficial to our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may fail to meet the continued market capitalization-based listing requirement or other continued listing requirements of The NYSE American.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The stock market in general, and the market for pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that may have been unrelated or disproportionate to the operating performance of the listed companies. The trading price of our common stock has been volatile and has been subject to wide price fluctuations in response to various factors, many of which are beyond our control. The volatility of our stock price has from time to time in recent periods affected our market capitalization. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Adverse fluctuations in the price per share of our common stock or our market capitalization may result in our failure to meet the continued listing requirements of The NYSE American, which would require us to take steps to gain compliance with alternate listing standards or take remedial steps to bring us into compliance. A failure to maintain or regain compliance with applicable listing standards could adversely affect the liquidity of our common stock and could result in an event of default under the indenture governing our 2021 Notes, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We currently have no significant product revenues and need to raise additional capital to operate our business, which may not be available on favorable terms, or at all, and which will have a dilutive effect on our stockholders.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not generated significant revenues from product sales and only minimal revenues from research and development services and other fees, other than the milestone and other payments we have received in connection with our agreements with Pfizer and Chiesi. For the years ended December&#160;31, 2020, 2019 and 2018, we had net losses from continuing operations of $6.5&#160;million, $18.3&#160;million and $26.5&#160;million, respectively, and for the quarter ended March&#160;31, 2021, we had net losses from continuing operations of $5.5&#160;million, primarily as a result of expenses incurred through a combination of research and development activities and expenses supporting those activities, which includes share-based compensation expense. Drug development and commercialization is very capital intensive. We fund all of our operations and capital expenditures from the revenues we generate from licensing fees and grants, the net proceeds of equity and debt offerings and other sources. In addition, changes may occur that could consume our existing capital at a faster rate than projected, including, among others, the cost and timing of regulatory approvals, changes in the progress of our research and development efforts and the costs of protecting our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We will need to finance our future cash needs through corporate collaboration, licensing or similar arrangements, public or private equity offerings or debt financings. To the extent that the regulatory pathway for our lead product candidate, PRX-102, is delayed and we must conduct additional clinical trials in light of the FDA CRL in connection with a resubmission or otherwise, we may be required to seek to raise additional capital. If we are unable to secure additional financing in the future on acceptable terms, or at all, we may be unable to commence or complete planned preclinical and clinical trials or obtain approval of our drug candidates from the FDA and other regulatory authorities. In addition, we may be forced to reduce or discontinue product development or product licensing, reduce or forego sales and marketing efforts and other commercialization activities or forego attractive business opportunities in order to improve our liquidity and to enable us to continue operations which would have a material adverse effect on our business and results of operations. Furthermore, any additional source of financing will likely involve the issuance of our equity securities, which will have a dilutive effect on our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are not currently profitable and delays in achieving profitability, if at all, will have a material adverse effect on our business and results of operations and could negatively impact the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may incur losses for the foreseeable future. We expect to continue to incur significant operating expenditures, and we anticipate that our expenses will increase in the foreseeable future as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">continue to undertake preclinical development and clinical trials for our current and new drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seek regulatory approvals for our drug candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seek to in-license additional technologies.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also may continue to experience negative cash flow for the foreseeable future as we fund our operating losses and capital expenditures. As a result, we will need to generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability in the foreseeable future, if at all. Delays in achieving profitability, or subsequent failures to maintain profitability, will have a material adverse effect on our business and results of operations and could negatively impact the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Commercialization of Drug Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">There has been continued non-compliance with the terms and conditions of the Brazil Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We do not control and may not be able to effectively influence Fiocruz&#8217;s ability to distribute BioManguinhos alfataliglicerase in Brazil. Any failure by Fiocruz to comply with the purchase requirements of the Brazil Agreement, or any other material breach by Fiocruz of the agreement, may have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We face the risk of lower than anticipated purchases of BioManguinhos alfataliglicerase by the Brazilian MoH. In addition, we may fail to supply the intended amounts on time, if at all. We also cannot accurately predict the amount of revenues we will generate under the Brazil Agreement in future periods, if any. Any failure by the Brazilian MoH to purchase BioManguinhos alfataliglicerase, by us to supply BioManguinhos alfataliglicerase for purchase or by Fiocruz to distribute BioManguinhos alfataliglicerase in Brazil, or the experience of significant delays in any of the foregoing, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have limited experience in selling, marketing or distributing products and limited internal capability to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We currently have very limited sales, marketing or distribution capabilities and no experience in building a sales force and distribution capabilities. Under our arrangements with Pfizer, Chiesi and SarcoMed, we have out-licensed the marketing rights to Elelyso, pegunigalsidase alfa and alidornase alfa via inhalation, except that we retained the marketing rights to BioManguinhos alfataliglicerase in Brazil. We have not licensed the marketing or commercialization rights to any of our other product candidates to any party. The commercialization of a drug product requires that we commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution capabilities. Factors that may inhibit our efforts to commercialize our products directly and without strategic partners include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the inability of sales personnel to obtain access to an adequate numbers of physicians or to pursuance them to prescribe our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;&#160;and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may not be successful in recruiting or retaining the sales and marketing personnel necessary to sell BioManguinhos alfataliglicerase or any of our products upon approval, if at all, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may enter into distribution arrangements and marketing alliances for certain products and any failure to successfully identify and implement these arrangements on favorable terms, if at all, may impair our ability to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may need to establish a sales force to market one or more of our product candidates, if approved. We do not anticipate having the resources in the foreseeable future to develop global sales and marketing capabilities for all of the products we are developing. We may elect to pursue arrangements regarding the sales and marketing and distribution of one or more of our product candidates, and our future revenues may depend, in part, on our ability to enter into and maintain arrangements with other companies having sales, marketing and distribution capabilities and the ability of such companies to successfully market and sell any such products. Any failure to enter into such arrangements and marketing alliances on favorable terms, if at all, could delay or impair our ability to commercialize our product candidates and could increase our costs of commercialization. Any use of distribution arrangements and marketing alliances to commercialize our product candidates will subject us to a number of risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may be required to relinquish important rights to our products or product candidates;</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may not be able to control the amount and timing of resources that our distributors or collaborators may devote to the commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our distributors or collaborators may experience financial difficulties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our distributors or collaborators may not devote sufficient time to the marketing and sales of our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may need to enter into additional co-promotion arrangements with third parties where our own sales force is neither well situated nor large enough to achieve maximum penetration in the market. We may not be successful in entering into any co-promotion arrangements, and the terms of any co-promotion arrangements we enter into may not be favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If physicians, patients, third party payors and others in the medical community do not accept and use taliglucerase alfa, or any of our other product candidates, if approved, our ability to generate revenue from product sales will be materially impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Physicians and patients, and other healthcare providers, may not accept and use any of our products or any product candidates, if approved for marketing. Future acceptance and use of any of our products or any product candidates, if approved, will depend upon a number of factors including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">perceptions by physicians, patients, third party payors and others in the medical community about the safety and effectiveness of taliglucerase alfa or our other drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the prevalence and severity of any side effects, including any limitations or warnings contained in our products&#8217; approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">pharmacological benefits of taliglucerase alfa or our other drug candidates relative to competing products and products under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the efficacy and potential advantages relative to competing products and products under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">effectiveness of education, marketing and distribution efforts by us and our licensees and distributors, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">publicity concerning taliglucerase alfa or our other drug candidates or competing products and treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">coverage and reimbursement of our products by third party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the price for our products and competing products.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A lack of market acceptance of BioManguinhos alfataliglicerase in Brazil, or globally for any of our other products candidates, if approved, would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If the market opportunities for other product candidates, and for BioManguinhos alfataliglicerase in Brazil, are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, our development efforts have focused mainly on relatively rare disorders with small patient populations, in particular Gaucher disease and Fabry disease. Currently, most reported estimates of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas, which are then extrapolated to estimate the prevalence of the diseases in the broader world population. As new studies are performed, the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Gaucher disease or Fabry disease in the study populations, particularly in these newer studies, accurately reflect the prevalence of these diseases in the broader world population. If the market opportunities for our current product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Coverage and reimbursement may not be available for one or more of our product candidates, if approved, in all territories, which could diminish our sales or affect our ability to sell any such products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Market acceptance and sales of any one or more of our product candidates, if approved, will depend on coverage and reimbursement policies in the countries in which they are approved for sale. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. Obtaining reimbursement approval for an approved product from governments and other third party payors is a time consuming and costly process that requires our collaborators or us, as the case may be, to provide supporting scientific, clinical and cost-effectiveness data for the use of our products, if and when approved, to every payor. We may not be able to provide data sufficient to gain acceptance </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">with respect to coverage and reimbursement or we might need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of approved products, if any, to such payors&#8217; satisfaction. Such studies might require our collaborators or us to commit a significant amount of management time and financial and other resources. Even if a payor determines that an approved product is eligible for reimbursement, the payor may impose coverage limitations that preclude payment for some uses that are approved by the FDA or other regulatory authorities. In addition, full reimbursement may not be available for high priced products. Moreover, eligibility for coverage does not imply that any approved product will be reimbursed in all cases or at a rate that allows us to make a profit or even cover our costs. Limited reimbursement amounts may reduce the demand for, or the price of, our product candidates. If coverage and reimbursement are not available or are available only to limited levels, the sales of our products, if approved, may be diminished or we may not be able to sell such products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We and our collaborating partners may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All marketing activities associated with drug products that are approved for sale in the United States, if any, will be, directly or indirectly through our customers, subject to numerous federal and state laws governing the marketing and promotion of pharmaceutical products in the United States, including, without limitation, the federal Anti-Kickback Law, the federal False Claims Act and HIPAA. These laws may adversely impact, among other things, our proposed sales, marketing and education programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The federal Anti-Kickback Law prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of co-payments and deductibles, ownership interests and providing anything at less than its fair market value. Despite a series of narrow safe harbors, the federal Anti-Kickback Law prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal Anti-Kickback Law include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other state or federal healthcare programs. Many states have also adopted laws similar to the federal Anti-Kickback Law, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs, and do not contain identical safe harbors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The federal False Claims Act imposes liability on any person who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payer and not merely a federal healthcare program. Violations of the federal False Claims Act and the analogous state laws may result in substantial financial penalties, some as much as three times the actual damages sustained by the government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">HIPAA created several new federal crimes, including health care fraud, and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private third-party payers. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are unable to predict whether we could be subject to actions under any of these or other fraud and abuse laws, or the impact of such actions. Moreover, to the extent that taliglucerase alfa or any of our product candidates, if approved for marketing, will be sold in a foreign country, we and our future collaborators may be subject to similar foreign laws and regulations. If we or any of our future collaborators are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment or restructuring or our operations, any of which could have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Intellectual Property Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The intellectual property and assets owned by our subsidiaries are subject to security agreements that secure our payment and other obligations under our 2021 Notes, and our subsidiaries have guaranteed all of those obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the issuance of our 2021 Notes, we entered into security agreements pursuant to which our subsidiaries provided first priority security interests in all of their assets, which consist of all of our intellectual property and other material assets. The security agreements secure certain payment, indemnification and other obligations under the 2021 Notes. If we were to default on certain of our obligations, or in certain other circumstances generally related to a bankruptcy or insolvency, holders of our outstanding 2021 Notes&#160;could seek to foreclose on the collateral under the security agreements to obtain satisfaction of our obligations, and our business could be materially and adversely impacted, which would in turn have a material adverse effect on our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Furthermore, in connection with the issuance of the 2021 Notes, our subsidiaries guaranteed all of our obligations under the indenture governing such convertible notes. If we were to default on our obligations under the indenture, the holders could require our subsidiaries to satisfy all of those obligations under the guarantees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to adequately protect or enforce our intellectual property rights or secure rights to third party patents, the value of our intellectual property rights would diminish and our business, competitive position and results of operations would suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of March&#160;31, 2021, we had more than 35 pending patent applications of which two are joint pending patent applications with a third party. However, the filing of a patent application does not mean that we will be issued a patent, or that any patent eventually issued will be as broad as requested in the patent application or sufficient to protect our technology. Any modification required to a current patent application may delay the approval of such patent application which would have a material adverse effect on our business, results of operations and financial condition. In addition, there are a number of factors that could cause our patents, if granted, to become invalid or unenforceable or that could cause our patent applications to not be granted, including known or unknown prior art, deficiencies in the patent application or the lack of originality of the technology. Our competitive position and future revenues will depend in part on our ability and the ability of our licensors and collaborators to obtain and maintain patent protection for our products, methods, processes and other technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing the proprietary rights of third parties. We have filed U.S. and international patent applications for process patents, as well as composition of matter patents, for taliglucerase alfa and our product candidates. However, we cannot predict:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the degree and range of protection any patents will afford us against competitors and those who infringe upon our patents, including whether third parties will find ways to invalidate or otherwise circumvent our licensed patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">if and when patents will issue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether or not others will obtain patents claiming aspects similar to those covered by our licensed patents and patent applications; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether we will need to initiate litigation or administrative proceedings, which may be costly, whether we win or lose.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of March&#160;31, 2021, we held, or had license rights to, more than 90 patents. If patent rights covering our products or technologies are not sufficiently broad, they may not provide us with sufficient proprietary protection or competitive advantages against competitors with similar products and technologies. Furthermore, if the USPTO or foreign patent offices issue patents to us or our licensors, others may challenge the patents or circumvent the patents, or the patent office or the courts may invalidate the patents. Thus, any patents we own or license from or to third parties may not provide any protection against our competitors and those who infringe upon our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Furthermore, the life of our patents is limited. The patents we hold, and the patents that may be issued in the future based on patent applications from the patent families, relating to our ProCellEx protein expression system are expected to expire by 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on confidentiality agreements that could be breached and may be difficult to enforce which could have a material adverse effect on our business and competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our policy is to enter agreements relating to the non-disclosure of confidential information with third parties, including our contractors, consultants, advisors and research collaborators, as well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants while we employ them. However, these agreements can be difficult and costly to enforce. Moreover, to the extent that our contractors, consultants, advisors and research collaborators apply or independently develop intellectual property in connection with any of our projects, disputes may arise as to the proprietary rights to the intellectual property. If a dispute arises, a court may determine that the right belongs to a third party, and enforcement of our rights can be costly and unpredictable. In addition, we rely on trade secrets and proprietary know-how that we seek to protect in part by confidentiality agreements with our employees, contractors, consultants, advisors and others. Despite the protective measures we employ, we still face the risk that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">these agreements may be breached;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">these agreements may not provide adequate remedies for the applicable type of breach; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our trade secrets or proprietary know-how will otherwise become known.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any breach of our confidentiality agreements or our failure to effectively enforce such agreements may have a material adverse effect on our business and competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we infringe the rights of third parties we could be prevented from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs and may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have not received to date any claims of infringement by any third parties. However, as our drug candidates progress into clinical trials and commercialization, if at all, our public profile and that of our drug candidates may be raised and generate such claims. Defending against such claims, and occurrence of a judgment adverse to us, could result in unanticipated costs and may have a material adverse effect on our business and competitive position. If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we may incur substantial costs and we may have to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">obtain licenses, which may not be available on commercially reasonable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">redesign our products or processes to avoid infringement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">stop using the subject matter claimed in the patents held by others, which could cause us to lose the use of one or more of our drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial diversion of management resources; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">pay damages.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any costs incurred in connection with such events or the inability to sell our products may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we cannot meet requirements under our license agreements, we could lose the rights to our products, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We depend on licensing agreements with third parties to maintain the intellectual property rights to certain of our product candidates. Our license agreements require us to make payments and satisfy performance obligations in order to maintain our rights under these agreements. All of these agreements last either throughout the life of the patents that are the subject of the agreements, or with respect to other licensed technology, for a number of&#160;years after the first commercial sale of the relevant product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our license agreements in a timely manner, we could lose the rights to our proprietary technology which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Relating to our Operations in Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Potential political, economic and military instability in the State of Israel, where the majority of our senior management and our research and development facilities are located, may adversely affect our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our executive office and operations are located in the State of Israel. Accordingly, political, economic and military conditions in Israel directly affect our business. Since the State of Israel was established in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners, or a significant downturn in the economic or financial condition of Israel, could affect adversely our operations and product development. Although Israel has entered into various agreements with Egypt, Jordan and the Palestinian Authority, Israel periodically experiences an increase in unrest and terrorist activity. The establishment in 2006 of a government in the Gaza Strip by representatives of the Hamas militant group has created additional unrest and uncertainty in the region. Our facilities in northern Israel are in range of rockets that were fired from Lebanon into Israel during a 2006 war with the Hizbollah in Lebanon, and suffered minimal damages during one of the rocket attacks. Our insurance policies do not cover us for the damages incurred in connection with these conflicts or for any resulting disruption in our operations. The Israeli government, as a matter of law, provides coverage for the reinstatement value of direct damages that are caused by terrorist attacks or acts of war; however, the government may cease providing such coverage or the coverage might not be enough to cover potential damages. If our facilities are damaged as a result of hostile action, our operations may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There is currently a civil war in Syria, also bordering Israel, and Israel has been hit by rockets and mortars originating from Syria. The ultimate effect of these developments on the political and security situation in the Middle East and on Israel&#8217;s position within the region is not clear at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our operations may be disrupted by the obligations of our personnel to perform military service which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Many of our male employees in Israel, including members of senior management, are obligated to perform up to one&#160;month (in some cases more) of annual military reserve duty until they reach the age of 45 and, in the event of a military conflict, could be called to active duty. Our operations could be disrupted by the absence of a significant number of our employees related to military service or the absence for extended periods of military service of one or more of our key employees. A disruption may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Because a certain portion of our expenses is incurred in New Israeli Shekels, our results of operations may be seriously harmed by currency fluctuations and inflation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We report our financial statements in U.S.&#160;dollars, our functional currency. Although most of our expenses are incurred in U.S.&#160;dollars, we pay a portion of our expenses in New Israeli Shekels, or NIS, and as a result, we are exposed to risk to the extent that the inflation rate in Israel exceeds the rate of devaluation of the NIS in relation to the U.S.&#160;dollar or if the timing of these devaluations lags behind inflation in Israel. In that event, the U.S.&#160;dollar cost of our operations in Israel will increase and our U.S.&#160;dollar-measured results of operations will be adversely affected. To the extent that the value of the NIS increases against the U.S.&#160;dollar, our expenses on a dollar cost basis increase. Our operations also could be adversely affected if we are unable to guard against currency fluctuations in the future. To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The tax benefits available to us require that we meet several conditions and may be terminated or reduced in the future, which would increase our taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are able to take advantage of tax exemptions and reductions resulting from the &#8220;Approved Enterprise&#8221; status of our facilities in Israel. To remain eligible for these tax benefits, we must continue to meet certain conditions, including making specified investments in property and equipment, and financing at least 30% of such investments with share capital. If we fail to meet these conditions in the future, the tax benefits would be canceled and we may be required to refund any tax benefits we already have enjoyed. These tax benefits are subject to investment policy by the Investment Center and may not be continued in the future at their current levels or at </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">any level. In recent&#160;years the Israeli government has reduced the benefits available and has indicated that it may further reduce or eliminate some of these benefits in the future. The termination or reduction of these tax benefits or our inability to qualify for additional &#8220;Approved Enterprise&#8221; approvals may increase our tax expenses in the future, which would reduce our expected profits and adversely affect our business and results of operations. Additionally, if we increase our activities outside of Israel, for example, by future acquisitions, such increased activities generally may not be eligible for inclusion in Israeli tax benefit programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The Israeli government grants we have received for certain research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel and require us to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received together with interest and penalties which could have a material adverse effect on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our research and development efforts have been financed, in part, through grants that we have received from NATI. We, therefore, must comply with the requirements of the Research Law. Under the Research Law we are prohibited from manufacturing products developed using these grants outside of the State of Israel without special approvals, although the Research Law does enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased royalties. We may not receive the required approvals for any proposed transfer of manufacturing activities. Even if we do receive approval to manufacture products developed with government grants outside of Israel, we may be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside of Israel, as well as at a possibly increased royalty rate. This restriction may impair our ability to outsource manufacturing or engage in similar arrangements for those products or technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additionally, under the Research Law, Protalix&#160;Ltd. is prohibited from transferring NATI-financed technologies and related intellectual property rights outside of the State of Israel, except under limited circumstances and only with the approval of NATI Council or the Research Committee. Protalix&#160;Ltd. may not receive the required approvals for any proposed transfer and, if received, Protalix&#160;Ltd. may be required to pay NATI a portion of the consideration that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that Protalix&#160;Ltd. has already paid to NATI, the amount of time that has elapsed between the date on which the know-how was transferred and the date on which NATI grants were received and the sale price and the form of transaction will be taken into account in order to calculate the amount of the payment to NATI. Approval of the transfer of technology to residents of the State of Israel is required, and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer, if requested, will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These restrictions may impair our ability to sell our technology assets or to outsource manufacturing outside of Israel. The restrictions will continue to apply for a certain period of time even after we have repaid the full amount of royalties payable for the grants. For the years ended December&#160;31, 2018, 2019 and 2020, we recorded grants totaling $2.2&#160;million, $0.1&#160;million and $0.1&#160;million from NATI, respectively. The grants represent 6.2%, 0.2% and 0.2%, respectively, of our gross research and development expenditures for the&#160;years ended December&#160;31, 2018, 2019 and 2020. If we fail to satisfy the conditions of the Research Law, we may be required to refund certain grants previously received together with interest and penalties, and may become subject to criminal charges, any of which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Investors may have difficulties enforcing a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal securities laws against us, our executive officers and most of our directors or asserting U.S. securities laws claims in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Most of our directors and all of our executive officers are residents of Israel, and accordingly, most of their assets and our assets are located outside the United States. Service of process upon our non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us, some of our directors and executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel that investors may find it difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws against us, our officers and our directors. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against us or our officers and directors because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Israeli courts might not enforce judgments rendered outside Israel which may make it difficult to collect on judgments rendered against us. Subject to certain time limitations, an Israeli court may declare a foreign civil judgment enforceable only if it finds that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the judgment may no longer be appealed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the obligation imposed by the judgment is enforceable according to the rules&#160;relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the judgment is executory in the state in which it was given.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Even if these conditions are satisfied, an Israeli court will not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel. An Israeli court also will not declare a foreign judgment enforceable if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the judgment was obtained by fraud;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">there is a finding of lack of due process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the judgment was rendered by a court not competent to render it according to the laws of private international law in Israel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the judgment is at variance with another judgment that was given in the same matter between the same parties and that is still valid; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">at the time the action was brought in the foreign court, a suit in the same matter and between the same parties was pending before a court or tribunal in Israel.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Investing in our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The market price of our common stock may fluctuate significantly.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">The market price of our common stock has experienced significant volatility as a result of the recent announcement relating to the receipt of the CRL from the FDA regarding the BLA for PRX-102. The securities of life sciences companies often experience significant volatility in connection with clinical trial and regulatory announcements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We anticipate that the market price of our common stock is likely to continue to fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our sale of shares of our common stock under our ATM program, or market expectations that such sales are to be executed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing of and any delays in anticipated marketing approvals for pegunigalsidase alfa;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the progress and results of our ongoing studies regarding pegunigalsidase alfa and our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">announcements regarding partnerships or collaborations by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">restatements of historical financial results and changes in financial forecasts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">purchases of BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">developments concerning intellectual property rights and regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the announcement of new products or product enhancements by us or our competitors;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">variations in our and our competitors&#8217; results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">changes in earnings estimates or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">developments in the biotechnology industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">general market conditions and other factors, including factors unrelated to our operating performance.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Price volatility of our common stock may be worse when the trading volume of our common stock is low. We have not paid, and do not expect to pay, any cash dividends on our common stock as any earnings generated from future operations will be used to finance our operations. As a result, investors will not realize any income from an investment in our common stock until and unless their shares are sold at a profit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Future sales of our common stock could reduce our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If our stockholders sell substantial amounts of our common stock, including shares of our common stock issuable upon conversion of our outstanding convertible notes or warrants, or if we sell a substantial amount of our common stock under our ATM program, the market price of our common stock could decrease significantly. The perception in the public market that our existing stockholders might sell shares of common stock could also depress the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A substantial majority of our outstanding shares of our common stock are freely tradable without restriction or further registration under the federal securities laws. In addition, we may sell additional shares of our common stock in the future to raise capital. A substantial number of shares of our common stock are reserved for issuance upon the exercise of stock options, upon conversion of our outstanding convertible notes and upon the exercise of our outstanding warrants. At March&#160;31, 2021, there were outstanding options to purchase common stock issued covering approximately 2.6&#160;million shares of our common stock with a weighted average exercise price of approximately $5.30 per share. Also at March&#160;31, 2021, there were approximately 1.5&#160;million shares of common stock available for future for issuance in connection with future grants of incentives under our amended 2006 stock incentive plan, approximately 6.8&#160;million shares of common stock reserved for issuance upon conversion of our outstanding 2021 Notes and approximately 17.4&#160;million shares of common stock reserved for issuance upon the exercise of our outstanding warrants. The issuance and sale of substantial amounts of common stock, or the perception that such issuances and sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If securities analysts stop publishing research or reports about us or our business or if they downgrade our common stock, the market price of our common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. We do not control these analysts. If any analyst who covers us downgrades our stock or lowers its future stock price targets or estimates of our operating results, the market price for our common stock could decline rapidly. Furthermore, if any analyst ceases to cover us, we could lose visibility in the market, which in turn could cause the market price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our common stock is listed to trade on more than one stock exchange, and this may result in price variations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our common stock is listed for trade on both the NYSE American and the TASE. Dual-listing may result in price variations between the exchanges due to a number of factors. First, our common stock is traded in U.S.&#160;dollars on the NYSE American and in NIS on the TASE. In addition, the exchanges are open for trade at different times of the day and on different&#160;days. For example, the TASE opens generally during Israeli business hours, Sunday through Thursday, while the NYSE American opens generally during U.S.&#160;business hours, Monday through Friday. The two exchanges also have differing vacation schedules. Differences in the trading schedules, as well as volatility in the exchange rate of the two currencies, among other factors, may result different trading prices for our common stock on the two exchanges. Other external influences may have different effects on the trading price of our common stock on the two exchanges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses, divert management&#8217;s attention from operating our business which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The laws, rules, regulations and standards including the rules&#160;promulgated by the national securities exchanges, including the NYSE American, to which we are subject are changed and/or amended from time to time. New or changed laws, rules, regulations and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">standards are subject to varying interpretations in many cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving laws, rules, regulations and standards are likely to continue to result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. Members of our Board of Directors and our executive officers, could face an increased risk of personal liability in connection with the performance of their duties. As a result, we may have difficulty attracting and retaining qualified directors and executive officers, which could have a material adverse effect on our business. If our efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies, we may incur additional expenses to comply with standards set by regulatory authorities or governing bodies which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The issuance of preferred stock or additional shares of common stock could adversely affect the rights of our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our Board of Directors is authorized to issue up to 100,000,000 shares of preferred stock without any further action on the part of our stockholders. Our Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Currently, we have no shares of preferred stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 0pt 0pt;">Our Board of Directors may, at any time, authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, before the redemption of our common stock, which may have a material adverse effect on the rights of the holders of our common stock. In addition, our Board of Directors, without further stockholder approval, may, at any time, issue large blocks of preferred stock. In addition, the ability of our Board of Directors to issue shares of preferred stock without any further action on the part of our stockholders may impede a takeover of our company and may prevent a transaction that is favorable to our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.29;margin:0pt 18pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><a id="_c4ee5777_5ee1_44ef_903b_6030b4581d6f"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d17c84f5_5727_47c7_8452_b29515118868"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2d456c5a_a7fd_46df_a750_cc3e80c32bc1"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2b3c9b7b_27b0_4fcf_ba46_8f300cf55bee"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_aee0a7ba_9067_4123_8fd2_ca1698542605"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Indenture, dated as of December&#160;7, 2016, between Protalix BioTherapeutics, Inc. the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Financing)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Exchange)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First Supplemental Indenture, dated as of July</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">24, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee, and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;25, 2017</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Supplemental Indenture, dated as of November&#160;27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">December&#160;1, 2017</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032540/tm205240d1_ex4-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.7</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.9&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.8</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.10</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.9</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Agreement between Protalix&#160;Ltd. and Comercio e Servi&#231;os Ltda. dated June&#160;17, 2013</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.2&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Technology Transfer and Supply Agreement made as of June&#160;18, 2013 by and between Protalix&#160;Ltd. and Funda&#231;&#227;o Oswaldo Cruz</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.3&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210331xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Binding Term Sheet between Protalix Ltd. and Chiesi Farmaceutici S.p.A.</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210331xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="background-color:#ffffff;color:#333333;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#8224;&#160;&#160;&#160;Portions of this exhibit were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment under Rule&#160;24b-2 of the Exchange Act.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_287f7ed5_356c_472c_a7fb_ae937e0f9244"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;14, 2021</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;14, 2021</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>plx-20210331xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/14/2021 11:03:29 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Execution Version</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">[***] Represents material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:56.1pt;margin:0pt;">This Agreement is made and entered into on this <u style="text-decoration:underline;text-decoration-color:#000000;"> 17</u> day of June, 2013</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:56.1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Between</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PROTALIX LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">a company duly incorporated under the laws of Israel of 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 20100, Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<b style="font-weight:bold;">&#8220;Protalix&#8221;</b>)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ATME Comercio e Servi&#231;os Ltda</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">a company duly incorporated under the laws of Brazil</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">of Alameda Tocantis, 75, room 1110, Alphaville, Barueri CEP 06455-020, Sao Paulo, Brazil</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<b style="font-weight:bold;">&#8220;ATME&#8221;</b>)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:92.4pt;text-align:justify;text-indent:-92.4pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:24.75pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WHEREAS:</p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Protalix and ATME entered into that certain May 2012 Agreement (the &#8220;<b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Original Agreement</b>&#8221;) and this Agreement amends and restates in its entirety the Original Agreement.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:92.4pt;text-align:justify;text-indent:-92.4pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:37.1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WHEREAS</b>:</p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Protalix is engaged,<i style="font-style:italic;"> inter alia</i>, in the development, manufacture, marketing, distribution and sale, both on its own and together with Pfizer, Inc. (&#8220;<b style="font-weight:bold;">Pfizer</b>&#8221;), of a proprietary enzyme replacement therapy product for the treatment of Gaucher Disease based on taliglucerase alfa (the &#8220;<b style="font-weight:bold;">Product</b>&#8221;); and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:92.4pt;text-align:justify;text-indent:-92.4pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:61.9pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WHEREAS</b></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Protalix and Pfizer entered into that certain Exclusive License and Supply Agreement, dated November 30, 2009 (the &#8220;<b style="font-weight:bold;">Original Pfizer Agreement</b>&#8221;), which is expected by Pfizer and Protalix to be amended by letter in 2013 to provide Protalix exclusive rights to commercialize the Product in the Territory (the &#8220;<b style="font-weight:bold;">Pfizer Amendment</b>&#8221;, and the Original Pfizer Agreement, as amended by the Pfizer Amendment, the &#8220;<b style="font-weight:bold;">Pfizer Agreement</b>&#8221;); and</p></td></tr><tr style="height:37.1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">&#160;</b>&#160;</p></td><td style="vertical-align:top;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WHEREAS</b>:</p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Protalix is interested in penetrating the market for the Product(s) in Brazil (the &#8220;<b style="font-weight:bold;">Territory</b>&#8221;) by way of sales of the Product(s) in the Territory and/or entering into a definitive transfer of technology and supply agreement with a manufacturer in, and for, the Territory; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:92.4pt;text-align:justify;text-indent:-92.4pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:24.75pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WHEREAS</b>:</p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ATME has the requisite knowledge, experience and expertise to assist Protalix in achieving its objectives for the Product(s) in the Brazilian market; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:92.4pt;text-align:justify;text-indent:-92.4pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:74.25pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WHEREAS</b>:</p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At Protalix&#8217;s request and in furtherance of its aims, and based on the parties&#8217; understanding regarding mutually agreeable compensation of ATME if a successful transaction with respect to the Brazilian market were consummated, ATME applied such knowledge, experience and expertise to assist Protalix in its efforts to enter into a definitive agreement to supply the Product(s) to Fundacao Oswaldo Cruz, an agency of the Federal Brazilian Ministry of Health (&#8220;<b style="font-weight:bold;">Fiocruz</b>&#8221;) for distribution and sale in the Brazilian market; and</p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 0pt 36pt;">-1-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:86.6pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WHEREAS</b>:</p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Such assistance from ATME has contributed to the success of such efforts by Protalix which is expected to result in the execution of a definitive Technology Transfer and Supply Agreement in 2013 by and between Protalix and Fiocruz (the &#8220;<b style="font-weight:bold;">2013 Contract</b>&#8221;) and, together with all other agreements with FIOCRUZ that contain substantially the same economics of the 2013 Contract, (the &#8220;<b style="font-weight:bold;">Other Contract/s</b>&#8221;) if any, entered into between Protalix and Fiocruz, within [***] years from the date of the 2013 Contract, for the transfer of technology with respect to, and the supply of, Product(s) to Fiocruz for distribution and sale in the Brazilian market, the &#8220;<b style="font-weight:bold;">Contracts</b>&#8221;); and</p></td></tr><tr style="height:49.5pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WHEREAS</b>:</p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The parties wish to confirm their understanding regarding the compensation by Protalix of ATME in consideration of such assistance and such contribution by ATME to Protalix&#8217;s efforts and success in entering into, and the substantial economic benefits which may be realized by Protalix pursuant to, the Contracts (such assistance and contribution being sometimes referred to as the &#8220;<b style="font-weight:bold;">Services</b>&#8221;).</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:92.4pt;text-align:justify;text-indent:-92.4pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 24.2pt;"><b style="font-weight:bold;">NOW THEREFORE, it is agreed between the parties hereto that the Original Agreement is hereby amended and restated in its entirety to read as follows:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 24.2pt;"><b style="font-weight:bold;">&#160;</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:42%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.</p></td><td style="vertical-align:top;width:87.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Fees</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:46.2pt;text-align:justify;text-indent:-46.2pt;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:170.55pt;"><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.1.</p></td><td colspan="2" style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Upon the terms and subject to the conditions set forth herein, and in reliance on ATME&#8217;s representations and warranties contained herein and in the Certification attached hereto as Exhibit A (the &#8220;<b style="font-weight:bold;">Certification</b>&#8221;), Protalix hereby agrees to pay ATME five percent (5%) of its Proceeds under the 2013 Contract and four percent (4%) of its Proceeds under the Other Contract/s (collectively, the &#8220;<b style="font-weight:bold;">Fees</b>&#8221;). For purposes of this Section, &#8220;<b style="font-weight:bold;">Proceeds</b>&#8221; shall mean the revenue for supply of Product(s) actually collected and recognized by Protalix from Fiocruz pursuant to the applicable Contract in accordance with US GAAP or any other accounting practice adopted by Protalix from time to time, after deduction of any commissions or royalties payable to third parties in respect to any activities under the applicable Contract and any amounts refunded for Product returns. For the avoidance of doubt, no (i) amounts paid to Protalix in reimbursement of expenses or for technical services performed pursuant to the applicable Contract; (ii) revenue collected or recognized by Protalix for Product supplied (or agreed to be supplied) at cost and not pursuant to Section 7 of the 2013 Contract (or any similar provision of any other Contract); or (iii) revenue collected or recognized by Protalix for Product supplied (or agreed to be supplied) prior to the date of this Agreement, shall be included in the definition of &#8220;<b style="font-weight:bold;">Proceeds</b>&#8221; under this Agreement. Notwithstanding the foregoing, in the event of a material change in the economic terms of the applicable Contract, the Parties will negotiate in good faith to adjust the Fees to reflect such change in economic terms.</p></td></tr><tr style="height:67.95pt;"><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.2.</p></td><td colspan="2" style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Fees constitute the sole and entire consideration and compensation which ATME is entitled to receive for the Services (and, except to the extent expressly agreed in writing by Protalix and ATME, any other services provided to Protalix by ATME, or any employee or principal thereof, to the extent related to the Product(s) in the Territory). Protalix shall not be required to reimburse ATME for any costs or expenses incurred by ATME in connection with this Agreement, the Services or otherwise, all of which shall be ATME&#8217;s sole responsibility.</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p></td><td colspan="2" style="vertical-align:top;width:47.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Terms of Payment</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:37.1pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.1.</p></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Payment of Fees, if any shall have become payable, shall be made within [***] after Protalix receipt of any payment from FIOCRUZ with respect to Proceeds. Protalix shall provide ATME with a quarterly report which shall set forth the amount of Proceeds in respect of the preceding quarter.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:46.2pt;text-align:justify;text-indent:-46.2pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:24.75pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.2.</p></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Fees shall be paid in the same currency as the Proceeds and shall be inclusive of all sales and other taxes and fees, which shall be borne by ATME.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:74.25pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.3.</p></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If Protalix is required by applicable law to make any tax deduction, tax withholding or similar payment or withholding from any amount paid or payable by Protalix hereunder, including but not limited to on account of income tax, tax on profit or any other taxes or fees imposed on ATME (&#8220;<b style="font-weight:bold;">Withholding Tax</b>&#8221;), then Protalix shall notify ATME of this requirement and shall deduct the Withholding Tax from the payments referred to above, as prescribed by applicable law and shall not be required to &#8220;gross-up&#8221; or otherwise increase any such payments to accommodate for such Withholding Tax.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 0pt 36pt;">-2-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:46.2pt;text-align:justify;text-indent:-46.2pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:41.4pt;"><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.4.</p></td><td colspan="2" style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Notwithstanding anything to the contrary herein, Protalix shall be obligated to pay the Fees only (i) after ATME has obtained and secured all consents, permits, licenses and approvals, if any, required in connection with the execution, delivery, performance, validity and enforceability of this Agreement, and provided copies thereof to Protalix, [***].</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:45.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.</p></td><td colspan="2" style="vertical-align:top;width:45.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Termination</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:19.8pt;text-align:justify;text-indent:-19.8pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:61.9pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td style="vertical-align:top;width:91.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Agreement (i) shall automatically terminate (with respect to the applicable Contract, or as a whole if in relation to all existing Contracts) upon the termination of the applicable Contract for any reason and (ii) may be terminated by Protalix by notice to ATME if the representation or warranty of ATME in Section 7.2.3, 7.2.4 or 7.2.5 shall have been or be inaccurate in any material respect or ATME shall have failed to perform or comply in any material respect with any covenant of ATME contained herein</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:19.8pt;text-align:justify;text-indent:-19.8pt;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:61.9pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(b)</p></td><td style="vertical-align:top;width:91.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Without limiting the generality of paragraph 3(a) and for the avoidance of doubt, Protalix may terminate this Agreement, effective immediately upon notice by Protalix to ATME, if (i) Protalix determines, based on information from sources it reasonably believes are credible, that any representation, warranty or other statement contained in the Certification is inaccurate in any material respect or (ii) ATME shall have failed to perform or comply in any material respect with any covenant or agreement of ATME set forth in the Certification.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:19.8pt;text-align:justify;text-indent:-19.8pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:74.25pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(c)</p></td><td style="vertical-align:top;width:91.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Upon termination of this Agreement in accordance with its terms, all rights and duties of the parties hereunder shall cease, except that (i) ATME shall be entitled to payment of Fees in accordance with the provisions of Section 3 above to the extent such Fees became payable prior to the effective date of termination and provided such termination was not pursuant to clause (ii) of paragraph (a) or pursuant to paragraph (b) of this Section 3, (ii) the provisions of Section 4 below shall survive any such termination and (iii) such termination shall not relieve a party from liability for breach prior to such termination of any representation, warranty, covenant or agreement set forth herein.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.8pt;text-align:justify;text-indent:-30.8pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:53.24%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.</p></td><td style="vertical-align:top;width:89.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Confidentiality</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">ATME acknowledges that proprietary and/or confidential information of Protalix and/or Pfizer and/or relating to the Product(s), this Agreement and/or any Contract (including, without limitation, information relating to the business, operations, research and development activities, products, technology or other intellectual property of Protalix or Pfizer) may have been obtained by or disclosed to ATME in the course of, for the purpose of, or otherwise in connection with, the performance (or anticipated performance) of, the Services, whether orally, in writing, electronically or in any other form, and whether obtained or disclosed prior to or during the Term (collectively, the &#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">ATME agrees to keep the Confidential Information and the terms of this Agreement and the Contracts in strict confidence and ATME shall not, without the prior written consent of Protalix, disclose such information to any third party. Upon the termination of this Agreement for any reason or upon request by Protalix, ATME shall promptly return to Protalix (or, at Protalix&#8217;s option, destroy) any and all Confidential Information and any and all manifestations and copies of the Confidential Information in the possession or control of ATME. The provisions of this Section 4 shall survive any expiration or termination of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.8pt;text-align:justify;text-indent:-30.8pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:57.09%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.</p></td><td style="vertical-align:top;width:90.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Independent Contractor</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">ATME has been, is and shall remain at all times an independent contractor for all purposes (including, but not limited to employee benefits, unemployment benefits, income tax withholding, health and other insurance), and is not, and shall not represent itself as, the agent, partner, officer or employee of Protalix. The Parties acknowledge and agree that ATME has assisted Protalix only in relation to the Contracts and has not been appointed an agent of Protalix, as defined under the Brazilian Agency Law or any other applicable law, and, therefore, is not entitled to any benefits, payments, protections or indemnities established by any such laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">For the removal of doubt, ATME has had, currently has, and shall have, no authority to bind or commit Protalix by or to any contract or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 0pt 36pt;">-3-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:53.49%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.</p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Costs and Expenses</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">Each party shall bear all of its own costs and expenses incurred both directly or indirectly as a result of performing its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:82.66%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.</p></td><td style="vertical-align:top;width:93.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Additional Representations, Warranties and Covenants of ATME</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:46.2pt;text-align:justify;text-indent:-46.2pt;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:65.25pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.1.</p></td><td colspan="2" style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ATME acknowledges that it has been advised that Protalix is a party to the Pfizer Agreement which addresses,<i style="font-style:italic;"> inter alia,</i> &#160;Protalix&#8217;s rights to register, manufacture, market, distribute and sell the Product in the Territory, and that it is subject to certain restrictions thereunder. ATME hereby represents and warrants to Protalix, and covenants with Protalix, that it shall not have any claim against Protalix, of any nature, in respect of the exercise, by Pfizer, of its rights under the Pfizer Agreement, regardless of whether ATME was previously informed of such rights or not;</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.</p></td><td style="vertical-align:top;width:82.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ATME hereby further represents and warrants to Protalix, and covenants with Protalix, that</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:61.6pt;text-align:justify;text-indent:-61.6pt;margin:0pt 0pt 0pt 78.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.1.</p></td><td style="vertical-align:top;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">it does not have any pre-existing obligations that are inconsistent with this Agreement;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:61.6pt;text-align:justify;text-indent:-61.6pt;margin:0pt 0pt 0pt 78.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:76.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:40.5pt;"><td style="vertical-align:top;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.2.</p></td><td colspan="2" style="vertical-align:top;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">so long as ATME remains entitled to receive Fees hereunder, it shall not render services to any other person or entity to facilitate, directly or indirectly, the promotion, marketing or sale in Brazil of any product for the treatment of Gaucher Disease or any other Product covered under any Contract.</p></td></tr><tr style="height:121.95pt;"><td style="vertical-align:top;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.3.</p></td><td colspan="2" style="vertical-align:top;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">in its performance of the Services and otherwise in connection with its activities, communications and other conduct relating, directly or indirectly, to any Contract or this Agreement, it has complied, and shall comply, with all, and has not taken and shall not take any action that would cause Protalix to violate any, (i) applicable laws and regulations, &#160;including the U.S. Foreign Corrupt Practices Act of 1977 (the &#8220;<b style="font-weight:bold;">FCPA</b>&#8221;), including but not limited to acquiring and maintaining any consents, permits, licenses and approvals and fulfilling any reporting requirements which may be applicable to the Services or this Agreement, in the Territory, and (ii) of Pfizer&#8217;s Anti-Bribery and Anti-Corruption Principles set forth on Appendix 10.1(t) of the Pfizer Agreement, a copy of which is attached hereto as Exhibit B (for this purpose substituting throughout such document &#8220;Protalix&#8221; for &#8220;Pfizer&#8221; in each place that the word &#8220;Pfizer&#8221; appears (the &#8220;<b style="font-weight:bold;">Principles</b>&#8221;));</p></td></tr><tr style="height:37.1pt;"><td style="vertical-align:top;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.4.</p></td><td colspan="2" style="vertical-align:top;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">the representations, warranties and other statements contained in the Certification are true and correct, and ATME has performed and complied, and will perform and comply, with the covenants and agreements of ATME set forth therein.</p></td></tr><tr style="height:129.6pt;"><td style="vertical-align:top;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.5.</p></td><td colspan="2" style="vertical-align:top;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">it has not employed or utilized as a subcontractor or otherwise, does not currently employ or utilize as a subcontractor or otherwise, and will not employ or utilize as a subcontractor or otherwise, any person that has been debarred or has otherwise been disqualified or suspended from performing scientific or clinical investigations or otherwise subjected to any restrictions or sanctions by the ANVISA or any other Governmental Authority or professional body with respect to the performance of scientific or clinical investigations, or any person finally convicted of a criminal offense, with no existing rights to appeal such conviction, in relation to: (i) the development or approval (including the process for development or approval) of an abbreviated drug application; (ii) the development or approval of any drug product or otherwise relating to the regulation of any drug product; or (iii) bribery payment of illegal gratuities, fraud, perjury, racketeering, blackmail, extortion, falsification or destruction of records or interference with, obstructions of an investigation into a prosecution of any criminal offense; and</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.6.</p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:61.6pt;text-align:justify;text-indent:-61.6pt;margin:0pt 0pt 0pt 78.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:76.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:49.5pt;"><td colspan="2" style="vertical-align:top;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.7.</p></td><td colspan="2" style="vertical-align:top;width:76.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Protalix will allow ATME or independent accounting firm or law firm designated by Protalix, periodic, but not less than annually, access to Protalix&#8217;s relevant books and records for the purpose of confirming the accuracy of the quarterly reports provided by Protalix to ATME hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 0pt 36pt;">-4-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:31.5pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.3.</p></td><td colspan="3" style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ATME shall provide Protalix with an updated executed copy of the Certification annually for five (5) years after the execution of the 2013 Contract.</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.4.</p></td><td colspan="2" style="vertical-align:top;width:34.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.8pt;text-align:justify;text-indent:-30.8pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80.52%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.</p></td><td style="vertical-align:top;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Pfizer Indemnification Agreement; Indemnification of Protalix</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:46.2pt;text-align:justify;text-indent:-46.2pt;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:86.6pt;"><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.1.</p></td><td colspan="2" style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ATME hereby agrees that neither ATME nor [***] and/or any of their affiliates, principals, officers, directors, employees, owners, family members, agents, contractors, or consultants, whether such persons are acting independently or as agents of [***] and/or ATME (each such person or entity, together with [***] and/or ATME, an &#8220;<b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ATME Person</b>&#8221;) will assert any claims against Pfizer for which Protalix has indemnified Pfizer pursuant to Protalix&#39;s agreement to indemnify Pfizer against any claims asserted by any ATME Person and certain other claims relating to Protalix&#39;s relationship and interactions with ATME (the &#8220;<b style="font-weight:bold;">Pfizer Indemnification</b>&#8221;).</p></td></tr><tr style="height:148.05pt;"><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.2.</p></td><td colspan="2" style="vertical-align:top;width:87.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ATME shall indemnify, defend and hold Protalix and its affiliates, and their respective directors, officers, shareholders, representatives, agents, successors, assigns, licensors and employees harmless from and against all liability, claims, losses, damages, causes of actions, and costs and expenses (including reasonable attorney&#8217;s fees) resulting from or arising out of (a) any acts or omissions of ATME in connection with ATME&#8217;s performance of the Services, (b) the inaccuracy or breach of any representation, warranty, covenant or agreement made by ATME in this Agreement or in the Certification or the Principles, (c) any acts or omissions of ATME or of any principal, owner, affiliate, officer, director, employee, contractor, consultant or agent of ATME that are inconsistent with ATME&#39;s agreement not to assert claims against Pfizer set forth in Section 8.1 above, (d) any inquiry, investigation, litigation or proceeding by a governmental authority or third party regarding any ATME Person in connection with the commercialization of the Product in Brazil by Protalix, any Contract, or any other actions of an ATME Person on behalf of Protalix, or (e) any amounts Protalix is required to pay to Pfizer under the Pfizer Indemnification. The provisions of this Section 8 shall survive any termination of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.</p></td><td colspan="2" style="vertical-align:top;width:39.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Notices</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">Except as otherwise provided in this Agreement, all notices permitted or required by this Agreement shall be in writing and shall be deemed to have been duly served (i) if personally delivered, when actually delivered; (ii) if sent by facsimile, upon transmission thereof (receipt of which has been orally confirmed by the recipient); or (iii) 7 (seven) business days after being mailed, postage prepaid, return receipt requested, if sent by registered mail and addressed to the address of the parties set out below or in accordance with such other address information as the party to receive notice may provide in writing to the other party in accordance with the above notice provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">If to Protalix:</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;"><b style="font-weight:bold;">Protalix Ltd.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">2 Snunit Street Science Park</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">P.O. Box 455</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">Carmiel 20100</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">Facsimile: + 972-4-988-8092</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">Attention: Dr David Aviezer CEO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 29.7pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 29.7pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">If to ATME</u>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 29.7pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 29.7pt;"><b style="font-weight:bold;">ATME Comercio e Servi&#231;os Ltda</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 29.7pt;">Alameda Tocantes, 75</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 29.7pt;">Alphaville, Barueri, CEP 06455-020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 29.7pt;">Sao Paulo Brazil</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 29.7pt;">Facsimile: +55.11-4195-6621</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 29.7pt;">Attention: Abraham Meizler</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 29.7pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 0pt 36pt;">-5-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:62%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.</p></td><td style="vertical-align:top;width:91.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Governing Law and Jurisdiction</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">This Agreement shall be governed by and construed in accordance with the laws of Israel, without giving effect to its principles of conflicts of law that direct that the laws of another jurisdiction apply and the parties hereto hereby submit to the exclusive jurisdiction of the competent courts in Tel-Aviv- Jaffa. Notwithstanding the foregoing, Protalix may apply to any court of competent jurisdiction in Brazil or any other applicable jurisdiction for injunctive or other equitable relief or to enforce any judgment obtained against ATME in connection with this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.8pt;text-align:justify;text-indent:-30.8pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:62.46%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.</p></td><td style="vertical-align:top;width:91.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Entire Agreement; Amendments</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">This Agreement constitutes the entire agreement between the parties hereto in respect of their Product-related collaboration in the Territory, and supersedes all prior agreements or understandings between the parties relating to the subject-matter hereof. This Agreement may only be amended by a written document signed by both of the parties to this Agreement. This Agreement shall be binding on and inure to the benefit of the parties hereto and their respective successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.8pt;text-align:justify;text-indent:-30.8pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:49.68%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.</p></td><td style="vertical-align:top;width:89.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Assignment</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">ATME is not entitled to assign or transfer this Agreement or any rights or obligations hereunder, without the prior written consent of Protalix which may be withheld in its sole and absolute discretion. Protalix shall have the right to assign its rights and obligations pursuant to this Agreement, in whole or in part, to Pfizer or any other party which may have an interest in the applicable Product; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that it provides written notice to ATME following such assignment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.8pt;text-align:justify;text-indent:-30.8pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:49.95%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.</p></td><td style="vertical-align:top;width:89.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Severability</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">The provisions of this Agreement are severable and, in the event that any court of competent jurisdiction determines that any one or more of the provisions or part of a provision contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.8pt;text-align:justify;text-indent:-30.8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:46.11%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">14.</p></td><td style="vertical-align:top;width:88.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Waivers</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">No waiver of any term of this Agreement shall be effective unless set forth in writing and duly executed by or on behalf of the party hereto waiving such term or condition. Neither the waiver of any term or condition of this Agreement, nor the failure to enforce or exercise any rights or remedies available under this Agreement, shall be deemed or construed to be a waiver of such term or condition for any similar instance in the future or of any subsequent breach of this Agreement. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.8pt;text-align:justify;text-indent:-30.8pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:46.8%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15.</p></td><td style="vertical-align:top;width:88.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Publicity</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">ATME shall not make any press release or public statement (written or oral) concerning the terms of, or events related to, this Agreement or any Contract, or concerning the Services, Protalix, Pfizer, or the Product(s), without the prior written consent of Protalix which may be withheld in its sole and absolute discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.8pt;text-align:justify;text-indent:-30.8pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:51.6%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.</p></td><td style="vertical-align:top;width:89.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Counterparts</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 30.8pt;">This Agreement may be executed in counterparts (including counterparts transmitted by facsimile), each of which shall be deemed to be an original, but which taken together shall be deemed to be an original and to constitute one and the same instrument .</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;font-weight:bold;">[Intentionally left blank]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;font-weight:bold;">&#160;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 0pt 36pt;">-6-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30.8pt;"><font style="font-style:italic;font-weight:bold;">IN WITNESS WHEREOF</font><i style="font-style:italic;">, the parties hereto have caused this Agreement to be duly executed as of the date first aforementioned.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30.8pt;"><i style="font-style:italic;">&#160;</i></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.98%;"><tr style="height:12.4pt;"><td colspan="2" style="vertical-align:top;width:41.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:43.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td colspan="2" style="vertical-align:top;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX LTD.</b></p></td><td style="vertical-align:top;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ATME Comercio e Servi&#231;os Ltda.</b></p></td></tr><tr style="height:12.4pt;"><td colspan="2" style="vertical-align:top;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:43.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:36.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Aviezer</p></td><td style="vertical-align:top;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:37.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Abraham Meizler</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:36.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Aviezer</p></td><td style="vertical-align:top;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:37.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Abraham Meizler</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:36.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CEO</p></td><td style="vertical-align:top;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:37.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President/Partner</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:36.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 18, 2013</p></td><td style="vertical-align:top;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:37.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 17, 2013</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30.8pt;"><i style="font-style:italic;">&#160;&#160;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30.8pt;"><font style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30.8pt;"><font style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30.8pt;"><font style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 0pt 36pt;">-7-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Certification</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b>&#160;&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Pfizer&#39;s Anti-Bribery and Anti-Corruption Principles</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Training Completion Form</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>plx-20210331xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/14/2021 11:03:34 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-weight:bold;">[***] Represents material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT (this &#8220;AGREEMENT&#8221;) is made as of _________ __, 2013 by and between<b style="font-weight:bold;"> &#160;PROTALIX LTD.</b> , a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O.B 455, Carmiel 20100, Israel (&#8220;PROTALIX&#8221;), and<b style="font-weight:bold;"> FUNDA&#199;&#195;O OSWALDO CRUZ</b> , an agency of the Brazilian Ministry of Health organized under the laws of Brazil, including its manufacturing unit &#8220;BIO-MANGUINHOS&#8221;, with registered offices at Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, Cep 21045-900, Brazil, CGC NI 33.781.055/0001-35, represented by its President, Dr. PAULO ERNANI GADELHA VIEIRA, hereinafter collectively referred to as &quot;FIOCRUZ&quot;. For the purposes of this AGREEMENT, PROTALIX and FIOCRUZ each are referred to as a &#8220;PARTY&#8221; and collectively as the &#8220;PARTIES&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-weight:bold;">WHEREAS,</b> PROTALIX owns or otherwise controls certain patents, patent applications, technology, know-how and scientific and technical information relating to an enzyme replacement therapy for the treatment of Gaucher Disease; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-weight:bold;">WHEREAS,</b> FIOCRUZ is a foundation affiliated with the Ministry of Health of the Brazilian Government and is a manufacturer of vaccines predominantly for the Brazil National Program of Immunization (&#8220;NPI&#8221;) which owns, controls and operates Bio-Manguinhos;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-weight:bold;">WHEREAS,</b> FIOCRUZ desires to obtain from PROTALIX, and PROTALIX desires to provide to FIOCRUZ, (i) the necessary rights and technical assistance and information, in various stages, to enable FIOCRUZ to MANUFACTURE and supply the Product in the Territory (as defined below), and (ii) the SUPPLIED MATERIALS (as defined below), pursuant to and in accordance with the terms of this AGREEMENT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-weight:bold;">NOW, THEREFORE,</b> in consideration of the premises, and the mutual covenants and agreements set forth herein, the PARTIES hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:56.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">ARTICLE 1. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">DEFINITIONS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For purposes of this AGREEMENT, the following terms shall have the meaning ascribed to such term herein:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;ADVISORY COMMITTEE&#8221; shall mean the committee organized and acting pursuant to Article&#160;5.5 which shall have the overall responsibility for advising on and monitoring the implementation of the TECHNOLOGY TRANSFER up to and including the first successful production of the FINAL PRODUCT for commercial sale, pursuant to and in accordance with the terms and conditions of this AGREEMENT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;AFFILIATE&#8221; means any entity directly or indirectly controlled by, controlling, or under common control with, a PARTY to this AGREEMENT, but only for so long as such control shall continue. For purposes of this definition, Article 12.3(d) and Article 20.6 only, &#8220;control&#8221; (including, with correlative meanings, &#8220;controlled by&#8221;, &#8220;controlling&#8221; and &#8220;under common control with&#8221;) means (a) possession, direct or indirect, of the power to direct or cause direction of the management or policies of an entity (whether through ownership of securities or other ownership interests, by contract or otherwise), or (b) beneficial ownership of at least 50% of the voting securities or other ownership interest (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests of an entity, it being understood and agreed that for purposes of clause (a), neither ownership of voting securities or other ownership interests of an entity nor membership or representation on (if less than half of the members of) an entity&#8217;s board of directors shall, by themselves, be presumed to constitute the power to direct or cause direction of the management or policies of such entity. With respect to the grant of license or other rights by PROTALIX hereunder, &#8220;AFFILIATE&#8221; shall exclude any Third PARTY that becomes an Affiliate due to such Third PARTY&#8217;s acquisition of PROTALIX or any other Person with an ownership interest in PROTALIX.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">1</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;ANVISA&#8221; means the National Sanitary Surveillance Agency of the Brazilian Government (or any successor or replacement agency that has the authority to grant the necessary GOVERNMENTAL APPROVALS).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;BULK PRODUCT&#8221; means the DRUG SUBSTANCE component of a PRODUCT in liquid or frozen form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;BUSINESS DAY&#8221; means a day other than a Saturday, Sunday, or bank or other public holiday in Brazil and/or Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&quot;CELL BANK&quot; means a cell bank of vials with carrot cells producing<i style="font-style:italic;"> taliglucerase alfa</i> with information on its characterization and release, as well as information on its origin, plasmid, nature and sequence of the gene used, that is able to provide a sufficient number of vials for the production of the PRODUCT for a period time not less than 20 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;CERTIFICATE OF ACCEPTANCE&#8221; means a certificate in the form attached hereto as Appendix III, executed by PROTALIX and FIOCRUZ to confirm the COMPLETION of each STAGE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;CHALLENGE&#8221; shall have the meaning ascribed to such term in Article 4.8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;COMMERCIALIZATION&#8221; means the marketing, distribution, offering for sale, selling and importation of the PRODUCTS. When used as a verb, &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;"> Commercialize</u> &#8221; means to engage in Commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;COMPOUND&#8221; means (a) a plant cell expressed recombinant Glucocerebrosidase enzyme having the sequence set forth in <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u> to this AGREEMENT, and (b) any analogs, derivatives and variants thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;COMPLETION&#8221; means the completion of a STAGE after achieving the COMPLETION REQUIREMENTS of such STAGE, as confirmed by the ADVISORY COMMITTEE and the execution of the CERTIFICATE OF ACCEPTANCE by FIOCRUZ and PROTALIX, evidencing such completion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;COMPLETION REQUIREMENTS&#8221; mean, in relation to each STAGE and the TECHNOLOGY TRANSFER as a whole, the corresponding requirements established in Article 5.2 and Appendix II for advancement to the next STAGE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;CONFIDENTIAL INFORMATION&#8221; shall have the meaning ascribed to such term in Article 11.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;CONTROL&#8221; or &#8220;CONTROLLED&#8221; means, with respect to any compound, material, Technology, or intellectual property right, that a PARTY owns or has a license to use, commercialize, manufacture, market, distribute or sell, and has the ability to grant to the other PARTY access and/or a license or a sublicense (as applicable under this AGREEMENT) to such compound, material, Technology, or intellectual property right as provided for herein without violating (a) the terms of any agreement or other arrangements with any Third PARTY existing before or after the EXECUTION Date or (b) any LAW applicable to such license or sublicense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;DISCLOSING PARTY&#8221; shall have the meaning ascribed to such term in Article 11.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;DRUG SUBSTANCE&#8221; means the Compound component of a pharmaceutical drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;EFFECTIVE DATE&#8221; shall have the meaning ascribed to such term in Article 3.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;EXECUTION DATE&#8221; means the date on which the last PARTY signs this AGREEMENT so as to make it signed by each of the PARTIES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;FACILITIES&#8221; means the facilities of FIOCRUZ in BIO-MANGUINHOS related to the PRODUCT, including the primary production facility, the secondary facilities and the quality control laboratories to be adequated or built and validated, maintained and operated by FIOCRUZ, solely, for each STAGE, after receipt by FIOCRUZ of written approval of PROTALIX following a full inspection of such facility to ensure such facility is acceptable for the purpose contemplated hereunder for such STAGE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;FIELD&#8221; means enzyme replacement therapy for the treatment of Gaucher Disease for the approved indications, dosage forms and strengths.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;FILL/FINISH&#8221; means (a) formulating the Product using Drug Substance and required excipients, (b) filling the Product into vials, (c) lyophilization of the Drug Substance for incorporation into the Product, and (d) testing, including ongoing stability testing, and release </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">of the Product. For the avoidance of doubt, Fill/Finish shall not include any activities included in the definition of Labeling and Packaging.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;FINAL PRODUCT&#8221; shall mean PRODUCT produced entirely by FIOCRUZ at the FACILITIES from the CELL BANK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;FINISHED PACKAGED PRODUCT&#8221; means the PRODUCT that has undergone FILL/FINISH and LABELING AND PACKAGING to be supplied by PROTALIX to FIOCRUZ until the registration of PRODUCT 2 by ANVISA in PROTALIX&#39;s or FIOCRUZ&#39;s name.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;FORCE MAJEURE EVENT&#8221; shall have the meaning ascribed to such term in Article 20.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;FORECAST&#8221; shall have the meaning ascribed to such term in Article 6.2.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;GOOD MANUFACTURING PRACTICES&#8221; or &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">GMP</u>&#8221; means all applicable Good Manufacturing Practices including, (a) the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the quality standards appropriate for their intended use, as defined in ANVISA RDC 17 and RDC 66-07 laying down the principals and guidelines of good manufacturing practice, (b) WHO GMP guidelines, and (c) the equivalent Laws in any relevant country or other sovereign entity in which PRODUCT is marketed, manufactured, distributed, offered for sale, sold or imported by or on behalf of FIOCRUZ, each as may be amended and applicable from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;GOVERNMENTAL AUTHORITY&#8221; means any court, agency, department, authority or other instrumentality of any national, state, country, city or other political subdivision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;GOVERNMENTAL APPROVAL&#8221; means the authorizations and approvals (including regulatory and pricing approvals) of a Governmental Authority that are necessary for the TECHNOLOGY TRANSFER, or the COMMERCIALIZATION, MANUFACTURE, use or exploitation of the SUPPLIED MATERIALS, COMPOUND, DRUG SUBSTANCE or PRODUCTS in the TERRITORY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;GOVERNMENT OFFICIAL&#8221; shall have the meaning ascribed to such term in Article 17.2(f).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;IMPROVEMENT&#8221; means any enhancements to the Protalix Technology enabling superior productivity, therapeutic activity, feasibility, profitability and/or improvement of the production processes included in the Protalix Technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;INDEMNIFIED PARTY&#8221; shall have the meaning ascribed to such term in Article 16.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;INDEMNIFYING PARTY&#8221; shall have the meaning ascribed to such term in Article 16.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&quot;INITIAL FORECAST&quot; shall have the meaning ascribed to such term in Article 6.2.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;INPI&#8221; means the Brazilian National Institute of Industrial Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;LABELING AND PACKAGING&#8221; means the final product labeling and packaging of the Product as intended for commercial distribution and sale of such PRODUCT to THIRD PARTIES in the TERRITORY, including insertion of materials such as patient inserts, patient medication guides, professional inserts and any other written, printed or graphic materials accompanying the Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;LAWS&#8221; means all laws, statutes, rules, regulations, codes, administrative or judicial orders, judgments, decrees, injunctions and/or ordinances of any Governmental Authority, and other legal requirements of any kind, whether currently in existence or hereafter promulgated, enacted, adopted or amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;LOSSES&#8221; means any and all damages (including all incidental, consequential, statutory and treble damages), awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees (including reasonable attorney fees), liabilities, obligations, taxes, liens, losses and expenses, including those incurred by or awarded to Third PARTIES with respect to a Third PARTY Claim by reason of any judgment, order, decree, stipulation or injunction, or any settlement entered into, and all other documented costs and expenses incurred in investigating, preparing or defending any Third PARTY Claim litigation or proceeding, commenced or threatened, or in complying with any judgments, orders, decrees, stipulations and injunctions (including court costs, interest and reasonable fees of attorneys, accountants and other experts).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;MANUFACTURE&#8221; or &#8220;MANUFACTURING&#8221; means all activities related to the manufacturing of the COMPOUND, Drug Substance or Products, and/or any ingredient thereof, including manufacturing for commercial sale, in-process and finished product testing, Fill/Finish, Labeling and Packaging, release of product, quality assurance activities related to manufacturing and release of product and ongoing stability tests and regulatory activities related to any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;NAKED VIALS&#8221; means unlabelled vials [***] of PRODUCT that have undergone FILL/FINISH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;NET SALES&#8221; means the gross receipts of all sales of FINAL PRODUCT by or on behalf of FIOCRUZ, less any sales taxes actually incurred and paid by FIOCRUZ and reasonable out-of-pocket costs of transportation insurance and transportation for such FINAL PRODUCT actually incurred and paid by FIOCRUZ. A Royalty Payment obligation shall accrue upon the receipt of payment for such FINAL Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&quot;OCS&quot; means the Office of the Chief Scientist of the Israeli Ministry of Trade, Industry and Labor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;ORAL FORMULATION&#8221; means an oral formulation of a drug product for the treatment of Gaucher Disease which contains any Compound as the active pharmaceutical ingredient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PATENT APPLICATION&#8221; means any application for a Patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PATENT RIGHTS&#8221; means Patents and Patent Applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PATENTS&#8221; means issued patents, whether domestic or foreign, including issued patents granted with respect to all continuations, continuations-in-part, divisions, provisionals and renewals, patents of addition, supplementary protection certificates, registration or confirmation patents and all reissues, re-examination and extensions thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PERMITS&#8221; means all approvals, authorizations, stamps, registrations, clearances, consents, licenses, permits, certificates, or regulatory approvals of any Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PERSON&#8221; means an individual, corporation, partnership, company, joint venture, unincorporated organization, limited liability company or partnership, sole proprietorship, association, bank, trust company or trust, whether or not legal entities, or any Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PHARMACOVIGILANCE AGREEMENT&#8221; means the PHARMACOVIGILANCE Agreement(s) set forth as Appendix VIII, between PROTALIX and FIOCRUZ.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PRICE&#8221; means the price to be charged by PROTALIX for SUPPLIED MATERIAL manufactured and supplied hereunder as delivered to FIOCRUZ, and which price is set forth in Article 6, herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PRODUCT&#8221; means the pharmaceutical product<i style="font-style:italic;"> plant cell expressed recombinant Glucocerebrosidase</i> in any finished dosage form of a drug product that contains Drug Substance (excluding any ORAL FORMULATION), which is the object of the TECHNOLOGY TRANSFER under this AGREEMENT, and, as used in this AGREEMENT, refers to any one of PRODUCT 1, PRODUCT 2, PRODUCT 3 and FINAL PRODUCT (and PRODUCTS, as used in this AGREEMENT, refers to all of PRODUCT 1, PRODUCT 2, PRODUCT 3 and FINAL PRODUCT).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PRODUCT 1&#8221; shall mean the FINISHED PACKAGED PRODUCT supplied to FIOCRUZ by PROTALIX.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&quot;PRODUCT 2&quot; shall mean PRODUCT LABELED AND PACKAGED by FIOCRUZ at the FACILITIES from NAKED VIALS supplied to FIOCRUZ by PROTALIX.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PRODUCT 3&#8221; shall mean PRODUCT FILLED/FINISHED and LABELED AND PACKAGED by FIOCRUZ at the FACILITIES from BULK PRODUCT supplied to FIOCRUZ by PROTALIX.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PRODUCT MARKS&#8221; means the names and marks on the labeling and packaging of the FINISHED PACKAGED PRODUCTS supplied to FIOCRUZ hereunder by PROTALIX.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PROTALIX PATENT RIGHTS&#8221; means all Patent Rights owned by PROTALIX or otherwise Controlled by PROTALIX as of the EFFECTIVE DATE or at any time during the Term that claim the composition of matter, MANUFACTURE or use of the Compound, Drug Substance or a drug product that contains Drug Substance, including the Patent Rights listed in &#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PROTALIX TECHNOLOGY&#8221; means any Technology possessed or otherwise Controlled by PROTALIX as of the EFFECTIVE DATE or at any time during Term 1 that is necessary for the MANUFACTURE of the PRODUCTS as MANUFACTURED by, on behalf of, or under license from, PROTALIX as of the EFFECTIVE DATE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;PURCHASE ORDER&#8221; means a firm purchase order in written or electronic form submitted by FIOCRUZ in accordance with the terms of this Agreement to PROTALIX authorizing the manufacture and supply of SUPPLIED MATERIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;RATE&#8221; shall have the meaning ascribed to such term in Article 9.4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;RECIPIENT&#8221; shall have the meaning ascribed to such term in Article 11.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;REPORTING PERIOD&#8221; shall have the meaning ascribed to such term in Article 9.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;ROYALTY PAYMENTS&#8221; shall have the meaning ascribed to such term in Article 9.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;SPECIFICATIONS&#8221; means the specifications of the Drug Substance, PRODUCTS, and SUPPLIED MATERIALS designated by PROTALIX, as initially set forth in Appendix I, which may be updated from time to time by PROTALIX, including with respect to MANUFACTURING (including standard operating procedures for manufacturing), performance, quality control, release, and fill/finish specifications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;STAGES&#8221; shall have the meaning ascribed to such term in Article 5.1.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;SUPPLIED MATERIALS&#8221; means the FINISHED PACKAGED PRODUCT, Naked Vials, Bulk Product and any other materials supplied to FIOCRUZ by PROTALIX for the MANUFACTURE and/or COMMERCIALIZATION by FIOCRUZ of PRODUCTS in the TERRITORY for the FIELD in accordance with this AGREEMENT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;TECHNOLOGY&#8221; means all materials, technology, data, results and non-public technical, scientific and clinical information, in any tangible or intangible form, including know-how, expertise, trade secrets, practices, techniques, methods, processes, developments, specifications, formulations, formulae, and any intellectual property rights embodying any of the foregoing, but excluding any Patent Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;TECHNOLOGY TRANSFER&#8221; means the provision to FIOCRUZ of the data and information comprising the Protalix Technology and the non-exclusive, non-transferable rights to use the Protalix Technology in the TERRITORY granted to FIOCRUZ hereunder), reasonably necessary to produce the PRODUCT, to be implemented in various stages as described in Article 5.2 and Appendix II of this AGREEMENT, for the sole purpose of enabling FIOCRUZ to MANUFACTURE the Products for sale within the Territory for the FIELD, and all data and documentation in PROTALIX&#39;s possession or control reasonably necessary for FIOCRUZ to obtain registration of the PRODUCTS by ANVISA, in accordance with and subject to the terms and conditions hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;TERM&#8221; shall mean &quot;TERM 1&quot; and &quot;TERM 2&quot;, and such terms shall have the meanings ascribed to such terms in Articles 12.1 and 12.2, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;THIRD PARTY&#8221; means any Person other than PROTALIX, FIOCRUZ or any of their respective Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;THIRD PARTY CLAIM&#8221; shall have the meaning ascribed to such term in Article 16.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;THIRD PARTY LICENSE&#8221; means each license agreement between PROTALIX and a THIRD PARTY pursuant to which or from which PROTALIX obtains a license to PROTALIX TECHNOLOGY or PROTALIX PATENT RIGHTS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;TERRITORY&#8221; means Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:108.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Except where expressly stated otherwise in this AGREEMENT, the following rules of interpretation apply to this AGREEMENT: (a) &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; are not limiting and mean include, includes and including, without limitation; (b) definitions contained in this AGREEMENT are applicable to the singular as well as the plural forms of such terms; (c) references to an agreement, statute or instrument mean such agreement, statute or instrument as from time to time amended, modified or supplemented; (d) references to a Person are also to its permitted successors and assigns; (e) references to an &#8220;Article&#8221;, &#8220;Section&#8221;, &#8220;Exhibit&#8221;, &#8220;Appendix&#8221; or &#8220;Schedule&#8221; refer to an Article or Section of, or any Exhibit, Appendix or Schedule to, this AGREEMENT unless otherwise indicated; (f) the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;; and (g) the word &#8220;any&#8221; shall mean &#8220;any and all&#8221; unless otherwise indicated by context.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:77.2pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;ARTICLE 2. </font></font>AGREEMENT PURPOSE AND SCOPE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The primary purpose and scope of this AGREEMENT is the TECHNOLOGY TRANSFER from PROTALIX to FIOCRUZ in order to enable FIOCRUZ to produce and supply PRODUCTS in the TERRITORY for the FIELD, as follows:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt 0pt 0pt 56.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.98%;"><tr style="height:1pt;"><td style="vertical-align:top;width:15.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:82.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:99pt;"><td style="background-color:#ffffff;vertical-align:top;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.25pt;margin:0pt 0pt 0pt -31.25pt;">(i)</p></td><td style="background-color:#ffffff;vertical-align:top;width:82.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">during the TECHNOLOGY TRANSFER, the sale and supply exclusively by PROTALIX to FIOCRUZ of the SUPPLIED MATERIALS for the purpose of FIOCRUZ manufacturing PRODUCTS in accordance with the STAGES and the provisions of Articles 5 and 6 in such quantities as provided herein, in order to satisfy the requirements of the Brazilian MOH for<i style="font-style:italic;"> &#160;plant cell expressed recombinant Glucocerebrosidase</i> during the period of the TECHNOLOGY TRANSFER and until registration of the FINAL PRODUCT by ANVISA in FIOCRUZ&#39;s name. For the avoidance of doubt, subject to Section 4.8, sales by FIOCRUZ outside of Brazil will only apply to FINAL PRODUCT and shall only take place after full completion of the TECHNOLOGY TRANSFER and in accordance with the terms and conditions of this AGREEMENT;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt 0pt 0pt 56.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.98%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ii)</p></td><td style="background-color:#ffffff;vertical-align:top;width:81.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">the supply of all of the, documentation and technical information reasonably necessary for the manufacturing and releasing of the PRODUCTS;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt 0pt 0pt 56.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.99%;"><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(iii)</p></td><td style="background-color:#ffffff;vertical-align:top;width:81.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a non-exclusive, non-transferable and non-sublicensable license of Protalix Patent Rights in the TERRITORY for the term of such PATENTS in the TERRITORY, subject to the terms and conditions of this AGREEMENT; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt 0pt 0pt 56.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:94.03%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:16.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(iv)</p></td><td style="background-color:#ffffff;vertical-align:top;width:80.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">the provision of TECHNICAL ASSISTANCE by PROTALIX to FIOCRUZ.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:56.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">ARTICLE 3. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">CONDITIONS PRECEDENT</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:111.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This AGREEMENT shall become effective upon the last to occur of (a) the date of written notification by either PARTY to the other PARTY of approval by INPI of this AGREEMENT, (b) the date of written notification by either PARTY to the other PARTY of approval by OCS of this AGREEMENT, and (c) registration of the Product by ANVISA in the name of PROTALIX or, along with Laborat&#243;rios Pfizer Ltda.&#39;s approval to import the PRODUCT into Brazil set forth on Appendix V, in the name of Laborat&#243;rios Pfizer Ltda. (the later of (a), (b) and (c), the &#8220;EFFECTIVE DATE&#8221;). If for any reason the supply of the FINISHED PACKAGED PRODUCT by PROTALIX to FIOCRUZ becomes prohibited under Brazilian LAW, notwithstanding anything to the contrary herein, PROTALIX shall not be required to supply such FINISHED PACKAGED PRODUCT for so long as such supply is prohibited and FIOCRUZ shall pay for any FINISHED PACKAGED PRODUCT already shipped to FIOCRUZ pursuant to the terms of this Agreement.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:74.25pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall, at its sole cost and expense, submit this AGREEMENT to the INPI for approval and recordation (and take all other actions reasonably necessary to obtain such approval and recordation) promptly following the EXECUTION DATE and shall promptly notify PROTALIX of the approval and recordation of this AGREEMENT by INPI. PROTALIX shall, at its sole cost and expense, submit this AGREEMENT to the OCS for approval (and take all other actions reasonably necessary to obtain such approval) promptly following the EXECUTION DATE and shall promptly notify FIOCRUZ of the approval of this AGREEMENT by OCS.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:56.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">ARTICLE 4. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">GRANT OF RIGHTS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.83%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:143.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subject to the terms and conditions set forth herein, PROTALIX hereby grants to FIOCRUZ (a) the non-exclusive, non-transferable rights, as applicable, to use the Protalix Technology provided to FIOCRUZ hereunder, and (b) the non-exclusive, non-transferable and non-sublicensable license or sublicense, as applicable, under all PROTALIX PATENT RIGHTS in the TERRITORY for the duration of such Patent Rights, solely, with respect to the foregoing (a) and (b), for the purpose of MANUFACTURING PRODUCTS in the FACILITIES, and the COMMERCIALIZATION of such PRODUCTS, for sale within the Territory for the Field, as appropriate for each STAGE, in accordance with this AGREEMENT. Notwithstanding the foregoing, FIOCRUZ&#8217;s right to COMMERCIALIZE the PRODUCTS in the TERRITORY for the FIELD shall be exclusive; <u style="text-decoration:underline;text-decoration-color:#000000;"> provided</u> &#160;that (x) such right shall become non-exclusive in the event that FIOCRUZ fails to comply with this Article 4.1 or Article 7.2 or is unable to meet demand for the PRODUCTS in the TERRITORY, and (y) shall not be exclusive with respect to any Protalix PATENTS RIGHTS or Protalix Technology that is subject to a THIRD PARTY LICENSE that does not provide PROTALIX the rights to grant exclusive sublicenses thereof. Any sublicense obligations required by a THIRD PARTY LICENSE to be included in a sublicense shall be deemed to be included in this AGREEMENT as obligations of FIOCRUZ [***].</p></td></tr><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall not directly or indirectly market, promote, supply, distribute, offer for sale, or sell Products nor any other pharmaceutical product that contains DRUG SUBSTANCE or is derived from Protalix Technology or otherwise use or otherwise exploit the PROTALIX PATENTS RIGHTS, Protalix Technology, or SUPPLIED MATERIALS, in, for or to territories outside the TERRITORY or a field other than the Field, in connection with any other pharmaceutical products, or in any manner other than as expressly permitted hereunder.</p></td></tr><tr style="height:76.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.3</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall not, without the prior written consent of PROTALIX directly or indirectly (a) disclose or otherwise make available the Protalix Technology, nor assign, transfer, license, or sublicense any rights obtained by FIOCRUZ hereunder, to any AFFILIATE or THIRD PARTY, (b) use the Protalix Technology for research or development, (c) MANUFACTURE or COMMERCIALIZE ProductS in any facility or plant other than the Facilities or through any unit of FIOCRUZ other than BIO-MANGUINHOS, nor (d) other than for the PRODUCTS, use the PROTALIX PATENTS RIGHTS or Protalix Technology in connection with any pharmaceutical products (including any successor or alternative delivery, presentations or dosing regimens of the Product).</p></td></tr><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the Term, FIOCRUZ shall not directly or indirectly market, promote, supply, distribute, offer for sale, sell or otherwise exploit any other products that, in PROTALIX&#8217;s good faith judgment may compete with the PRODUCT.</p></td></tr><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.5</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the Technology Transfer, PROTALIX shall make available to FIOCRUZ all Improvements CONTROLLED by such PARTY that are useful to the MANUFACTURE of the PRODUCTS.</p></td></tr><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.6</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Except for the licenses and other rights granted to FIOCRUZ herein, all right, title and interest in and to the Protalix Patent Rights and Protalix Technology shall remain solely with PROTALIX and its licensors, as applicable.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:85.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.7</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ hereby covenants and agrees not to, directly or indirectly, commence (or assist any other Person in connection with) any claim, suit, action or other proceeding (including in front of any court or Governmental Authority, including any intellectual property office or registry), that challenges the legality, validity, enforceability, scope or ownership of any PROTALIX Patent Right or PROTALIX TECHNOLOGY (a &#8220;CHALLENGE&#8221;). If FIOCRUZ directly or indirectly commences (or assists any other Person in connection with) any Challenge, PROTALIX shall (a) have the right to immediately terminate this AGREEMENT by written notice effective upon receipt by FIOCRUZ, and (b) shall be entitled to recover from FIOCRUZ any and all costs and expenses, including reasonable attorneys&#8217; fees and expenses of investigation and defense, incurred by PROTALIX in connection with such Challenge.</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.8</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Notwithstanding anything to the contrary herein, following COMPLETION of the TECHNOLOGY TRANSFER, [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.9</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the avoidance of doubt, notwithstanding the license granted hereunder, PROTALIX shall retain its exclusive right in the TERRITORY to partner with patient advocacy groups, and provide patient support and medical education services to health care professionals, during the TERM and thereafter until COMPLETION of the TECHNOLOGY TRANSFER or for so long as PROTALIX continues to supply PRODUCTS to the TERRITORY.</p></td></tr><tr style="height:99pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.10</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time throughout the TERM, PROTALIX will provide to FIOCRUZ information regarding the status of its development programs for the ORAL FORMULATION. Upon FIOCRUZ&#39;s reasonable request in writing (made no more than once per every twelve month period), PROTALIX agrees to discuss in good faith a possible collaboration with FIOCRUZ, or a license or sale to FIOCRUZ of rights, with respect to the ORAL FORMULATION. Any agreement resulting from such discussions relating to the ORAL FORMULATION (including any rights to be granted with respect to the ORAL FORMULATION) shall be separate and apart from this AGREEMENT. PROTALIX&#39;s obligations and FIOCRUZ&#39;s rights set forth in this Article 4.10 shall be PROTALIX&#39;s sole obligations and FIOCRUZ&#39;s sole rights hereunder with respect to the ORAL FORMULATION.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 5. </font></font>TECHNOLOGY TRANSFER</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">5.1 General</u>.&#160; The TECHNOLOGY TRANSFER shall commence upon the EFFECTIVE DATE and shall be implemented as set forth in the following chart (and as set forth in this Article 5 and Appendix II):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Estimated Time Table of Milestones in Product Production and Supply,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">as a Result of Technology Transfer As Specified In Appendix II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.99%;"><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:bottom;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stages</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplied&#160;by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX&#160;for</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PRODUCT&#160;supply&#160;&#160;&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:17.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIOCRUZ&#160;activity</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stages&#160;Quantity</p></td></tr><tr style="height:29.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">Stage 0 -&#160;&#160;&#160; Immediately after the EFFECTIVE DATE</p></td><td style="background-color:#ffffff;vertical-align:top;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr style="height:30.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">Stage 1 -&#160; Immediately after registration by ANVISA of PRODUCT 2 in FIOCRUZ&#39;s name</p></td><td style="background-color:#ffffff;vertical-align:top;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr style="height:30.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">Stage 2 - After validation of FIOCRUZ new FILL AND FINISH facility</p></td><td style="background-color:#ffffff;vertical-align:top;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr style="height:42.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">Stage 3 - After construction and validation of FIOCRUZ Plant Cell culturing facility and registration by ANVISA of FINAL PRODUCT in FIOCRUZ&#39;s name</p></td><td style="background-color:#ffffff;vertical-align:top;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr style="height:18.15pt;"><td colspan="5" style="background-color:#ffffff;vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">TOTAL QUANTITY: [***] vials (or equivalent depending on PRODUCT type)</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">8</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Note: The FIOCRUZ activity set forth in each STAGE in the above chart (other than STAGE 0) shall only commence following the TECHNOLOGY TRANSFER by PROTALIX for, and the COMPLETION of, the prior STAGE, as set forth in Appendix II (so that FIOCRUZ is able to properly perform such activity). COMMERCIALIZATION of the FINAL PRODUCT shall only occur following COMPLETION of the TECHNOLOGY TRANSFER. During each STAGE, as applicable, PROTALIX shall use commercially reasonable efforts to provide, at FIOCRUZ&#39;s cost, any proprietary or non-commercial reagents and standards to FIOCRUZ that are required by FIOCRUZ in connection with its responsibilities for such STAGE, and use commercially reasonable efforts to help FIOCRUZ to become self-sufficient to produce or obtain such materials or reagents on its own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:123.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.1.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subject to the terms and conditions hereof, PROTALIX shall make available to FIOCRUZ at and for the FACILITIES, on a STAGE by STAGE basis, all Protalix Technology that is necessary for such STAGE and for the related MANUFACTURING, quality control and registration by ANVISA of the PRODUCTS by FIOCRUZ (including or as reasonable necessary for obtaining requisite GOVERNMENTAL APPROVALS) in accordance with this AGREEMENT. All PROTALIX TECHNOLOGY shall be provided in the English language. FIOCRUZ may translate any such documents at its own risk, cost and expense. Notwithstanding anything to the contrary herein, PROTALIX will transfer the PROTALIX TECHNOLOGY relating to [***] as the last step of STAGE 3 of the TECHNOLOGY TRANSFER only following positive completion by FIOCRUZ of clinical trials for the FINAL PRODUCT and registration by ANVISA of the FINAL PRODUCT in FIOCRUZ&#39;s name (as well as the other steps of STAGE 3 [***].</p></td></tr><tr style="height:123.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.1.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The PARTIES hereby agree that the TECHNOLOGY TRANSFER will be implemented in sequential stages (the &#8220;STAGES&#8221;) as set forth in Article 5.1, Article 5.2 and Appendix II. Each STAGE will take the time required to achieve the COMPLETION of such STAGE as provided by Article 5.2 and Appendix II. The beginning of each STAGE following STAGE 0 will be subject to the achievement of the COMPLETION REQUIREMENTS of the previous STAGE, as specified in Article 5.2 and Appendix II. FIOCRUZ will purchase the quantity of PRODUCTS set forth for each STAGE in the STAGES chart in Section 5.1, in order for COMPLETION of each such STAGE and commencement of the following STAGE (in addition to COMPLETING the other COMPLETION REQUIREMENTS), emphasizing that, notwithstanding anything to the contrary herein, proceeding to the STAGE 3 will only occur with the total purchase by FIOCRUZ of the estimated quantities for the STAGES 0, 1 and 2.</p></td></tr><tr style="height:136.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.1.3</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PROTALIX and FIOCRUZ shall each appoint, no later than thirty (30) calendar days after the EXECUTION DATE, its respective Technical Project Managers (whose duties are set forth in Articles 5.3 and 5.4 below) and prepare a coordination plan that will set forth and coordinate the activities of the PARTIES to take place during the period of the TECHNOLOGY TRANSFER. The coordination plan will take into account the contractual obligations of the PARTIES and shall include clauses such as addresses, correspondence, numbers, numbers of copies to be released, scheduling of activities, persons in charge, standards to be used for equipment and construction and other matters required or useful for the successful implementation of the TECHNOLOGY TRANSFER. Each of FIOCRUZ and PROTALIX shall notify the other in writing, at least thirty (30) days prior to replacing any of its Technical Project Managers and, in such case, shall cause both the replaced Technical Project Manager and the replacement Technical Project Manager to work together during a transition term of at least thirty (30) days.</p></td></tr><tr style="height:111.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.1.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During all STAGES, FIOCRUZ shall, at its own cost and expense, be responsible for (a) obtaining all GOVERNMENTAL APPROVALS required to MANUFACTURE and COMMERCIALIZE the PRODUCTS MANUFACTURED in the FACILITY in the Territory in accordance with the applicable STAGE, and (b) the construction, validation, maintenance and operation of the FACILITIES (including the new lyophilization suite, bioreactor facility and purification suites). FIOCRUZ shall be permitted to conduct any clinical trials approved by ANVISA required to obtain GOVERNMENTAL APPROVALS in the TERRITORY for the PRODUCTS entirely MANUFACTURED by FIOCRUZ at the FACILITY for the FIELD; <u style="text-decoration:underline;text-decoration-color:#000000;"> provided</u> FIOCRUZ provides PROTALIX prior written notice thereof and reasonably consults with PROTALIX upon PROTALIX&#8217;s request.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">9</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:86.6pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.1.5</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Notwithstanding Article 5.1.4, and for the avoidance of doubt, (a) FIOCRUZ acknowledges and agrees that PROTALIX shall be permitted to obtain and maintain, and take all actions necessary to obtain and maintain its own GOVERNMENTAL APPROVALS for the PRODUCTS or similar pharmaceutical products in the TERRITORY, and (b) the PARTIES acknowledge and agree that until FIOCRUZ obtains its own GOVERNMENTAL APPROVAL for the Products, FIOCRUZ shall COMMERCIALIZE the FINISHED PACKAGED PRODUCT supplied by PROTALIX under the GOVERNMENTAL APPROVALS obtained prior to the Effective Date by PROTALIX for the Territory.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.1.6</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The purchase by and supply to FIOCRUZ of SUPPLIED MATERIALS during each STAGE of TECHNOLOGY TRANSFER shall occur in accordance with Article 6. As part of the TECHNOLOGY TRANSFER, PROTALIX may supply specific SUPPLIED MATERIALS to FIOCRUZ for the sole purpose of testing, validation and training, and for preparation for the following STAGE. FIOCRUZ shall utilize such SUPPLIED MATERIALS solely for such purpose and not for any commercial use.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">STAGES</u>. The TECHNOLOGY TRANSFER will be implemented in the sequential STAGES set forth in Appendix II, subject to and in accordance with the terms hereof, including Appendix II.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.3</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Responsibilities of PROTALIX</u>. The sole obligations of PROTALIX relating to the TECHNOLOGY TRANSFER are set forth in this Article 5 and FIOCRUZ agrees that PROTALIX shall have no other obligations, express or implied, with respect thereto.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.3.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The PROTALIX Project Technical Manager will represent PROTALIX with respect to the implementation of the TECHNOLOGY TRANSFER. The PROTALIX Project Technical Manager will coordinate all activities of PROTALIX in relation to the TECHNOLOGY TRANSFER in cooperation with the FIOCRUZ Project Technical Manager. The PROTALIX Project Technical Manager shall not be responsible for the responsibilities of FIOCRUZ nor for management of FIOCRUZ&#8217;s employees or other personnel.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.3.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Following [***], in the event that FIOCRUZ&#39;s CELL BANK is damaged or otherwise becomes defective, PROTALIX shall utilize its own CELL BANK to provide a new CELL BANK to FIOCRUZ.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:49.5pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.3.3</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All of PROTALIX&#8217;s obligations under this Article 5 shall (a) be conditioned on FIOCRUZ&#8217;s cooperation in connection therewith and compliance with this AGREEMENT (including fulfillment of its responsibilities set forth in this Article 5), and (b) cease upon Completion of the final STAGE of the TECHNOLOGY TRANSFER.</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.4</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:56.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Responsibilities of FIOCRUZ</u></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:74.25pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.4.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The FIOCRUZ Project Technical Manager will represent FIOCRUZ with respect to the implementation of the TECHNOLOGY TRANSFER. The FIOCRUZ Project Technical Manager of FIOCRUZ will coordinate all activities of FIOCRUZ in relation to the TECHNOLOGY TRANSFER in cooperation with the PROTALIX Project Technical Manager. The FIOCRUZ Project Technical Manager shall not be responsible for the responsibilities of PROTALIX nor for management of PROTALIX&#8217;s employees or other personnel.</p></td></tr><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.4.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***] in the event that PROTALIX&#39;s CELL BANK is damaged or otherwise becomes defective, FIOCRUZ shall utilize its own CELL BANK to provide a new CELL BANK to PROTALIX.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">10</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:123.75pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.4.3</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall take all necessary steps to ensure the FACILITY is constructed, maintained and operated in a manner that enables the safe and proper use of the PROTALIX TECHNOLOGY solely for the MANUFACTURE of the PRODUCTS in accordance with this AGREEMENT. FIOCRUZ will be responsible for the construction, validation, maintenance and operation of the FACILITIES during the term of this AGREEMENT and those FACILITIES shall at all times be (a) approved by ANVISA, (b) appropriate and adequate for implementing the then-current STAGE, and (c) in compliance with all the applicable LAWS, SPECIFICATIONS and GMP. The MANUFACTURING, COMMERCIALIZATION and storage operations, procedures and processes used by FIOCRUZ in connection with the MANUFACTURE of PRODUCTS hereunder (including any FACILITY) shall be in full compliance with all applicable SPECIFICATIONS and LAWS, including GMP and health and safety LAWS.</p></td></tr><tr style="height:49.5pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.4.4</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All costs and expenses related to the FACILITIES, including their construction, operation, maintenance and validation, shall be borne by FIOCRUZ. FIOCRUZ shall staff the FACILITIES with qualified personnel to perform all STAGES of the production and operation process and obtain the required GOVERNMENTAL APPROVALS therefor.</p></td></tr><tr style="height:49.5pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.4.5</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Except as otherwise expressly set forth herein, FIOCRUZ shall be responsible for the production and acquisition, at its own cost and expense, of all necessary materials. FIOCRUZ shall be responsible for the ensuring the quality of all such materials, including that such materials meet all requirements of applicable Brazilian LAWS.</p></td></tr><tr style="height:74.25pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.5</p></td><td colspan="7" style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">ADVISORY COMMITTEE</u>. PROTALIX and FIOCRUZ shall establish an ADVISORY COMMITTEE as of the EFFECTIVE DATE composed of three (3) senior members of each of PROTALIX and FIOCRUZ. The members of the ADVISORY COMMITTEE may be represented at any meeting by a designee appointed by such member for such meeting. The chairperson of the ADVISORY COMMITTEE shall be designated by PROTALIX. FIOCRUZ shall designate one of its representative members as secretary to the ADVISORY COMMITTEE. Each such PARTY shall be free to change its representative members by notice to the other such PARTY.</p></td></tr><tr style="height:49.5pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.5.1</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Responsibilities. The ADVISORY COMMITTEE shall be responsible for advising on and monitoring the implementation of the TECHNOLOGY TRANSFER, including clinical development work and regulatory activities in relation to PRODUCTS in a manner which is consistent with the terms and conditions of this AGREEMENT.</p></td></tr><tr style="height:135pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.5.2</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Meetings. The ADVISORY COMMITTEE shall meet at least twice every calendar year, (and more frequently should PROTALIX and FIOCRUZ agree to such more frequent meetings), on such dates and at such times as PROTALIX and FIOCRUZ shall agree. Additional meetings may also be called by either PROTALIX or FIOCRUZ as reasonably required, on forty (40) calendar days written notice to the other, unless such notice is waived by such other PARTY. The meetings shall alternate between the offices of PROTALIX and FIOCRUZ, unless the PARTIES otherwise agree. The chairperson shall be responsible for sending notices of meetings to all members. The ADVISORY COMMITTEE may also convene or be polled or consulted from time to time by means of telecommunications, video conferences or correspondence, as deemed necessary or appropriate. Fifteen (15) calendar days prior to each ADVISORY COMMITTEE meetings described above, an English summary of progress under the TECHNOLOGY TRANSFER shall be provided by FIOCRUZ to the members of the ADVISORY COMMITTEE, including detailed accounting of the expenditures.</p></td></tr><tr style="height:61.9pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.5.3</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Decisions. All decisions of the ADVISORY COMMITTEE shall be made by unanimous consent of the members present in person or by telephone or teleconferences/videoconferences at any meeting, with FIOCRUZ members cumulatively having one (1) vote and PROTALIX members cumulatively having one (1) vote. A quorum for a meeting shall require at least one (1) representative from FIOCRUZ and at least one (1) representative from PROTALIX.</p></td></tr><tr><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.5.4</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the event that unanimity cannot be reached by the ADVISORY COMMITTEE with respect to a matter that is subject to its decision-making authority, then the matter shall be referred for further review and resolution to the President of PROTALIX or such other similar position designated by PROTALIX from time to time, and the President of FIOCRUZ, or such other similar position designated by FIOCRUZ from time to time. The designated persons at each of PROTALIX and FIOCRUZ shall use reasonable efforts to resolve the matter within thirty (30) days after the matter is referred to them. In the event that the designated officers fail to resolve the matter during such time period, PROTALIX and FIOCRUZ agree to submit the matter to be resolved with the assistance of a suitably qualified independent mediator or expert. In the event that the matter is still not resolved within fifty (50) days after the matter was referred to the designated persons at each of PROTALIX and FIOCRUZ the proposal or </p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">11</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">determination of PROTALIX&#8217;s President shall prevail (provided such proposal or determination shall be made in good faith).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:111.4pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.5.5</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Minutes. Within fifteen (15) BUSINESS DAYS after each ADVISORY COMMITTEE meeting, the secretary of the ADVISORY COMMITTEE shall prepare and distribute minutes of the meeting, which shall provide a description in reasonable detail of the discussions held at that meeting and a list of any actions, decisions and/or determinations approved by the ADVISORY COMMITTEE. The secretary shall be responsible for circulation of all drafts and final minutes. Draft minutes shall be first circulated to the chairperson, edited and approved by the chairperson and then circulated in final draft form to all members of the ADVISORY COMMITTEE sufficiently in advance of the next meeting to allow adequate review and comment prior to the meeting. Minutes shall be approved or disapproved, and revised as necessary, at the next meeting. Final minutes shall be distributed to the members of the ADVISORY COMMITTEE.</p></td></tr><tr style="height:24.75pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.5.6</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expenses. Each PARTY shall be responsible for all travel and related costs for its representatives to attend meetings of, and otherwise participate on, the ADVISORY COMMITTEE.</p></td></tr><tr style="height:61.9pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.5.7</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the term of this AGREEMENT, the ADVISORY COMMITTEE shall be assisted by specific task forces (&#8220;TASK FORCES&#8221;) which shall be responsible for advising the ADVISORY COMMITTEE within their area of responsibilities and implementing the decisions made by the ADVISORY COMMITTEE to the extent such decisions are within the competence of the TASK FORCES. The following TASK FORCES shall be organized:</p></td></tr><tr style="height:12.4pt;"><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="background-color:#ffffff;vertical-align:top;width:46.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a technical TASK FORCE;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt 0pt 0pt 56.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:72.72%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ii)</p></td><td style="background-color:#ffffff;vertical-align:top;width:74.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a clinical and regulatory TASK FORCE;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt 0pt 0pt 56.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:73.12%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:21.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(iii)</p></td><td style="background-color:#ffffff;vertical-align:top;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a manufacturing TASK FORCE; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt 0pt 0pt 56.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.98%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(iv)</p></td><td style="background-color:#ffffff;vertical-align:top;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">other TASK FORCES may be established upon the decision of the ADVISORY COMMITTEE.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.1pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.1pt;">The composition and numbers of representatives of each PARTY on each TASK FORCE shall be decided by both PROTALIX and FIOCRUZ on an ad hoc basis. Each of PROTALIX and FIOCRUZ shall be responsible for all travel and related costs for its representatives to attend TASK FORCE meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:56.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">ARTICLE 6. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">PURCHASE AND SUPPLY OF SUPPLIED MATERIALS</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:52.63%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:94.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Agreement to Supply</u>.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.1.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing on the EFFECTIVE DATE and continuing until the COMPLETION of the TECHNOLOGY TRANSFER, PROTALIX will supply and FIOCRUZ will purchase SUPPLIED MATERIALS, in the form (<u style="text-decoration:underline;text-decoration-color:#000000;"> e.g.</u> , FINISHED PACKAGED PRODUCT, NAKED VIALS, BULK PRODUCT, etc.) appropriate for the then-current STAGE, that are necessary for FIOCRUZ to MANUFACTURE and/or COMMERCIALIZE the PRODUCTS in the TERRITORY for the FIELD, at the pricing set forth herein. [***]</p></td></tr><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.1.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commercial supply will commence as soon as commercially reasonable, following the receipt of ANVISA approval for the PRODUCT.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 34.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.1.3</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing on the EFFECTIVE DATE and continuing until the later of COMPLETION of the TECHNOLOGY TRANSFER, FIOCRUZ shall purchase the SUPPLIED MATERIALS from PROTALIX on an exclusive basis.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 33pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">12</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:99pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.1.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the TECHNOLOGY TRANSFER, if FIOCRUZ is unable to MANUFACTURE the PRODUCTS in accordance with the then-current STAGE, then FIOCRUZ shall, in accordance with this Article 6, submit to PROTALIX orders for, and PROTALIX shall use commercially reasonable efforts to fulfill such orders for, SUPPLIED MATERIALS in the form required by FIOCRUZ to MANUFACTURE and/or COMMERCIALIZE the PRODUCTS (<u style="text-decoration:underline;text-decoration-color:#000000;"> e.g.</u> , if, during STAGE 3, FIOCRUZ cannot adequately FILL/FINISH the BULK PRODUCT to create PRODUCTS, then PROTALIX shall use commercially reasonable efforts to supply [***] ordered by FIOCRUZ); <u style="text-decoration:underline;text-decoration-color:#000000;"> provided</u> &#160;that FIOCRUZ provides PROTALIX sixty (60) days advance notice thereof.</p></td></tr><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.1.5</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FINISHED PACKAGED PRODUCT will be provided with a minimum [***] remaining shelf life and NAKED VIALS will be provided with a minimum [***] remaining shelf life.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.2</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Forecasts and Purchase Orders</u>.</p></td></tr><tr style="height:239.85pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.2.1</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On the EFFECTIVE DATE, or such later date that is at least ninety (90) days preceding the first requested delivery date for SUPPLIED MATERIALS, FIOCRUZ shall deliver to PROTALIX, FIOCRUZ&#8217;s quarterly projection of the quantities of SUPPLIED MATERIALS that FIOCRUZ anticipates ordering from PROTALIX for the four (4) calendar quarters commencing with the first quarter that includes the first requested delivery date (the &#8220;INITIAL FORECAST&#8221;), together with a Purchase Order for SUPPLIED MATERIALS for the first two (2) calendar quarters covered by such Initial Forecast. The quantities of SUPPLIED MATERIALS specified for the remaining quarters of such Initial Forecast shall be non-binding. Thereafter, ninety (90) days prior to the first business day of each subsequent calendar quarter during the Term, FIOCRUZ shall deliver to PROTALIX a rolling four (4) calendar quarter forecast updating the prior forecast (together with the Initial Forecast, each a &#8220;FORECAST&#8221;), together with a Purchase Order for the first two (2) calendar quarters of such Forecast. The quantities of SUPPLIED MATERIALS specified for the remaining two (2) quarters of such Forecast shall be non-binding. Unless agreed separately between the PARTIES, each Purchase Order shall specify no more than three (3) delivery dates for the SUPPLIED MATERIALS in each calendar quarter. Purchase Orders shall be in writing, and no verbal communications or e-mail shall be construed to mean a commitment to purchase or sell. PROTALIX shall confirm receipt of any valid Purchase Order as soon as reasonably practicable after receipt. Subject to Sections 6.2.2, PROTALIX shall provide SUPPLIED MATERIALS to FIOCRUZ pursuant to valid Purchase Orders issued by FIOCRUZ to PROTALIX. FIOCRUZ shall provide PROTALIX with a written acknowledgment of receipt of SUPPLIED MATERIALS within three (3) BUSINESS DAYS of its receipt of SUPPLIED MATERIALS. This written acknowledgment shall confirm the quantity of SUPPLIED MATERIALS delivered and the date of delivery.</p></td></tr><tr style="height:86.6pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.2.2</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Unless otherwise agreed in writing by PROTALIX, in no event shall PROTALIX be obligated to deliver quantities of SUPPLIED MATERIALS specified in a Purchase Order for a quarter which exceed [***] of the quantities specified by FIOCRUZ for the same period in the Forecast delivered in the prior calendar quarter. PROTALIX shall, however, use commercially reasonable efforts, but will be under no obligation, to supply SUPPLIED MATERIALS in excess of [***] of such quantities specified in such Forecast. Without limitation to the foregoing, in no event shall PROTALIX be required to supply quantities of SUPPLIED MATERIALS in excess of those commercially reasonable for PROTALIX to supply for any given period.</p></td></tr><tr style="height:4.5pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.2.3</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subject to Section 6.2.2, FIOCRUZ shall purchase all SUPPLIED MATERIALS ordered and specified in a Purchase Order. Purchase Orders may be delivered electronically or by other means to such location and in such manner as the PARTIES shall agree All Purchase Orders, confirmations of receipt of Purchase Orders and other notices contemplated under this Section 6.2 shall be sent to the attention of such persons as each party may identify to the other in writing from time to time in accordance with Section 20.9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:24.75pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.2.4</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Forecasts shall show demand for SUPPLIED MATERIALS on a monthly basis, and for the first three months of any such Forecast shall state the dates of required delivery for such SUPPLIED MATERIAL.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.2.5</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All Forecasts and Purchase Orders shall set forth the presentation of such SUPPLIED MATERIALS (e.g., FINISHED PACKAGED PRODUCT, NAKED VIALS, BULK PRODUCT).</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">13</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:40.5pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.2.6</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall not submit Purchase Orders for, and PROTALIX shall not be required to supply, any single delivery of SUPPLIED MATERIALS of less than [***] of SUPPLIED MATERIALS (or the equivalent thereof with respect to DRUG SUBSTANCE). For the avoidance of doubt, all vials supplied hereunder shall be [***].</p></td></tr><tr style="height:24.75pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.2.7</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PROTALIX shall use commercially reasonable efforts to meet FIOCRUZ requests for additional quantities beyond those set forth in Purchase Orders.</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.3</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Delivery; Risk of Loss</u>.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.3.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PROTALIX shall ship SUPPLIED MATERIALS ordered by FIOCRUZ as set forth in the applicable Purchase Order, in accordance with the terms hereof. PROTALIX shall deliver SUPPLIED MATERIALS to FIOCRUZ by the delivery date set forth in the applicable Purchase Order, or such other date as may be agreed to in writing by the PARTIES from time to time. PROTALIX shall deliver SUPPLIED MATERIALS to FIOCRUZ FCA Protalix airport, customs cleared at shipping point, as per Incoterms 2000.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.3.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PROTALIX shall include certificates of analysis with all shipments of SUPPLIED MATERIAL.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.3.3</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title to SUPPLIED MATERIAL shall pass to FIOCRUZ when the SUPPLIED MATERIAL has been delivered to FIOCRUZ pursuant to Article 6.3.1 above.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:37.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.3.4</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ is responsible for acquiring import permits, letters of credit, customs clearance in Brazil and local transportation and distribution necessary for the supply and receipt of SUPPLIED MATERIALS to be supplied to FIOCRUZ hereunder.</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.4</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Price; Payment; Taxes</u>.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 34.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.4.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:95.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the event the TECHNOLOGY TRANSFER is not COMPLETED by the end of the initial seven (7) year period, FIOCRUZ shall continue to obtain from PROTALIX its requirements of PROTALIX BULK PRODUCT for production of the PRODUCT at the same terms and conditions as described above and, for the renewal periods in TERM 1, PROTALIX shall provide [***]% discount over the last price of BULK PRODUCT as described in table below (6.4.2).</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 34.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.96%;"><tr style="height:1pt;"><td colspan="3" style="vertical-align:bottom;width:39.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:17.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.4.2</p></td><td colspan="7" style="background-color:#ffffff;vertical-align:top;width:83.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During TERM 1, the pricing for the SUPPLIED MATERIALS shall be as follows:</p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:bottom;width:39.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;"> [***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:17.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;"> [***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;"> [***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:37.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:bottom;width:39.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">FINISHED&#160;PACKAGED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PRODUCT&#160;PRICE&#160;</b> [***]</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:17.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NAKED&#160;VIALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PRICE&#160;</b> [***]</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BULK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PRODUCT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PRICE&#160;</b> [***]</p></td></tr><tr style="height:31.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:39.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5.5pt 0pt 0pt 0pt;">From the EFFECTIVE DATE until one (1) year after the EFFECTIVE DATE.</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td></tr><tr style="height:31.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:39.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5.5pt 0pt 0pt 0pt;">From the end of the foregoing period until two (2) years after the EFFECTIVE DATE.</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td></tr><tr style="height:31.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:39.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5.5pt 0pt 0pt 0pt;">From the end of the foregoing period until three (3) years after the EFFECTIVE DATE.</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td></tr><tr style="height:31.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:39.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5.5pt 0pt 0pt 0pt;">From the end of the foregoing period until four (4) years after the EFFECTIVE DATE.</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td></tr><tr style="height:31.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:39.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5.5pt 0pt 0pt 0pt;">From the end of the foregoing period until five (5) years after the EFFECTIVE DATE.</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td></tr><tr style="height:31.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:39.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5.5pt 0pt 0pt 0pt;">From the end of the foregoing period until six (6) years after the EFFECTIVE DATE.</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td></tr><tr style="height:43.45pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:39.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5.5pt 0pt 0pt 0pt;">From the end of the foregoing period until the COMPLETION of the TECHNOLOGY TRANSFER</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td><td style="background-color:#ffffff;vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:5.5pt 0pt 0pt 0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">14</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.4.3</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Invoices and Payment</u>. PROTALIX shall submit invoices to FIOCRUZ upon shipment of SUPPLIED MATERIALS to the address in the TERRITORY set forth in the applicable Purchase Order. FIOCRUZ shall pay all amounts due in U.S. Dollars within [***] from the date of receipt of the invoice by FIOCRUZ.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:76.25%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.4.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:79.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Taxes</u>. Subject to Article 9.5 of this Agreement:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9.9pt;text-align:justify;text-indent:-9.9pt;margin:0pt 0pt 0pt 62.69pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I.</p></td><td style="background-color:#ffffff;vertical-align:top;width:82.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">the Price includes all taxes except such sales, value-added and use taxes which PROTALIX is required by law to collect from FIOCRUZ;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9.9pt;text-align:justify;text-indent:-9.9pt;margin:0pt 0pt 0pt 62.69pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.99%;"><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">II.</p></td><td style="background-color:#ffffff;vertical-align:top;width:82.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">such taxes, if any, will be separately stated in PROTALIX&#39;s invoice and will be paid by FIOCRUZ to PROTALIX, unless FIOCRUZ provides an exemption to PROTALIX, and subject to receipt of a valid receipt or invoice to FIOCRUZ in the form and manner required by LAW to allow FIOCRUZ to recover such taxes to the extent allowable by LAW; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9.9pt;text-align:justify;text-indent:-9.9pt;margin:0pt 0pt 0pt 62.69pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.99%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">III.</p></td><td style="background-color:#ffffff;vertical-align:top;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PROTALIX shall be solely responsible for the timely payment of all such taxes to the applicable GOVERNMENTAL AUTHORITY.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:76.15%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.5</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Purchase Order Effective Upon Anvisa Approval; Letter of Credit</u>.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:283.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.5.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Notwithstanding anything to the contrary herein, (i) the PURCHASE ORDER set forth in Appendix IV for the first delivery, for [***], of PRODUCT for STAGE 0 of the Agreement shall be deemed to be delivered by FIOCRUZ to PROTALIX concurrently upon the EFFECTIVE DATE, and (ii) the PURCHASE ORDER for [***] of PRODUCT for completion of STAGE 0 of the AGREEMENT, shall be deemed to be delivered by FIOCRUZ to PROTALIX [***]. As security for payment of the PRICE for the PRODUCT to be ordered pursuant to such PURCHASER ORDER for the first delivery of STAGE 0, concurrently with the execution and delivery of this Agreement, FIOCRUZ shall execute and deliver to PROTALIX the letter of credit attached hereto as Appendix VI.&#160; For the avoidance of doubt, the quantity of PRODUCT purchased pursuant to such PURCHASE ORDER shall count towards and satisfy the first delivery requirement for STAGE 0 set forth in Section 5.1. As security for payment of the PRICE for the PRODUCT to be ordered pursuant to PURCHASE ORDERS, (a) concurrently with the execution and delivery of this AGREEMENT, FIOCRUZ shall request an irrevocable letter of credit to be confirmed by a first class USA bank covering the PURCHASE ORDER for the first delivery of STAGE 0 of this AGREEMENT, in the form of the request attached hereto as Appendix VI, (b) within thirty (30) days of the execution and delivery of this AGREEMENT, FIOCRUZ shall provide to PROTALIX a fully executed and effective irrevocable letter of credit confirmed by a first class USA bank covering the PURCHASE ORDER for the first delivery of STAGE 0 of this AGREEMENT, in a form reasonably acceptable to PROTALIX, and (c) on or prior to submission of each subsequent PURCHASE ORDER [***] FIOCRUZ shall execute and deliver other irrevocable letters of credit confirmed by a first class USA bank covering the PURCHASE ORDER for such delivery under the AGREEMENT (in the same form as the letter of credit provided by FIOCRUZ for the first delivery of STAGE 0 of this AGREEMENT), together covering the total amount of the AGREEMENT, along the duration of the AGREEMENT.&#160; [***]&#160; Notwithstanding anything to the contrary herein, PROTALIX shall have no obligation to ship any PRODUCT for any year of this AGREEMENT until a fully executed and effective letter of credit for such PURCHASE ORDER of the AGREEMENT (that complies with the terms of this Section 6.5.1) is delivered to PROTALIX.</p></td></tr><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.5.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the event that COMPLETION of the TECHNOLOGY TRANSFER is not achieved prior to the date occurring seven (7) years following the EFFECTIVE DATE, this AGREEMENT may be renewed, pursuant to and in accordance with Section 12.1; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> &#160;that, for each such renewal period, PURCHASE ORDERS and a letter of credit equivalent to those provided for in Section 6.5.1 are executed by FIOCRUZ and delivered to PROTALIX prior to such renewal</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">15</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:56.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">ARTICLE 7. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">MANUFACTURE; COMMERCIALIZATION AND QUALITY CONTROL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:48.15%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:94.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Manufacture</u></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.1.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the TERM following the EFFECTIVE DATE, FIOCRUZ shall perform the applicable MANUFACTURING steps with respect to the PRODUCTS solely in the FACILITY and solely from the SUPPLIED MATERIALS supplied by PROTALIX to FIOCRUZ.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="4" style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:61.9pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.1.2</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall employ only the MANUFACTURING and other processes, and shall comply with the quality control standards, included in the PROTALIX TECHNOLOGY provided to FIOCRUZ and shall ensure that the PRODUCTS complies with the SPECIFICATIONS, GMP standards and all applicable Brazilian LAWS. There shall be no changes made to such processes, standards, or SPECIFICATIONS without PROTALIX&#8217;s prior written consent.</p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="4" style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:37.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.1.3</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ represents and warrants that the FACILITIES and FIOCRUZ&#8217;s MANUFACTURING practices at the FACILITIES shall at all times comply with all applicable Brazilian LAWS, SPECIFICATIONS and GMP standards.</p></td></tr><tr style="height:61.9pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.1.4</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall use the PROTALIX TECHNOLOGY and SPECIFICATIONS (including any items provided pursuant to the TECHNOLOGY TRANSFER, such as the bioreactors, growth media, and cell banks) solely for the purposes of MANUFACTURING the PRODUCTS in the FACILITY, pursuant to and in accordance with this AGREEMENT, and not in connection with any other pharmaceutical products unless agreed to by the PARTIES in writing in advance.</p></td></tr><tr style="height:49.5pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.1.5</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PROTALIX may, in its sole discretion, modify the SPECIFICATIONS upon written notice to FIOCRUZ. PROTALIX shall use commercially reasonable efforts to provide written justification of such changes (which shall include information and data supporting such change) to FIOCRUZ in a reasonably prompt manner so that FIOCRUZ may update the PRODUCT registration in ANVISA held by FIOCRUZ.</p></td></tr><tr style="height:15.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Commercialization</u></p></td></tr><tr style="height:27.45pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.1</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall use its best efforts to diligently COMMERCIALIZE the PRODUCTS in accordance with this AGREEMENT.</p></td></tr><tr style="height:31.05pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.2</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ represents and warrants that FIOCRUZ&#8217;s COMMERCIALIZATION shall at all times comply with all applicable Brazilian LAWS and the highest commercial and ethical standards.</p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="4" style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:24.75pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2.3</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ&#8217;s COMMERCIALIZATION, including with respect to the marketing and promotion, of the PRODUCTS shall only be for the approved indications, dosage forms and strengths included in the FIELD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:18.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.3</p></td><td colspan="5" style="background-color:#ffffff;vertical-align:top;width:80.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Access to the Facilities and Technical Visits; Payment for Technical Assistance</u>.</p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="4" style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:86.6pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.3.1</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the TECHNOLOGY TRANSFER, PROTALIX shall have the right to enter the FACILITIES, during normal business hours to check and verify the FACILITY, DRUG SUBSTANCES, PRODUCTS, SUPPLIED MATERIALS and any MANUFACTURING processes, quality control standards and other activities relating to the foregoing or this AGREEMENT that are performed at the FACILITY to ensure compliance with this AGREEMENT (including compliance with the SPECIFICATIONS, GMP standards, and applicable Brazilian LAW and achievement of COMPLETION REQUIREMENTS). FIOCRUZ shall implement any mitigation plan reasonably identified by PROTALIX to address any such findings.</p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="4" style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.3.2</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall allow PROTALIX and/or its representatives/designees reasonable access to the FACILITIES and to its records in order to enable PROTALIX to conduct periodic reviews during normal business hours of the health and safety practices and performance of the FACILITIES. In connection with such audit or evaluation, FIOCRUZ shall cooperate in the completion of a Health &amp; Safety survey by PROTALIX or in the scheduling of a Health &amp; Safety audit of any FACILITY, as applicable. FIOCRUZ shall correct, at its own cost and expense, any material deficiencies in its health and safety management practices that are identified to it. FIOCRUZ acknowledges that such reviews and evaluations conducted by PROTALIX are for the benefit of PROTALIX only and are not a substitute for FIOCRUZ&#8217;s own health and safety management obligations under this AGREEMENT and, accordingly, FIOCRUZ may not rely upon them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">16</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.4</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:60.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Quality Control Testing/Validation</u>.</p></td></tr><tr style="height:111.4pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.4.1</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For each STAGE of the TECHNOLOGY TRANSFER, FIOCRUZ shall be responsible for validation of the MANUFACTURING and operating processes and quality control testing as conducted by FIOCRUZ at the FACILITIES. During the TECHNOLOGY TRANSFER, upon PROTALIX&#8217;s request, FIOCRUZ shall, at FIOCRUZ&#8217;s sole cost and expense, (a) submit a sample of any production batch of the PRODUCTS for parallel quality control testing to be performed by PROTALIX or representatives/designees, (b) make available to PROTALIX any books and records relating to the MANUFACTURING and operating processes, quality control testing, DRUG SUBSTANCE, SUPPLIED MATERIALS and the PRODUCTS, and (c) provide to PROTALIX all documentation reasonably necessary to evidence that the PROTALIX TECHNOLOGY and SUPPLIED MATERIALS have been used only in accordance with this AGREEMENT.</p></td></tr><tr style="height:61.9pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.4.2</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the TERM of the AGREEMENT, in accordance with Section 7.4.1(a), FIOCRUZ will supply with each sample supplied to PROTALIX, a certificate of analysis duly signed by an individual qualified and authorized with respect to the PRODUCTS in sufficient detail to demonstrate conformity with the SPECIFICATIONS. If any delivery consists of the PRODUCTS of more than one production batch, FIOCRUZ shall provide a certificate of analysis for each such batch.</p></td></tr><tr style="height:121.5pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.4.3</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the event that the results of the quality control tests of PROTALIX and FIOCRUZ are not consistent, FIOCRUZ shall, and PROTALIX, shall have the right but not the obligation to, repeat such tests, at FIOCRUZ&#8217;s sole cost and expense. In the event PROTALIX and FIOCRUZ repeated such tests and such inconsistency remains, an independent laboratory having a confirmed experience in<i style="font-style:italic;"> &#160;Recombinant Enzyme</i> &#160;testing agreed upon by both PROTALIX and FIOCRUZ in good faith shall be requested to perform the test and such test shall determine whether a batch can be released or not. The costs of such test by the laboratory shall be borne by FIOCRUZ. Any batch that has been finally rejected shall be destroyed at FIOCRUZ&#8217; expense and FIOCRUZ shall provide PROTALIX with destruction certificates. In case FIOCRUZ experiences, during the TECHNOLOGY TRANSFER, problems in meeting the quality of SPECIFICATIONS of PRODUCTS, the PARTIES will define corrective measures to ensure quality and carry out validation of such measures.</p></td></tr><tr style="height:49.5pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.4.4</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall be responsible for and reimburse PROTALIX for costs and reasonably agreed upon expenses incurred to provide technical assistance or training to FIOCRUZ, including all costs and expenses relating to travel (business class tickets for all flights), local transportation, hotel, food, and reasonable per diem expenses.</p></td></tr><tr style="height:37.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.4.5</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with the payment terms in Article 9, FIOCRUZ shall pay PROTALIX for the technical assistance and training provided by PROTALIX to FIOCRUZ (as agreed upon by PROTALIX and FIOCRUZ), at the following rates:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:92.99%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1.1pt;">Employee (other than Supervisors, Managers or Directors)</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***] U.S. dollars per hour</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1.1pt;">Supervisor:</p></td><td style="background-color:#ffffff;vertical-align:top;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***] U.S. dollars per hour</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1.1pt;">Manager:</p></td><td style="background-color:#ffffff;vertical-align:top;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***] U.S. dollars per hour</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1.1pt;">Senior Manager or Director</p></td><td style="background-color:#ffffff;vertical-align:top;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***] U.S. dollars per hour</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 8. </font></font>USE OF NAMES AND MARKS; PATENT RIGHTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:86.6pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Product Mark License to FIOCRUZ</u>. PROTALIX hereby grants to FIOCRUZ, during the Term, a non-exclusive, non-transferable, non-sublicensable, limited license to use the Product Marks as they exist on the labeling and packaging of the FINISHED PACKAGED Product at the time such FINISHED PACKAGED PRODUCT is supplied to FIOCRUZ by PROTALIX hereunder in connection with COMMERCIALIZATION of such PRODUCT within the Territory for the Field in accordance with the terms and conditions of this AGREEMENT. For the avoidance of doubt, FIOCRUZ is not granted any rights to display the PRODUCT MARKS other than on the labeling and packaging of such FINISHED PACKAGED PRODUCT as such PRODUCT MARKS are already displayed thereon.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">17</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:48.33%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:94.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Quality Control</u>.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.2.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall not alter, remove, cover or otherwise modify the labeling or packaging of any FINISHED PACKAGED PRODUCT (or any PRODUCT MARK thereon). The quality of the FINISHED PACKAGED PRODUCT sold or otherwise distributed by FIOCRUZ must be of the same quality as the FINISHED PACKAGED PRODUCT at the time it was supplied to FIOCRUZ hereunder.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:86.6pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.2.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall (a) comply with all applicable Brazilian Laws pertaining to the proper use and designation of the Product Marks, (b) modify the labeling and packaging of any FINISHED PACKAGED PRODUCT as directed by PROTALIX, (c) not use any Product Mark as a corporate name, business name, or trade name, (d) not use the PRODUCT MARKS in connection with any SUPPLIED MATERIALS or PRODUCTS other than the FINISHED PACKAGED PRODUCT or in any manner not expressly permitted hereunder, and (e) not use any Product Mark in a manner that would reasonably be expected to materially impair the validity, reputation, or distinctiveness of any Product Mark.</p></td></tr><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.3</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Prosecution and Maintenance of Product Marks</u>. PROTALIX (or its licensors) shall have the sole right, but not the obligation, through counsel of its choosing, to prosecute and maintain the Product Marks in and outside the Territory.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.15%;"><tr style="height:63pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.4</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Enforcement of Product Marks</u>. FIOCRUZ shall promptly notify PROTALIX in the event of any actual, potential or suspected infringement of a Product Mark by any Third PARTY. [***] shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third PARTY infringement of Product Marks. [***] shall be solely entitled to any and all recoveries from THIRD PARTIES resulting from such litigation or other appropriate action, after reimbursement from such recoveries of [***] costs and expenses in enforcing the PRODUCT MARKS in such litigation or other action [***].</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.5</p></td><td style="background-color:#ffffff;vertical-align:top;width:44.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Use of Names</u>.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.5.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">No right, expressed or implied, is granted by this AGREEMENT to FIOCRUZ to use in any manner the name or any other trade name of PROTALIX or its Affiliates.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.5.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Notwithstanding the foregoing Article 8.5.1, FIOCRUZ shall have the right to use the PROTALIX corporate name, subject to PROTALIX&#8217;s trademark usage guidelines provided to FIOCRUZ from time to time, on package inserts, packaging or trade packaging associated with the Products in the Territory solely to the extent required by applicable Laws. FIOCRUZ will submit for PROTALIX&#8217;s prior written approval a sample of each such proposed use of the PROTALIX corporate name prior to any use thereof.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:52.79%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.6</p></td><td style="background-color:#ffffff;vertical-align:top;width:94.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">FIOCRUZ Covenants</u>.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.15%;"><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:83.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:73.35pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.6.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:83.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other than as expressly permitted in this Article 8, FIOCRUZ shall not (a) use, register, or apply to register any name, mark, domain name, or logo that consists of or is confusingly similar to any name, mark, domain name, or logo owned or controlled by PROTALIX or its AFFILIATES; (b) use any name, mark, domain name, or logo owned or controlled by PROTALIX or its AFFILIATES together with any other mark or name, without prior written consent from such PARTY; or (c) take any action whereby any name, mark, domain name, or logo owned or controlled by PROTALIX or its AFFILIATES becomes invalid, unenforceable, generic or otherwise impaired.</p></td></tr><tr style="height:37.1pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.6.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:83.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall not take any action that in any way might tend to disparage, diminish, or reflect negatively upon the goodwill, reputation or value of PROTALIX, the PRODUCT, FIOCRUZ or any name, mark domain name or logo owned or controlled by PROTALIX or its AFFILIATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">.</p></td></tr><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.7</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Prosecution and Maintenance of PROTALIX PATENT RIGHTS</u>. PROTALIX shall have the sole right, but not the obligation, through counsel of its choosing, to prosecute and maintain the PROTALIX PATENT RIGHTS in and outside the TERRITORY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 73.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 57.75pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">18</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.15%;"><tr style="height:112.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.8</p></td><td colspan="4" style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Enforcement of PROTALIX PATENT RIGHTS</u>. FIOCRUZ shall promptly notify PROTALIX in the event of any actual, potential or suspected infringement of a PROTALIX PATENT RIGHT by any Third PARTY. PROTALIX shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third PARTY infringement of PROTALIX PATENT RIGHTS. FIOCRUZ shall [***] cooperate with PROTALIX in any such litigation or other remedial measure, including by being named as a party if necessary to institute or maintain such litigation or other remedial measure. If FIOCRUZ is so named, it may hire its own counsel at its sole cost and expense to participate in such litigation or other remedial measure, provided that PROTALIX and its counsel shall at all times and in all cases control such litigation or other remedial measure. [***][***] shall be entitled to any and all recoveries from THIRD PARTIES resulting from such litigation or other remedial action, after reimbursement from such amount of [***] costs and expenses in enforcing the PROTALIX PATENT RIGHTS in such litigation or action [***].</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 9. </font></font>ROYALTY, REPORTING AND PAYMENT TERMS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:98.55pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Royalties</u>. Commencing upon FIOCRUZ&#8217;s completion of a Phase III clinical trial and obtaining a GOVERNMENTAL APPROVAL from ANVISA for the MANUFACTURE entirely by FIOCRUZ of the FINAL PRODUCT in the TERRITORY, FIOCRUZ shall pay to PROTALIX for the exploitation of the PROTALIX patent RIGHTs and the PROTALIX TECHNOLOGY in the TERRITORY a running royalty of [***] of Net Sales (the &#8220;ROYALTY PAYMENTS&#8221;), on a quarterly basis in the manner described in this Article 9. For the avoidance of doubt, (i) FIOCRUZ shall not COMMERCIALIZE the FINAL PRODUCT until completion of a Phase III clinical trial and obtaining a GOVERNMENTAL APPROVAL from ANVISA for the MANUFACTURE entirely by FIOCRUZ of the FINAL PRODUCT in the TERRITORY, and (ii) the requirement to pay ROYALTY PAYMENTS shall survive any termination or expiration of this AGREEMENT until the expiration of the last to expire PROTALIX patent in Brazil.</p></td></tr><tr style="height:86.6pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Royalty Reporting and Payment</u>. Not later than thirty (30) days after the end of each calendar quarter during the Term (a &#8220;REPORTING PERIOD&#8221;), FIOCRUZ shall (a) submit to PROTALIX a written report setting forth in reasonable detail (i) gross sales of FINAL Product during the Reporting Period, (ii) Net Sales and number of units of FINAL Product sold or distributed during the Reporting Period, as well as the computation of such Net Sales amounts, (iii) inventory of FINAL PRODUCT at the beginning and end of such Reporting Period, and (iv) all other information related to the business of FIOCRUZ during such Reporting Period to the extent necessary to enable the calculation of amounts payable hereunder to be verified, and (b) pay PROTALIX all amounts due for such Reporting Period.</p></td></tr><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.3</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Other Payments</u>. Other than the Royalty Payments, which are subject to Article 9.2, all other payments (including any reimbursements) arising hereunder shall, unless otherwise set forth herein, be paid not later than [***] of receipt of an invoice or notice therefor.</p></td></tr><tr style="height:74.25pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Interest and other Charges</u>. In the event that PROTALIX does not receive on or prior to the date when due hereunder all amounts owed by FIOCRUZ to PROTALIX, such unpaid amount shall be automatically subject to a flat penalty of [***] and monthly adjustment for inflation based on the positive variation of the [IGP-M/FGV] in the period. Any such amount (as increased by the penalty and the monetary correction mentioned above) shall bear default interest from the due date until payment is received by such PARTY at a rate of [***] per month (the &#8220;RATE&#8221;). The above additional charges shall be in addition to, and not in lieu of, any other remedy available to PROTALIX hereunder.</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.5</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Taxes and Other Charges</u>. FIOCRUZ represents and warrants to PROTALIX that, as of the EXECUTION DATE, there are no Brazilian taxes, customs, duties, assessments, excises, registration fees, surtax, stamp duties, or any other charges that are required to be levied upon or withheld from the importation of or assessed against the material furnished or rights licensed by PROTALIX hereunder, or for or on account of the operation of the FACILITY, the purchase, MANUFACTURE, COMMERCIALIZATION by or on behalf of FIOCRUZ of the SUPPLIED MATERIALS and PRODUCTS, or other business of FIOCRUZ contemplated under this AGREEMENT, including any withholding taxes or any such payments related to the registration or recording of this AGREEMENT, or any related documents (not including any ANVISA registration fees) (collectively &quot;TAXES AND FEES&quot;), other than as set forth in Exhibit C (which shall include details regarding applicable percentages and amounts if any such TAXES AND FEES, and the PARTY to be responsible therefore). If there are any TAXES AND FEES under Brazilian LAW that are not set forth on Exhibit C and are, or during the TERM become, in effect (whether as a result of any change in, or amendment to, Brazilian LAWS or otherwise), and such TAXES AND FEES materially change the dollar amount or timing of payments expected to be received by PROTALIX hereunder, then (i) the PARTIES shall discuss in good faith how to address such change in a mutually acceptable manner to compensate PROTALIX for such change (e.g., by an increase in pricing of PRODUCT, an increase in amount of PRODUCT to be purchased, etc.), and (ii) if the PARTIES do not come to an agreement in writing with respect thereto within thirty (30) calendar days, PROTALIX shall have the right to terminate this AGREEMENT immediately upon written notice to FIOCRUZ.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">19</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:86.6pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.6</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Currency and Mode of Payment</u>. All payments to be made hereunder by one PARTY to another PARTY shall be paid in United States dollars, by electronic transfer in immediately available funds via either a bank wire transfer, an electronic funds transfer mechanism, at the paying PARTY&#8217;s election, to the bank account designated in Appendix VII or otherwise designated by the PARTY entitled to receive such payment. ROYALTY PAYMENTS and other payments due hereunder shall be converted into U.S. dollars at the exchange rate quoted by Brazilian Central Bank (or its successor in interest) at its market rate for the purchase of U.S. dollars with the applicable currency that needs to be converted (e.g., the currency of the Net Sales received) and applied by that bank on the day such payment is made.</p></td></tr><tr style="height:99pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.7</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Permits</u>. FIOCRUZ assumes the sole responsibility of procuring Permits for the export of funds as may be required in the Territory; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that to the extent that it is impossible to make such payments due to the &#8220;blocking&#8221; of funds by LAW, such &#8220;blocked&#8221; funds shall be deposited to the credit of PROTALIX, in such depository as PROTALIX designates or, at the option of PROTALIX, paid directly to a Brazilian entity designated by PROTALIX. Other than as set forth on Exhibit C, there shall be no deduction or offset from, nor shall FIOCRUZ have any right to hold back any payment of, any payments owed by FIOCRUZ hereunder for any reason, including for any uncollectible accounts or other TAXES AND FEES for which FIOCRUZ is responsible hereunder, or for any banking cost or cost of exchange or expense of transmitting said funds. FIOCRUZ shall not conduct its business in any manner intended to reduce the ROYALTY PAYMENTS required to be paid by FIOCRUZ hereunder.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 10. </font></font>OWNERSHIP OF ENHANCEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:86.6pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any invention made, conceived or reduced to practice by PROTALIX in connection with the performance of the obligations of this AGREEMENT relating to: (i) a pharmaceutical product with the same chemical composition as the PRODUCT or (ii) an IMPROVEMENT to the PRODUCT or (iii) an IMPROVEMENT to the process or specifications provided by PROTALIX to FIOCRUZ, shall be the exclusive property of PROTALIX. PROTALIX, in its sole discretion, may file for patent protection in its own name for any such invention. PROTALIX shall, and hereby does, grant to FIOCRUZ a non-exclusive, irrevocable, perpetual, worldwide, royalty-free license to use, sublicense, practice and otherwise exploit in any manner any such invention and any patent or other intellectual property or proprietary rights therein throughout the world.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 11. </font></font>CONFIDENTIALITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:185.6pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All non-public information, which is received or made available by or on behalf of PROTALIX or FIOCRUZ (each, in such capacity, the &#8220;RECIPIENT&#8221;) from or on behalf of the other (in such capacity, the &#8220;DISCLOSING PARTY&#8221;) prior to or during the Term of this AGREEMENT in connection with this AGREEMENT or relating hereto, including without limitation, relating to the PRODUCT or any other pharmaceutical product that contains DRUG SUBSTANCE (&#8220;CONFIDENTIAL INFORMATION&#8221;) shall be maintained in confidence and shall not be disclosed to any Third PARTY nor used for purposes other than as set forth herein, without the prior written consent of the DISCLOSING PARTY, except to the extent that the CONFIDENTIAL INFORMATION: (a) is known to the RECIPIENT prior to disclosure by the DISCLOSING PARTY to the RECIPIENT through no wrongful act of the RECIPIENT, provided that the RECIPIENT is able to provide competent proof of such prior knowledge; (b) is obtained by the RECIPIENT in a lawful manner from a source other than the DISCLOSING PARTY, which source (i) was not required to hold such secrets or information in confidence, and (ii) was not limited or restricted in its disclosure thereof, (c) has become public knowledge other than through the fault of the RECIPIENT; (d) has been developed by the RECIPIENT independently of the information received as established by written records. The PROTALIX TECHNOLOGY, SPECIFICATIONS and all other information relating thereto or to the business, operations, research or development of PROTALIX, shall be deemed included in the CONFIDENTIAL INFORMATION of PROTALIX.</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Notwithstanding the foregoing, RECIPIENT shall be entitled to disclose CONFIDENTIAL INFORMATION to the extent disclosure by the RECIPIENT is required: (a) to submit applications by the RECIPIENT for GOVERNMENTAL APPROVALS (i) in the case of FIOCRUZ as RECIPIENT, to MANUFACTURE and COMMERCIALIZE the Product in accordance with the terms and conditions of this AGREEMENT, or (ii) in the case of PROTALIX as the RECIPIENT, in relation to the COMPOUND, DRUG SUBSTANCE, or PRODUCT, (b) in the case of PROTALIX as the RECIPIENT, in connection with filing or prosecution of the PROTALIX PATENT RIGHTS or the PRODUCT MARKS, prosecuting or defending litigation relating thereto or to the PROTALIX TECHNOLOGY, or (c) by LAW or by any THIRD PARTY LICENSE; <u style="text-decoration:underline;text-decoration-color:#000000;"> provided</u> &#160;that the RECIPIENT shall use commercially reasonable efforts to obtain confidential treatment of any CONFIDENTIAL INFORMATION to the extent applicable and, if reasonably practicable under the circumstances, provide the DISCLOSING PARTY with sufficient advance notice of such intended disclosure so that the DISCLOSING PARTY will have the opportunity to seek, at its own cost, an appropriate protective order or other remedy, to the extent applicable, or waive compliance with the provisions of this AGREEMENT. If the DISCLOSING </p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">20</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PARTY seeks a protective order, the RECIPIENT will cooperate. If the DISCLOSING PARTY fails to obtain a protective order or waive compliance with the relevant portions of this AGREEMENT, the RECIPIENT will disclose only that portion of information concerning the COMPOUND or PRODUCT which its legal counsel determines it is required to disclose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:98.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.3</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the avoidance of doubt, the [***] shall be deemed included in the CONFIDENTIAL INFORMATION of PROTALIX. In addition to the obligations set forth in Article 11.1 and 11.2, FIOCRUZ agrees to (i) treat the [***] with the utmost confidence and in a manner at least as protective as the manner in which FIOCRUZ protects its own most highly sensitive confidential information, trade secrets and know-how, (ii) not use such [***] for any purpose other than for the MANUFACTURING of the FINAL PRODUCT, and (iii) not disclose the information to any PERSON, other than as permitted pursuant to Article 11.2 to PERSONS (a) who have a need to know such information for the purpose of MANUFACTURING the FINAL PRODUCT, (b) who are informed by FIOCRUZ of the confidential nature thereof and the obligations under this AGREEMENT with respect thereto, and (c) who agree in writing with PROTALIX to comply with the obligations of FIOCRUZ under this Article 11 with respect thereto.</p></td></tr><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The confidentiality obligations set forth in this Article 11 shall survive the termination or expiration of this AGREEMENT until fifteen (15) years from the EFFECTIVE DATE. Notwithstanding anything to the contrary herein, FIOCRUZ&#39;s obligations under this Article 11 with respect to the [***] shall survive the termination or expiration of this AGREEMENT for no less than fifteen (15) years from the completion of the transfer of such [***] to FIOCRUZ.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 12. </font></font>TERM AND TERMINATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:87.3pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This AGREEMENT shall come into force and effect as of the EFFECTIVE DATE, and shall remain in force for seven (7) years following the EFFECTIVE DATE, and may be renewed upon the written agreement of FIOCRUZ and PROTALIX, if INPI authorizes such renewal, for additional five (5) years periods. If in the end of the initial seven (7) year period or any such renewal period the TECHNOLOGY TRANSFER has not been COMPLETED, the PARTIES may renew the AGREEMENT for the period needed for the COMPLETION of the TECHNOLOGY TRANSFER in accordance with the foregoing sentence (the initial period and any such renewal periods, collectively, &quot;TERM 1&quot;), and upon COMPLETION of the TECHNOLOGY TRANSFER TERM 1 shall immediately and automatically expire and TERM 2 shall immediately and automatically commence.</p></td></tr><tr style="height:72pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall pay royalties hereunder to PROTALIX for the PROTALIX PATENT RIGHTS for the period of time beginning on the completion of TERM 1 until the later of expiration of the last to expire PROTALIX patent in Brazil in accordance with ARTICLE 9 (&quot;TERM 2&quot;). The TERM 2 is valid only for the purpose of royalties payment, any terms and conditions relating to PROTALIX PATENT RIGHTS or PRODUCT MARKS in any way (including, for the avoidance of doubt, all license rights and restrictions), and any other obligations that survive termination or expiration of this AGREEMENT. The other obligations of this AGREEMENT (i.e., those obligations not referenced in the foregoing sentence) shall expire with the end of TERM 1.</p></td></tr><tr style="height:18pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.3</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Without limiting any other provision of this AGREEMENT, this AGREEMENT may be terminated by PROTALIX as follows:</p></td></tr><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:97.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">if FIOCRUZ materially breaches its representations or warranties made in this AGREEMENT, or materially breaches or materially defaults in the performance or observance of any of its obligations under this AGREEMENT, and such breach or default is not cured within [***] after the giving of written notice by PROTALIX, specifying such breach or default, then PROTALIX shall have the right to terminate this AGREEMENT by providing FIOCRUZ written notice following the expiration of such [***][***] period (such termination to be effective upon receipt of such termination notice);</p></td></tr><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(b)</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">immediately upon written notice to FIOCRUZ if any GOVERNMENTAL AUTHORITY announces plans to privatize FIOCRUZ and a competitor of PROTALIX acquires FIOCRUZ or any part of FIOCRUZ that is responsible for the MANUFACTURE or COMMERCIALIZATION of PRODUCTS;</p></td></tr><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(c)</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:97.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">if FIOCRUZ fails to make any payment when due in accordance with the terms and conditions of this AGREEMENT and such failure to pay is not cured within [***] after the giving of written notice by PROTALIX of such failure, then PROTALIX shall have the right to terminate this AGREEMENT by providing FIOCRUZ written notice following the expiration of such [***] period (such termination to be effective upon receipt of such termination notice);</p></td></tr><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d)</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">immediately upon written notice if FIOCRUZ undergoes a change of control (as such term is defined in the definition of AFFILIATE);</p></td></tr><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(e)</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:97.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">immediately upon written notice if FIOCRUZ orders, purchases, accepts or otherwise imports from a third party any product that is a therapy for the treatment of Gaucher Disease;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 34.1pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">21</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.15%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:97.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:52.65pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(f)</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">immediately upon written notice in the event of: (i) FIOCRUZ&#8217;s insolvency or bankruptcy, (ii) a liquidation committee or team being formed pursuant to the liquidation rules or Laws of any applicable jurisdiction with respect to FIOCRUZ, or substantially all of the property or assets of FIOCRUZ is under custody by the liquidation committee under the provisions of any bankruptcy, insolvency, or similar LAW, (iv) FIOCRUZ making an assignment for the benefit of its creditors, or (v) FIOCRUZ being dissolved; and</p></td></tr><tr style="height:74.25pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(g)</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The purchase by and supply to FIOCRUZ of SUPPLIED MATERIALS during each STAGE in order to proceed to the subsequent STAGE of TECHNOLOGY TRANSFER shall occur subject to [***] and PROTALIX&#8217;s prior written approval of such quantities. In the event that (i) PROTALIX does not agree in advance in writing with such quantities proposed by the Brazilian MOH or (ii) the [***] and corresponding PURCHASE ORDERS issued by FIOCRUZ to PROTALIX for any year are less than the amount set forth in the following chart for any given year, PROTALIX shall have the right to terminate this AGREEMENT immediately upon providing FIOCRUZ written notice:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Yearly Termination Threshold</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="background-color:#ffffff;vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Termination Threshold</b></p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From January 1, 2014 until July 31, 2015</p></td><td style="background-color:#ffffff;vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From August1, 2015 until July 31, 2016</p></td><td style="background-color:#ffffff;vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From August 1, 2016 until July 31, 2017</p></td><td style="background-color:#ffffff;vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From August 1, 2017 until July 31, 2018</p></td><td style="background-color:#ffffff;vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From August 1, 2018 until July 31, 2019</p></td><td style="background-color:#ffffff;vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From August 1, 2019 until July 31, 2020</p></td><td style="background-color:#ffffff;vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.1pt;">&#160;&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Without limiting any other provision of this AGREEMENT, this AGREEMENT may be terminated by FIOCRUZ as follows:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 34.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:top;width:97.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:97.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">if PROTALIX materially breaches its representations or warranties made in this AGREEMENT, or materially breaches or defaults in the performance or observance of any of its respective obligations under, this AGREEMENT, and such breach or default is not cured within [***] after the giving of written notice by FIOCRUZ to PROTALIX specifying such breach or default, then FIOCRUZ shall have the right to terminate this AGREEMENT by providing PROTALIX written notice following the expiration of such [***] period (such termination to be effective upon receipt of such termination notice);</p></td></tr><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(b)</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">immediately upon notice to PROTALIX if FIOCRUZ due to any change in Brazilian LAW is unable to maintain compliance with this AGREEMENT; &#160;<u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> FIOCRUZ used its best efforts to prevent any of the foregoing events from occurring and to mitigate or cure any effects thereof prior to exercising such termination right; and</p></td></tr><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(c)</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:97.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">if the pharmaceutical product<i style="font-style:italic;"> plant cell expressed recombinant Glucocerebrosidase</i> in a finished dosage form of a drug product that contains DRUG SUBSTANCE (excluding any ORAL FORMULATION) is recalled by both ANVISA and the United States Food and Drug Administration in a manner that is not curable within [***]. In the case of termination pursuant to this Section 12.4(c), FIOCRUZ shall not be required to pay any outstanding payment obligations incurred prior to the effective date of such termination under this AGREEMENT for any PRODUCT batches subject to such recall.</p></td></tr><tr style="height:29.25pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.5</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall notify PROTALIX at least twenty (20) days prior to the occurrence of any of the events or scenarios described in Articles 12.3(b) and (d) and 12.4(b), or, if not possible on such time frame, as soon as possible prior to such occurrence.</p></td></tr><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.6</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Termination of this AGREEMENT shall be in addition to, and not in lieu of, any other rights or remedies available to the terminating PARTY under this AGREEMENT or applicable Brazilian LAW. Termination of this AGREEMENT in accordance with the terms hereof shall not be the basis for any compensation or other claim for damages resulting therefrom (including any lost profits due to such termination), other than as set forth in Section 12.7.</p></td></tr><tr style="height:74.25pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.7</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Termination of this AGREEMENT for any reason (a) shall be without prejudice to and shall not impair or limit in any manner PROTALIX&#8217;s right to receive payment from FIOCRUZ in respect of any payment obligations incurred prior to the effective date of such termination, whether or not the due date for such payment is after such effective date of termination and (b) shall not release a PARTY hereto from any indebtedness, liability, payment or other obligation incurred hereunder (including liability for breach of this AGREEMENT) by such PARTY prior to the effective date of such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 52.6pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">22</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:77.2pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 13. </font></font>EFFECTS OF TERMINATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Except as expressly provided for hereunder, upon the effective date of termination of this AGREEMENT in accordance with this AGREEMENT, all licenses and rights granted to FIOCRUZ herein shall automatically and immediately terminate and FIOCRUZ shall immediately cease all use of the PROTALIX TECHNOLOGY, PROTALIX PATENTS, SPECIFICATIONS and any other CONFIDENTIAL INFORMATION provided to FIOCRUZ hereunder.</p></td></tr><tr style="height:148.05pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall, promptly after termination of this AGREEMENT, provide to PROTALIX or its designee (or upon PROTALIX&#8217;s direction with respect to specific items, destroy) all documents, data, reports, records, regulatory correspondence and other materials and information (and any copies thereof) that contain or are related to the PROTALIX TECHNOLOGY, CONFIDENTIAL INFORMATION disclosed by PROTALIX, and the COMPOUNDS, DRUG SUBSTANCES, CELL BANK, reagents, and PRODUCTS (including and GOVERNMENTAL APPROVALS and regulatory filings with respect thereto) in a form and format useable by PROTALIX. Upon such termination, FIOCRUZ shall assign and transfer to PROTALIX or its designee all of FIOCRUZ&#8217;s right, title and interest in and to all GOVERNMENTAL APPROVALS for or related to the PRODUCTS, COMPOUND or DRUG SUBSTANCE in the Territory and any related data and other materials transferred or delivered or deliverable by FIOCRUZ pursuant to this Article 13.2. FIOCRUZ shall execute and deliver to PROTALIX such documents, and take such other actions requested by PROTALIX that are necessary or appropriate to carry out the intent and purposes of this Article 13.2 and to perfect and confirm such assignment, including submitting letters to the GOVERNMENTAL AUTHORITIES in forms reasonably acceptable to PROTALIX.</p></td></tr><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.3</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Following termination of this AGREEMENT, upon a PARTY&#8217;s reasonable request and at such requesting PARTY&#8217;s cost, the other PARTY shall reasonably cooperate with the requesting PARTY (including by providing relevant information and data) in connection with any requests or investigations of a regulatory authority, any Third PARTY claims against the requesting PARTY, or such requesting PARTY&#8217;s efforts to comply with Laws, relating to the PRODUCTS, COMPOUND, DRUG SUBSTANCE, PROTALIX TECHNOLOGY, or SPECIFICATIONS.</p></td></tr><tr style="height:74.25pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Upon termination of this AGREEMENT, FIOCRUZ shall terminate the MANUFACTURE and COMMERCIALIZATION of any COMPOUND, DRUG SUBSTANCE, or PRODUCTS and, at PROTALIX&#8217;s sole option, shall (a) only in the event of termination by PROTALIX pursuant to Article 12.3, arrange the sale to PROTALIX or its designee at FIOCRUZ&#8217;s cost of all (or at PROTALIX&#8217;s option, a portion of the) SUPPLIED MATERIAL, DRUG SUBSTANCES and PRODUCTS in FIOCRUZ&#8217;s inventory, and/or (b) dispose of all (or at PROTALIX&#8217;s option, a portion of the) SUPPLIED MATERIAL, DRUG SUBSTANCES and PRODUCTS in FIOCRUZ&#8217;s inventory.</p></td></tr><tr style="height:52.65pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.5</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Upon termination of this AGREEMENT, FIOCRUZ shall cooperate with PROTALIX to effect a cancellation or termination of any recordation of this AGREEMENT with the appropriate Governmental Authorities in the Territory, and the FIOCRUZ will grant, and hereby does grant, to PROTALIX an irrevocable power of attorney coupled with an interest to effect such cancellation within twenty (20) days after the termination of this AGREEMENT.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:77.2pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 14. </font></font>BOOKS AND RECORDS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">14.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall keep and maintain during the TERM and for one (1) years after the termination of this AGREEMENT, accurate and correct books and records setting forth gross sales of the PRODUCTS, Net Sales, number of units of PRODUCT sold, inventory of PRODUCT and all other information related to the business of FIOCRUZ necessary to enable the calculation of amounts payable hereunder to be verified and the confirmation of FIOCRUZ&#8217;s compliance with this AGREEMENT. PROTALIX shall have the right to request that an independent accountant reasonably selected by it examine FIOCRUZ&#8217;s books and records at any reasonable time, upon reasonable notice and at the Facilities or other facilities where such books and records are normally kept. The opinion of such independent accountants regarding such payments shall be binding on the PARTIES, other than in the case of manifest error. Except as set forth below, the auditing PARTY shall bear the cost of any such examination and review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">14.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If the review of FIOCRUZ&#8217;s records reveals that FIOCRUZ failed to accurately report information pursuant to Article 9.2 or otherwise underpaid any amounts due hereunder, then FIOCRUZ&#8217;s shall promptly pay PROTALIX the amount of any underpayment due hereunder, which shall be subject to all additional charges mentioned in Article 9.4 above, including the default interest at the Rate. If such discrepancy is greater than five percent (5%) of the amount due, FIOCRUZ shall promptly reimburse all costs incurred by PROTALIX in connection with such examination.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">23</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 15. </font></font>GOVERNING LAW</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The PARTIES agree that this AGREEMENT shall be governed by and construed in accordance with the laws of Brazil and the courts of Brazil shall have jurisdiction over any disputes arising in connection with this AGREEMENT. It is acknowledged that PROTALIX and FIOCRUZ shall not be excluded from adjudicating and enforcing their rights under this AGREEMENT as relate to countries other than Brazil (including but not limited to enforcing any restriction on a PARTY outside the TERRITORY) in courts other than the courts of Brazil.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 16. </font></font>INDEMNIFICATION; DISCLAIMER; LIMITATION OF LIABILITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:99pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.1</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall indemnify, defend and hold PROTALIX and its AFFILIATES and their respective directors, officers, shareholders, representatives, agents, successors, assigns, licensors and employees harmless from and against all Losses, in each case to the extent arising out of (a) any acts or omissions of FIOCRUZ or any of its Affiliates, agents, consultants or contractors in connection with its activities under this AGREEMENT, including MANUFACTURE, use or sale of the SUPPLIED MATERIALS, COMPOUND, Drug Substance and/or Products, unless such Losses are for Losses to which FIOCRUZ is entitled to indemnification pursuant to Article 16.2, as applicable, (b) the breach of any covenant, warranty or representation made by FIOCRUZ under this AGREEMENT, or (c) the negligence, recklessness, or willful misconduct of, or violation of Brazilian LAW by, FIOCRUZ or any of its Affiliates, agents, consultants or contractors.</p></td></tr><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.2</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PROTALIX shall indemnify, defend and hold FIOCRUZ and its AFFILIATES and their respective directors, officers, shareholders, representatives, agents, successors, assigns, and employees harmless from and against all Losses arising from Third PARTY Claims that the MANUFACTURE and sale of the PRODUCTS by FIOCRUZ within the Territory for the Field in accordance with the terms and conditions hereof, infringes any Patent Rights of any THIRD PARTY.</p></td></tr><tr style="height:106.65pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.3</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For purposes of this AGREEMENT, &#8220;THIRD PARTY CLAIM&#8221; means a claim asserted by a Third PARTY (in no event to include any Affiliate of either PARTY) against a PARTY or any of its Affiliates, or any of their respective directors, officers, shareholders, representatives, agents, successors, assigns, licensors or employees. In the event a Third PARTY Claim is asserted or LOSSES are incurred with respect to any matter for which a PARTY or any of its Affiliates, or any of their respective directors, officers, shareholders, representatives, agents, successors, assigns, licensors and employees (the &#8220;INDEMNIFIED PARTY&#8221;) is entitled to indemnification hereunder, then the Indemnified PARTY shall promptly notify in writing the PARTY obligated to indemnify the Indemnified PARTY (the &#8220;INDEMNIFYING PARTY&#8221;) thereof; <u style="text-decoration:underline;text-decoration-color:#000000;"> provided</u> , however, that no delay on the part of the Indemnified PARTY in notifying the Indemnifying PARTY shall relieve the Indemnifying PARTY from any obligation hereunder unless (and then only to the extent that) the Indemnifying PARTY is prejudiced thereby.</p></td></tr><tr style="height:131.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:95.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Indemnifying PARTY shall assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third PARTY Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying PARTY and reasonably acceptable to the Indemnified PARTY. The Indemnified PARTY shall have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense of any Third PARTY Claim that the Indemnifying PARTY is defending as provided in this AGREEMENT. Notwithstanding anything to the contrary contained herein, an Indemnified PARTY shall be entitled to assume the defense of any Third PARTY Claim with respect to the Indemnified PARTY, (i) upon written notice to the Indemnifying PARTY, in which case the Indemnifying PARTY shall be relieved of liability under Article 16.1 or 16.2, as applicable, solely for such Third PARTY Claim and related Losses, or (ii) in the event the INDEMNIFYING PARTY refuses or fails to assume the defense as required hereunder, in which case the Indemnifying PARTY shall not be relieved of liability under Article 16.1 or 16.2, as applicable, solely for such Third PARTY Claim and related Losses.</p></td></tr><tr style="height:111.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.5</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ will not enter into any settlement of any THIRD PARTY CLAIM for which PROTALIX or any of its Affiliates, or any of their respective directors, officers, shareholders, representatives, agents, successors, assigns, licensors or employees is entitled to indemnification hereunder involving PROTALIX TECHNOLOGY, PROTALIX PATENT RIGHTS, CONFIDENTIAL INFORMATION of PROTALIX, PRODUCT MARKS, COMPOUND, Drug Substance, PRODUCTS or SUPPLIED MATERIALS, without such Indemnified PARTY&#8217;s prior written consent. Without limiting the foregoing, FIOCRUZ shall not, without the written consent of the Indemnified PARTY (which consent shall not be unreasonably withheld), effect any settlement of any pending or threatened litigation in which the Indemnified PARTY has sought indemnification hereunder by FIOCRUZ, unless such settlement involves solely monetary damages and includes an unconditional release of the Indemnified PARTY from all liability on claims that are the subject matter of such litigation.</p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">24</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:160.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">&#160;</font>&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.6</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE UNDER THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING LOSS OF PROFITS OR REVENUE, SUFFERED BY PROTALIX, FIOCRUZ OR ANY OF THEIR RESPECTIVE AFFILIATES. THE FOREGOING SENTENCE SHALL NOT LIMIT (A) THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY AS PROVIDED HEREUNDER, (B) ANY LIABILITIES RESULTING FROM A BREACH OF THE CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 11 OR FROM USE OF ANY INTELLECTUAL PROPERTY OTHER THAN IN ACCORDANCE WITH THE LICENSE GRANTED PURSUANT TO ARTICLE 4, OR (C) ANY PAYMENT OBLIGATIONS UNDER THIS AGREEMENT. &#160;EXCEPT FOR LOSSES TO THE EXTENT RESULTING FROM PROTALIX&#39;S GROSS NEGLIGENCE, FRAUD OR WILLFUL MISCONDUCT, IN NO EVENT SHALL PROTALIX&#39;S TOTAL LIABILITY TO FIOCRUZ ARISING IN CONNECTION WITH THE SUPPLY OF SUPPLIED MATERIALS PURSUANT TO SECTION 6 HEREOF EXCEED, ON A SUPPLIED MATERIAL-BY-SUPPLIED MATERIAL BASIS, THE TOTAL AMOUNT PAID BY FIOCRUZ FOR SUCH SUPPLIED MATERIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 17. </font></font>WARRANTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">17.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Each PARTY hereby represents and warrants as of the EXECUTION DATE and the Effective Date that such PARTY has the requisite corporate power and authority to execute and deliver this AGREEMENT and to perform its obligations hereunder, and that the execution, delivery and performance of this AGREEMENT by such PARTY has been duly and validly authorized and approved by proper corporate action on the part of such PARTY, and such PARTY has taken all other action required by LAW,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>its certificate of incorporation, by-laws or other organizational documents, required to authorize such execution, delivery and performance. Assuming due authorization, execution and delivery on the part of the other PARTY, each PARTY represents and warrants as of the EFFECTIVE DATE that this AGREEMENT constitutes a legal, valid and binding obligation of such PARTY, enforceable against such PARTY in accordance with its terms.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">17.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ hereby represents and warrants to PROTALIX as of the EXECUTION DATE and the EFFECTIVE DATE, and covenants to PROTALIX, as follows:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 34.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:111.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the COMPOUND, Drug Substance and Products Manufactured by, or under authority of, FIOCRUZ: (i) any FACILITY and all equipment, tooling and molds utilized in the Manufacture hereunder by FIOCRUZ shall be maintained in good operating condition and shall be maintained and operated in accordance with all applicable Brazilian Laws and GMP, (ii) the Manufacturing, COMMERCIALIZATION and storage operations, procedures and processes utilized by FIOCRUZ hereunder (including any Facility) shall be in full compliance with all applicable Brazilian Laws, including GMP and Brazilian health and safety Laws, (iii) FIOCRUZ shall hold all Permits required by any Governmental Authority for it to Manufacture, COMMERCIALIZE and otherwise distribute the COMPOUND, Drug Substance and PRODUCTS in accordance with this AGREEMENT (subject to Article 5.1.5), and (iv) the PRODUCTS, or its containers, shall be marked by FIOCRUZ in accordance with the applicable patent marking LAWS.</p></td></tr><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(b)</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The COMPOUND, Drug Substance and Products, as applicable, shall be Manufactured, COMMERCIALIZED, packaged, labeled, handled, stored and shipped by FIOCRUZ, in accordance with the SPECIFICATIONS and in compliance with all applicable Brazilian Laws and GMP, and in accordance with the PHARMACOVIGILANCE AGREEMENT and any other quality assurance requirements provided in writing to FIOCRUZ by PROTALIX, and this AGREEMENT.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 34.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(c)</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall not allow the introduction into the Drug SUBSTANCE or PRODUCTS of (i) any material that has not been used, handled or stored in accordance with the Specifications, all applicable Brazilian Laws, GMP, the PHARMACOVIGILANCE AGREEMENT, (ii) any material that would cause the Drug Substance or Products to be adulterated or misbranded within the meaning of any Brazilian Laws, and (iii) any defects in material and workmanship.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 34.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:top;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:97.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d)</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Each PARTY does not, to such PARTY&#39;s knowledge, currently employ and will not knowingly employ during the Term, and does not, to such PARTY&#39;s knowledge, use as a subcontractor and will not knowingly use as a subcontractor during the Term, and such subcontractors do not, to such PARTY&#39;s knowledge, currently employ and will not employ or engage during the Term, any Person that has been debarred or has otherwise been disqualified or suspended from performing scientific or clinical investigations or otherwise subjected to any restrictions or sanctions by the ANVISA or any other Governmental Authority or professional body with respect to the performance of scientific or clinical investigations, or any Person finally convicted of a criminal offense, with no existing rights to appeal such conviction, in relation to: (i) the development or approval (including the process for development or </p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">25</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:2.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#ffffff;vertical-align:top;width:97.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">approval) of an abbreviated drug application, (ii) the development or approval of any drug product or otherwise relating to the regulation of any drug product, or (iii) bribery, payment of illegal gratuities, fraud, perjury, racketeering, blackmail, extortion, falsification or destruction of records or interference with, obstruction of an investigation into a prosecution of any criminal offense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:30.6pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(e)</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:97.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall operate and maintain all equipment used at the Facilities in a safe manner and provide adequate employee training with respect thereto.</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(f)</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:97.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Each PARTY has not, to such PARTY&#39;s knowledge, and will not knowingly offer or pay, or authorize such offer or payment, of any money or anything of value or improperly seek to influence any Government Official in connection with this AGREEMENT. For purposes of this Article, a &#8220;GOVERNMENT OFFICIAL&#8221; is defined as and includes: (i) any elected or appointed government official (e.g., a member of a ministry of health); (ii) any employee or person acting for or on behalf of a government official, agency, or enterprise performing a governmental function; (iii) any political party, officer, employee, or person acting for or on behalf of a political party or candidate for public office; (iv) an employee or person acting for or on behalf of a public international organization; or (v) any person otherwise categorized as a Government Official under local law where &#8220;government&#8221; includes all levels and subdivisions of non-U.S. governments (i.e., local, regional, or national and administrative, legislative, or executive).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(g)</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FIOCRUZ shall (i) not use, sell or distribute the PRODUCTS or any other product that contains the DRUG SUBSTANCE, for any purpose other than as set forth herein, (ii) use the SUPPLIED MATERIALS and PROTALIX TECHNOLOGY solely for the purpose of converting such SUPPLIED MATERIALS into the PRODUCTS for sale within the Territory in the Field, in accordance with this AGREEMENT, (iii) not source materials for inclusion in the PRODUCTS other than through PROTALIX, and (iv) not sell, distribute or use a Product if it does not conform with the SPECIFICATIONS.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">17.3</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PROTALIX hereby represents and warrants to FIOCRUZ that, to its knowledge, as of the EXECUTION DATE and the Effective Date:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 34.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The COMPOUND, DRUG SUBSTANCE, BULK PRODUCT, NAKED VIAL, CELL BANK and the FINISHED PACKAGED PRODUCT supplied by PROTALIX to FIOCRUZ hereunder is in full compliance with all applicable Brazilian Laws, including GMP and Brazilian health and safety Laws.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22pt;text-align:justify;text-indent:-22pt;margin:0pt 0pt 0pt 34.1pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.15%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(b)</p></td><td style="background-color:#ffffff;vertical-align:top;width:97.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The PROTALIX PATENT RIGHTS, PROTALIX TECHNOLOGY, PRODUCT MARKS or CONFIDENTIAL INFORMATION does not infringe any THIRD PARTY rights.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">17.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PROTALIX hereby covenants to FIOCRUZ that the COMPOUND, DRUG SUBSTANCE, BULK PRODUCT, NAKED VIAL, CELL BANK and the FINISHED PACKAGED PRODUCT supplied by PROTALIX to FIOCRUZ hereunder shall be in full compliance with GMP.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">17.5</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Disclaimer of Warranty</u>. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE COMPOUND, DRUG SUBSTANCE, THE PRODUCT, PROTALIX PATENT RIGHTS, PROTALIX TECHNOLOGY, PRODUCT MARKS OR CONFIDENTIAL INFORMATION. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 18. </font></font>PHARMACOVIGILANCE AGREEMENT/QUALITY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:24.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The PARTIES agree to comply with the terms and conditions of the Pharmacovigilance Agreement set forth as Appendix VIII.</p></td></tr><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.2</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The PARTIES agree in good faith to establish&#160;mutually agreeable quality guidelines&#160;following the EXECUTION DATE and prior to distribution of PRODUCT by FIOCRUZ, which shall cover, amongst other matters, delivery and storage of PRODUCT by FIOCRUZ.&#160; The PARTIES agree to comply with such quality guidelines during the TERM.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">26</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:56.1pt;text-align:justify;text-indent:-56.1pt;margin:0pt 0pt 0pt 30.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 19. </font></font>APPROVALS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:68.85pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19.1</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Except where expressly stated otherwise herein, all approvals and consent rights of a PARTY under this AGREEMENT shall be in such PARTY&#8217;s sole and absolute but good faith discretion. Any approval or consent may be subject to such conditions as such PARTY deems appropriate or be granted on a &#8220;test&#8221; or temporary basis, in each case to the extent identified to the PARTY requesting such approval or consent. If a PARTY does not grant any required approval or consent within ten (10) business Days of any submission or request for approval or consent, such submission or request shall be deemed to be disapproved.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ARTICLE 20. </font></font>MISCELLANEOUS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.1</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Force Majeure</u>. Neither PARTY shall be liable to the other PARTY for any losses or damages attributable to a default under or breach of this AGREEMENT that is the result of war (whether declared or undeclared), acts of God, revolution, acts of terror, fire, earthquake, flood, pestilence, riot, enactment or change of LAW (following the EXECUTION Date) making performance of this AGREEMENT by such PARTY impossible, accident(s), labor trouble, shortage of or inability to obtain material equipment or transport or any other cause beyond the reasonable control of such PARTY (each, a &#8220;FORCE MAJEURE EVENT&#8221;); &#160;<u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> &#160;that if such a cause occurs, then the PARTY affected will promptly notify the other PARTY of the nature and likely result and duration (if known) of such cause and use its commercially reasonable efforts to avoid or remove such causes of nonperformance as soon as is reasonably practicable. Upon termination of the Force Majeure Event, the performance of any suspended obligation or duty shall promptly recommence. If the event lasts for a period of longer than one (1) month, the PARTIES shall meet and work diligently to implement appropriate remedial measures. Notwithstanding anything to the contrary herein, despite the existence of any such Force Majeure Event affecting FIOCRUZ&#39;s ability to pay all monies due hereunder for PRODUCTS delivered or services or licenses provided hereunder, FIOCRUZ shall pay any such amounts immediately upon the termination of such FORCE MAJEURE EVENT without penalty for any such delay during the continuance of the FORCE MAJEURE EVENT, in accordance with the terms hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.2</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Severability</u>. If and solely to the extent that any provision of this AGREEMENT shall be invalid or unenforceable, such offending provision shall be of no effect and shall not affect the enforceability or validity of the remainder of this AGREEMENT or any of its provisions; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, the PARTIES shall use their respective reasonable efforts to mutually agree to replace the invalid provisions in a manner that best accomplishes the original intentions of the PARTIES.</p></td></tr><tr style="height:87.75pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.3</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Waivers</u>. Any term or condition of this AGREEMENT may be waived at any time by the PARTY that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the PARTY waiving such term or condition. Neither the waiver by any PARTY of any term or condition of this AGREEMENT nor the failure on the part of any PARTY, in one or more instances, to enforce any of the provisions of this AGREEMENT or to exercise any right or privilege, shall be deemed or construed to be a waiver of such term or condition for any similar instance in the future or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements contained in this AGREEMENT shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement.</p></td></tr><tr style="height:85.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.4</p></td><td style="background-color:#ffffff;vertical-align:top;width:96.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Entire Agreement; Amendments</u>. This AGREEMENT (together with any agreements between the PARTIES expressly contemplated to be entered into by this AGREEMENT) sets forth the entire agreement and understanding between the PARTIES as to the subject matter hereof and supersedes all agreements or understandings, verbal or written, made between FIOCRUZ and PROTALIX before the EXECUTION DATE with respect to the subject matter hereof. All Confidential Information disclosed between FIOCRUZ and PROTALIX prior to the Effective Date will be deemed to have been disclosed pursuant to and under this AGREEMENT. None of the terms of this AGREEMENT shall be amended, supplemented or modified except in writing signed by the PARTIES.</p></td></tr><tr style="height:86.6pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.5</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Survival</u>. The provisions of Articles 1, 4.3, 4.6, 4.7, 8.6, 9 (for any payment obligations incurred during the TERM until the date of termination), 10, 11, 12.6, 12.7, 13, 14, 15, 16, 17, 19 and 20, as well as (i) any other Articles, Exhibits, Schedules or Appendices or defined terms referred to in such Articles necessary to give them effect and (ii) any other provision that by its terms expressly survives termination of this AGREEMENT, shall survive termination of this AGREEMENT and remain in force until discharged in full. Furthermore, any other provisions required to interpret and enforce the PARTIES&#8217; rights and obligations or to wind up their outstanding obligations under this AGREEMENT shall survive to the extent required, including any payment obligations incurred during the Term or pursuant to any surviving Article.</p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">27</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:121.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.6</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Assignment; Binding Effect</u>. Neither this AGREEMENT nor any rights or obligations of FIOCRUZ in, to or under this AGREEMENT may be assigned or otherwise transferred by FIOCRUZ without the prior written consent of PROTALIX. For purposes of this AGREEMENT, an &#8220;assignment&#8221; includes any change of control of FIOCRUZ (as such term is defined in the definition of AFFILIATES) or assignment by operation of LAW. PROTALIX may assign this AGREEMENT or any of its rights or obligations hereunder, in whole or in part, with the prior consent of FIOCRUZ (such consent not to be unreasonably withheld or delayed); <u style="text-decoration:underline;text-decoration-color:#000000;"> provided</u> &#160;that, for the avoidance of doubt, no such consent of FIOCRUZ shall be required for an assignment in connection with a change of control (as such term is defined in the definition of AFFILIATES), merger or reorganization of PROTALIX or any of its AFFILIATES, or a sale or other transfer by PROTALIX or any of its AFFILIATES of all or substantially all of the assets or business to which this AGREEMENT relates. Subject to the foregoing, this AGREEMENT shall be binding upon and inure to the benefit of the PARTIES and their successors, respective heirs, and legal representatives. Any purported assignment in violation of this Article 20.6 shall be void<i style="font-style:italic;"> ab initio</i>. Any permitted assignee shall assume all obligations of its assignor under this AGREEMENT. Notwithstanding the foregoing, should Bio-Manguinhos become a company controlled by FIOCRUZ (Empresa Brasileira de Biotecnologia em Sa&#250;de - Bio-Manguinhos), both parties consent that this agreement may be transferred to such company at FIOCRUZ&#39;s sole discretion without Protalix written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:49.5pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.7</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Independent Contractor</u>. The relationship between the PARTIES is that of independent contractors. The PARTIES are not joint venturers, partners, principal and agent, employer and employee, and have no other relationship other than independent contracting parties. Neither PARTY has the authorization or right hereunder to make any representations, enter into any agreements or assume any other obligations on behalf of the other PARTY.</p></td></tr><tr style="height:86.6pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.8</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Publicity</u>. FIOCRUZ shall not make (and shall cause its Affiliates not to make) any press release or public statement (written or oral) concerning the terms of, or events related to, this AGREEMENT or concerning PROTALIX, the PRODUCT, COMPOUND, DRUG SUBSTANCE, SUPPLIED MATERIALS, or PROTALIX TECHNOLOGY, without the prior written approval of PROTALIX, except where such statement is required by Brazilian LAW. In the case of any press release or public statement (written or oral) that is required by Brazilian LAW, FIOCRUZ shall use all reasonable efforts to give PROTALIX sufficient advance notice of the text of any such public statement, so that PROTALIX will have the opportunity to comment upon the statement, and give due consideration to any of PROTALIX&#39;s comments on such text.</p></td></tr><tr style="height:37.1pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.9</p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:96.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Notices</u>. All notices, consents, approvals, requests or other communications required hereunder given by one PARTY to the other hereunder shall be in writing and made by registered or certified air mail, facsimile, express overnight courier or delivered personally to the following addresses of the respective PARTIES:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If to PROTALIX:</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Protalix Ltd.</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2 Snunit Street</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Science Park</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">P.O.B 455</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Carmiel 20100, Israel</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Attention:&#160;&#160;&#160;Chief Executive Officer</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facsimile:&#160;&#160;972-4-988-9489</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If to FIOCRUZ:</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fiocruz</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Bio-Manguinhos</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pavilh&#259;o Rocha Lima - 6 andar</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Avenida Brasil, 4365, Manguinhos</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Rio de Janeiro, CEP: 21040-360</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Brazil</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Attention: Bio-Manguinhos Director</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile: + 55 21 3882-7176</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Notices hereunder shall be deemed to be effective (a) upon receipt if personally delivered, (b) on the tenth (10th) Business Day following the date of mailing if sent by registered or certified air mail and (c) on the first (1st) Business Day following the date of transmission or delivery to the overnight courier if sent by facsimile or overnight courier. A PARTY may change its address listed above by sending notice to the other PARTY in accordance with this Article 20.9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">28</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.10</p></td><td style="background-color:#ffffff;vertical-align:top;width:95.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Third Party Beneficiaries</u>. Except for the rights of PERSONS not a PARTY to this AGREEMENT to indemnification pursuant to Article 16 (which is intended to benefit such PERSONS), none of the provisions of this AGREEMENT shall be for the benefit of or enforceable by any Third PARTY, including any creditor of any PARTY. No Third PARTY shall obtain any right under any provision of this AGREEMENT or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against any PARTY.</p></td></tr><tr style="height:61.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.11</p></td><td style="background-color:#ffffff;vertical-align:top;width:95.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Subcontractors</u>. FIOCRUZ shall not use any subcontractors to perform its obligations or exercise its rights hereunder, without the prior written consent of PROTALIX. PROTALIX may use one or more of its Affiliates or any reasonably able Third PARTIES to exercise its rights or perform its obligations hereunder (including each other). Despite any such subcontracting the PARTIES shall remain liable hereunder for the performance of all of its obligations hereunder (including the payment of any amounts due hereunder).</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.12</p></td><td style="background-color:#ffffff;vertical-align:top;width:95.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Headings</u>. Headings in this AGREEMENT are included herein for ease of reference only and shall have no legal effect.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:justify;text-indent:-27.5pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.15%;"><tr style="height:74.25pt;"><td style="background-color:#ffffff;vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.13</p></td><td style="background-color:#ffffff;vertical-align:top;width:95.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Language.</u> This AGREEMENT has been prepared in the English language and has been translated into the Portuguese language and the Portuguese language version shall control all questions of interpretation and performance hereof. If there is any difference in meaning between any portion of the English version and any other version, the Portuguese version shall prevail. Unless otherwise specifically required by Brazilian LAW or by written agreement of the PARTIES or as otherwise provided herein, all notices and other communications required or permitted under this AGREEMENT shall be made in the English language.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:center;text-indent:-27.5pt;margin:0pt 0pt 0pt 5.5pt;"><i style="font-style:italic;">&#160;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:center;text-indent:-27.5pt;margin:0pt 0pt 0pt 5.5pt;"><i style="font-style:italic;">[Signature Page Follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:27.5pt;text-align:center;text-indent:-27.5pt;margin:0pt 0pt 0pt 5.5pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">29</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IN WITNESS WHEREOF the PARTIES hereto have caused this AGREEMENT to be executed by their duly authorized officers upon the date set out below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Funda&#231;&#259;o Oswaldo Cruz</b></p></td></tr><tr style="height:12.4pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(on behalf of itself and the Immunobiological</p></td></tr><tr style="height:12.4pt;"><td colspan="3" style="background-color:#ffffff;vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;Technology Institute (Bio-Manguinhos))</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Paulo Gadelha</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:&#160;&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paulo Gadelha</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:&#160;&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Protalix Ltd.</b></p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Aviezer</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Aviezer</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and CEO</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:&#160;&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Technology Transfer and Supply Agreement]</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">30</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">APPENDIX I</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">PROTALIX TECHNOLOGY (INCLUDING SPECIFICATIONS)</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Appendix I]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">APPENDIX II</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">TECHNOLOGY TRANSFER</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Appendix II]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">APPENDIX III</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">FORM OF ACCEPTANCE CERTIFICATE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ACCEPTANCE CERTIFICATE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[DATE]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">RE:</font></font>Completion of Technology Transfer Stage [#]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Reference is hereby made to the Technology Transfer Agreement by and between PROTALIX LTD., a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O.B 455, Carmiel 20100, Israel (&#8220;Protalix&#8221;) and FUNDA&#199;&#195;O OSWALDO CRUZ, an agency of the Brazilian Ministry of Health organized under the laws of Brazil, including its manufacturing unit &#8220;BIO-MANGUINHOS&#8221;, with registered offices at Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, Cep 21045-900, Brazil, CGC NI 33.781.055/0001-35 (the &#8220;Agreement&#8221;). All capitalized terms contained herein shall have the meaning ascribed to such terms in the Agreement. Pursuant to the Agreement, PROTALIX and FIOCRUZ hereby acknowledge and agree that (i) the COMPLETION REQUIREMENTS of STAGE [X] of the TECHNOLOGY TRANSFER have been achieved, (ii) PROTALIX has fulfilled its obligations with respect to STAGE [X], including the TECHNOLOGY TRANSFER, supply of the SUPPLIED MATERIALS, and any technical assistance and training for such STAGE, and (iii) STAGE [X] is now complete and the Parties can proceed to STAGE [X+1].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">PROTALIX LTD.</p></td><td style="background-color:#ffffff;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">FUNDA&#199;&#195;O OSWALDO CRUZ</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">By:&#160;&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:30.5pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">By: </font></font>&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">Print Name:</p></td><td style="background-color:#ffffff;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">Print Name:&#160;&#160;</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">Date:</p></td><td style="background-color:#ffffff;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">Date:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Appendix III]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">APPENDIX IV - PURCHASE ORDER</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:112.2pt;text-indent:-112.2pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:112.2pt;text-indent:-112.2pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Appendix IV]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">APPENDIX V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PFIZER APPROVAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">To</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Ag&#234;ncia Nacional de Vigil&#226;ncia Sanit&#225;ria (ANVISA/MS)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:-7.7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.7pt;margin:0pt;"><b style="font-weight:bold;">DECLARATION OF IMPORT AUTHORIZATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.7pt;margin:0pt;">BY LEGAL ENTITY WHICH DOES NOT HOLD REGULARIZATION BEFORE ANVISA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.7pt;margin:0pt;">(Legal Basis: RDC N&#186; 81/08 - CHAPTER VII - ITEM 7B)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.7pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">REFERENCE: Import License/IL n&#186;</b> _____/_________________-________</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The company Laborat&#243;rios PFIZER Ltda., with (address), duly regularized before ANVISA - Ag&#234;ncia Nacional de Vigil&#226;ncia Sanit&#225;ria under N&#186; ___________, represented by its Legal Representative ______________________________ and Legal Responsible ______________________________, and by its Technical Responsible _______________________________, undersigned, grants authorization to import, directly from its supplier Protalix Ltd., the product indicated below, and which holds the regularization document before Minist&#233;rio da Sa&#250;de/Ag&#234;ncia Nacional de Vigil&#226;ncia Sanit&#225;ria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><div style="padding-left:0.4pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.99%;"><tr style="height:50.35pt;"><td style="background-color:#ffffff;vertical-align:top;width:28.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;"><b style="font-weight:bold;">Authorized Importer:</b></p></td><td style="vertical-align:top;width:71%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fiocruz - Instituto de Tecnologia em Imunobiol&#243;gicos, Bio-Manguinhos</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">CNPJ n&#186; 33.781.055/0015-30</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><div style="padding-left:0.4pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:13.2pt;"><td style="background-color:#ffffff;vertical-align:top;width:49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 5.5pt 0pt 5.5pt;"><b style="font-weight:bold;">Description of the health product:</b></p></td><td style="background-color:#ffffff;vertical-align:top;width:31%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 5.5pt 0pt 5.5pt;"><b style="font-weight:bold;">Registration n&#186; at ANVISA</b></p></td><td style="background-color:#ffffff;vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 5.5pt 0pt 5.5pt;"><b style="font-weight:bold;">Term</b></p></td></tr><tr style="height:49.5pt;"><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">____________________________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:31%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">_________________________</p></td><td style="background-color:#ffffff;vertical-align:top;width:20%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.5pt 0pt 5.5pt;">________________</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In compliance with the determination of RDC n&#186; 81/08, we authorize exclusively the importer mentioned above to use the abovementioned register, and, therefore, its transfer is prohibited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We expressly assume the commitment to and compliance with the standards and procedures of health legislation, as well as the science of the penalties to which we will be subject, pursuant to Law No. 6437, August 1977.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Legal Representative: ___________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Legal Responsible:___________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Technical Responsible: ___________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Valid for 90 days from issuance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Rio de Janeiro, __________________________.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:50%;" align="center"><tr style="height:12.4pt;"><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Legal Representative</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal Responsible</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">_____________________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;">Technical Responsible</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Appendix V]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="color:#000000;font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">APPENDIX VI - LETTER OF CREDIT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Appendix VI]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">APPENDIX VII</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ACCOUNT INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Appendix VII]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">APPENDIX VIII</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PHARMACOVIGILANCE AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Appendix VIII]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">EXHIBIT A</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">AMINO ACID SEQUENCE FOR DRUG SUBSTANCE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.7pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.99%;"><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EFARPCIPKS</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FGYSSVVCVC</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NATYCDSFDP</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PTFPALGTFS</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RYESTRSGRR</p></td><td style="background-color:#ffffff;vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MELSMGPIQA</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">61</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NHTGTGLLLT</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LQPEQKFQKV</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">KGFGGAMTDA</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AALNILALSP</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PAQNLLLKSY</p></td><td style="background-color:#ffffff;vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FSEEGIGYNI</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">121</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IRVPMASCDF</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SIRTYTYADT</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PDDFQLHNFS</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LPEEDTKLKI</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PLIHRALQLA</p></td><td style="background-color:#ffffff;vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">QRPVSLLASP</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">181</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WTSPTWLKTN</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GAVNGKGSLK</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GQPGDIYHQT</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WARYFVKFLD</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AYAEHKLQFW</p></td><td style="background-color:#ffffff;vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AVTAENEPSA</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">241</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GLLSGYPFQC</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LGFTPEHQRD</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIARDLGPTL</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANSTHHNVRL</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LMLDDQRLLL</p></td><td style="background-color:#ffffff;vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PHWAKVVLTD</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">301</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PEAAKYVHGI</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AVHWYLDFLA</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PAKATLGETH</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RLFPNTMLFA</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SEACVGSKFW</p></td><td style="background-color:#ffffff;vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EQSVRLGSWD</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">361</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RGMQYSHSII</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TNLLYHVVGW</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TDWNLALNPE</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GGPNWVRNFV</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DSPIIVDITK</p></td><td style="background-color:#ffffff;vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DTFYKQPMFY</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">421</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HLGHFSKFIP</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EGSQRVGLVA</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SQKNDLDAVA</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LMHPDGSAVV</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">VVLNRSSKDV</p></td><td style="background-color:#ffffff;vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PLTIKDPAVG</p></td></tr><tr style="height:12.4pt;"><td style="background-color:#ffffff;vertical-align:top;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">481</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FLETISPGYS</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">IHTYLWHRQD</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">LLVDTM</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Exhibit A]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">EXHIBIT B</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">PROTALIX PATENT SCHEDULE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EXHIBIT C</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">APPLICABLE TAXES AND FEES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A [***]% tax will be withheld from payments for services made by FIOCRUZ pursuant to Section 7.4.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There are no withholding or other taxes applicable to any payments required to be made by FIOCRUZ under this AGREEMENT, including those made for the purchase of PRODUCTS during each STAGE of the TECHNOLOGY TRANSFER.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>plx-20210331xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/14/2021 11:03:37 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:9.52%;padding-right:9.52%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] Represents material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Binding Term Sheet between Chiesi Farmaceutici S.p.A. (&#8220;</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Chiesi</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;) and Protalix Ltd. (&#8220;</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Protalix</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;) for amending the U.S. and Ex-U.S. Exclusive License and Supply Agreements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">This binding term sheet (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">Term Sheet</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) is intended to advance the discussions between Protalix and Chiesi and to create alignment between the two companies on the terms and structure of a potential amendment to the Exclusive U.S. License and Supply Agreement, dated July 23, 2018 (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">Chiesi US ELSA</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), and the Exclusive License and Supply Agreement, dated October 17, 2017 (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">Chiesi ex-US ELSA</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; and together with the Chiesi US ELSA, the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">Chiesi ELSAs</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). This Term Sheet is intended to be and shall be construed only as a summary of the indication of the interest of the Parties in such a possible amendment.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:21.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Scope</b></p></td><td style="vertical-align:top;width:78.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">This Term Sheet is made between Chiesi and Protalix solely for purposes of reaching a settlement regarding the payment of certain milestones under the Chiesi ELSAs. Capitalized terms used herein shall have the meanings given to them in the Chiesi ELSAs.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:21.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Consideration and Milestone Payments</b></p></td><td style="vertical-align:top;width:78.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">Chiesi shall pay Protalix $10,000,000 prior to June 30, 2021 (the &#8220;Payment&#8221;).  In exchange for the Payment, the Event Milestone Payment associated with [***] in the Chiesi ex-US ELSA, due upon regulatory approval in the EU as provided in the Chiesi ex-US ELSA, will be reduced by $25,000,000.  All other Event Milestone Payments in the Chiesi ELSAs shall remain unchanged. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:21.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Other Matters</b></p></td><td style="vertical-align:top;width:78.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The parties will negotiate in good faith the content and the terms of that certain [***], in order to reach an agreement on mutually acceptable terms at the earliest possible date. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:21.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Binding Effect</b></p></td><td style="vertical-align:top;width:78.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">Upon both Parties&#8217; execution of this Term Sheet, this Term Sheet shall be binding.  Unless and until this Term Sheet is finalized and becomes binding, it shall not be publicly disclosed and shall remain confidential.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:21.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Confidentiality</b></p></td><td style="vertical-align:top;width:78.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">This Term Sheet is Confidential Information of the Parties under the confidentiality provisions set forth in the Chiesi ELSAs.  Unless and until this Term Sheet is finalized and becomes binding, it shall not be publicly disclosed and shall remain confidential</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">[***] Redacted pursuant to confidential treatment request.</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.52%;margin-right:9.52%;margin-top:30pt;page-break-after:always;width:80.95%;border-width:0;"><div style="max-width:100%;padding-left:9.52%;padding-right:9.52%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:21.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Governing Law</b></p></td><td style="vertical-align:top;width:78.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">This Agreement shall be governed by and construed in accordance with the substantive Laws of the State of New York, without regard to conflicts of law rules.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:21.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Other Agreements</b></p></td><td style="vertical-align:top;width:78.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">There are no other agreements, understandings, or amendments being discussed with respect to this Term Sheet, and the terms set forth herein represents the totality of the agreements and understandings of the parties.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">[Signatures appear on following page]</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.52%;margin-right:9.52%;margin-top:30pt;page-break-after:always;width:80.95%;border-width:0;"><div style="max-width:100%;padding-left:9.52%;padding-right:9.52%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:44.82%;"><tr><td style="vertical-align:top;width:18.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By: </font></p></td><td style="vertical-align:bottom;width:81.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Ugo Di Francesco</font></p></td></tr><tr><td style="vertical-align:top;width:18.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title:</font></p></td><td style="vertical-align:bottom;width:81.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CEO</font></p></td></tr><tr><td style="vertical-align:top;width:18.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name:</font></p></td><td style="vertical-align:bottom;width:81.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Ugo Di Francesco</font></p></td></tr><tr><td style="vertical-align:top;width:18.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date:</font></p></td><td style="vertical-align:bottom;width:81.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">May 13, 2021</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Protalix Ltd. (&#8220;Protalix&#8221;)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:47.62%;"><tr style="height:1pt;"><td style="vertical-align:top;width:17.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:82.46%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:17.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By: </font></p></td><td style="vertical-align:bottom;width:82.46%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:70.8pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">/s/ Eyal Rubin</font></font><font style="display:inline-block;width:35.4pt;"></font><font style="font-family:'Times New Roman','Times','serif';">/s/ Dror Bashan</font></p></td></tr><tr><td style="vertical-align:top;width:17.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title:</font></p></td><td style="vertical-align:bottom;width:82.46%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:35.4pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">CFO</font></font><font style="display:inline-block;width:35.4pt;"></font><font style="display:inline-block;width:35.4pt;"></font><font style="font-family:'Times New Roman','Times','serif';">CEO</font></p></td></tr><tr><td style="vertical-align:top;width:17.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name:</font></p></td><td style="vertical-align:bottom;width:82.46%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:70.8pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Eyal Rubin</font></font><font style="display:inline-block;width:35.4pt;"></font><font style="font-family:'Times New Roman','Times','serif';">Dror Bashan</font></p></td></tr><tr><td style="vertical-align:top;width:17.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date:</font></p></td><td style="vertical-align:bottom;width:82.46%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:70.8pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">5/13/2021</font></font><font style="display:inline-block;width:35.4pt;"></font><font style="font-family:'Times New Roman','Times','serif';">5/13/2021</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:35.4pt;"></font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">[Signature Page to Term Sheet]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:9.52%;margin-right:9.52%;margin-top:30pt;page-break-after:avoid;width:80.95%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>plx-20210331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/14/2021 11:03:40 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;14, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>plx-20210331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/14/2021 11:03:43 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;14, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>plx-20210331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/14/2021 11:03:47 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;14, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>plx-20210331xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/14/2021 11:03:50 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;14, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>plx-20210331x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210331x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &?!#@# 2(  A$! Q$!_\0
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M?^]3:* '>8_]ZCS'_O4VB@!WF/\ WJ/,?^]3:* '>8_]ZCS'_O4VB@!WF/\
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M+BQ@FEB:*1XPS(Q!()'MQ5B@ HHHH **** "BBB@!5^\*M557[PJU0 4444
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M;5%<W#XI"6-L]S:R><\0EF"N@V*>_+<YQG R:U+/51?7<L4-O*8H^#.2NPG
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ML!L)P<YW=>GM6[10!!9QS0V4,5P\;RH@5FC4JI(] 22*GHHH **** "BBB@
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MOGZTV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBLK6/$.G:%):)?RNC74GE
MQ!4+9/OZ"@#5HHKG?$NI:E87VF#3\.K.[30X'[U%7) /8^E '145S9\1QQZC
M/<-.SZ>+%)XT1026+8X[Y[8K0TW6OMUR]I/87-C=*GF"*XVDLG3(*DCZCJ*
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M 4444 %%%% !1110 4444 %%%% !1110!6?[Y^M-IS_?/UIM !1110 4444
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M))SZFNDM].:#6+V^,JE;E44(!RNT>M7Z*+@%%%% "K]X5:JJOWA5J@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K/\
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M5V%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKQ)(;5F^09 ( R3@#Z4_QE96X\6>#[,0K]F64H(\9&T%<"O0HXTBB2.- B(
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MYFVX.&X^7(/;- '345@MKUQ#>P6]S:V\'F;?G><A6SV0E,$CT)%;U !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5G^^?K3
M:<_WS]:;0 445 ]W&DA3!)'7% $]%1PS"9E"@C<">:6>3R8W8+O*_P (.,T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3;NXO+4O=64EG.K%6C<[AQW5OXA[U<H BMK>*TMH[>%2L4:A5!.<#ZU+110
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MQ"ZR+&P5 [[2"-W/J#GFNA.G637ANS:PFX(P9"@SZ?RID6D:= I6*R@0%P^
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MR, <YXQU%:%EX@UA;6]-_$\(CCWQW5WI[VZ!LXV[0S%O;')H ["BN&A\5ZG
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MUQ4EU%YK)K*&\-N8!"0[+N SOSP1Z8YJI%J/]FLDWV>*3;/=/EDRPP.Q[>]
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M:-+]Q>?:C;BU*H2(^0'QC.>C9Z57MM>U2[N8X1.RBY86T>(P"DB']ZW3T]:
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M:2X1Y4/DL,= HR@Y(PQ_K1?ZO=I?'_B8FWD&H10):@(1)"2/FP1GG)Y!]J+
M=?14:7$,A 26-B<X 8'..#^524 %%%% !1110 4444 %%%% %9_OGZTVG/\
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MWTFVDO1<N96(8.(VE8H&'0A>E7J* (C;0F>.;RQOC#!3Z9QG^52T44 %%%%
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M 1M#-=?9VD!+8/RQD@KZ9'XUT6I7-WHWAJ:?[2UU<QK_ *Z5%')/4A0!@9H
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MD61'+!75BIP<'.#0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNZ'G[.F"?;>*ZK0K:,31W!?]X@**1_=[9]ZU1FSL8-+BGTU(Y6F65HP&*OD
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MI91[Y?-E2YMS*DA]3@A@?<$4_1/#EKI%K$A2)YXW:0.D>Q5+==JYX'YULT4
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MT4S.BE%?)X!ZBIJ //[>]GMM(C6QOII6\EC/&<'R2&&W Q\O?ZU%>-</:W$
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M#2O;P:=:I&NG&?SY_.E=W4@YP@/ !/N,5T5% !P. ,#THHHH **** "BBB@
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ME;+-:))M(0*JJK @C Z'->A:?;8 PM96EZ8840,H!P-P!SS]:ZFUB  H0@>
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M5T.KA1XIGW@E3;#('>L#3G8ZWIQ?&5;:,#MN!'\S70Z]@>(GXQF#[V?8T/\
MAA]LSRS+8QLAPW[S'UP*[6>$+86<6[<\MPD^%Z@# S^IKCH$W1QJ02%\QV]
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MQVUP>) &4G[H(R.?6JIPO&S)J2]ZZ#0[]-7?4DM8!;VPM&\IF'[QBO<G//\
M3-=C:P_;H84("I<VA5F4<J>"O/MDUPGA!HDU>Y8#:DMC)\Q_B)/'X5Z-HK*+
M&QCW+O\ +!QGD@8']:W226ADW?<MZ3IZ65JD*%V"#&YSDD^I-:B1^U.AAVC
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ML?R'%3@5RW-K7W(H;6"W7$,4<8]$4#^52XI:*104444 %%%% !1110 4444
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M?W>O2K:VENMS]I6)1-L$>_OM':IJ* "BBB@!5^\*M557[PJU0 4444 %%%%
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MUM44 4M.TJTTN)TMEDRYW.\LK2.Y]V8DFKM%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !116-KLNO126(T6WMID:8"Y,QP53VYH
MV:KW>H66GHKWMY;VR,<!IY50$^Q)JQ7,>*8;F?4]%2TCLY)C-)A;Q2T?W#U
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M0!V]%<1_:FK"/3M0.KY2]N&1K41( @&>%.,]N<U-I%]K"OHUS>:HUS'?LR/
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M/R1XZ'@9W8YZYJ."345_LZ><7EQ<[(P8'$L9'."0P^7/<A_2NWHH !THHHH
M**** "BBB@ HHHH **** *S_ 'S]:;4LJ<[ATJ*@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K)U;1I=1NK6ZM]0ELI[8/L:.-7SN&.0W!K6HH Y\>$[
M4QPI+<2R[5E\UF S*T@P6/I[8IG_  BKS12+?:M<W;>0T$#/&B^4I&"<#[S8
M[FNCHH Q;W0&G6TDM;^2TNK:+R5F6)) R8 (*MQVS[57O?"S7;6LJZK.MQ"C
M1M+)!'(7!.3@$84^XKHJ* .:A\)-:6MJEEJUS;W-NKQ_:!$C&1&.2&!XSGO4
MDOA2*61MU]<F-[<02!L,S$'*OO/((/X5T-% './X5>ZAG^WZM<75Q*@B69HD
M78@.<!1QDXY-;-_81:CI\EG,6".H&Y3@J1T(]ZM44 <Y_P (HTQNGO\ 5KF[
MEN(! 7,:(5 .00!QG^=-;PD\Z71N]7N+B:XA6%I&B1<!3D8 XKI:* ,34?#D
M>H733M=2(6B2/ 0'[K!L_I4.N:*9OME]$MQ//(D82* JKH4.0REN"?8UT-%
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AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>plx-20210331x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210331x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '3!#@# 2(  A$! Q$!_\0
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M/&>IK?D\,VLVIB\EO-0DC$PN!9O<%H!(#D,%(SP><9Q[46?AFUL+U9X+S41
MCEX[,W)\B-CDDA>O<\$D>U)=+@[:G/76J:MJAT.^>*UBTRXU6+R5C=O.4 N
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M:&*5)+Y95$^\ D+*H*(5SCYNIJO<:WK>F:MX@E#6ES&M[:06\3[P%\P*!SG
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MK9=UQ]H=9RY#,>I#*=RGW%;M%"D[W!Q35C&\/Z,^DI=M*T7F7,OF%(<[$ &
M 3R?J:V:**&VW=A&*BK(****0PHHHH **** "BBB@ HHHH **** "BBB@"&Z
M_P!4/]X40_=IMY_J1_O"E@^Z* )Z*** "C)]:** #)/>BBB@ R?6BBB@ K*U
M308=4G29KW4+9PNQOLER8Q(N<X8=/7D8/O6K10,BMK>&SM8K:W01PQ($1!T4
M#@"HM2L(=5TVXL+DOY,Z%'V-@X]C5JB@0#@ 9/%%%% !1110 9/K1D^IHHH
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M+3^Z*=10%AOEI_=%'EI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y:?W13J*
ML-\M/[HH\M/[HIU% 6&^6G]T4>6G]T4ZB@+#?+3^Z*/+3^Z*=10%AOEI_=%'
MEI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y:?W13J* L-\M/[HH\M/[HIU%
M6&^6G]T4>6G]T4ZB@+#?+3^Z*/+3^Z*=10%AOEI_=%'EI_=%.HH"PWRT_NBC
MRT_NBG44!8:$4'( !HIU% !1110 45P_BIBWB>"%UU26+[(6\O3W(;.[J1Z?
M_6HT[4'B\.IYS33E=32%8YY666)2PP'(P21UQTJE&ZO_ %O8X7CDJDJ;6W^5
MSN**YFY\2W:"]O(+.-].L93#,S2$2,1C<5&,8&>YYJ!M:.G:EKUT1).JFV6&
M+=P6=< #/3)/-"BS26,II_UV;OY[,ZVBN;D\27&F_;(=4M8Q<06WVE/L[EE=
M<[<9(&#DBFC6]1%TMG?6<">;927&8I6/0?=Z @\\_I2Y6/ZU3O;]'Z:G345R
MUKK=W+;:?9Z9:1-</9"Z833-M5>@4'DDD^M=);22RVT<D\/DRLH+1[@VT^F1
MUH<;%TJ\:OP_\#[R6BBBD;!1110 4444 %%%% !1110 4444 %%%% !1110
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M1>< H,D6X;<C@<<Y/O[4 =;17*3>-4L]+EFOK,6U[%=?9#;R7"!-Y7<#YAP
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M@C< K@8.0>O48-'6P'=T5RD/B*6-'M[.RN+V]EO+E(XI)U "QM\S%B/E49
MP>N*&\87$LEI;6>CRS7TQGCD@>94\F2+;N!;D8^88(]J .KHKFFUUY]+T_6$
M22!!<BWN;=B#MW/Y;9QW5L$'_&I-<U74;+Q!HEM;0J]K<22>>QD"\!<]QV'S
M>^,4 =#17-67BJ2YN+1YM+E@TZ^?R[2Z,BG>2"5W(.5#8XZ]NE6-;U0:=J5F
M2LS?N+F7:L@5&V(#AACGV]/>@#=HKDX?%VHW'E)'X>F\ZYMQ<VJM<( Z<;MQ
M_@QN&.N<]J</%US=/:1Z9H\MU+<68NPK3+'L&[:5)/?T]: .JHKF(_%S7=W9
MQ66G/(D]L+J1Y)1'Y*!]K[AZ@]AUI;7Q5<3R6SR:1+#9WV193M*I\QMI90RC
ME-P''7\* .FHKG6\76J6=I=-$PCEM)+N?YN850#(/J=QV_G47A_QG;ZWJ)L6
M2".9HS+$(;N.?*C&0VT_*W(X_6CR Z>BN2NM9U.R\4:G%;6,U_#%;02&-950
M1CY]Q&>K' X[XZBG-XH@CO)[B".ZN/.M[5K>$. )&E+;0 ?NGCDD]![4 ]#J
MZ*Y&[\07D\(MIK:33]0AO+02QK*'#1R2  AAU!PP/TJS_P )9(+CSO[,E_LC
M[1]F^W>8OW]^S.SKLW<9_2@#I:*Y>3Q;.LZ/'I,KZ?)>+9I=>:HRYDV$[>NT
M'.#WQVJ.V\23):P6]C97%]?3S7.V*6X482.0JS%R.!G  Q[>] '6456T^[-]
M80W+6\UNTBY,,R[70]P15F@ HHHH **** "BBB@ HHHH Q=5\.IJ>H)>K?WE
MI,D?E9MW"Y7.?2FQ>%[2*Q%MY]P[?:5N7F=@SR.IR,G\*L:KKUII+Q12)--<
M2@E(($WN0.IQZ5)I>LVFK0220%T:)MLL<J[7C/H0:I.5M#D<,,ZK3MS/_+_+
M\"I<>&+2XGG/GW"6]Q())[9& CD;U/&1G'.#S4DWAVRN'U RF1EO1'O4'&PH
M,*5]#6E-<16\$L\KA8XE+.?0"H(-1CN1:O#%*T-Q'YBRX&U1@$ \YR<TKLMT
MJ*=FE=_\-^OXF;+X=C%I>M(TNH74\'D[KB0*2O900,#GG..M9NE:'J$NI)/>
MI<11QV;6Q,\R2,2V/N[>  .YY-==O3^\.F>O:HY;CRYH4$,CB4D;UQM3 SD\
M_P LT^9DRPU)M2[?CKUZF2WAF 0VH@N[FWFMX/LXFB8;FC]#D8K6M;9;2UBM
MT:1EC7:&D8LQ^I/6I!(C' =2?0&D:6-49RZ[4&6.>E)M]36%*G!WBA]%4;75
M8;V*TFMHY98;G)$@  0#NV3D9J[N4MMR,^E)JQ<9QDKQ8M%-WJ3C<,].M.H*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EJG_'JO^^*+/[@I-5_X]5_
MWQ_6BR^X* +U%%% %/5;$:II%Y8&3RQ<P/#OQG;N!&<=^M9&G:-XBLY;<3^(
MX)[:+ :(:<$+*!C&[><?E71U%/<16MM+<3.$BB4N['HH R31L&^AR6I>%);?
M2M1N;:YEGU"XM+A+O$?_ !^%E.T8S\I4X"]<#CO4MCX2DNK1!K5_+>)]B-K%
M"8EC,*NH#Y(^\W &>/I721W]M-<_9XY5:7REFV=]C$@'\<'\JAU#6+73%D>Z
M\U8XXQ(SB)BH!8+C(&,Y(XZ]Z/(##@\(72V5[:W.KK,D]L]M'LLHXR@88W,1
MRS#V*CVJY?>%H-16SCN)V,,%G+:.@7!<.JJ3G/!&W/>M[(QFHKJZ@LK66YN9
M!'#$NYW/0"@+',Q>#[HV%]:76KK,EQ;/;1E+&.(H&&-S$<LWT*CVJ_?^&(-1
MGC:XF8PC3Y;%XPN"ROM^;/8C9^M;@8$ ^M+GF@$<H?"%U=V<L&J:[<79"(MN
M1"J+$48,KE>0[Y R3QC(P,U)'X3G?3;B"\U027#NDD,UO:1P"%D.Y6"C.3GK
MDD'T%=/1GG% &'HVA76G:C>:A>ZF;ZYNHHXW/DB-5V;ON@$X'S=/UJ.+PNL>
MJQWWVLDIJ$M]L\OKOB\O;G/;KFN@SS1D4 <W)X4?[2+FWU#RIEU-K]280PPR
M;&3&?3//;/2H['PC)IVHJ]OJ2KIZ2F5;;['&7!+%MOFGG;D^F?>NF>01QLY!
M(4$D*,G\!WIL,RSP1RJ'42*& =2K#/J#R#[&A 8-OX56#3;"S^V%OLFH&]W^
M7]_+NVW&>/OXS[5#JO@[^TGOI5OA')<745T@>W$B*R)LPRDX<=^W./2NBBNX
M)KB>".0-+ 0)5'\)(R,_A4V10'6YR6F^"6L7:234O.9KZ*].VV6, HFW: IP
M!_+WZUI:UX=&L7/G&Z,7^@W%G@)N_P!;M^;KVV].^:U+F[@M(A+/($0NJ GN
MS$ #\214]&_]>5OR#8Q+GPXEU/;N]RP6*PELBH7E@X4;LYXQMZ>]97_"%721
MVKPZO$MY%;K;33/8I(LJ(3L^4GY6 .,YP?2NGN;Z"TDMHYF(:YE\J/"DY;:6
M_#A35G-']?U]X>7]?UH8<'AN*+49KF6X:9);!+%XV0+N +$L2N!SN/  JA;>
M$+N*ZLGN-<DN(+%)(K:)K=5*HR;!N8'YF QSQ].]=7FC(H>H'&7G@26\TRST
MQ]51K*"V2W>.6Q20_*,;HV)S&QQ[X.,5=G\*7 OYI+#6;BRM;HHUU"B N[*
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MWU[5YI#)#=_V[8V\T<EI)I#S&*VOY;E3*K9!WMWZ9"\>M>N]13%AB0 +&B@
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M9HM1MO.EU-?#YEB8S.V9-S*.,X/'8]_>O42JD@D D=,CI2+&B$%448&!@=J
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M]>M)@<YK<CQ^&M-*.R$W-F,JV.#(F17.I9&1([W[;>K/+KLMJ66Y8 1-(P*
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MDCN2)#"X;>#PISG&,<5HVL]SMNH)TNI1X=M)H6\LE7FD880J>Y\H Y[%J[W
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M4.H"_AN;VZDO9;>1D660Q9*\'(7H,>@%0D6UO;QV6IRS+X?MM3NX)"TK[5
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M?6][!;SV[M&Q0.1CD-M.0<#!X)YJWJ/A26[CU);>ZBC%S/!-'$Z$Q[8T"['
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M:4.FW>[$DELX)[=:<MW8%;2YK:;XP@OC;O/I]Y96]S;-<P3SA=LB*H9NA)&
M<\]:@@\275_XBT:%+*[LK6Z2>0>>JXG0("K#!)')S@X/-6CX9\VUT:VFG5HK
M&TDMI0%(\P/$(R1Z>M16'A_58M4TRXO=3@N(=.22*)$@*,RL@4%CDC=QVXI]
M1+8T-8UJ72RHBTN[O?D+NT11%0#U9R 3[#FL]_&4<C6ZZ?I=[?M/9+>J(=@Q
M&20<[B,$8Z=^U)XA\+W&LZG'=1W%GL$/DM'=VYF$?).]!D#=SWST%2:#X:ET
M=[<R74<ODZ:MC\J$9*NS;OI@]*6O]?/_ ( _Z_+_ ((Z7Q7#)%;G3[&[O3-:
MBZ;R57]S$<X9LD<Y!^49/!J&'5;Q_AJ-5,Y-Z=-,_F[1G?M)!QC%1VGA?4=-
MMK-=/U*"*9;-;.Y:2 NKJI)#+R,,-QZ\<U?CT&1/!7]@&X4R?8C;>=M.,D8W
M8HEL[?UN"W1B^'[DZM)Y<'BS5IYC;EF22Q2-5) &X$QC)!/ S4NEP:J-:U1;
MKQ)?RVVF2QG8T,(\U3&'(;"Y]1QBNN@0Q6\418ML15SZX&*HV6F&UU/5;IY%
M=+Z2-PF/NA8PA!]<XIO?02VU,2W3Q!J.DIK<6L"&26+[1#8B!3#M(RJL3\Q)
M&,D$<GI6W:ZQ;S^'HM9D/E6[6PN'S_ -N3^7-9*^']9M[8Z99ZS%%I6THI:W
M+7$2'^!6SMX' )&16S-I-K-H;Z0%*6K6_P!G 4\JNW'YTGL[#ZZF4GBU DC7
M>EWMG_HTEU;B<+^_1!DXP3@XP<'!J;2?$JZG>16TFFWEF;BW^TV[3A<3)QDC
M!."-PX..M4G\,ZI?(PU/5+>8Q6LMM:^5 4QO7:7DY.3CL,#K6I'H[IJ6E77G
M+BRM'MV7:?G+!!D>GW?UI]?Z\_\ @"_K\C"\0^(M4L[[7+2"WDBAM-,%Q%<C
M8</D_-C.2#C &.H-:,7BR"-+K^T;.[L3;6PNOWX7][&3C<H4GG/&#SR*36_#
MEUJ=Y?207<,45[I_V.19(R2""2K @].3D4_5O#":Q/,9YPL,NG_8RH7)#;PP
M;G@C('%+7^OG_P  >E_Z\O\ @DNC>)8-7NY+1K:2UN53S5CDD1]Z9QN!1B!S
MC(/(S2:EXD%C>S6T&FWE\;9!)=/;A<0J02,Y(W' )P,G%1>'_#TNE7,MQ.FD
MJQ3RU%A8"#(SG+'DD^PXHU'0]2?4+NXTO48+9+]%2Z6: R$$+MWH01AMO'/'
M%#\@7F8VL^++\'6OL,;I:0:7'=VUVNTC+'AL9R<C@#'8^U;2^++>);TZA975
M@;6%;C$X4F2,G:&7!/)/&#SR*I7O@^5XKBULKN*.TFTR.P*RH6<&,_*P(/N<
MBKNL^&$UJYN6GF"PSV(M=H3)5A)O#<\$9 XI_P!?F']?E_P2NOC>T6ROI[BS
MGAEM(A.T&^-V>,MMR"K$=3T/-7=2U*[7PCJ.H+;S6-S';2O&DNUF4@':W&1[
MXK)7P;.^EZA;2-I$$MS$(D:QL!"  P;+'J2<=.E=)JUBVI:+>V"N(VN('B#D
M9"DC&:3V!;F9IWB4W#-!<Z=?03K:"ZC#H";A. 2H4DYR?NG!YJ ^,XX4OQ>:
M7=VLUI:M=^4[1L9(P<'&UC@Y['%3ZCX=EOY%9+TP8TU['<BG<"Q4[A[?+T]Z
MQ(O 5T!>LUSIL)N=/DL]EK:M&JDD$,222W3G/X4/?^O/_@ O/^MO^";4/BV
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MBX6*]%6/(7U-'D+ZFBX6*]%6/(7U-'D+ZFBX6*]%6/(7U-'D+ZFBX6,76_\
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M -=%_K3--^X*?KO_ !XK_P!=%_K3--^X* -8=**!THH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M73?GKR0-PZ]: )E\;:-*)Q#+,[QPO,@-O(HF51DE"1\_;IFI?#_B>UURTLB
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M5_LXW1\[S/)W>6WE^9_<WXV[O;.:L:OKMAH<<+WTCIYS%(PD;.68 G "@DG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*:$0.7"@,P +8Y.*=10 4444 %%%% !1110 4444 1I!#'(\B1(KORS*H!;Z
MGO4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!FZY_P >*_\ 71?ZTS3?]6*?K?\
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M?;^$M-MTA^:YDDCF:<S2R[GD=HS&2Q/7Y3@>F!6]10!SEAX*TK3]HC>[D2.
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M9=Z;A@X]Q^%6LC.*8!10"#29'//2@!:**KW=[;V-L;BYD"1!E7=[L0H'YD4
M6**,\XHR,XH **3(QG-+UH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6-;FTGMSYD!(5U9P1UY%7]6\->;%#'9AF$FHK=S[I,$#&#M-7?\ A&K$VES
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH
M9Y2>E'E)Z4^B@!JQJIR!S13J* "BBB@ HK'U;6WLKN*QL[-[R]D0R")2 %4<
M9)[55E\2SV^AWE[<:9+#/:LJM"YX;)'1NXYIV9A+$TXMIO;R?:_Y'145R]]X
MP6STG3KQ;0N]V<-'OQY>#@Y..Q.*??>)+Z'5+RSM-*^TK:A6=_."_>&>A_&G
MRLAXRBNO;H^JNOP1TM%5--OX]3TRWOHP529 X#=12V^IV-W*\5O=PRR)]Y4<
M$BE9[&ZJ1:33WV+5%58-3L;J5XH+N&22/[RJX)%0KKFE/]W4+<_)OXD'W?6E
M8/:0[HT**IMJVGK!%.UY (ICB-RXPQ]JK7NNV\-E;W5J4N8YKA(-R/P-QQG\
M*=F*5:G%7;\S5HJA'JD2B\>YE@BBMY?++B4'' ^]Z'GI3QJVGM;+<B\@,#/L
M63>,%O3/K18?M(=RY156'4;*X@DGANH7BC)#NK@A?K20ZG8W%N]Q#=PO#']]
MU<$+]:5A\\>Y;HJ"UO+:]B\VUGCFCSC<C9&:GH&FFKH****!A1110 4444 %
M%%% !1110!4U#_CW'^^*+7[@I;__ % _WA1;#Y10!:HHHH **P-/\5V$^E+>
MW\T%CNDG0++(.1$Y0G] ?QK0@UO2[F[2T@O[>2X>/S4C60%F3U ]* +]%9UK
MK^DWMTMK:ZC;33LN\1I("Q'KC\*J6GBC3VT6UU'4+B"Q%P6"K+(!R&(X/?I0
M!N45GW>NZ58;?M>HVT.Y X\R0#*DX!^F:?;ZMIUU=RVEO>P2W$*AI(T<%E![
MD4 7:*SK?7M)NQ<FWU&VE%L"9MD@/E@=2?2JTWBO18[&^NHM1MYULHC+*L<@
M) QQ^?3\: -JBL6/Q7HO]FV5[/J-M!'=H'C\R4#.>H_ \5#>^+;"WU6XTR.6
M%KJ*R-V/,E"H1S@$]N!G/I0"U.@HK.FUW3+66W@N[^VAN)U!2-I1EL^GK23>
M(-(M[S['-J5K'<[Q'Y32 -N(! QZX(_.@#2HJ&ZNK>RMGN+F9(84&6=VP /K
M6#K?C/3-,T%-3MKFVNEFE6&#$P5&8GNW8#J3V% '2453.H0V^F)>WTL-O'L5
MG8R#8I(_O=Q4,?B#2);)+Q-2M6MG?RUE$@VEL9QGUXH TJ*SDU[29+%+U=1M
MC:R/L642#:6ZXSZ\&J\WB.T,&GW%C)%>07EVML)(Y 0N03G\,=* -FBLB/Q#
M8Q:5;WNHWEG;+,2JGSP4)!(X;O4UYK^DZ>\*7FHVT#3 &,22 ;@>XH T:*PF
M\4V$&MW>GWL\%L(1#Y4DDH'FF0$X ]L5976X5U'4K>X*0PV4<4C3.^ 0X;\L
M8H U**K6.HV>IVPN+&YBN(2<!XF##-0#7=*:2>,:A;%X%+2KY@R@!VDGTP>*
M -"BJ$&M:9<Z>]_#?V\EHF=TRR JOU-,@\0:1<JK0:E;2!F1%*R Y9\[1]3@
MX^E &E165J&N06<T,,12:5KN*VE0/S'YG()_#FI%U[27U(Z<NHVQO!G, D&_
M\J -&BL'3_&&C7^FW-_]MABMK>=X'>20  @D _CC(]JNRZ]I,-G%=RZC;);R
M@F.4R#:V.3@T :-%5$U.QDM4NDNXF@=Q&L@88+$[0/KGBDOM6T_3-GVZ\AM]
MX)7S7"YP0./Q(_.@"Y15%=9TU]2.G+?6YO0,F 2#>/PIIUW21?-9'4;;[4KJ
MAB\P;@QZ#'J: -"BJBZI8O!',MW"8I)?(1PXPTF2NT>^01CVJE#XBL%@C:]O
M+."221T11.&#8?8,'US@$=CQ0!L451BUG39]0?3XKZW>\C^]"L@+#\*@7Q+H
MCEPNJVA*1F5AYHX7.,_2@#5HK/DUS2HM-349-0MELG^[.9!L;Z&DN->TFUMX
MKB?4;:.&92\;M( ' ZD'OUH T:*Q+GQ5I5O>Z5;"ZB?^TV80.KC:0!U]\G ^
MIJ[9ZUIE_=2VMI?V\\\/^LCCD!9?J* +U%8\FOPP:Y>6%P$AAMK2.Y:=WP,,
MS#!^FW]:ED\1:-#<K;2ZG:I.S!!&TH#$D @8^A'YT :=%4;G6M,L[V.RN;^W
MBN9?N1/( S?05.EY;2*62>,J)#$2&_C!QM^N: )Z*SKO7])L'=+O4;:!DSN$
MD@&, $_^A#\ZM)>6TED+R.>-K8IY@E5LKMZYSZ4 3T5@:?XQT:]T*+5WO8+>
MVD<IF60## XQ]>A_&M=KVV6Q:]\]#;*AD,H;Y=H&<Y]*'H!8HKE+/QYI=T+&
M=Y(H+.ZM'N#-+* (V5E78??YOTK<NM:TRQM8KJZO[>&";'ER/( KYZ8/>@"_
M14+W*"S:YC(D0(74J>&&,]:Y33/%VIW"Z;<WVD0P66H-&L<D5T)'4N,KE<#C
MU]*.M@.QHK)77[."QEN]0NK2VB2XDAW^>"ORL1R?7CD=JCNO%.EVNHZ59FYC
M=M2+"%U<8( X/ODX ]Z -JBJ,&LZ;=7\EC!?6\EU']^%9 67ZBJMWXDTZ&WU
M'[-=6]Q=6,#S/;I(-WR@G!].E &Q169I.NV&L1@6UU"]P(U>6%) S1[@#@_G
M2SZQ!9WT\5W-;0P111N7>8!@78J 1V&0,'N:'IH!I450M];TN[LY;RWU"WDM
MH21)*L@*ICU/:J%EXKT^]O[N))X/LD*0%+D2@K(92P 'OE<?C0!O454GU2PM
M?M'GW<,?V95:;>X'EANA/IG!K,O_ !AHUE9V5V+V&6"\N%MXY$D!7)ZG/H.]
M &]16=%K^DS77V:/4;9Y]VWRUD!.<D8_,$?A5R.YAEFEACE1I(2!(H/*DC(S
M^% $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SNK6]]9:V
M-6LK1KM)+?[/-$C8< '(9?SK"_L;6'\/:LLB7CBX\K[/!/+YD@PV6)[#_P"M
M7?T52E8XZN"C4DVV];Z>JL_Z[G :AH&H.VK*EN[Q))']D '4-('?'TQ6FWAF
M+4_$VJ7%_!-Y)$7DL'*AOE^;IUKK**.9B^H4N:[UU_\ DO\ /\$4KBQ']CS6
M-F!"# T46. O&!7/6%G<RV*V T<VD\5DUN;ML##8Q\N.H)YS7744K[FTZ$92
M3VM_7Z'&V&FW<EQI$8TUK,Z=&RSRG $GRXPN/O GFH]-T.>.V\-"6QPT$DK7
M&4'RYS@M^E=M15<[,5@8*VO]>[_\BCSR6TFLDTF.>S+'^UYG6$@#<IR1C/%7
M/[*OI89[E;)X4N-4AG2WQRB*1EB!TSUKL9K2"XDBDEB5VA;?&2/NGU%34*=O
MZ]/\B%@%=W>G_ M^IQUS9ZG#'J3P69?S-2$G,8=O+VCYD!X)S5.+1KYK"6&2
MSF._5XYR'4<QX&2<<?6N]HI*5OZ]/\BY8&$G=M]?QO\ YG%W^B7L[Z^MO;82
M6>WEC3[JRA0"P%2:C8W.K:7>_9=(>S8RQ/SM5YPIY&.G';/6NPHHYG_7]>0W
M@H.^N]^W5M_^W,P/#=BT$EY<M%>1F=ES]J*@M@8SM4<>E;]%%)NYT4J:IPY4
M%%%%(T"BBB@ HHHH **** "BBB@"M??Z@?[PI;?[HHO.81_O"B#[HH L4444
M <#HN@W2WFA&\L&V6\NHN_F*"$WR90GZCI4NE:!+9VOATC3_ "I;>_GDF(0
MHC"4 D^AROZ5W-% =SS+PO:S7VG:#!!H[0FVNC=R:@0H5E#/D ]2S9P14,OA
M_5+>/3+J6WU/RUM'MVCLEC:1&,K-RK@\$$<CTYKTVUM(+*V2WMHEBA3.U%&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSJ.S="/S!H$7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2:]EFNA?)>S3LH!E9%V@8'"C%=!12 Y;5_!IU2ZFF34Y(!+=+<O'Y(=&*H$
M8$\@8SSWJ=_#E](L$[:Y*-1@WJEVMNHS&V,H4S@C(SFNBHHL,Q-/\-P:=>65
MS'/*[VZ3!B^"97E969R?7*U"GA5(OL)BOI4:UGGD)"#YUF)+)UXZ\'VKH:*!
M')Z?X(6PO+&?^TY)$LBPAB%NB#:RE?F(Y8\]?\:V[;2?LOAZ'28KJ5/*@$*S
MH '&._<5HT4P.6B\%0^5=M<7SR7DYC87$4*Q>6T;;D8*."<GJ>HXI;GPC+=P
M1M<:Q/+>I-YPGDA5D'R[<",_*!C]>:ZBBD,YS3O",5@8MU[)<;+R2[.] -Q>
M/85..,<Y_2GZ7X9;3+B,+J4LME""(;9H4&T8QAFQE@,^U=!13$8E]X9LYK:)
M-.$>F30SB>.6VA48< KRO /!(K(NO"MU!<60M;VY>234GO)KK:-T1,)7)'0C
M(''OBNRHI#,_2-+&E02AKA[FXGE,T\\@ +O@#H.    !69'X?,FGS:<SR6_V
M>\-S97,>"5W$L,9ZX+,"/2NCHIB.=B\*#SH;FYU":XO%NX[J2=D W[%950*.
M%&&-;-_:O>64D$5S);.V-LL8!*D'T/!'J*LT4AG+0^"HHK>5OM\@OWN$N5NH
MH5CV.@*@A!QT)!]<TZY\(/<PV[/JT[WL4KRF>6)9%8L "!&> , 8QTY]:Z>B
M@#F;'P;;6D,4,MU+<1I)<NP=0"_G+A@<?C5C3/#;6+[+C4)+RU6,Q1V\D" ;
M<8PQ RW'TK>HIB,2[\-P%K>72I!I4\&X*]M"NTJV-P*]#G Y]JJ1>$3:VMN+
M+5+B"\MWF*W1C5RRR/N964\'G'-=-12&8L?AFT33K:S:25_)N?M+2L?FE<G+
M;O8GJ*;/X8MIK#4;5973[=<"=WQDKA@P4>V0?S-;E%,1EW5B\&HWNL6^^6YD
MLQ;I !QE69@<_5OTJ?2+ :7I%I8AMWD1!"W]X]S^)S5VB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH DA_UHHHA_P!:**EE(=<?>7Z5#4UQ]Y:A
MIH3W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 1NE H/2@4 +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M '11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O\
M=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_P!T
M4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_ '11
ML7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O\ =%&Q
M?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_P!T4;%_
MNBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_ '11L7^Z
M*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O\ =%&Q?[HH
MHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_P!T4;%_NBBB
L@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@!0J@Y  HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>plx-20210331x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210331x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %*!#@# 2(  A$! Q$!_\0
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M_*I[T :U%4(-9T^YM+>Z@N1+!<2"*-XU+98]C@<=#G.,=ZOT %%%% !1110
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M0 4444 %<O=:C9:?X[9KV]M[97TU0IFE5 3YK=,GFNHJM<Z?97CAKFT@F8#
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MV\FCV6M65FMM-]K_ +0:4*_R_)M$C$[@><CMFKOA[6M5AMM)MK^UM_)NM/\
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M^-(;.V-NMN;>(PKC;&4&T8Z8'2A ]3@[,7.L:AIEI/J=\D4C:@91#<LC.%F
M49!R ,]NG2H[74/M T^VUG7+FTM(XY]EQ]I\DS21S%!N?N0H!V]\]#7H*6T"
M,K)#&K+G!"@$9.3^9K+U;0#J/D_9[Z:R$9)*111NC9.<[74@-G^(<\FET0=R
M+P7<27?A&PGEN)+AW5CYLARSC>V"?PK>JMIUA!IFGPV5N&\J%=J[CDGU)/J3
MS5FJ8D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)F=8KB,QLR$;@#Z9JTJA5"CH!BEHH **** "BBB@ J%?^/R7_<3^;5-4*_\
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M&68[N#QT^<]/:J5KX+M;6YLY%U+4GBLI-]M;O*OEQC!&W 49&">22?>NEHH
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M IK]*=3).@^M "BG4Q>E/H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_"T+;_H%R_]_1_A1_PM"V_Z!<O_ ']'^%>:T4>RB']M8S^;\$>E?\+0MO\
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M"TT874PMUGD N0FS)QCD<\U"_BV>6UTY[#2VN)[TR+Y+3!"A3[PSC![TV_\
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MH'R[CEL= /:E32[JWT>\AGO9=0G='\MY44,N5Q@8K..GWEMI_AVZ6UDEDT]
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MUKOI:_\ ?W_ZU)_PKK7?2U_[^_\ UJ.>/<?]G8O_ )]LY.BNL_X5WKOI:_\
M?W_ZU'_"N]=]+7_O]_\ 6HYX]Q?V=B_^?;.3HKJ_^%>:[Z6O_?[_ .M2?\*]
MUWTM?^_W_P!:CGCW#^SL7_S[9RM%=5_PK[7?2U_[_?\ UJ0_#_7/[MM_W^_^
MM1SQ[A_9V+_Y]LY:BNH_X0'7/[MM_P!_O_K4G_"!:Y_=MO\ O]_]:CGCW'_9
MN+_Y]LYBBNF/@36Q_!;?]_O_ *U-/@76Q_!;_P#?[_ZU'/'N']FXO_GVSFZ*
MZ/\ X0?6_P"Y;_\ ?[_ZU)_PA&M?\\[?_O\ ?_6HYX]P_LW%_P#/MG.T5T/_
M  A6M?\ /.W_ ._W_P!:D_X0O6?^><'_ '^_^M1SQ[A_9N+_ .?;.?HK?_X0
MS6?^><'_ '^_^M2?\(=K/_/*#_O]_P#6HYX]P_LW%_\ /MF#16]_PA^L_P#/
M*#_O]_\ 6I/^$0UC_GE!_P!_O_K4>TCW#^S<7_S[9A45N?\ "(ZQ_P \H/\
MO]_]:D_X1+6/^>4/_?[_ .M1[2/</[-Q?_/MF)16W_PB>L?\\H?^_P!_]:D_
MX1/5_P#GE#_W^_\ K4>TCW#^S<7_ ,^V8M%;7_"*:O\ \\8?^_W_ -:C_A%=
M7_YXP_\ ?[_ZU'M(]P_LW%_\^V8M%;/_  BNK_\ /&'_ +_?_6H_X175_P#G
MC#_W^_\ K4>TCW#^S<7_ ,^V8U%;/_"*ZO\ \\8?^_W_ -:C_A%=7_YXP_\
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M.UG_ )Y0?]_O_K4O_"&ZS_SR@_[_ '_UJ.>/</[-Q?\ S[9@45T'_"&:R?\
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M ._Z?XT<\>XG@,4O^7;^XYFBNF_X0'Q#_P ^D?\ W_7_ !H_X0#Q#_SZ1_\
M?]?\:.>/<7U#%?\ /M_<SF:*Z?\ X0#Q#_SZQ?\ ?]?\:/\ A /$/_/K%_W_
M %HYX]P^H8K_ )]O[F<Q173_ /" >(?^?6+_ +_K1_P@'B'_ )]8O^_ZT<\>
MX_J&*_Y]O[CF**Z?_A7_ (A_Y]HO^_RTO_"O_$'_ #[1?]_EHYX]P^H8K_GV
M_N.7HKJ/^%?^(/\ GVA_[_+1_P *_P#$'_/O#_W^6CGCW#^S\5_S[?W'+T5U
M'_"O_$'_ #[P_P#?Y:/^%?>(/^?>'_O\M'/'N']GXK_GV_N.7HKJ?^%?>(/^
M>$/_ '^%'_"OO$'_ #PA_P"_PHYX]P_L_%?\^W]QRU%=3_PKW7_^>,'_ '^%
M+_PKW7_^>,'_ '^%'/'N']GXK_GV_N.5HKJO^%>Z_P#\\8/^_P */^%>Z_\
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M?E_^^5_PH\F7_GY?_OE?\* )Z*@\F7_GY?\ [Y7_  H\F7_GY?\ [Y7_  H
MGHJ#R9?^?E_^^5_PH\F7_GY?_OE?\* )Z*@\F7_GY?\ [Y7_  H\F7_GY?\
M[Y7_  H GK/U8XAB_P!_^AJSY,O_ #\O_P!\K_A6?J\4@@B_TE_O_P!U?0^U
M $UF?E%: Z5D64<FT?Z0_P#WPO\ A6B(9?\ GY?_ +Y7_"@">BH/)E_Y^7_[
MY7_"CR9?^?E_^^5_PH GQ28J'R9?^?E_^^5_PH\F7_GY?_OE?\* )L4FVHO)
ME_Y^7_[Y7_"CR9?^?E_^^5_PH EVTFP5'Y,O_/R__?*_X4>3+_S\O_WRO^%
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M_P"?E_\ OE?\*/L\G_/R_P#WRO\ A0!G_P!GCTI?L"^E7_L\G_/R_P#WRO\
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ME_\ OE?\*/)E_P"?E_\ OE?\* )=HHVU%Y,O_/R__?*_X4>3+_S\O_WRO^%
M$V*,5#Y,O_/R_P#WRO\ A1Y,O_/R_P#WRO\ A0!/BC%0>3+_ ,_+_P#?*_X4
M>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0>3+_ ,_+
M_P#?*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0
M>3+_ ,_+_P#?*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WR
MO^% $]%0>3+_ ,_+_P#?*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3
M+_S\O_WRO^% $]%0>3+_ ,_+_P#?*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R_
M_?*_X4>3+_S\O_WRO^% $]%0>3+_ ,_+_P#?*_X4>3+_ ,_+_P#?*_X4 3T5
M!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0>3+_ ,_+_P#?*_X4>3+_ ,_+_P#?
M*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0>3+_ ,_+_P#?*_X4>3+_
M ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0>3+_ ,_+_P#?
M*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0>3+_
M ,_+_P#?*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^%
M$]%0>3+_ ,_+_P#?*_X5*@*J 6+'U/>@!U%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M9K1Q;Q?]=/Z&M.L#Q?<R6FBF>+&]'!&1D>E %JQ/ K47I7F=IXJU)0,&'_OW
M5\>+=4]8?^_= '?45P7_  ENJ>L/_?O_ .O1_P );JGK#_W[_P#KT =[17!?
M\);JGK#_ -^__KT?\);JGK#_ -^__KT =[17!?\ "6ZIZP_]^_\ Z]'_  EN
MJ>L/_?O_ .O0!WM%<%_PENJ>L/\ W[_^O1_PENJ>L/\ W[_^O0!WM%<%_P )
M;JGK#_W[_P#KT?\ "6ZIZP_]^_\ Z] '>T5P7_"6ZIZP_P#?O_Z]'_"6ZIZP
M_P#?O_Z] '>T5P7_  ENJ>L/_?O_ .O1_P );JGK#_W[_P#KT =[17!?\);J
MGK#_ -^__KT?\);JGK#_ -^__KT =[17!?\ "6ZIZP_]^_\ Z]'_  ENJ>L/
M_?O_ .O0!WM%<%_PENJ>L/\ W[_^O1_PENJ>L/\ W[_^O0!WM%<%_P );JGK
M#_W[_P#KT?\ "6ZIZP_]^_\ Z] '>T5P7_"6ZIZP_P#?O_Z]'_"6ZIZP_P#?
MO_Z] '>T5P7_  ENJ>L/_?O_ .O1_P );JGK#_W[_P#KT =[17!?\);JGK#_
M -^__KT?\);JGK#_ -^__KT =[17!?\ "6ZIZP_]^_\ Z]'_  ENJ>L/_?O_
M .O0!WM%<%_PENJ>L/\ W[_^O1_PENJ>L/\ W[_^O0!WM%<%_P );JGK#_W[
M_P#KT?\ "6ZIZP_]^_\ Z] '>T5P7_"6ZIZP_P#?O_Z]'_"6ZIZP_P#?O_Z]
M '>T5P7_  ENJ>L/_?O_ .O1_P );JGK#_W[_P#KT =[17!?\);JGK#_ -^_
M_KT?\);JGK#_ -^__KT =[17!?\ "6ZIZP_]^_\ Z]'_  ENJ>L/_?O_ .O0
M!WM%<%_PENJ>L/\ W[_^O1_PENJ>L/\ W[_^O0!WM%<%_P );JGK#_W[_P#K
MT?\ "6ZIZP_]^_\ Z] '>T5P7_"6ZIZP_P#?O_Z]!\6:H>C0C_MG0!WM%<#_
M ,)7JO\ STB_[]BM"V\07TT"N73/0_)WH ZZBN7_ +;O?[Z?]\4?VW??WT_[
MXH ZBBN7_MJ^_OI_WQ1_;5[_ 'T_[XH ZBBN8_MJ]_OI_P!\4?VU>_WT_P"^
M* .GHKF/[:O?[Z?]\4O]M7O]]/\ OB@#IJ*YG^VKW^^G_?%']LWO]]/^^* .
MFHKF?[9O?[Z?]\4O]LWG]]/^^* .EHKFO[9O/[Z?]\4O]L7G]]/^^* .DHKF
M_P"V+S^^G_?%+_;%Y_?3_OB@#HZ*YS^U[S^^G_?%+_:]W_?3_OB@#HJ*YW^U
M[O\ OI_WS2_VM=_WT_[YH Z&BN>_M:[_ +Z?]\TO]JW?]]?^^: .@HK _M6Z
M_O+_ -\T?VK=?WE_[YH WZ*P?[4NO[R_]\TO]J77]Y?^^: -VBL+^T[G^\O_
M 'S2_P!IW/\ >7_OF@#<HK$_M*Y_O+_WS2_VE<_WE_[YH VJ*Q?[1N/[R_\
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MW+*N>!NP< 4MK:3G6+F;[(ADMT\T0Q#*LQ'RX]CG- &'15_6+0VFH./+9%D
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M^9_QI1H-I_S[+^9_QKI=O_3O-^2_XT8_Z=YOR7_&@#G!H%G_ ,^R_F?\:<-
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M+_GVC_6E_LNR_P"?:/\ 6I_/;_GWF_(?XT>>W_/O-^0_QH A_LNR_P"?:/\
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M2N>QZT . P,#I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&'MXG;T5Q']O:G_S\_\ CB_X4O\ ;VI?\_/_ (XO^%'(P]M$[:BN)_M[4O\
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MW_\ '1_A1_:]]_SW_P#'1_A1RL/:HZJBN6_M>]_Y[_\ CH_PI?[6O?\ GO\
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M'3CT(/YUJU-BT[A1110,**** "BBB@ HHHH **** "BBB@ KDOB/_P BC/\
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MFES3,TN: 'YI<TW-+F@!V:7--S2YH&.I<TW-+2 =FG U'FG9IC'YI:9FE!I
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M+L.2/8Y3^RD_YYTG]E+_ ,\_UKK/LR^E'V9?2B[#DCV.3_LI?^>?ZT?V6O\
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M?E1]CM_^>*?E4]% $'V.W_YXI^59^K6EOY$?[E/O^GL:UZH:J,PQ_P"__0T
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M\4_*IZ* (/L=O_SQ3\J/L=O_ ,\4_*IZ* (/L=O_ ,\4_*C[';_\\4_*IZ*
M(/L=O_SQ3\J/L=O_ ,\4_*IZ* (/L=O_ ,\4_*C[';_\\4_*IZ* (/L=O_SQ
M3\J/L=O_ ,\4_*IZ* (/L=O_ ,\4_*C[';_\\4_*IZ* (/L=O_SQ3\J/L=O_
M ,\4_*IZ* (/L=O_ ,\4_*C[';_\\4_*IZ* (/L=O_SQ3\J/L=O_ ,\4_*IZ
M* (/L=O_ ,\4_*C[';_\\4_*IZ* (/L=O_SQ3\J/L=O_ ,\4_*IZ* (/L=O_
M ,\4_*C[';_\\4_*IZ* (/L=O_SQ3\J/L=O_ ,\4_*IZ* (/L=O_ ,\4_*C[
M';_\\4_*IZ* (/L=O_SQ3\J/L=O_ ,\4_*IZ* (/L=O_ ,\4_*C[';_\\4_*
MIZ* (/L=O_SQ3\JE1%C4*H 4= *=10 4444 %5-4N)+32[JXBQYD<3,N1D9
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M7_[Z-1TM%@N/\V7_ )ZO_P!]&CS9?^>K_P#?1IE%*P$GFR_\]7_[Z-'FR_\
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MZFER?4TE+0 N3ZT9/K0**!BTN:2BD M+24M !1110 HHH%% !1112 6BBB@
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MVGC:6(('MUJO9HS]J^W0[*BBBLC<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *P/&0SX9N?\ @/\ Z$*WZPO& _XIJZ^B_P#H0JH?$B*G
MP,\VL@#=0 \CS%_G77&T@F\1?:H(E")+)#/%@$*P5L-CT('YBN/@8QR(XQE2
M&&?:M.WUFZMM0GO8PF^?=YB$':<_C7=.+>QYT));^1JQ3-;Z-IWEW]I:EXV+
M"6WWEOF/.=IJ'1[^=M3D@:2&6-A*Y(A7#$*2",C(' XJC'JH6U@MY;&TG$*E
M4:56S@G/9A4,-\UO>M<PPQ(2K*(P#M (P<<YI<FC^97/JM>QJ16/]K6 OIY9
MI9\$$6T28CQTW*,$Y]A57P^!_:3DE%VV\K!G7<%(7J1CM4-GJKV4:".VMFEC
MR8YF3YU_$'G\<U7M;N2UE>1 K,\;QG=Z,,'\:=G9HGF5TS<O5:?38EFN+>[E
MN956WDA@V!.<-DX'KTI+C0([/;*LCEHID5A(8\2#< 2H!)_ UC0WTT%I);+M
M*.ZR GJC#HR^AJ>?56G;?]DM$E+AWE2+#.0<\G/'OC%"C)/0;E%K7<U(]&AO
M]1NMRW8S=.@:*-1''SW)//T%-32;>XL[.U0NMRUU*CR8&,+U]^G3\:IIK]PK
MAVM[:1UE:6-G0DH6.3CGU]:B76KA0-L<099VG1MIRI;[PZ]#[U*C,IR@7IO#
MR"6#RYI(XW9A()2C,H"EMPV$@C /XU!>I9C0;=[,R,C7+Y,J@./E''';O^-5
MCJKI/%+;VMK;&-BV(8\;B>#G.21CMTIMWJ3W=LEN+>W@B1RZK"I')&#U)JDI
M=27*&MB^]_/8:/IOV?RAYB2%]T*MNPYZY%2S6,,GVAED6VBE6V=EVC:F\\\G
MD =>*SXM6V6L$$EC:3B'(1I58D9.>QQUIG]K7):X9Q&[3LC-N7(&TY  Z8[8
MI<KOI_6H<RMK_6AI2^'5-];V\1N460MEY54@J!G*LIP<^AJ.ZT.*&:VVO<;)
M7*&/"22 @9X"$@@_I58ZY<+Y8MX;>W1',A2)#M8D8Y!)XP2,4Q=6:*XCE@L[
M2 )N!2./ 8,,$$YST]Z$IC;I]C0E\/P)<68:6>".<NI6?9O!49 !!QSVS31X
M?#ZB8 +J.-(?-<2JH?KC .=I^N<54DUIW6"/['9K%"6*QB,E3D8(.3S]>M(=
M:G\Q-L-NL"(T?V<(3&5)R003DY..]%IA>F7?[ A%^D1GD"/$9%CW1^:6!QMS
MG;GOUK*U&T%E>O"HF  !Q,FUA]>WXBI!J0$^\6-D(]FSR?*^7'7/7.??-17M
M[)?3+)(J*$0(B(,!5'0"FE*^I,G"VA7!(((ZCD5T\3^9$CD8+*#BN;MXC-<)
M&/XC@_2NG    Z"JD$!:***DL*6DI: "BBB@8M%%%(!110** %%% HH&.%%
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A^+QGPU=_1?\
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MY%[_ ,_ _P"_0I?(O?\ GX'_ 'Z%+VL0]E(LTHJL(+W_ )^!_P!^A2^1>_\
M/P/^_0H]I$?LI%J@57$-Y_S\#_OT*407G_/P/^_0I>TB'LY%BEJN(+S_ )^!
M_P!^A3A;W?\ SW'_ 'Z%'M(C]G(GI14(M[O_ )[C_OT*<+>Z_P">X_[]BCVD
M0]G(FI140MKK_GN/^_8IXMKG_GN/^_8I>TB'LY#Z44T6MQ_SW'_?L4\6D_\
MSV'_ '[%'/$?)(*6E%I/_P ]O_'!3Q9S?\]O_'!2YT/D8P4X4\6<O_/;_P <
M%/%G)_SU_P#'*.=!R,BI14PLG_YZ_P#CM.%DW_/7_P =I<R'RL@I15@63?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>plx-20210331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/14/2021 11:04:10 AM-->
<!--Modified on: 5/14/2021 11:04:10 AM-->
<schema xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:plx="http://www.protalix.com/20210331" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.protalix.com/20210331" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePromissoryNote" id="DisclosurePromissoryNote">
        <link:definition>10501 - Disclosure - PROMISSORY NOTE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" id="DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" id="DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePromissoryNoteDetails" id="DisclosurePromissoryNoteDetails">
        <link:definition>40501 - Disclosure - PROMISSORY NOTE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="Notes2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_Notes2021Member" substitutionGroup="xbrli:item" />
  <element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="AmendedPfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiExUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PaymentOnNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNoteMember" substitutionGroup="xbrli:item" />
  <element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" name="UpfrontNonrefundableNonCreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_IncreaseDecreaseInRestrictedDeposit" name="IncreaseDecreaseInRestrictedDeposit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_LicenseAgreementInitialCashPayment" name="LicenseAgreementInitialCashPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_TermToSignSupplyAgreement" name="TermToSignSupplyAgreement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" name="AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_SarcomedUsaInc.AgreementMember" name="SarcomedUsaInc.AgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>plx-20210331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/14/2021 11:04:10 AM-->
<!--Modified on: 5/14/2021 11:04:10 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637565870497384871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637565870497384871" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565870497384871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637565870497384871" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565870497384871" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637565870497384871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637565870497384871" xlink:to="plx_ShortTermBankDeposits_637565870497384871" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637565870497384871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637565870497384871" xlink:to="us-gaap_AccountsReceivableNetCurrent_637565870497384871" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637565870497384871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637565870497384871" xlink:to="us-gaap_OtherAssetsCurrent_637565870497384871" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637565870497384871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637565870497384871" xlink:to="us-gaap_InventoryNet_637565870497384871" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637565870497384871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637565870497384871" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637565870497394880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637565870497394880" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637565870497394880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637565870497394880" order="4" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637565870497394880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_637565870497394880" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637565870497394880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637565870497394880" xlink:to="us-gaap_LiabilitiesNoncurrent_637565870497394880" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637565870497394880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637565870497394880" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637565870497394880" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637565870497394880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637565870497394880" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637565870497394880" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637565870497394880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637565870497394880" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637565870497394880" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637565870497394880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637565870497394880" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637565870497394880" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637565870497404872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637565870497394880" xlink:to="us-gaap_LiabilitiesCurrent_637565870497404872" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637565870497404872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637565870497404872" xlink:to="us-gaap_AccountsPayableTradeCurrent_637565870497404872" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637565870497404872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637565870497404872" xlink:to="us-gaap_AccountsPayableOtherCurrent_637565870497404872" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637565870497404872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637565870497404872" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637565870497404872" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637565870497404872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637565870497404872" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637565870497404872" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637565870497404872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637565870497404872" xlink:to="us-gaap_ConvertibleDebtCurrent_637565870497404872" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637565870497404872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637565870497404872" xlink:to="us-gaap_NotesPayableCurrent_637565870497404872" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637565870497404872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_637565870497404872" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637565870497414862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637565870497414862" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637565870497414862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637565870497414862" xlink:to="us-gaap_CostOfRevenue_637565870497414862" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637565870497414862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637565870497414862" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637565870497414862" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637565870497414862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637565870497414862" xlink:to="us-gaap_Revenues_637565870497414862" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637565870497414862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637565870497414862" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637565870497414862" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637565870497414862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_637565870497414862" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637565870497414862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637565870497414862" xlink:to="us-gaap_OtherNonoperatingExpense_637565870497414862" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637565870497424878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637565870497414862" xlink:to="us-gaap_OtherNonoperatingIncome_637565870497424878" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637565870497424878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherIncome_637565870497424878" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637565870497434882" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_NetIncomeLoss_637565870497434882" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637565870497434882" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_ShareBasedCompensation_637565870497434882" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637565870497434882" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_Depreciation_637565870497434882" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637565870497434882" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637565870497434882" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637565870497434882" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637565870497434882" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637565870497434882" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637565870497434882" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637565870497434882" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637565870497434882" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637565870497434882" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637565870497434882" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637565870497434882" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637565870497434882" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637565870497444875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637565870497444875" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637565870497444875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637565870497444875" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637565870497444875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_IncreaseDecreaseInInventories_637565870497444875" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637565870497444875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637565870497444875" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637565870497444875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497434882" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637565870497444875" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565870497444875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565870497444875" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637565870497444875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565870497444875" xlink:to="plx_IncreaseDecreaseInBankDeposits_637565870497444875" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637565870497444875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565870497444875" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637565870497444875" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637565870497444875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565870497444875" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637565870497444875" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637565870497454872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565870497444875" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637565870497454872" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637565870497454872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565870497444875" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637565870497454872" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637565870497454872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565870497444875" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637565870497454872" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565870497454872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565870497454872" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637565870497454872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565870497454872" xlink:to="us-gaap_RepaymentsOfNotesPayable_637565870497454872" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637565870497454872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565870497454872" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637565870497454872" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637565870497454872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565870497454872" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637565870497454872" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637565870497464870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637565870497464870" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637565870497464870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637565870497464870" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637565870497464870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637565870497464870" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637565870497464870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637565870497464870" order="3" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>plx-20210331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/14/2021 11:04:10 AM-->
<!--Modified on: 5/14/2021 11:04:10 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosurePromissoryNoteDetails" roleURI="http://www.protalix.com/role/DisclosurePromissoryNoteDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637565870497474883" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637565870497474883" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637565870497494875" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637565870497494875" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637565870497504886" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637565870497504886" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637565870497534873" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637565870497534873" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_Notes2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870497544893" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870497544893" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SarcomedUsaInc.AgreementMember" xlink:label="plx_SarcomedUsaInc.AgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_SarcomedUsaInc.AgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637565870497554878" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637565870497554878" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637565870497554878" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637565870497554878" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637565870497564873" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637565870497564873" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637565870497574876" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637565870497574876" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637565870497584875" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637565870497584875" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637565870497594873" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637565870497594873" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637565870497594873" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_637565870497594873" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_LicenseAgreementInitialCashPayment" xlink:label="plx_LicenseAgreementInitialCashPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LicenseAgreementInitialCashPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_TermToSignSupplyAgreement" xlink:label="plx_TermToSignSupplyAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_TermToSignSupplyAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637565870497684889" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637565870497684889" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637565870497684889" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_637565870497684889" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_637565870497804902" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_637565870497804902" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosurePromissoryNoteDetails" xlink:type="extended" xlink:title="40501 - Disclosure - PROMISSORY NOTE (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>plx-20210331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/14/2021 11:04:10 AM-->
<!--Modified on: 5/14/2021 11:04:10 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Promissory note</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity (net of capital deficiency)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License And Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES - NET</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">OTHER INCOME</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS) FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income for the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC AND DILUTED</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC AND DILUTED</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, in shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" xlink:to="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from receivables from sale of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Receivables From Sale Of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Additional capital that the company can raise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net income (loss) to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss (gain) on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase in inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Decrease in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Purchase of bank deposits</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInRestrictedDeposit" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Increase (Decrease) In Restricted Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Decrease in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Net payment for promissory note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment for promissory note</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note Receivable from Issuance of Common Stock and Warrants, Net of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">PROMISSORY NOTE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">PROMISSORY NOTE</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (loss) per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_Notes2021Member" xlink:to="plx_Notes2021Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes 2021 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of liability component based on income approach</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's disaggregation of revenues</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_LicenseAgreementInitialCashPayment" xlink:label="plx_LicenseAgreementInitialCashPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAgreementInitialCashPayment" xlink:to="plx_LicenseAgreementInitialCashPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LicenseAgreementInitialCashPayment_lbl" xml:lang="en-US">The amount of initial cash payment under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LicenseAgreementInitialCashPayment_lbl" xml:lang="en-US">License Agreement, Initial Cash Payment</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_TermToSignSupplyAgreement" xlink:label="plx_TermToSignSupplyAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TermToSignSupplyAgreement" xlink:to="plx_TermToSignSupplyAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_TermToSignSupplyAgreement_lbl" xml:lang="en-US">Term To Sign Supply Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TermToSignSupplyAgreement_lbl" xml:lang="en-US">Term To Sign Supply Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_TermToSignSupplyAgreement_lbl" xml:lang="en-US">Term to sign supply agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non-Creditable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNoteMember" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">B [R]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost Of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SarcomedUsaInc.AgreementMember" xlink:label="plx_SarcomedUsaInc.AgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SarcomedUsaInc.AgreementMember" xlink:to="plx_SarcomedUsaInc.AgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SarcomedUsaInc.AgreementMember_lbl" xml:lang="en-US">Represents information pertaining to SarcoMed USA, Inc. licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SarcomedUsaInc.AgreementMember_lbl" xml:lang="en-US">Sarcomed Usa Inc. Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SarcomedUsaInc.AgreementMember_lbl" xml:lang="en-US">SarcoMed USA, Inc. Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi Us Agreement And Chiesi Ex Us Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">At Market Equity Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario, Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short Term Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Measurement Input, Yield [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Measurement Input Yield [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Measurement Input, Yield [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" xml:lang="en-US">Change In Accounting Estimate Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl" xml:lang="en-US">Change In Accounting Method Accounted For As Change In Estimate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl" xml:lang="en-US">Change in Accounting Method Accounted for as Change in Estimate [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>plx-20210331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/14/2021 11:04:10 AM-->
<!--Modified on: 5/14/2021 11:04:10 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosurePromissoryNote" roleURI="http://www.protalix.com/role/DisclosurePromissoryNote" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210331.xsd#DisclosurePromissoryNoteDetails" roleURI="http://www.protalix.com/role/DisclosurePromissoryNoteDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637565870497834903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637565870497834903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637565870497844907" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637565870497844907" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637565870497844907" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637565870497844907" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637565870497844907" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637565870497844907" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637565870497844907" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637565870497844907" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637565870497844907" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637565870497844907" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637565870497844907" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637565870497844907" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637565870497844907" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637565870497844907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637565870497844907" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637565870497854889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637565870497854889" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637565870497854889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637565870497854889" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637565870497854889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637565870497854889" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637565870497854889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637565870497854889" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637565870497854889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637565870497854889" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637565870497854889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637565870497854889" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637565870497854889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637565870497854889" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637565870497854889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637565870497854889" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637565870497854889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637565870497854889" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637565870497854889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637565870497854889" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637565870497864885" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637565870497864885" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637565870497864885" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637565870497864885" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637565870497864885" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637565870497864885" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637565870497864885" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637565870497864885" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637565870497864885" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637565870497864885" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637565870497864885" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_637565870497864885" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637565870497864885" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637565870497864885" xlink:to="us-gaap_AssetsCurrentAbstract_637565870497864885" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637565870497864885" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565870497874897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637565870497864885" xlink:to="plx_ShortTermBankDeposits_637565870497874897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637565870497864885" xlink:to="us-gaap_AccountsReceivableNetCurrent_637565870497874897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637565870497864885" xlink:to="us-gaap_OtherAssetsCurrent_637565870497874897" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637565870497864885" xlink:to="us-gaap_InventoryNet_637565870497874897" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637565870497864885" xlink:to="us-gaap_AssetsCurrent_637565870497874897" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637565870497864885" xlink:to="us-gaap_AssetsNoncurrentAbstract_637565870497874897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637565870497874897" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637565870497874897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637565870497874897" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637565870497874897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637565870497874897" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637565870497874897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637565870497864885" xlink:to="us-gaap_Assets_637565870497874897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565870497874897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565870497874897" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637565870497874897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637565870497874897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637565870497874897" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637565870497874897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637565870497884892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637565870497874897" xlink:to="us-gaap_AccountsPayableTradeCurrent_637565870497884892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637565870497884892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637565870497874897" xlink:to="us-gaap_AccountsPayableOtherCurrent_637565870497884892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637565870497884892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637565870497874897" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637565870497884892" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637565870497884892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637565870497874897" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637565870497884892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637565870497884892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637565870497874897" xlink:to="us-gaap_ConvertibleDebtCurrent_637565870497884892" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637565870497884892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637565870497874897" xlink:to="us-gaap_NotesPayableCurrent_637565870497884892" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637565870497884892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637565870497874897" xlink:to="us-gaap_LiabilitiesCurrent_637565870497884892" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637565870497884892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565870497874897" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637565870497884892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637565870497884892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637565870497884892" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637565870497884892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637565870497884892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637565870497884892" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637565870497884892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637565870497894889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637565870497884892" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637565870497894889" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637565870497894889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637565870497884892" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637565870497894889" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637565870497894889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565870497874897" xlink:to="us-gaap_LiabilitiesNoncurrent_637565870497894889" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637565870497894889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565870497874897" xlink:to="us-gaap_Liabilities_637565870497894889" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637565870497894889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565870497874897" xlink:to="us-gaap_StockholdersEquity_637565870497894889" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637565870497894889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565870497874897" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637565870497894889" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="us-gaap_StatementTable_637565870497904896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870497904896" xlink:to="srt_ProductOrServiceAxis_637565870497904896" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637565870497904896" xlink:to="srt_ProductsAndServicesDomain_637565870497904896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637565870497904896" xlink:to="us-gaap_ProductMember_637565870497904896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637565870497904896" xlink:to="us-gaap_LicenseAndServiceMember_637565870497904896" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870497904896" xlink:to="us-gaap_StatementLineItems_637565870497904896" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_Revenues_637565870497904896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_CostOfRevenue_637565870497904896" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637565870497904896" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637565870497904896" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_OperatingIncomeLoss_637565870497904896" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_OtherNonoperatingExpense_637565870497904896" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_OtherNonoperatingIncome_637565870497904896" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_NonoperatingIncomeExpense_637565870497904896" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637565870497904896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_OtherIncome_637565870497904896" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_NetIncomeLoss_637565870497914883" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637565870497914883" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497904896" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637565870497914883" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_637565870497914883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870497914883" xlink:to="us-gaap_IncomeStatementLocationAxis_637565870497914883" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637565870497914883" xlink:to="us-gaap_IncomeStatementLocationDomain_637565870497914883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637565870497914883" xlink:to="us-gaap_CostOfSalesMember_637565870497914883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637565870497914883" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637565870497914883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637565870497914883" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637565870497914883" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870497914883" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637565870497914883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637565870497914883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637565870497914883" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637565870497914883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_637565870497924897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870497924897" xlink:to="us-gaap_StatementEquityComponentsAxis_637565870497924897" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637565870497924897" xlink:to="us-gaap_CommonStockMember_637565870497924897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637565870497924897" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637565870497924897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637565870497924897" xlink:to="us-gaap_RetainedEarningsMember_637565870497924897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637565870497924897" xlink:to="us-gaap_EquityComponentDomain_637565870497924897" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870497924897" xlink:to="us-gaap_StatementLineItems_637565870497924897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="us-gaap_StockholdersEquity_637565870497924897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="us-gaap_SharesOutstanding_637565870497924897" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637565870497924897" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637565870497924897" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637565870497924897" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_637565870497924897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_637565870497924897" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637565870497934906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637565870497934906" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637565870497934906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637565870497934906" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637565870497934906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_637565870497934906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_637565870497934906" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_637565870497934906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement_637565870497934906" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_637565870497934906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637565870497934906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637565870497934906" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637565870497934906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637565870497934906" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637565870497934906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="us-gaap_NetIncomeLoss_637565870497934906" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637565870497934906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="us-gaap_StockholdersEquity_637565870497934906" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637565870497934906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870497924897" xlink:to="us-gaap_SharesOutstanding_637565870497934906" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637565870497944894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_637565870497944894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="us-gaap_NetIncomeLoss_637565870497944894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="us-gaap_ShareBasedCompensation_637565870497944894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="us-gaap_Depreciation_637565870497944894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637565870497944894" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637565870497944894" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637565870497944894" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637565870497944894" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637565870497944894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637565870497944894" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565870497954901" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565870497954901" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637565870497954901" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565870497954901" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637565870497954901" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565870497954901" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637565870497954901" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565870497954901" xlink:to="us-gaap_IncreaseDecreaseInInventories_637565870497954901" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565870497954901" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637565870497954901" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565870497954901" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637565870497954901" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637565870497944894" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565870497954901" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565870497954901" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565870497954901" xlink:to="plx_IncreaseDecreaseInBankDeposits_637565870497954901" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637565870497954901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565870497954901" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637565870497954901" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637565870497964895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565870497954901" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637565870497964895" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637565870497964895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565870497954901" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637565870497964895" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637565870497964895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565870497954901" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637565870497964895" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637565870497964895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565870497954901" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637565870497964895" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565870497964895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565870497954901" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565870497964895" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565870497964895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565870497964895" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637565870497964895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565870497964895" xlink:to="us-gaap_RepaymentsOfNotesPayable_637565870497964895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637565870497964895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565870497964895" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637565870497964895" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637565870497964895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565870497964895" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637565870497964895" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565870497974891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565870497964895" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565870497974891" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637565870497974891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637565870497974891" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637565870497974891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637565870497974891" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565870497974891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565870497974891" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6375658704979748911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6375658704979748911" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637565870497974891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637565870497974891" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637565870497974891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637565870497974891" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637565870497974891" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637565870497984890" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637565870497974891" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637565870497984890" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637565870497984890" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637565870497974891" xlink:to="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637565870497984890" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637565870497984890" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637565870497984890" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_637565870497984890" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637565870497984890" xlink:to="plx_InterestReceivedNet_637565870497984890" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637565870497984890" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637565870497984890" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637565870497994903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_637565870497994903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637565870497994903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637565870497994903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_637565870497994903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_637565870497994903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosurePromissoryNote" xlink:type="extended" xlink:title="10501 - Disclosure - PROMISSORY NOTE">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637565870497994903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637565870497994903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_637565870497994903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_637565870497994903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637565870497994903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637565870497994903" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637565870497994903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637565870497994903" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637565870498004906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637565870498004906" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637565870498004906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637565870498004906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637565870498004906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_637565870498004906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637565870498004906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870498004906" xlink:to="us-gaap_DebtInstrumentAxis_637565870498004906" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637565870498004906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637565870498004906" xlink:to="us-gaap_DebtInstrumentNameDomain_637565870498004906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member_637565870498004906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637565870498004906" xlink:to="plx_Notes2021Member_637565870498004906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637565870498004906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870498004906" xlink:to="us-gaap_StatementLineItems_637565870498004906" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637565870498004906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870498004906" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637565870498004906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_637565870498004906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_637565870498004906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_637565870498014903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637565870498014903" xlink:to="us-gaap_TypeOfArrangementAxis_637565870498014903" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637565870498014903" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498014903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498014903" xlink:to="plx_AmendedPfizerAgreementMember_637565870498014903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498014903" xlink:to="plx_ChiesiAgreementsMember_637565870498014903" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_637565870498014903" xlink:to="plx_ChiesiUSAgreementMember_637565870498014903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_637565870498014903" xlink:to="plx_ChiesiExUSAgreementMember_637565870498014903" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SarcomedUsaInc.AgreementMember" xlink:label="plx_SarcomedUsaInc.AgreementMember_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498014903" xlink:to="plx_SarcomedUsaInc.AgreementMember_637565870498014903" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498014903" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637565870498014903" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637565870498014903" xlink:to="dei_LegalEntityAxis_637565870498014903" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637565870498014903" xlink:to="dei_EntityDomain_637565870498014903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_637565870498014903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637565870498014903" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_637565870498014903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637565870498024902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637565870498014903" xlink:to="srt_StatementGeographicalAxis_637565870498024902" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637565870498024902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637565870498024902" xlink:to="srt_SegmentGeographicalDomain_637565870498024902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR_637565870498024902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637565870498024902" xlink:to="country_BR_637565870498024902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637565870498024902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637565870498014903" xlink:to="srt_RangeAxis_637565870498024902" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637565870498024902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637565870498024902" xlink:to="srt_RangeMember_637565870498024902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637565870498024902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637565870498024902" xlink:to="srt_MinimumMember_637565870498024902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637565870498024902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637565870498024902" xlink:to="srt_MaximumMember_637565870498024902" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637565870498024902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637565870498014903" xlink:to="us-gaap_DebtInstrumentAxis_637565870498024902" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637565870498034911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637565870498024902" xlink:to="us-gaap_DebtInstrumentNameDomain_637565870498034911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_637565870498034911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637565870498034911" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_637565870498034911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637565870498034911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637565870498014903" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637565870498034911" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637565870498034911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637565870498034911" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637565870498034911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_637565870498034911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637565870498034911" xlink:to="plx_AtMarketEquityOfferingMember_637565870498034911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637565870498034911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637565870498014903" xlink:to="us-gaap_SubsequentEventTypeAxis_637565870498034911" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637565870498034911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637565870498034911" xlink:to="us-gaap_SubsequentEventTypeDomain_637565870498034911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637565870498034911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637565870498034911" xlink:to="us-gaap_SubsequentEventMember_637565870498034911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637565870498044902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637565870498014903" xlink:to="srt_StatementScenarioAxis_637565870498044902" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637565870498044902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637565870498044902" xlink:to="srt_ScenarioUnspecifiedDomain_637565870498044902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_637565870498044902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637565870498044902" xlink:to="us-gaap_ScenarioPlanMember_637565870498044902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_637565870498044902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637565870498014903" xlink:to="us-gaap_ShortTermDebtTypeAxis_637565870498044902" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637565870498044902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_637565870498044902" xlink:to="us-gaap_ShortTermDebtTypeDomain_637565870498044902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember_637565870498044902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_637565870498044902" xlink:to="us-gaap_ConvertibleNotesPayableMember_637565870498044902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_637565870498044902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637565870498014903" xlink:to="plx_SignificantAccountingPoliciesLineItems_637565870498044902" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_LicenseAgreementInitialCashPayment" xlink:label="plx_LicenseAgreementInitialCashPayment_637565870498054909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_LicenseAgreementInitialCashPayment_637565870498054909" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_TermToSignSupplyAgreement" xlink:label="plx_TermToSignSupplyAgreement_637565870498054909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_TermToSignSupplyAgreement_637565870498054909" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637565870498054909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637565870498054909" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637565870498054909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637565870498054909" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637565870498054909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637565870498054909" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637565870498054909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637565870498054909" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_637565870498054909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_637565870498054909" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637565870498064900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="us-gaap_SharesIssuedPricePerShare_637565870498064900" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637565870498064900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="us-gaap_RepaymentsOfNotesPayable_637565870498064900" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_637565870498064900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_SaleOfStockMaximumOfferingPrice_637565870498064900" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637565870498064900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637565870498064900" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637565870498064900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637565870498064900" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637565870498064900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637565870498064900" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_637565870498074898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_AgreementAmendmentPaymentReceivable_637565870498074898" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637565870498074898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637565870498074898" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637565870498074898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637565870498074898" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637565870498074898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_PaymentOnNetSalesPercentage_637565870498074898" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637565870498074898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637565870498074898" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637565870498084899" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637565870498084899" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637565870498084899" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="us-gaap_ConvertibleDebtCurrent_637565870498084899" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637565870498084899" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637565870498084899" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_637565870498084899" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="plx_RevenuePerformanceObligationNumber_637565870498084899" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637565870498084899" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637565870498044902" xlink:to="us-gaap_DebtInstrumentFaceAmount_637565870498084899" order="23" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637565870498094900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637565870498094900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637565870498094900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637565870498094900" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637565870498094900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637565870498094900" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637565870498094900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_637565870498094900" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498094900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498094900" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637565870498094900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498094900" xlink:to="us-gaap_DebtInstrumentAxis_637565870498094900" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637565870498094900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637565870498094900" xlink:to="us-gaap_DebtInstrumentNameDomain_637565870498094900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637565870498094900" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637565870498094900" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637565870498094900" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498094900" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637565870498104910" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637565870498104910" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637565870498104910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637565870498104910" xlink:to="us-gaap_FairValueInputsLevel3Member_637565870498104910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498094900" xlink:to="us-gaap_MeasurementInputTypeAxis_637565870498104910" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637565870498104910" xlink:to="us-gaap_MeasurementInputTypeDomain_637565870498104910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637565870498104910" xlink:to="us-gaap_MeasurementInputSharePriceMember_637565870498104910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637565870498104910" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637565870498104910" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637565870498104910" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637565870498104910" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637565870498104910" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637565870498104910" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637565870498104910" xlink:to="plx_MeasurementInputYieldMember_637565870498104910" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498094900" xlink:to="us-gaap_StatementLineItems_637565870498104910" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_637565870498104910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870498104910" xlink:to="us-gaap_DebtInstrumentMeasurementInput_637565870498104910" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498114898" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498114898" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637565870498114898" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637565870498114898" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637565870498114898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637565870498114898" xlink:to="us-gaap_FairValueInputsLevel3Member_637565870498114898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498114898" xlink:to="us-gaap_DebtInstrumentAxis_637565870498114898" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637565870498114898" xlink:to="us-gaap_DebtInstrumentNameDomain_637565870498114898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637565870498114898" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_637565870498114898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565870498114898" xlink:to="us-gaap_StatementLineItems_637565870498114898" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870498114898" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637565870498114898" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870498114898" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637565870498114898" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637565870498114898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870498114898" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637565870498114898" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637565870498124909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_637565870498124909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637565870498124909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870498124909" xlink:to="srt_ProductOrServiceAxis_637565870498124909" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637565870498124909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637565870498124909" xlink:to="srt_ProductsAndServicesDomain_637565870498124909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637565870498124909" xlink:to="us-gaap_ProductMember_637565870498134913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637565870498124909" xlink:to="us-gaap_LicenseAndServiceMember_637565870498134913" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870498124909" xlink:to="us-gaap_TypeOfArrangementAxis_637565870498134913" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637565870498134913" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498134913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498134913" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637565870498134913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870498124909" xlink:to="srt_StatementGeographicalAxis_637565870498134913" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637565870498134913" xlink:to="srt_SegmentGeographicalDomain_637565870498134913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637565870498134913" xlink:to="plx_PfizerMember_637565870498134913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637565870498134913" xlink:to="country_BR_637565870498134913" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870498124909" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis_637565870498134913" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_637565870498134913" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_637565870498134913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_637565870498134913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain_637565870498134913" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_637565870498134913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637565870498144907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870498124909" xlink:to="us-gaap_StatementLineItems_637565870498144907" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637565870498144907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870498144907" xlink:to="us-gaap_Revenues_637565870498144907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosurePromissoryNoteDetails" xlink:type="extended" xlink:title="40501 - Disclosure - PROMISSORY NOTE (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637565870498144907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_StatementTable_637565870498144907" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637565870498144907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870498144907" xlink:to="us-gaap_TypeOfArrangementAxis_637565870498144907" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498144907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637565870498144907" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498144907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637565870498144907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565870498144907" xlink:to="plx_AmendedPfizerAgreementMember_637565870498144907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637565870498144907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565870498144907" xlink:to="us-gaap_StatementLineItems_637565870498144907" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637565870498144907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870498144907" xlink:to="us-gaap_NotesPayableCurrent_637565870498144907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637565870498144907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565870498144907" xlink:to="us-gaap_RepaymentsOfNotesPayable_637565870498144907" order="2" use="optional" priority="2" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>plx-20210331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20210331"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20210331.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_fH-eFiWWTEWpXTsknvvImw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Nq3l1ggiG0WOrAXIuoXDsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RxigFEmVwUiEby_y9qE_KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DYn_82moD0GzQs7ZYeZtGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_56UcNId1aEWoJb4G10-Hmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Aa-Gbn7sR0WZ75YVpvDG2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bHkBYaLN-UGbRFDu8vTV9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__AQFGosJOEe3MtGAAmI2-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OwK6mWRUSEeU9FfVEMERyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_10T57iIY90SjOzgIZg1NUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bTggB3rqcE2CubUqXx-z4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Klv4TOV3SE-4-xc-l4SQKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ei_SgWNXwUO3DGpZNp_vXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_6pKW20bscE2Ku3nHfNM7Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_NTsUlyVWH0iAhOuc-JATrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_DpyYY9nDa0Cy_n2dtTOfHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_AVEnMunZKE2ZyjoOzJX63A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_8WJteDHFv0uHhDDSYCX3ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_HgUCN56GCUCbhH5dRyjtRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_rsuCkhAchUKfvtMJQ7Jdkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-PP3WwL7Ek624e-6Fj9uCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ThxKgBuf2UK2nF6qftr2kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-29</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_TQRiEj4vMkeo1dXynWjINA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2021_To_2_17_2021_u_XK6e7UVESYlSBODfH83Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_e7hdGudACk2S__aUdhpOSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Kv2xZBEDnEuhBJxoFSUWfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tflQqgNDrUGhPnHhxKjf9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_IWN34CGSq02efTOZFIDwQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BaH8L0w5DEycxituHyiDNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_BMaSMHlJfkSwlgEYxqWOuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_n58i0vokQU6Bu9njK42qFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_5NM-tGWaUkyvfqzfREuJnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_2fSRYl5U6ki6zEDhNxZMXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_tJnyJJMrvk64LWQ_LMBvfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_W7bSf7UauU2UcKXEjO21YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2021_Y55Ar_XSM0Cn4NkSAnOr_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-02-17</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_iGxYDoGsbk6P98GCsK8Y4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_5TDbx3U0ik6qCFvcE8CLmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_gqv2DN3kKEGHFA_c0gXKWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_1WvGJ0fXT0ubQS8uTighiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_MeqgCdhT4kqsQK5qJtNerQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QgHea-r4HEW3mtx9OaLcmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NxPZGRi_0kq-YVHiOyngKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_cUvfdjvwYEa9IMFmcOD8nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_j3-U2lgv9kaYDYpnq-Cz7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1dyrNNFEr0ipVKxmpMMfoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_d3BrXmiZ10eL6A392JU9mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7aJC2MSBhke9XBhPUx6xiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_1_2020_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_G_tb6sGRnk6B27_FVPjvUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_2Iwh_PZxMUuR2b_zQIjxjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember__7guBnYaGk-PHQNjbXG97Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_1sBE3oSTM0etPlYlt5LcuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_IZDIDKW0ckix5UQLj_kyyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r-lq86-0tUWqJBQNVq0i8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_ora0XsBMfkOq7xYpZZOFwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SarcomedUsaInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-10</startDate>
            <endDate>2021-02-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIaRfShWUKuo071QwzGrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_r3AHKZ-r30CFs0FZk9Nlzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_5_14_2021_To_5_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_CVQTExGFqUyzhQ6JuwB5tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-14</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="As_Of_5_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iMSRRkNGFEqFLRRG3ATJ0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B8rfirlHo0-scc7zqwmU3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wEgmk_bQ70CSJwv5vY46ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_UZb52YP5Gkqo2veFUnlg_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2021_70AbjOnoG0OAleWM0jsOrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_crDxDnAv7EmGAesWUEmcsw">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_ebGjDoarPEWjA7aoaQm4Lg_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_l4SZtZLsmUKCc8rlAGHR_A_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_0Lb3D1SL9kKA9kXqYb4LeQ_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_NThTlAdS1kqHaFx23GttaQ_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_5a6h5I4JiU2cNVAJesCY-Q">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_kHxRnx6fYk6-3QCiVeoHpA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_ei4wgWyxe067UkSgbedr3Q">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_xIr894sPlU2chju0BmNTYg">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_iKTN4tn6X02QJK7jPgtMKA">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_TyM_H7InSUCkpMcF5SfLHw">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_1k6YhTvjm0aiGq_A7fUPcw">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_UApuCiyAcU249rnlySCkKg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr__fjBPbnj0Umk1bSbXJbfHQ">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_4WXmgMo9ykKLHehN09R2Cg">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_CqD1m3s71Eu290vsMbiVHg">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_91bcYlD0-USctkTlHCGaZw">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_hmJQV6UOFU2mEA862l7Bng">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_-6S10Jjr6UaZZ_CSvLpGkw_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_vAPNsUsfXkmLbjdnz_JPTA">(201)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_Cbv4_l7Mnk-kANZ2opqbLQ">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_SEotxD6BfU-c8d_tSfI1rA_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_VoWD1VSh-02aRBcB7RK5Rg_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_udRF2SUBLUyHvP3gLu5zbw_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_nT8VZlMug0GjxaI59XGPzQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_fTICM7dlgU2k8IOJ42zVLg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_ApZyONRcukiGGaMjt7tsyw_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_HI2t4jaVBUq7vfkioyfcWw_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tc_RHuSRUZMFEuXzhvWavSAxA_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Narr_jol2JdyjWUCDbzHg1RiCbw">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_5_10_2021_70AbjOnoG0OAleWM0jsOrQ"
      decimals="INF"
      id="Narr_ctjqavY3IEqwQ7uZCDEZ3g"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">45382831</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_WlwpyyxntUWSu4kjCRmoTQ_6_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">19830000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_4IFg4eQFMEWe7cc5sPqAAQ_6_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">18265000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_m_RwQojYjEezyPFM3byMfg_7_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">50600000</plx:ShortTermBankDeposits>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_P1vFqcsCi0CjQUiQxZaKiw_7_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">20280000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_Okv2JAh7k0uufY5gy_lh-A_8_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4599000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_35lbIvr7NUKebXXOc1wE1g_8_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_R8589l7-hUyzcUyZDgomSw_9_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1754000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_l-DEfSzJz0iNB7kLo2ySbQ_9_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2096000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_8_dah6NzaESUD8O2TIdMIQ_10_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">13915000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc__EwjItM3FEaseFzKUBh7YQ_10_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">13082000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_AubjmjTi2U6Zc__fe1yPZA_11_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">90698000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_7MHj9RDlTEukbx0sQRYT4Q_11_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">55723000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_rGivOtytLkWhkzyGuXtSEA_14_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1776000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_LHY2kphP2USiDqF0dGGhUw_14_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1799000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_OZeMA5zjGUq7COMsfJlCtA_15_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4828000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_EaRp8Bui8EaFmSene_0Vrw_15_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4845000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_7KTiZutid0uuxyH73mkcQA_16_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">5490000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_qdb82AufZE6_a8M8kJLBqQ_16_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">5567000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_bCLbhtn1kEmhTxpqFs5gzQ_17_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">102792000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_2wJdV0vRC0CaVtRJhbRaJw_17_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">67934000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_JLfCkO2OCkesrrvWJC8cUg_23_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">6376000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_3rR_JMgxbUOlChcP2tbX7w_23_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">7221000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_3De_hTlbXUeyLsD_b34v9g_24_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">15167000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_Z-UWcVavC0yDhaaMX80hHw_24_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">13926000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_n7d1tn9rH02PaHO-xAdC6A_25_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1386000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_O_XVeiMrXUyP5ulC11E4FA_25_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1420000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_Hjb01ds2M0eYe-Ga05Fbfw_26_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2560000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_aO3iL-L9IUyNdJvTHamqng_26_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">5394000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_Oen0kqqTf0Owv3A26nf6xg_27_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">55372000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_weM3Z0Ej8ki5Tp2oEuITLQ_27_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">54427000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_nMdg1UBFOUatqvkMucVH3w_28_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4086000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_YEEZT8G2wki49BazeNx35Q_29_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">80861000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_ScRYOkwtcUCOXharWtzitA_29_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">86474000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_8ymusNhIxkuJVepDkQgHLQ_32_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">858000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_5UW__SZB1kWIuUAKTjJPnQ_32_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1716000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_mAS6-MSPzk-HDhbvyS5Z_g_33_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2224000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_t0tC8vv4ZUSwk57nzf5P4g_33_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2263000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_ppKFI8y5Q0CVTozFaVX_Zg_34_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4319000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_mFz2xdoH5k6SsHvUcmcZhw_34_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4467000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_K3nzXGuCh0-u41L3n2Urnw_35_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">26000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_How34sYzrUqKygL783qGtQ_35_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">51000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_vJxeW2FlAU2W8-xrfmoP4g_36_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">7427000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_8KnuhwLXA0y0wGOp7yhaPQ_36_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">8497000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_Z_4NTylUpUOnGPLIK65AIQ_37_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">88288000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_obhJUjBudkmN-6qmAEZiDw_37_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">94971000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_rXlcWb01Qkep6nCL_LDLyg_39_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">14504000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_hWCy1TkhjUyzYWXaAYgV_Q_39_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_8foOhYF_2kCtP_Zunlr7uA_40_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">102792000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_vbLGitI-6UidENf24GoP7w_40_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">67934000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_NTsUlyVWH0iAhOuc-JATrg"
      decimals="-3"
      id="Tc_a8uhjyl09EyZI7WwcNSnyA_3_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4511000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_rsuCkhAchUKfvtMJQ7Jdkw"
      decimals="-3"
      id="Tc_-7XW_hEdPE6kJKrIPm3Niw_3_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">5031000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_DpyYY9nDa0Cy_n2dtTOfHA"
      decimals="-3"
      id="Tc_qhbYG12GaU2_PlGjnSnNQw_4_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">6809000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-PP3WwL7Ek624e-6Fj9uCQ"
      decimals="-3"
      id="Tc_Q_8CIv3wHEScwETU1DiOoQ_4_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">16615000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_6e91kn1dG0SaEMiDdXmahA_5_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">11320000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_6NpKs5vB1k2ZNMOWfuhVOA_5_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">21646000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_Yw3wcWFGSka907xn6Lv1ww_6_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4765000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_9eREpW5XdUutlzAa5vvOEA_6_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">3426000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_8ccmMdc2oEWK500X1xRitw_7_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">7122000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_kwZ3nUllNkCVml5Vz2VX0w_7_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">10340000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_Q_UVBociTUSy8YM3pVGE5w_8_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">3138000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_5uK2XgY1IECIvVfIJ88JiA_8_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">3187000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_DbirLCIa702BjrTB8zbydQ_9_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-3705000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_mqdQGfi690q0Y41vZxpi4g_9_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4693000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_2TKsIFkmfUuHEsbVA7SwpA_10_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2156000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_20Lqenp3tEmtiAYaTeL6sg_10_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">3229000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_5golq-VLhUKYEJVb-yKsoA_11_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">335000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_7mQz5Gb2VUKOxrB6g-xfPw_11_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">203000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_TO1qPDpyJ0u9mPHFf8wIsw_12_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-1821000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_Jz-FMKRoYUqJZaL_OspNsg_12_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-3026000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_0EbBoayEI0W6Z_tfrW74vQ_13_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">51000</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_jFed7Q0NVU-fysb_S2_U6Q_14_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-5475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_EC0yoXSPL0WP2KyhIugaTA_14_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1667000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="2"
      id="Tc_YaHYOdfOp02G3scxHqpGJQ_15_3"
      unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="2"
      id="Tc_4BNp9lUVskq1OM78luI9cw_15_6"
      unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA">0.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="0"
      id="Tc_GHB6DjV5C02taLWMQjYE2w_17_3"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">39933972</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="0"
      id="Tc_3AtXLRA3eUOvS4KdvCRBIA_17_6"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">17381074</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_MeqgCdhT4kqsQK5qJtNerQ"
      decimals="-3"
      id="Tc_IgU0Y4t8V02W0ChT0ALkKg_18_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">109000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_1WvGJ0fXT0ubQS8uTighiQ"
      decimals="-3"
      id="Tc_OAvKXxtjBEGZ8u-rDFe07w_19_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">210000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NxPZGRi_0kq-YVHiOyngKQ"
      decimals="-3"
      id="Tc_y06kepjqc0CTrj6cT5dqIg_19_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">78000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_gqv2DN3kKEGHFA_c0gXKWQ"
      decimals="-3"
      id="Tc_xwW2kiFrj0-ZgIK6YzR4Gw_20_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">497000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QgHea-r4HEW3mtx9OaLcmQ"
      decimals="-3"
      id="Tc_sm6nG-JqH0G0CesHR9i7SQ_20_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">353000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ei_SgWNXwUO3DGpZNp_vXQ"
      decimals="INF"
      id="Tc_aguZ4qGbNUeFZnqMBcg_eg_6_2"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ei_SgWNXwUO3DGpZNp_vXQ"
      decimals="-3"
      id="Tc_B_nYyXrpL0KQKysw0m5vWg_6_5"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OwK6mWRUSEeU9FfVEMERyQ"
      decimals="-3"
      id="Tc_3-OS3InHfUW1Z1gNoOidDg_6_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">270492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__AQFGosJOEe3MtGAAmI2-g"
      decimals="-3"
      id="Tc_gK08wUOKqEm6vKQ8YAge0g_6_11"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-340829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_5TDbx3U0ik6qCFvcE8CLmQ"
      decimals="-3"
      id="Tc_4X2AIvhymUGEjpaYm15G3g_6_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-70322000</us-gaap:StockholdersEquity>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIaRfShWUKuo071QwzGrg"
      decimals="INF"
      id="Tc_iCBDbDyf30qZbg68LwlsHA_8_2"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">17604423</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIaRfShWUKuo071QwzGrg"
      decimals="-3"
      id="Tc_sbRCu5xwV0mklo65l4_XTg_8_5"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">18000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B8rfirlHo0-scc7zqwmU3A"
      decimals="-3"
      id="Tc_2NckslJqdUyooQ6X5O365g_8_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">41325000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_hbV37Wn2U0ukRCUfirs8JQ_8_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">41343000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B8rfirlHo0-scc7zqwmU3A"
      decimals="-3"
      id="Tc_B0hVb940lkWpMx3ocST2zA_9_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4000000</plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants>
    <plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_Y46VBuAWrU63IM7iO2MhnA_9_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4000000</plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B8rfirlHo0-scc7zqwmU3A"
      decimals="-3"
      id="Tc_bZCu3iDki0eAOTArtETSgg_10_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_vMK7qVV7fEaFTkae-0lx5g_10_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tflQqgNDrUGhPnHhxKjf9A"
      decimals="-3"
      id="Tc_YHQvzluX9Eu6CUh7cpVeog_11_11"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1667000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_Tz8wzTnoUUWhuUSM5Xym0w_11_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1667000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Klv4TOV3SE-4-xc-l4SQKw"
      decimals="INF"
      id="Tc_awBTyJ9d6UaDqHlQrm5PAg_12_2"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">32442636</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Klv4TOV3SE-4-xc-l4SQKw"
      decimals="-3"
      id="Tc_L66y5Dd3HUeWLWRJIsiHwg_12_5"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bHkBYaLN-UGbRFDu8vTV9Q"
      decimals="-3"
      id="Tc_vr4bb5skMEyeUltwng1VLA_12_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">308248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Aa-Gbn7sR0WZ75YVpvDG2Q"
      decimals="-3"
      id="Tc_5n3RYBMSPUGQEX20erjdgQ_12_11"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-339162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_iGxYDoGsbk6P98GCsK8Y4A"
      decimals="-3"
      id="Tc_GDTov4v7tky2AoUhaS000g_12_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-30881000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bTggB3rqcE2CubUqXx-z4g"
      decimals="INF"
      id="Tc_DvKqjgP5Ek6KwhJ7oHYahg_13_2"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">34765280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bTggB3rqcE2CubUqXx-z4g"
      decimals="-3"
      id="Tc_IwDqvlrzKkq2XWO7YxmyvQ_13_5"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_56UcNId1aEWoJb4G10-Hmg"
      decimals="-3"
      id="Tc_jJ7B96U7l0Wnb_fQfEJZsw_13_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">320280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DYn_82moD0GzQs7ZYeZtGA"
      decimals="-3"
      id="Tc_JMLYn6Tbj0apOwIiEZyU3g_13_11"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-347352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_M4KIs5zdG0KbkjMsXXr2jg_13_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1dyrNNFEr0ipVKxmpMMfoA"
      decimals="INF"
      id="Tc_YA06EQEv3UyU7Zozm-ckLg_15_2"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1dyrNNFEr0ipVKxmpMMfoA"
      decimals="-3"
      id="Tc_qFmJmLTMekaCrFXUFlpeKQ_15_5"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7aJC2MSBhke9XBhPUx6xiQ"
      decimals="-3"
      id="Tc_VlvVUMz9rESLk0UJNMVfFg_15_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">37616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_L2kC_5iqgEqh11cB9auHSw_15_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">37625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1dyrNNFEr0ipVKxmpMMfoA"
      decimals="INF"
      id="Tc_z6lp43I1PkKN1f6RB1PijQ_16_2"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">1867552</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1dyrNNFEr0ipVKxmpMMfoA"
      decimals="-3"
      id="Tc_5pus0Mr3zUyE8DHxX9f2Mw_16_5"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7aJC2MSBhke9XBhPUx6xiQ"
      decimals="-3"
      id="Tc_SPiQwcCkkkujS_6qy4hl7w_16_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">8573000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_gSyLt6q5R0S7T_xmKXZlAA_16_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">8575000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7aJC2MSBhke9XBhPUx6xiQ"
      decimals="-3"
      id="Tc_aNwp6DQvX0asYrnFV5UApQ_17_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">510000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_L8SXqNBTlEGAXwppw0jl0A_17_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">510000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7aJC2MSBhke9XBhPUx6xiQ"
      decimals="-3"
      id="Tc_mBYYP165RUCk-QFFB3qZww_18_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">306000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_d3VPJCETdkSD8IeD9mT-Jw_18_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">306000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Kv2xZBEDnEuhBJxoFSUWfA"
      decimals="-3"
      id="Tc_FKDkCGXaXUGgVASxiiTAQw_19_11"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-5475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_0UuddWohi0yxQsIeuBsEig_19_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-5475000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_10T57iIY90SjOzgIZg1NUA"
      decimals="INF"
      id="Tc_OfP6nAECrE-SSnVpwy-89w_20_2"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">45382831</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_10T57iIY90SjOzgIZg1NUA"
      decimals="-3"
      id="Tc_OJU3-5Kos0auiqcZv71AGw_20_5"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_RxigFEmVwUiEby_y9qE_KQ"
      decimals="-3"
      id="Tc_Qbt5XKj2OUWTuc8qZWFt1A_20_8"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">367285000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Nq3l1ggiG0WOrAXIuoXDsQ"
      decimals="-3"
      id="Tc_CnoKGWZcvEq2WLqfNISryQ_20_11"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-352827000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_fVPI2VQrqke-stMhs1KS8g_20_14"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">14504000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2020_iGxYDoGsbk6P98GCsK8Y4A"
      decimals="INF"
      id="Narr_JpdetSnbDkKhLAqKNSS4KA"
      unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="INF"
      id="Narr_R3YY3Su13kO8BBzJIr6i_A"
      unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2020_iGxYDoGsbk6P98GCsK8Y4A"
      decimals="0"
      id="Narr_DBYJwJuPzEOPOoNi6ruT8Q"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="0"
      id="Narr_CkZ7UrucOUuZnqozMh_uqQ"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_8-LI__dbLUKGptZ1injQGw_4_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-5475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_Ry1l1RJ5aEmY58sL4WQENg_4_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1667000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_0qoAaVqDLkCIu7rPMrKchw_6_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">816000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_9JjXSwRGVE68U0Koofx3bg_6_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">431000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_5mMBlkbCgEOoQabMJqC0fg_7_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">286000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_hI1kfNzz3UuvEMEorfcXnA_7_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">376000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_eSFOTVOVH0GeTSNJrtDP1w_8_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">168000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_hc5kj90oGkGijGpT4p8GpA_8_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">241000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_T7TxR4Lku0WncM3afOuBfQ_9_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">42000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_U4A1dJEWF0Od91_OAZJdYg_9_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">44000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_xxRINiuKbkCuyTMnGxDwuA_10_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">14000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_PArJAO0Vf0qfYfPFhAnZ-g_10_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-59000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_srt4T6WFu0mpbV6jwCop6Q_11_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">51000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_v8YXTjQvfEOPn6xeKmR2kw_12_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">945000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_dsIBgVlmpEOHeyW87lfeZw_12_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">820000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_59lXlZjScUGHQxjD0UyH_w_14_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-3692000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_twFSUvoVeUygoa33Z0PPDg_14_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-7171000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_bhEunQHSMkqP5bnBVrgLkQ_15_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2282000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_zUxcZyeZ8kyFbnq6NeDsAg_15_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4091000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_wkkE1uB6Rkq_ZO2rqZ-iAw_16_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-42000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_uAE0I0FR50CyWXds00VCKw_16_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-10000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_fkEKI9pjv0Wog5wxcuHz9Q_17_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">833000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_MlAODJXNKUS1yUoXnlj3lA_17_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1333000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_VeaYqrINpEGIbNUFV6F_5A_18_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">575000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_94QyWxfm4UGpMFsvNLPEdQ_18_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2611000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_9VgLrCeQ8EmK_8CJSz9-yA_19_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-25000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_idAAarv6A0iOurXAJ-GL_Q_19_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-299000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_5OofKwnxfkeXqxkeDf5YNg_20_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-9834000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_zDGWyO3AeE-VoiHeFg_RDw_20_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-7117000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_VWdcu9ONlU2OzRRrtXgVdw_23_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">37835000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_V-ckcPLW0EizM_EJGQr02A_23_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">35000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_GFU_i6PXTkyNMjtURWoB6g_24_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">7500000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_f3wV2hJuw0GAwQDszxEUfg_25_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">386000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_epyQAjT4vkOpUFDQE8cyJw_25_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">66000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_nqvBomnZQ0q5dySjJFMTiw_26_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">53000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_ucUdkU1wwkmZHd_OsPMDHg_27_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-12000</plx:IncreaseDecreaseInRestrictedDeposit>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_g3N7C9fMW0K_2iz2aXZp7w_27_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-22000</plx:IncreaseDecreaseInRestrictedDeposit>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_y8rmLVlnREecNRcEZNoY3A_28_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">28000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_DGMPTU7r0U6HviTovfBtYA_28_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">35000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_erbcjpPIfEe1NgjYXktvig_29_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-30684000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_-ic8Tweho0Ke_UHJ48zXLw_29_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-35079000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_ytHP4vth8EK4kRCxEQcJOg_32_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4086000</us-gaap:RepaymentsOfNotesPayable>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_QCuAru6PUES0aAgWr-ov-g_33_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">37625000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_rDm8TS9dCEWcEwy--V-kpg_33_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">38607000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_D7UZcRG29UumL_PfuNyUhA_34_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">8575000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_7s2_rDPJ4USgtF9RfOPERw_35_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">42114000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_UsMqrdogdE2EHBstjijNVw_35_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">38607000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_heydiMhfVEubP-36aw7oVw_36_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-31000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_DvCFdmC14UCwxhAYRPBajQ_36_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-37000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_bnvMuebMg0u85jKPm4Egfg_37_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">1565000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_9Vuloj2L2UCZT79Ht5o7Bg_37_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-3626000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_pkFNNL8Y3k-cmM80KW4MMQ_38_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">18265000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_5TDbx3U0ik6qCFvcE8CLmQ"
      decimals="-3"
      id="Tc_oc_Dq5CEB0yL6vMfGHxHkQ_38_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">17792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_3kPRqR4ALUiXx44R5FToDA_39_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">19830000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2020_iGxYDoGsbk6P98GCsK8Y4A"
      decimals="-3"
      id="Tc_C_CKSf0qsUGdacNB8iKZhw_39_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">14166000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_T0ZBPvGhC0a4pxNqWmgv8A_4_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">202000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_um3cdFsCmEiRlwCWT6CIrA_4_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">147000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_LL1X4iSns0q4RXEY67WNqA_5_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">122000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_NLGt0RY72UuYVIk82jatYA_5_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">233000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="-3"
      id="Tc_DHRq2LSXDU603GT1wq-nUA_6_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2736000</plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="-3"
      id="Tc_mGGzNEpWwESwRZy039SSiQ_9_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">136000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_uenhpmNZS06iZS1X55iY8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder. A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The FDA also indicated in its BLA filing communication letter that it did not plan to hold an advisory committee meeting to discuss the application. On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), announced that they received a Complete Response Letter (CRL) from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In the CRL, the FDA noted that an inspection of Protalix&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve the BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease, or COVID-19, the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;), a therapy used to treat Fabry patients, was recently converted to full approval which must be addressed in the context of any potential resubmission seeking accelerated approval of PRX-102. The Company intends to work collaboratively with the FDA to identify the most expeditious pathway to approval, including accelerated approval. Protalix remains confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. The Company intends to request a Type-A meeting with the FDA, and will provide further updates on next steps after this meeting; however, the Company cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which is subject to an exclusive worldwide license agreement with SarcoMed USA, Inc. (&#x201c;SarcoMed&#x201d;) for use in the treatment&lt;/span&gt;&lt;span style="color:#000000;direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat refractory gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;10, 2021, the Company entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. Under the terms of the agreement, SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, and the clinical research and development of such candidates. The Company is entitled to an initial cash payment of $3.5&#160;million, subject to certain conditions, and to additional regulatory and commercial milestone payments and tiered royalties on net sales of products that are commercialized under the license agreement. In addition to the foregoing, the parties agreed to commence negotiation of clinical and commercial supply agreements for alidornase alfa. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within 60 days of the execution of the license agreement, and SarcoMed has the right to terminate the license agreement if the parties do not successfully do so.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;) acted as book-running manager for the offering with Oppenheimer &amp;amp; Co. acting as co-manager.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March 29, 2021, the Company made a payment of approximately $4.0&#160;million to Pfizer Inc. (&#x201c;Pfizer&#x201d;) satisfying the outstanding promissory note payable to Pfizer in full.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;1, 2020, the Company entered into an ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with BofA Securities as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of Common Stock having an aggregate offering price of up to $30.0&#160;million (the &#x201c;ATM Shares&#x201d;). During 2021 to date, the Company sold 1,867,552 ATM Shares for gross proceeds of $8.8 million. As of the issuance date of the financial statements, the Company has the right to raise an additional $16.2&#160;million of capital under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Subsequent to March&#160;31, 2021, the Company signed a binding term sheet with Chiesi, pursuant to which the parties reached certain agreements including a $10.0&#160;million payment by Chiesi prior to June&#160;30, 2021 in exchange for the reduction of a longer-term regulatory milestone payment set forth in the Chiesi EX-US Agreement by $25.0&#160;million. All other regulatory and commercial milestone payments remain unchanged.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and bank deposits as of March&#160;31, 2021 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. The Company expects that such cash and cash equivalents and bank deposits will be sufficient to satisfy the full payment of the principal amount of the Company&#x2019;s 7.50% convertible secured promissory notes due November&#160;15, 2021 equal to $57.9&#160;million, unless the notes are refinanced, restructured or converted before that date.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Earnings (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 10,694,517 and 26,769,693 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding convertible notes and outstanding warrants for the three months ended March&#160;31, 2020 and 2021, respectively, because their effect would be anti-dilutive.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from selling products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_zZYghbVqPEKXGEI2AQ5jrg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder. A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The FDA also indicated in its BLA filing communication letter that it did not plan to hold an advisory committee meeting to discuss the application. On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), announced that they received a Complete Response Letter (CRL) from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In the CRL, the FDA noted that an inspection of Protalix&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve the BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease, or COVID-19, the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;), a therapy used to treat Fabry patients, was recently converted to full approval which must be addressed in the context of any potential resubmission seeking accelerated approval of PRX-102. The Company intends to work collaboratively with the FDA to identify the most expeditious pathway to approval, including accelerated approval. Protalix remains confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. The Company intends to request a Type-A meeting with the FDA, and will provide further updates on next steps after this meeting; however, the Company cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which is subject to an exclusive worldwide license agreement with SarcoMed USA, Inc. (&#x201c;SarcoMed&#x201d;) for use in the treatment&lt;/span&gt;&lt;span style="color:#000000;direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat refractory gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;10, 2021, the Company entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. Under the terms of the agreement, SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, and the clinical research and development of such candidates. The Company is entitled to an initial cash payment of $3.5&#160;million, subject to certain conditions, and to additional regulatory and commercial milestone payments and tiered royalties on net sales of products that are commercialized under the license agreement. In addition to the foregoing, the parties agreed to commence negotiation of clinical and commercial supply agreements for alidornase alfa. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within 60 days of the execution of the license agreement, and SarcoMed has the right to terminate the license agreement if the parties do not successfully do so.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;) acted as book-running manager for the offering with Oppenheimer &amp;amp; Co. acting as co-manager.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March 29, 2021, the Company made a payment of approximately $4.0&#160;million to Pfizer Inc. (&#x201c;Pfizer&#x201d;) satisfying the outstanding promissory note payable to Pfizer in full.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;1, 2020, the Company entered into an ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with BofA Securities as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of Common Stock having an aggregate offering price of up to $30.0&#160;million (the &#x201c;ATM Shares&#x201d;). During 2021 to date, the Company sold 1,867,552 ATM Shares for gross proceeds of $8.8 million. As of the issuance date of the financial statements, the Company has the right to raise an additional $16.2&#160;million of capital under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Subsequent to March&#160;31, 2021, the Company signed a binding term sheet with Chiesi, pursuant to which the parties reached certain agreements including a $10.0&#160;million payment by Chiesi prior to June&#160;30, 2021 in exchange for the reduction of a longer-term regulatory milestone payment set forth in the Chiesi EX-US Agreement by $25.0&#160;million. All other regulatory and commercial milestone payments remain unchanged.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and bank deposits as of March&#160;31, 2021 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. The Company expects that such cash and cash equivalents and bank deposits will be sufficient to satisfy the full payment of the principal amount of the Company&#x2019;s 7.50% convertible secured promissory notes due November&#160;15, 2021 equal to $57.9&#160;million, unless the notes are refinanced, restructured or converted before that date.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <plx:LicenseAgreementInitialCashPayment
      contextRef="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_ora0XsBMfkOq7xYpZZOFwQ"
      decimals="-5"
      id="Narr_eoujTyHuk0ai4tP7rQH_wg"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">3500000</plx:LicenseAgreementInitialCashPayment>
    <plx:TermToSignSupplyAgreement
      contextRef="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_ora0XsBMfkOq7xYpZZOFwQ"
      id="Narr_aU0tKn4iy0Ocm5fOD3qbFw">P60D</plx:TermToSignSupplyAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_17_2021_To_2_17_2021_u_XK6e7UVESYlSBODfH83Q"
      decimals="INF"
      id="Narr_Y73LSETzfEmQhsm73I9NAw"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_2_17_2021_Y55Ar_XSM0Cn4NkSAnOr_g"
      decimals="INF"
      id="Narr_ADb2dJMxhkSaEuitVtZ0FQ"
      unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_17_2021_To_2_17_2021_u_XK6e7UVESYlSBODfH83Q"
      decimals="-5"
      id="Narr_Rx5wdpKAlUWhHY7b7beIrw"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">40200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_17_2021_Y55Ar_XSM0Cn4NkSAnOr_g"
      decimals="2"
      id="Narr_IdKGoB1M6UyhDMw3DtOEVA"
      unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA">4.60</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ThxKgBuf2UK2nF6qftr2kw"
      decimals="-5"
      id="Narr_L5SCL7RC7U6eDGAWA1AWMQ"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4000000.0</us-gaap:RepaymentsOfNotesPayable>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_G_tb6sGRnk6B27_FVPjvUg"
      decimals="-6"
      id="Narr_BHpMLKHvdE-IwiNOfAH3pQ"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">30000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_d3BrXmiZ10eL6A392JU9mw"
      decimals="INF"
      id="Narr_6J6gVV_ulUq01nMz0kIrKg"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">1867552</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_d3BrXmiZ10eL6A392JU9mw"
      decimals="-5"
      id="Narr_tX-8c0QgIEWXfArAGMOKTQ"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">8800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_fH-eFiWWTEWpXTsknvvImw"
      decimals="-5"
      id="Narr_Z3_4D32fyk246Pv69FhbLQ"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">16200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <plx:UpfrontNonrefundableNonCreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_j3-U2lgv9kaYDYpnq-Cz7Q"
      decimals="-5"
      id="Narr_XmXQu5LlOkm-EnzBkhDr9Q"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">25000000.0</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNonCreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_cUvfdjvwYEa9IMFmcOD8nQ"
      decimals="-5"
      id="Narr_tbeNPUWVokeqBLfLYnaPlg"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">25000000.0</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_UZb52YP5Gkqo2veFUnlg_w"
      decimals="-5"
      id="Narr_h8WrgVi1l0CXwkDM4BP92Q"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_UZb52YP5Gkqo2veFUnlg_w"
      decimals="-5"
      id="Narr_r5DzFpZVJUWLJyZYzMFdww"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">10000000.0</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_UZb52YP5Gkqo2veFUnlg_w"
      decimals="-5"
      id="Narr_Be_mbKGdm0OYi55yPi6Pxg"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wEgmk_bQ70CSJwv5vY46ow"
      decimals="-5"
      id="Narr_w_SXIiR6XUe0z1hi_aXP5g"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wEgmk_bQ70CSJwv5vY46ow"
      decimals="-5"
      id="Narr_gfMxvWH8R0eTG9kPHpWt4A"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_wEgmk_bQ70CSJwv5vY46ow"
      decimals="-5"
      id="Narr_FrBsfrmJjkeMtkr5msDTcQ"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_1sBE3oSTM0etPlYlt5LcuA"
      decimals="INF"
      id="Narr_07OCTqmJvkSCF3lMmhSWTw"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r-lq86-0tUWqJBQNVq0i8A"
      decimals="INF"
      id="Narr_-7YBa8uutEKqb8CblfMwIg"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember__7guBnYaGk-PHQNjbXG97Q"
      decimals="INF"
      id="Narr_QENQEU-Z00aVaTJ_7mYjKA"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_IZDIDKW0ckix5UQLj_kyyw"
      decimals="INF"
      id="Narr_AdpAhfw3ZkmlNHrkH479mQ"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iMSRRkNGFEqFLRRG3ATJ0A"
      decimals="-5"
      id="Narr_TjsL5Qu_30C3fo6QsJPcyA"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_14_2021_To_5_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_CVQTExGFqUyzhQ6JuwB5tA"
      decimals="-5"
      id="Narr_I03SwUDs_EiAtu2vQXNlFQ"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">-25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_r3AHKZ-r30CFs0FZk9Nlzw"
      decimals="2"
      id="Narr_GlxBkwX1s0qp7822fXWCgQ"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_tJnyJJMrvk64LWQ_LMBvfQ"
      decimals="INF"
      id="Narr_NaCDZUyy8028lrE8n2bLcA"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_tJnyJJMrvk64LWQ_LMBvfQ"
      decimals="-5"
      id="Narr_iJvVeJWG7kyyhcXhcApcbw"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">57900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_k-fJEYi7R022IRugBXWjYg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_5h4nwhWkr0CWTsMqdmgfzg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Earnings (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 10,694,517 and 26,769,693 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding convertible notes and outstanding warrants for the three months ended March&#160;31, 2020 and 2021, respectively, because their effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_3_31_2020_xpMLQzwCXkaAvT-ey-EsCg"
      decimals="INF"
      id="Narr_BK11l2OxAkeunAHLzlQXqw"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">10694517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      decimals="INF"
      id="Narr_qYYHr_fyUEqRJ1FsWDehCQ"
      unitRef="Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A">26769693</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_mTYiF7M0WEWzyJm2N6OD9w">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from selling products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_2Iwh_PZxMUuR2b_zQIjxjQ"
      decimals="INF"
      id="Narr_SdZ52QL26UGzSyxrBWpE7Q"
      unitRef="Unit_Standard_agreement_crDxDnAv7EmGAesWUEmcsw">2</plx:RevenuePerformanceObligationNumber>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_RarTieQF1UmwL1Gl5svbXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at March&#160;31, 2021 and December&#160;31, 2020 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,427&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,215&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,848&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,915&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_Sb9lvx-djESTY6gLXy7deg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,427&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,215&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,848&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,915&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_jnHZ1VxQ40mPdngjB-P57w_3_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">3427000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_AW94Ka6FuUWcTt0gRZu4mw_3_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">3347000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_qXW69xTIjk60Edw78-295A_4_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2273000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_3dYDfxO3-UKWPiISbK7nQw_4_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2887000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_LU7T-gFvAkayN4-UkHjExw_5_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">8215000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_E18-TrxgNUqP2FjEV6F2Sw_5_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">6848000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ"
      decimals="-3"
      id="Tc_YGGFY4S7Q0eDj4FI7NkSbA_6_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">13915000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A"
      decimals="-3"
      id="Tc_yqxfbxSRUEKyjQ5uiGVkPw_6_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">13082000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_J0iN26XDfkqDJVwmC3YmLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;As of March&#160;31, 2021, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;The fair value of the $57.9&#160;million aggregate principal amount of the Company&#x2019;s outstanding 7.50% 2021 Notes as of March&#160;31, 2021 is approximately $59.8&#160;million based on a Level 3 measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of March&#160;31, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.46&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.54&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_W7bSf7UauU2UcKXEjO21YA"
      decimals="-5"
      id="Narr_kOBR_ID1fkSB59_1TBCz5w"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">57900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_W7bSf7UauU2UcKXEjO21YA"
      decimals="INF"
      id="Narr_-cLhT1rtoUGgFGlAGb9SqA"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_W7bSf7UauU2UcKXEjO21YA"
      decimals="-5"
      id="Narr_xf5wSgTXk02inRXTuVhlSg"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">59800000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_IWN34CGSq02efTOZFIDwQA"
      id="Tb_o1cceICqbUikI0McrcBVEQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.46&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.54&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BaH8L0w5DEycxituHyiDNw"
      decimals="2"
      id="Tc_hIlPSWEd_0Cm4HphrRveQA_2_2"
      unitRef="Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA">4.46</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_5NM-tGWaUkyvfqzfREuJnw"
      decimals="2"
      id="Tc_4YHBSKRwpEaGjHKtoWMg8A_3_2"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">0.63</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_BMaSMHlJfkSwlgEYxqWOuQ"
      decimals="2"
      id="Tc_9NpYIut4h0ac63VAxMiMDw_4_2"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">0.05</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_n58i0vokQU6Bu9njK42qFQ"
      decimals="2"
      id="Tc_1LeHojCKeU2nSSsWFd3dTw_5_2"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">71.89</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_2fSRYl5U6ki6zEDhNxZMXQ"
      decimals="2"
      id="Tc_yB1ddKomn0qxwCNUGwgyig_6_2"
      unitRef="Unit_Standard_pure_BpZkC4OIRkS8NuoACZJ41A">11.54</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_zJPyiGZZ4keHe_b3fT4kig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,511&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,016&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,015&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,511&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,031&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 36pt;"&gt;During the three months ended March&#160;31, 2020, the Company recorded revenue in the amount of $6.7&#160;million following a change in estimate of the total costs expected to be incurred in connection with the Chiesi Agreements.&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_iFQipl3vMkCC9ALeeGsmdQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,511&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,016&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,015&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,511&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,031&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_6pKW20bscE2Ku3nHfNM7Zw"
      decimals="-3"
      id="Tc_Gi22Jnw3Ak-QoRKPiJ78og_3_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4511000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_8WJteDHFv0uHhDDSYCX3ng"
      decimals="-3"
      id="Tc_g383-SA-P02_ZItfqfp-8Q_3_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">2016000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_HgUCN56GCUCbhH5dRyjtRw"
      decimals="-3"
      id="Tc_Zyi1QV-2yUS76VKBmjdBvw_4_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">3015000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_NTsUlyVWH0iAhOuc-JATrg"
      decimals="-3"
      id="Tc_lXVn9FFPhUGbTkj52_afAA_5_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4511000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_rsuCkhAchUKfvtMJQ7Jdkw"
      decimals="-3"
      id="Tc_XBx6EmV85E-VnuV4UuCnaw_5_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">5031000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_DpyYY9nDa0Cy_n2dtTOfHA"
      decimals="-3"
      id="Tc_MDAvrTvFIkSqtbUv5N6Jbw_6_3"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">6809000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-PP3WwL7Ek624e-6Fj9uCQ"
      decimals="-3"
      id="Tc_GIN6mGN0HkaOptT3TEWUAw_6_6"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">16615000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_AVEnMunZKE2ZyjoOzJX63A"
      decimals="-5"
      id="Narr_Av5MJOJEaESQLuYS2-7RSg"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">6700000</us-gaap:Revenues>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ"
      id="Tb_arfQEJc2aUK7k1d07ARIsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; PROMISSORY NOTE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In September 2020, the Company amended the outstanding $4.3&#160;million promissory note payable to Pfizer by November 2020 to extend the maturity date to the earlier of (a) January&#160;31, 2022 and (b) the date that the Company receives any milestone payment from Chiesi, if at all, subject to certain conditions and exceptions. The amendment also required that the Company make a payment of $430,000 to Pfizer. The payment was creditable against the principal amount of the note, in whole or in part, if the Company was to satisfy the note in full on or prior to September&#160;30, 2021, depending on the date the note is satisfied. On March&#160;29, 2021, the Company made a payment of approximately $4.0&#160;million to Pfizer satisfying the note in full.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_e7hdGudACk2S__aUdhpOSQ"
      decimals="-5"
      id="Narr_cceJuf1sXkafC1y7KBZajQ"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4300000</us-gaap:NotesPayableCurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_TQRiEj4vMkeo1dXynWjINA"
      decimals="0"
      id="Narr_LtFZ9MD5qUSr7XpGRRScxA"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">430000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ThxKgBuf2UK2nF6qftr2kw"
      decimals="-5"
      id="Narr_4yGUsBH1JE27QNn9puAKVw"
      unitRef="Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ">4000000.0</us-gaap:RepaymentsOfNotesPayable>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_9eREpW5XdUutlzAa5vvOEA_6_6"
          xlink:label="Tc_9eREpW5XdUutlzAa5vvOEA_6_6"
          xlink:type="locator"/>
        <link:footnote id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:label="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9eREpW5XdUutlzAa5vvOEA_6_6"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Yw3wcWFGSka907xn6Lv1ww_6_3"
          xlink:label="Tc_Yw3wcWFGSka907xn6Lv1ww_6_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Yw3wcWFGSka907xn6Lv1ww_6_3"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_kwZ3nUllNkCVml5Vz2VX0w_7_6"
          xlink:label="Tc_kwZ3nUllNkCVml5Vz2VX0w_7_6"
          xlink:type="locator"/>
        <link:footnote id="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:label="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_kwZ3nUllNkCVml5Vz2VX0w_7_6"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_8ccmMdc2oEWK500X1xRitw_7_3"
          xlink:label="Tc_8ccmMdc2oEWK500X1xRitw_7_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_8ccmMdc2oEWK500X1xRitw_7_3"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_5uK2XgY1IECIvVfIJ88JiA_8_6"
          xlink:label="Tc_5uK2XgY1IECIvVfIJ88JiA_8_6"
          xlink:type="locator"/>
        <link:footnote id="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:label="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_5uK2XgY1IECIvVfIJ88JiA_8_6"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Q_UVBociTUSy8YM3pVGE5w_8_3"
          xlink:label="Tc_Q_UVBociTUSy8YM3pVGE5w_8_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Q_UVBociTUSy8YM3pVGE5w_8_3"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434219221928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,382,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434219239000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,830<span></span>
</td>
<td class="nump">$ 18,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">50,600<span></span>
</td>
<td class="nump">20,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">4,599<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,754<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">13,915<span></span>
</td>
<td class="nump">13,082<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">90,698<span></span>
</td>
<td class="nump">55,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,828<span></span>
</td>
<td class="nump">4,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,490<span></span>
</td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">102,792<span></span>
</td>
<td class="nump">67,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">6,376<span></span>
</td>
<td class="nump">7,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">15,167<span></span>
</td>
<td class="nump">13,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">5,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">55,372<span></span>
</td>
<td class="nump">54,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">80,861<span></span>
</td>
<td class="nump">86,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,319<span></span>
</td>
<td class="nump">4,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">7,427<span></span>
</td>
<td class="nump">8,497<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">88,288<span></span>
</td>
<td class="nump">94,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</a></td>
<td class="nump">14,504<span></span>
</td>
<td class="num">(27,037)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (net of capital deficiency)</a></td>
<td class="nump">$ 102,792<span></span>
</td>
<td class="nump">$ 67,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434216661128">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,320<span></span>
</td>
<td class="nump">$ 21,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,765)<span></span>
</td>
<td class="num">(3,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(7,122)<span></span>
</td>
<td class="num">(10,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(3,138)<span></span>
</td>
<td class="num">(3,187)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,705)<span></span>
</td>
<td class="nump">4,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,156)<span></span>
</td>
<td class="num">(3,229)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">335<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES - NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,821)<span></span>
</td>
<td class="num">(3,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">OTHER INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS) FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,475)<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC AND DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC AND DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,933,972<span></span>
</td>
<td class="nump">17,381,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,511<span></span>
</td>
<td class="nump">$ 5,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,809<span></span>
</td>
<td class="nump">$ 16,615<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434307112776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 497<span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434219302040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 270,492<span></span>
</td>
<td class="num">$ (340,829)<span></span>
</td>
<td class="num">$ (70,322)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">14,838,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">41,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares', window );">Issuance of common stock and warrants, net of issuance cost (in shares)</a></td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants', window );">Note receivable from issuance of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">308,248<span></span>
</td>
<td class="num">(339,162)<span></span>
</td>
<td class="num">(30,881)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">32,442,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">320,280<span></span>
</td>
<td class="num">(347,352)<span></span>
</td>
<td class="num">(27,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">34,765,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">8,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,475)<span></span>
</td>
<td class="num">(5,475)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 367,285<span></span>
</td>
<td class="num">$ (352,827)<span></span>
</td>
<td class="nump">$ 14,504<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">45,382,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from receivables from sale of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434222656456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKOLDERS' EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434216532616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (5,475)<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
<td class="num">(168)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contracts liability (including non-current portion)</a></td>
<td class="num">(3,692)<span></span>
</td>
<td class="num">(7,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
<td class="num">(2,282)<span></span>
</td>
<td class="num">(4,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(833)<span></span>
</td>
<td class="num">(1,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accruals</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Decrease in other long term liabilities</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,834)<span></span>
</td>
<td class="num">(7,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Purchase of bank deposits</a></td>
<td class="num">(37,835)<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(386)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInRestrictedDeposit', window );">Decrease in restricted deposit</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(30,684)<span></span>
</td>
<td class="num">(35,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Net payment for promissory note</a></td>
<td class="num">(4,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="nump">37,625<span></span>
</td>
<td class="nump">38,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">8,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">42,114<span></span>
</td>
<td class="nump">38,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="num">(3,626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">18,265<span></span>
</td>
<td class="nump">17,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">19,830<span></span>
</td>
<td class="nump">14,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Note receivable from issuance of common stock and warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note receivable from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434309894536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder. A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The FDA also indicated in its BLA filing communication letter that it did not plan to hold an advisory committee meeting to discuss the application. On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that they received a Complete Response Letter (CRL) from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In the CRL, the FDA noted that an inspection of Protalix&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve the BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease, or COVID-19, the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>), a therapy used to treat Fabry patients, was recently converted to full approval which must be addressed in the context of any potential resubmission seeking accelerated approval of PRX-102. The Company intends to work collaboratively with the FDA to identify the most expeditious pathway to approval, including accelerated approval. Protalix remains confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. The Company intends to request a Type-A meeting with the FDA, and will provide further updates on next steps after this meeting; however, the Company cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which is subject to an exclusive worldwide license agreement with SarcoMed USA, Inc. (&#8220;SarcoMed&#8221;) for use in the treatment</span><span style="color:#000000;direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;10, 2021, the Company entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. Under the terms of the agreement, SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, and the clinical research and development of such candidates. The Company is entitled to an initial cash payment of $3.5&#160;million, subject to certain conditions, and to additional regulatory and commercial milestone payments and tiered royalties on net sales of products that are commercialized under the license agreement. In addition to the foregoing, the parties agreed to commence negotiation of clinical and commercial supply agreements for alidornase alfa. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within 60 days of the execution of the license agreement, and SarcoMed has the right to terminate the license agreement if the parties do not successfully do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities, Inc. (&#8220;BofA Securities&#8221;) acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March 29, 2021, the Company made a payment of approximately $4.0&#160;million to Pfizer Inc. (&#8220;Pfizer&#8221;) satisfying the outstanding promissory note payable to Pfizer in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;1, 2020, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;) with BofA Securities as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of Common Stock having an aggregate offering price of up to $30.0&#160;million (the &#8220;ATM Shares&#8221;). During 2021 to date, the Company sold 1,867,552 ATM Shares for gross proceeds of $8.8 million. As of the issuance date of the financial statements, the Company has the right to raise an additional $16.2&#160;million of capital under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Subsequent to March&#160;31, 2021, the Company signed a binding term sheet with Chiesi, pursuant to which the parties reached certain agreements including a $10.0&#160;million payment by Chiesi prior to June&#160;30, 2021 in exchange for the reduction of a longer-term regulatory milestone payment set forth in the Chiesi EX-US Agreement by $25.0&#160;million. All other regulatory and commercial milestone payments remain unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and bank deposits as of March&#160;31, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. The Company expects that such cash and cash equivalents and bank deposits will be sufficient to satisfy the full payment of the principal amount of the Company&#8217;s 7.50% convertible secured promissory notes due November&#160;15, 2021 equal to $57.9&#160;million, unless the notes are refinanced, restructured or converted before that date.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 10,694,517 and 26,769,693 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding convertible notes and outstanding warrants for the three months ended March&#160;31, 2020 and 2021, respectively, because their effect would be anti-dilutive.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434222529880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2021 and December&#160;31, 2020 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,427</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,215</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,848</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434221152616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of March&#160;31, 2021, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the $57.9&#160;million aggregate principal amount of the Company&#8217;s outstanding 7.50% 2021 Notes as of March&#160;31, 2021 is approximately $59.8&#160;million based on a Level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of March&#160;31, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.46</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.54</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434221193928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,511</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,511</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,031</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 36pt;">During the three months ended March&#160;31, 2020, the Company recorded revenue in the amount of $6.7&#160;million following a change in estimate of the total costs expected to be incurred in connection with the Chiesi Agreements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434221151784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>PROMISSORY NOTE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PROMISSORY NOTE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; PROMISSORY NOTE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In September 2020, the Company amended the outstanding $4.3&#160;million promissory note payable to Pfizer by November 2020 to extend the maturity date to the earlier of (a) January&#160;31, 2022 and (b) the date that the Company receives any milestone payment from Chiesi, if at all, subject to certain conditions and exceptions. The amendment also required that the Company make a payment of $430,000 to Pfizer. The payment was creditable against the principal amount of the note, in whole or in part, if the Company was to satisfy the note in full on or prior to September&#160;30, 2021, depending on the date the note is satisfied. On March&#160;29, 2021, the Company made a payment of approximately $4.0&#160;million to Pfizer satisfying the note in full.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434293020024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder. A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The FDA also indicated in its BLA filing communication letter that it did not plan to hold an advisory committee meeting to discuss the application. On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that they received a Complete Response Letter (CRL) from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In the CRL, the FDA noted that an inspection of Protalix&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve the BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease, or COVID-19, the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>), a therapy used to treat Fabry patients, was recently converted to full approval which must be addressed in the context of any potential resubmission seeking accelerated approval of PRX-102. The Company intends to work collaboratively with the FDA to identify the most expeditious pathway to approval, including accelerated approval. Protalix remains confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. The Company intends to request a Type-A meeting with the FDA, and will provide further updates on next steps after this meeting; however, the Company cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which is subject to an exclusive worldwide license agreement with SarcoMed USA, Inc. (&#8220;SarcoMed&#8221;) for use in the treatment</span><span style="color:#000000;direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;10, 2021, the Company entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. Under the terms of the agreement, SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, and the clinical research and development of such candidates. The Company is entitled to an initial cash payment of $3.5&#160;million, subject to certain conditions, and to additional regulatory and commercial milestone payments and tiered royalties on net sales of products that are commercialized under the license agreement. In addition to the foregoing, the parties agreed to commence negotiation of clinical and commercial supply agreements for alidornase alfa. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within 60 days of the execution of the license agreement, and SarcoMed has the right to terminate the license agreement if the parties do not successfully do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities, Inc. (&#8220;BofA Securities&#8221;) acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March 29, 2021, the Company made a payment of approximately $4.0&#160;million to Pfizer Inc. (&#8220;Pfizer&#8221;) satisfying the outstanding promissory note payable to Pfizer in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;1, 2020, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;) with BofA Securities as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of Common Stock having an aggregate offering price of up to $30.0&#160;million (the &#8220;ATM Shares&#8221;). During 2021 to date, the Company sold 1,867,552 ATM Shares for gross proceeds of $8.8 million. As of the issuance date of the financial statements, the Company has the right to raise an additional $16.2&#160;million of capital under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Subsequent to March&#160;31, 2021, the Company signed a binding term sheet with Chiesi, pursuant to which the parties reached certain agreements including a $10.0&#160;million payment by Chiesi prior to June&#160;30, 2021 in exchange for the reduction of a longer-term regulatory milestone payment set forth in the Chiesi EX-US Agreement by $25.0&#160;million. All other regulatory and commercial milestone payments remain unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and bank deposits as of March&#160;31, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. The Company expects that such cash and cash equivalents and bank deposits will be sufficient to satisfy the full payment of the principal amount of the Company&#8217;s 7.50% convertible secured promissory notes due November&#160;15, 2021 equal to $57.9&#160;million, unless the notes are refinanced, restructured or converted before that date.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (loss) per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 10,694,517 and 26,769,693 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding convertible notes and outstanding warrants for the three months ended March&#160;31, 2020 and 2021, respectively, because their effect would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434222577928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,427</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,215</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,848</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434222850616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member', window );">Notes 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of liability component based on income approach</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.46</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.54</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434222577928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's disaggregation of revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,511</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,511</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,031</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434210408312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 14, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Additional capital that the company can raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible Debt, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,769,693<span></span>
</td>
<td class="nump">10,694,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Additional capital that the company can raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember', window );">Seven Point Five Percentage Convertible Notes [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Revenue, Performance Obligation, Number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="num">$ (25,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_SarcomedUsaInc.AgreementMember', window );">SarcoMed USA, Inc. Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_LicenseAgreementInitialCashPayment', window );">License Agreement, Initial Cash Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TermToSignSupplyAgreement', window );">Term to sign supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LicenseAgreementInitialCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of initial cash payment under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LicenseAgreementInitialCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_TermToSignSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term To Sign Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_TermToSignSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNonCreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_SarcomedUsaInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_SarcomedUsaInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434292936792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,427<span></span>
</td>
<td class="nump">$ 3,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">8,215<span></span>
</td>
<td class="nump">6,848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 13,915<span></span>
</td>
<td class="nump">$ 13,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434293430216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details) - 2021 Notes [Member] - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">4.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">71.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">11.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434293396936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - Additional Information (Details) - Fair Value, Inputs, Level 3 [Member] - Seven Point Five Percentage Convertible Notes [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 57.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">$ 59.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434216800152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Company's disaggregation of revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 11,320<span></span>
</td>
<td class="nump">$ 21,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,511<span></span>
</td>
<td class="nump">5,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,511<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 6,809<span></span>
</td>
<td class="nump">16,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member] | Chiesi US Agreement and Chiesi Ex US Agreement [Member] | Change in Accounting Method Accounted for as Change in Estimate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434292993864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,086,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="nump">$ 430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>40
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M5L9+*;"*42'2.>TT3]U6&R,J2H:#>_TLT%"]Y)PX]//S%S+E7J(@7Z58N-)
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MW6$A6%&]^'I@0K"LNMQ2F"BY-(#_-PPD\[B0[]+J=Z>#?P%02P,$%     @
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M6U!N ,_7 DXBY2#_S'/\<#CY!U!+ P04    " "5.*Y2H[9ZZUX"  "N!0
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MWHN=<: AOY1EALUT>:E<K3=,!&Z0VV:##V\Z(6^R6E2Z4J050N,SM6E*+"_
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MHL?O/!3U$*ZT^")A!QS95.Q:AZ2.RJ0+EC+C:KC'#)Z&7%\M?IC/.EN0ESX
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MY^T[#*<E@Z2B'_L!I[Y3*QUB>9'[/KO,@]_]'4&N7X3N;'W'AD$1EU[6G_P
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M]&P>@.ZZ;F=8U?A.=U"6^J;_K>BA0NT":+Y0RIX,M\#P]&W^ 5!+ P04
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M1(_?>2CJ(5QI\47"#CBRJ=BU#DD=E4D7+&7&U7"/&3P-N;Y:_#"?=;8@+WT
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MHS [="<!5NG="G##F^]M"'!/B.B%E6@)[51)%7O[V99*B#%#CP)HNKUB%[L
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MFEI*.HJ2CIZ2Q\#\K+3AW0&TOIXZ"KE.2\>K3W%YJI(M4_)7)C^]>NZ:_HK
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M*'N1QH1@[3Y,^^"2([&:V,PVT%;[\;.=D(974?:%Q.=[SL]S)G?77'+Q(!,
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M(^%S25@DFZ[2O$QT=U)PZ.8<_#T< C3@3"42]5D$T3K>U7I*4?Y*5-<_&'!
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MP]XU XOMNB]A\FE'=XR8,HE2F.J0WD5#W[K(!XA\H?C,]N![KG1'MZ^)'KI
M& >]/^5<K1;F@'*,:_\#4$L#!!0    ( )4XKE)^,M*!7 (  +L&   9
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;*U56V^;,!3^*Q;:0RMMP0'"NBI!
MRJ73^I &A773-.W!"8?$JL',=D*S7S_;4)1M),JTO8 OY[N<3]@,*RZ>Y!9
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" "5.*Y2,0[;WZ "  !R#P  #P   'AL+W=O<FMB;V]K+GAM;,676V^;,!2
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M&K4+5]M&6X?^V15QRO^GC&R[Q26:L_)8(RJ[.G)$&D J]O@@'$!AC69.OP1
M6H&(2E4D$-,NE5K;[%3]=%QUNY8*5ZLAGV(UP>.J!;<'&:;)/$KR: [46YXN
MXGE0J,'W8!$D800T2-\ Z5\$,B_4XS%*-,BA 7)X0<A?O@8Y,D".+@DYU"#'
M!LCQ)2%'&N3$ #FY).18@[PR0%[9A<SCAR2^C\,@*4 0ANDJ*>+D 2P5;AA'
MN09Y;8"\M@L9)^LH*=+L%.C& '1C%^@^B#.P#A:K"#Q&0;[*FD.FT,_K@>G
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MY )6R86L.1>RYES(FO\G6=^=6_[U?UF[9D8U]N ONI_?V2=02P$"% ,4
M" "5.*Y2!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( )4XKE* #=@3[P   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( )4XKE*97)PC
M$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ E3BN4K^<.N17!0  +A8  !@              ("!#@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( )4XKE)DMVT_
M>P4  $<5   8              " @9L-  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " "5.*Y28P7/T.X$  !W$0  &
M@(%,$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ E3BN
M4FF*G.W_ @  '@D  !@              ("!<!@  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( )4XKE*7]7MY%P4  $04   8
M      " @:4;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" "5.*Y2H[9ZZUX"  "N!0  &               @('R(   >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ E3BN4HQEX^KX!P  ;Q\  !@
M             ("!AB,  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( )4XKE)$(Z4<Q1<  #=&   8              " @;0K  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "5.*Y2_^$D:XT"   D
M!@  &               @(&O0P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ E3BN4AR/_7J !0  $PT  !D              ("!<D8
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "5.*Y24)Y#
M&0P#   &!P  &0              @($I3   >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( )4XKE*.?,CC1 ,  "P'   9
M  " @6Q/  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
ME3BN4L:>UQ'P%P  ED<  !D              ("!YU(  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " "5.*Y2H<C Q70"  #*!0  &0
M            @($.:P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( )4XKE*L^V5-90(  !X%   9              " @;EM  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ E3BN4IL)MZ"( @
MZP4  !D              ("!57   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " "5.*Y2EM@K:L,(   )*P  &0              @($4
M<P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )4XKE+G
M%WR>50(  !D&   9              " @0Y\  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ E3BN4L998QS% @  /P@  !D
M     ("!FGX  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M   N$@  #0              @ $IB@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( )4XKE*7BKL<P    !,"   +              "  7&-  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( )4XKE(Q#MO?H (  '(/   /              "
M 5J.  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "5.*Y2X!='6"T!  #Y
M#0  &@              @ $GD0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " "5.*Y2KQ%I,&@!   $#P  $P              @ &,
LD@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     '@ >  D(   EE      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>67</ContextCount>
  <ElementCount>210</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - PROMISSORY NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePromissoryNote</Role>
      <ShortName>PROMISSORY NOTE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails</Role>
      <ShortName>REVENUES - Company's disaggregation of revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40501 - Disclosure - PROMISSORY NOTE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePromissoryNoteDetails</Role>
      <ShortName>PROMISSORY NOTE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePromissoryNote</ParentRole>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="plx-20210331x10q.htm">plx-20210331x10q.htm</File>
    <File>plx-20210331.xsd</File>
    <File>plx-20210331_cal.xml</File>
    <File>plx-20210331_def.xml</File>
    <File>plx-20210331_lab.xml</File>
    <File>plx-20210331_pre.xml</File>
    <File>plx-20210331xex10d1.htm</File>
    <File>plx-20210331xex10d2.htm</File>
    <File>plx-20210331xex10d3.htm</File>
    <File>plx-20210331xex31d1.htm</File>
    <File>plx-20210331xex31d2.htm</File>
    <File>plx-20210331xex32d1.htm</File>
    <File>plx-20210331xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20210331x10q005.jpg</File>
    <File>plx-20210331x10q006.jpg</File>
    <File>plx-20210331x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20210331x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 67,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20210331x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20210331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 238,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 5
   },
   "keyCustom": 30,
   "keyStandard": 180,
   "memberCustom": 13,
   "memberStandard": 20,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REVENUES",
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - PROMISSORY NOTE",
     "role": "http://www.protalix.com/role/DisclosurePromissoryNote",
     "shortName": "PROMISSORY NOTE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_IWN34CGSq02efTOZFIDwQA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_IWN34CGSq02efTOZFIDwQA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_2_17_2021_To_2_17_2021_u_XK6e7UVESYlSBODfH83Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_2_17_2021_To_2_17_2021_u_XK6e7UVESYlSBODfH83Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - INVENTORIES (Details)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BaH8L0w5DEycxituHyiDNw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
     "shortName": "FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BaH8L0w5DEycxituHyiDNw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ",
      "decimals": "-3",
      "lang": null,
      "name": "plx:ShortTermBankDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_W7bSf7UauU2UcKXEjO21YA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_W7bSf7UauU2UcKXEjO21YA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
     "shortName": "REVENUES - Company's disaggregation of revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_6pKW20bscE2Ku3nHfNM7Zw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_12_31_2020_fmjC7uJbkUiogrLw7co48A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - PROMISSORY NOTE (Details)",
     "role": "http://www.protalix.com/role/DisclosurePromissoryNoteDetails",
     "shortName": "PROMISSORY NOTE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_e7hdGudACk2S__aUdhpOSQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_MeqgCdhT4kqsQK5qJtNerQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_MeqgCdhT4kqsQK5qJtNerQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ei_SgWNXwUO3DGpZNp_vXQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ei_SgWNXwUO3DGpZNp_vXQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_Yuq7Il8nX0Kl3VnF_wMnwA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_6U9V9tC-_UmCFWhAgEw-iQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__dJDLjGtIkGrSKrEOwpR1A",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UmWv6LXlykuyz2qq7CCMDQ",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - INVENTORIES",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_RK3CWqE7kUiHF-l_58ONRQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 33,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "B [R]",
        "terseLabel": "Brazil [Member]"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from receivables from sale of common stock and warrants.",
        "label": "Adjustments To Additional Paid In Capital Receivables From Sale Of Common Stock And Warrants",
        "negatedLabel": "Note receivable from issuance of common stock and warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable"
       }
      }
     },
     "localname": "AgreementAmendmentPaymentReceivable",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement [Member]",
        "terseLabel": "Amended Pfizer Agreement [Member]"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePromissoryNoteDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "At Market Equity Offering [Member]",
        "terseLabel": "ATM Shares"
       }
      }
     },
     "localname": "AtMarketEquityOfferingMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements [Member]",
        "terseLabel": "Chiesi Agreements [Member]"
       }
      }
     },
     "localname": "ChiesiAgreementsMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex U S Agreement [Member]",
        "terseLabel": "Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi U S Agreement [Member]",
        "terseLabel": "Chiesi US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi Us Agreement And Chiesi Ex Us Agreement [Member]",
        "terseLabel": "Chiesi US Agreement and Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative Arrangement Revenues and Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Purchase of bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInRestrictedDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit",
        "label": "Increase (Decrease) In Restricted Deposit",
        "negatedLabel": "Decrease in restricted deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedDeposit",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in liabilities for property, plant and equipment.",
        "label": "Increase In Liabilities For Property Plant And Equipment",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "IncreaseInLiabilitiesForPropertyPlantAndEquipment",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_InterestReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedNet",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, in shares.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, value.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_LicenseAgreementInitialCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of initial cash payment under the license agreement.",
        "label": "License Agreement, Initial Cash Payment"
       }
      }
     },
     "localname": "LicenseAgreementInitialCashPayment",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year"
       }
      }
     },
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MeasurementInputYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Yield [Member]",
        "label": "Measurement Input Yield [Member]",
        "terseLabel": "Measurement Input, Yield [Member]"
       }
      }
     },
     "localname": "MeasurementInputYieldMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note receivable from issuance of common stock and warrants, net of issuance cost.",
        "label": "Note Receivable from Issuance of Common Stock and Warrants, Net of Issuance Cost",
        "terseLabel": "Note receivable from issuance of common stock and warrants, net of issuance cost"
       }
      }
     },
     "localname": "NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_Notes2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes2021 [Member]",
        "terseLabel": "Notes 2021 [Member]"
       }
      }
     },
     "localname": "Notes2021Member",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer [Member]"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net of issuance cost.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost",
        "verboseLabel": "Proceeds from issuance of common stock and warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation [Member]",
        "terseLabel": "Protalix Bio Therapeutics Incorporation [Member]"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_RevenuePerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number"
       }
      }
     },
     "localname": "RevenuePerformanceObligationNumber",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumOfferingPrice",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SarcomedUsaInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to SarcoMed USA, Inc. licensing agreement.",
        "label": "Sarcomed Usa Inc. Agreement [Member]",
        "terseLabel": "SarcoMed USA, Inc. Agreement [Member]"
       }
      }
     },
     "localname": "SarcomedUsaInc.AgreementMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seven Point Five Percentage Convertible Note [Member]",
        "terseLabel": "Seven Point Five Percentage Convertible Notes [Member]"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNoteMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seven Point Five Percentage Convertible Notes [Member]",
        "terseLabel": "2021 Notes [Member]"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNotesMember",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_TermToSignSupplyAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term To Sign Supply Agreement",
        "label": "Term To Sign Supply Agreement",
        "terseLabel": "Term to sign supply agreement"
       }
      }
     },
     "localname": "TermToSignSupplyAgreement",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plx_UpfrontNonrefundableNonCreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non-Creditable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNonCreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20210331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r82",
      "r101",
      "r103",
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r83",
      "r101",
      "r104",
      "r154",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r94",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r5",
      "r31"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r5",
      "r31"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r20",
      "r84",
      "r85",
      "r102"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r112",
      "r113",
      "r116",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r61",
      "r129"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePromissoryNoteDetails",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r140",
      "r147"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r42"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r30",
      "r63"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r58",
      "r127"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r69",
      "r70",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r69",
      "r70",
      "r75",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change In Accounting Estimate Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A change from one acceptable accounting method to another based upon a revision in estimated future benefits or obligations.",
        "label": "Change In Accounting Method Accounted For As Change In Estimate [Member]",
        "terseLabel": "Change in Accounting Method Accounted for as Change in Estimate [Member]"
       }
      }
     },
     "localname": "ChangeInAccountingMethodAccountedForAsChangeInEstimateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r99",
      "r100",
      "r102"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r99",
      "r100",
      "r102"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r13",
      "r141",
      "r145",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost Of Sales [Member]",
        "terseLabel": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROMISSORY NOTE"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "PROMISSORY NOTE"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePromissoryNote"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r141",
      "r142",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r95",
      "r142",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r128",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r12",
      "r106",
      "r107",
      "r108",
      "r139",
      "r146"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r61",
      "r91"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's disaggregation of revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "verboseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC AND DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r72",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (loss) per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of liability component based on income approach"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r120",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r120",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r62",
      "r124",
      "r125",
      "r126"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Decrease in contracts liability (including non-current portion)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Decrease in other long term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r24",
      "r89"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r40",
      "r88"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r89"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r25",
      "r89"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r143",
      "r148"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (net of capital deficiency)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r15",
      "r16"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License And Service [Member]",
        "terseLabel": "License and R&amp;D Services [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input Price Volatility [Member]",
        "terseLabel": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input Share Price [Member]",
        "terseLabel": "Measurement Input, Share Price [Member]"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r58",
      "r59",
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r43",
      "r44",
      "r46",
      "r62",
      "r73",
      "r144",
      "r150"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "NET INCOME (LOSS) FOR THE PERIOD",
        "verboseLabel": "Net (loss) income for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL EXPENSES - NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Promissory note"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePromissoryNoteDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "OTHER INCOME"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r53",
      "r55",
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r17",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Goods [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r92",
      "r149"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Net payment for promissory note",
        "verboseLabel": "Payment for promissory note"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePromissoryNoteDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r118",
      "r158"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES, NET"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r45",
      "r78",
      "r79",
      "r81"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario Plan [Member]",
        "terseLabel": "Scenario, Plan [Member]"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r6",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r48",
      "r87"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosurePromissoryNoteDetails",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosurePromissoryNoteDetails",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r97",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Additional capital that the company can raise",
        "verboseLabel": "Issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r21",
      "r22",
      "r86"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePromissoryNoteDetails",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC AND DILUTED"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r159": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r161": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r162": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r163": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r164": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21843-107793"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01(a)(5))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(a)(5))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001558370-21-007157-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-007157-xbrl.zip
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MA'JC-?;3$!D,C7G%]/D#0ZX=XEK6))USHC0[$)%6]8W31CZ<#K'QB"WL8,3
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M,/$-A5'MX76%5^01VOG?_P]02P,$%     @ E3BN4FS/SBE"%0  63,! !0
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M%]@8/EN@;Q,31+XR'B!V\8G6SL?ZVGIM46LYNPB9F;K$ZJA9]QS;)*T D_S
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MM'JSR(6JC"'RQS9M@9[%_<__ 5!+ P04    " "5.*Y2=L_@XS$X   -YP(
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M@V-;5Y.75BL:B;JC@111F<N!7"U58YC7P'12_"K&(!1?)H1&\<O@V(K?Y,5
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M/'FY;S0_2A<&5^5FXFOV,79<\*/XR[\2L[%HZ5!BM<RI/MCH2@4I_#A-V$I
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M@ZJXT=X**FXR3K'0.VO:D,6>C=2O<6^)(]3@.);1QG[9*%2PUNU!STBSO*8
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M"Z&8 PB!]1C9@%K+L(JAH3Z4IG]M#!@ Z&PG8.U!DH0H*=-FN$!FN-:</!X
M,8]G!!YM-!T(MN%W']F,H.'ZX1B52]!QTOHQQ(4@INA<&XK& /TP&E2L>R-@
M=7FI=/4C)[_Z,3,7M>D$HR'[P7; <+-Z!9! WG&2^O#&5?.8LDOEC2FJ[00L
M;(S&#8;&BM262,GJ1@E'[6-:KFK6DO J$:*..S1VZ'SNX?4^1.M*B\XF,U?=
MR!4'$W-]K4D3G!GO PO9('39X*KD=(V4]'7C301&S-B-)HQU+0N9TX__@U;'
MH$-EBY"V;DSQ0HA9NM66I3,!EL[JSQ(90K)P;NM%4P_].8(S[ZN;1](^94TI
MR@&0$$1R;2@D*!Q:1W ,O3<["MABLG24O*94\:!(^%+OPDA5?>SY@>'\K[UF
M3@5)B6O*53Z&A"GUG@S<!70A,"C<''Y='S9R:YW8G^2O^%C[X[A19[ST7+H?
MXCA)?7C@JGG"A7I'Q!28&_Q[G;/7&=[X(7!QG"2-Z/+BYN964RZX:IYP0?(^
M?"P7,VC@Z/7I=O7J.00B4M_7AX7\:B<4D)P">CJ $F7UW\TPT)+BOR,EJP]Q
MW+5/^-/%1=#;0 PZVE7!TD/VW/C4:1@Y>7UX$D:1\*6+LV#@!@ #L]_ O1$8
M,1*&!Y64O&Y\":!(MFEU\1K@71;80XNSA0>WS%VD7:JZL9-?^824^@1!1,BF
M*\-Q[C:^[:)E&Y6\5*JZD9=?^80\DMM 9_+Z*P 7J'/_ KVOP3(.?Z.22$Q=
M-S+Y022DDCP,.I,Z70+'R>/R,%'=*,RM>\*<>M]$/)?R5BLO.CHU72+T_F@3
MX*.R>!U#GT8R,M6-,6$L"8,DCX;.;:^'[ 1Q/+0%WO\)Z,WO*%W:!E?(!I=Z
M\\E1_83"^H1AQ'/F!]LW#>=W8$!Z5!HM:7V(%$*0<%D?CTH2=[?']X ^(4U0
M*2GKPZ0(@(1(DFNE#D1&891\5!ZDK2N9>1 2.DF>%SWI[")P5@C0,4ASG]3W
M]:$MO]I)X#7)Z5*8JI].CX_VE#WP(W2]QZ'%J>=^.FU\[F=7+OJ[-QK>]X?3
M_CW^:SIZ'-QW9^@?=]W'[K#7;TU_Z?=G4_'C/XD4YX;_&AIMXY\L#&,=Z1$X
M@9]\<BS,^..7725'\P?;14AMU 2]**:><DQ()"O61?NB<W%V=GMU?7[6OKYM
M%VESY7%V?1_QEX,HG4B;IEC:X/N&*X!4T@FE $ ?/!;M;&41'T_]N/@_2JN=
M##BXHQ'. ZTAO./K2[JNA?^#+VUY,QP$W.\&/0/"+5J#AR=[*3K@RILVWO7%
MS:VB@ IQBK/R*(Y8N5PR)XW1!R_3I0>#&8"K.\/]XQZL<2]Y/'VFIFL$LV+H
M&,<8B[*X]SN>*^KYH\LC_ DP 5+TJP.&("#OC/)D:80J"@-E'**LTZ@P"I9H
M17-H.(H2L@D;Q3\G/$D'-%6SGMS.LD4BI_!]F*113.<"8YSHK!/'/(VZN>V9
MNRF7W9H(L/=$.<U#SS4%5G39Y)J27XAU3G053/%4" !?NND"ZPZXZ(]@[!AN
M9(4'#^)_Q)\?&(6B#.%R-)4,)_M9\<@Q@/+EGQQ5C:&W!C#88N3AC4]H$;S&
MKC;ZC(&5I6E:$<;:D,XFOB?:73P"PP<3>[$,1O-G'X3FI*T<6'F:)@QQL)(6
MDF\ OGH$7T-'Y;2$.0G1E/I"4XY*702*9YC)W98V\%%/E[W\.V?&R9M=.SE(
MW%TJ90-)0T>Z@U L)+[M)WH&[<12BF&F8'B02YITTL:00G&R\OS58V.+';+(
MKN@3N$%@1(54H"2=%<935;J+NZP1&K+".3('/E(*^#9#"#G2AKI!ACI3/)>1
M1':NC'*MT$RYA/L%0G(YS/'MRB77"HU<*.^OAV?OL3$S?4.B*6"(BI?1BK;L
M>YX;VNTW.UCV-G[@K0#D%!-/5NTD55HYA5$WI-]!^)&$ QNUQWOPFA/=04[<
M2%'PXFRF-PX_")%TTVQ)$%(V3P^\("N(]MA+X4(7)PRW\Z5Y0N#$*"LB1!]'
M+G>\ #./SH*0[(7C!-^<601]%I4;2<"96V?U<-(M./_,P=X03\D8N/@!==0
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M)39@]Q*TY T2@PC"LALC^O0$QZBCIL"K@BAU@T7  !AKH.Q[+JH7#EFT[)Z
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M3_<H>9LA"X_C909ZII>;MJ*73>\,W_9QP/)! W,M)I$SQ-V=0]\I+E.D-MV
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MQ"'-&#=.I!-IV43SK4MHH_FP)+5$1]T<'+N)!BXRQ 8C[;[;M/.NV83:$"U
M&-E/QH&+RK1ZTH;&"MQ[*\.F/\Q-3JX=@9Q<Y)&8@U#YB^S4(&T??_H$5J\
M'E%)2*$Y>SDD'+G+.* IITWRB(JF46" _J1UN-F$VC%>J,/EQ"7)RZ5P:-W-
M.:*WH[KNX1,M\1S8&KEH*8]F_M$A@Z'GPN2?H8<0YP\9G0%SZ=I_;N+%+W<8
M1Y6_K:\>V=)B!(1\N+EJNI9+ DN$UF\7V?5;$EZB=,7VP7$F6 >=J^N;B[/S
M6R2&VYM+13Y6Q(2Q6$!\<YV-7PJ.Z\G5P7#EU:Z#*$T38>I9V!"5-'V=3FC<
M@\"P';[>X:+ 08W6#_$OZ+T%SQGZW[F^EK*08)\*(+AQ^#*E)=S1(_8SSYSI
M549!D/5W\LS0#XSF77R<= %R_#S$M-J07X+&;-?-#U4K[\]!A?UH(FKL/YFA
MOWRD?QQR0O0D%"Q%&P6(DY<E7@9VY>X(8N??786#ZWAN_P5@%TU+0DA4EQ(K
MN7:,RV M/2 (P]>3]-X2=7SVKO[D=D]/^ T0+0!<S^<!(P#/T_PF34FI#<F"
M=)!XY .G<UOMO_-324C;)#)YX>G9+J?(1MX*6,^^,7#-S_F<LC-H0VQU77$!
M U00WRBO2_9W"/!UC8FD?>Z.FB__-R",\O;0XG)I/UG@^<#\O/#>3BU@1VL[
M],?QD@Y]]/((%H;31XO88$M8EA-2:*,%*8MQ7H#4_O\#*(JJ1HRQ./Y:&W)X
M[9IF(A>*GK.J<>RBOK.]V1) 8PTV@6WZ:(#QX-J+3N!0.V+^S%J1FTM5NGLM
MB5(Y[T3?F0^# [\9^M=QZT4?[7>%OP!O@8 O46_E$+I:9MJT4<Z04<YJW.F*
M0ZWR130^%L'BN++$#IF95AL6Q0DX(D\(H1:--S/JAL*%6TS]=?(/S/SU ?/Q
MQR]WDR.:]U_HQ:D0+WM.<^!H06"Q=CO!BP)*;[O[3AL.I?6N;&C4E<J'LD*<
M$1U]JPTS^48E$,# 4.,F]62[]FJSHM*7^EX_ AGU2E.8CZ/.)!KO;!(/OZ\S
MB;DXE'MV-3M)4_?A3Q G]3$L]21*.EES?J'L&2)!+O)(S$&HO#LF[]'@B,RQ
M9[O!@_T&Q@":V/@+T//<-P #&RD:GS^A;]F(Y-><^1P"C[9J2@-7+@A9[Q"\
M^K9E&W [-?"9[>B%!GH/3TVOC3JD=O1B<!DOVBF^<^2@]KB=C.8'^UC,82 _
MHS;$%^.,P'DQR,H[!'+47/!DP#] @)^D"K:C.:H):@KTJ#E&<OV(+D94>B00
M1JR<9WD=/_AS@TS<Q[=TX)C3G&Z?D%H;24CO]'G!,EZD5-WE9U&P>WI:>FU(
M+L(/%[LZ]^J5B($9/D],6P<1</7YXBCUE(#8_O 4K6\,U"/E[0T?IDL;XZ+F
MKALQF(R'7N5VZWPTQM5]=OTU,)$9@$7?(*:EU89.,2:.&!1"IV?++7 !700:
M/R_+[KDS"?4B78@\0I?-!Z\IK"\]&,P 7&$W5][TG)16&^[E3LZYH3(>?E0]
M-3_&P)Z8DU-K0Z\X,QRL-K]7/W(U^V-CBYL!LX-GYM%?$$*]O3A6Y<(0O[3@
MD7)3%G]&;5B7TLN7Q)THH*WB0@,B^X\VFK3X8'?&8X#O9HF>R46"/GQ:[H#Y
M_$QI])<(_:VFK+,)2S-?$#>CW<M];1[W93,/PPV?/-[N*DK@D)JVF=2)P:T@
M+D;]B^YX'P*_98]6-1N\AS &J$I6^-2!/P1?PZ_H-R+R9&Z>="3@EW2$DG;7
MU*6JV>%JY;FA6<8&','086*%%_DE[V=0YXBY.9NKHZ+@)9VO5'@1TAAZ)@"6
M_X ,BUN+X9I@-#^P!T4NN?F:*Y9BT*E!?7+Z&^&;TBH=O<*64W#P2N=MKHR*
MPV?$"Y6?!@D/7.35*VM@Q@$8/FL2+)"[>?J080!&>$%MW[^*P$=&&4.TY,N9
MT%#3IRUVA2S6KKEDBD%F;%8JZ$9D75R\CE;\_FA^Z/ZC:(26O+D2$4+,V J1
M,6<17G%3+AS:A?/%)VN2:+RP"9"&%W:.YI%?%+0LOZBD<81(__,:&<L-PLOG
MYQO7,D+'O]M#=;,#_(_8!3@!)K#?*)?]BA?23)%(LD.B&TD7!,N63->R[*A"
MW14V5M('SKR>A_JJ>_ &'&^-<?8\/R#ML0B6T$RQR#!"HI2R+MV,4H0??20J
M)>XI^VYX)SN&,IH?XXKAHJG6[\ @!<>+%]),O4BR0R*9LI[;BB2SOZP-7Z6+
M_^ 9@#ARI8UQ?7%S>], 410%GJA DNM5M@IZ2WPD?.!&/>,>RX,'N\BD2/61
M_B=@L7%PF5M\MY^W6@%HVH;S9*,E?N"Y&=^9U+*;J:AJS9/HKJP?MZK>YVA,
MCH=D&;*3570S55>I=1+1L4Z(REE,QYWOR!V"(/0S[L\X$R3!2-U,ED4!)\25
M=<16-4IY#BHYO.KP#1S<7YN\9=9_7^/ &A_[$",G-%T+A<MJIE+DFB/145E?
MK31/7!5WBPS< ""V@XD1@&@#GBHX\0+29KU!9JW[/I$D&R32JLK)>Z4J$&87
M!HP-U-M F-UK9"=NKF0$\"8A=R07L.(-P2ZR@64[&]S#3O'#H^';I/UWT]E8
MP,+1&6B"M=X$\3.$?0.ZR&9^LB<6S=,HBI!2=G,%5)UY$KTI>5N..$F*1VQ4
M][D'5V&PSZMC1X];#C>4"S'R,S5/'"5P)ZRK=P-7,;%Y,$QV;T-+WCR-%$*<
MJ(/D\<V,056^[3IP\9E_](NB+[F>95]R'0Q_[0]GHXGR5UL34-M]]3B>;67D
M>CF[4M3L=I6:&%^?T-P7VH;CHZ4Z]KOX +Y10Q'S,Z:%>:MN2T:(A&S#*XA4
M^1DYR0+YS8-_#-PPDM<74P@]9^,D(@BU(;?6[N _V*[M+X'UQ?,L,8W0<S9.
M(X)0E3]<)EDC"'&>&%"2QK%.PR3KO3$\!4O16^6L[L&P81AU_P0,_&\\(WVT
MC5?;03-+O([U7/3);X8?)K+N#!]8(Q<_$[0"W34JV3"78M/!\^QT\*$[F+1^
M[3X^]UM/_>[T>=)_0M-#],5L"5I.4IN6F52G]=7P6V]AA5JON$8MSVT%*&U4
MKU92,;5SRYUI]UA]CLDE*]O+Y94BE^*N5EW?!^$;?XE*T'H@U@X2Q@3[0[!/
M/WH$$";_1+JQ0PF%8IT!<^G:?V[B\^V43J3*G]2R4\IG/MLK?;B1J)-A]:Z&
M$I?L*U2 ,B;S'!-4*VDL 4E7]&L@!TXN\DC,0:A\:5OFBG[ZR_9B!6C.?0Z%
M:1^T!.3*-2%YQG*WW?WYBPT@HF&Y?<2AMXSQ@B]SRGP=]'^=[V-("<M)?--7
MHGP.%D9^%A%SL!$J0U\QB3/)D$5A4S2M6QJXZTW@AW8\9UY@Q\BAKV8*T\R0
M#B?^A@CEP((A\)SK3&G)]96(NC%*R%95/G4L113,(8B>03MA"+'"1VKSAY-C
MU&&(47BHF3FFY&6KA3B$1I%"B!LJ$AQ_;0; PA<0"LDDF['Y0N'$W) -X&/T
M$]O_XP$"<!A:+209>@'-EXX@]H;L#Q];(>QD?_4<1"7>QA-2#S%O\X7##UO6
MIK-<!^XQGM]MX%A4;RTC=7.H+@)4TK6)JCN$W<,UCY2;V^D)M>-?@]4KIY7J
M?SUK>AODN/%P;? =9]).3YQDYFWS<>$4N?/]HV..]D?(!VYX>@+_0S2PZ(P[
ML&C_<ZV#WVM@O-#-Q?=X(=E=<Z>C[IRV&/,*XX42(VD5+/+A>\(*E:*,<3E[
MPEK+1\V>L$YB$F=2ZIYPGCKJM4"J<$]8)\T4IKG$GG"SA"(KWE4K6:@;ESBM
MI%5<4A7QKCK(@9.+/!)S$"KO!\K$NY8-=]5T?! B,.U0+0]<N2 T<[%JH <-
M!@9.*TG:L-/&Q=HS(-QBB_+?UY'.HIV6.(G,&U4X4%;QH&:]+YIK$/_"F!G1
M((K5<'3]&<F'2)$!1\[F\%\4;!5#0I5[,<F5G/BHM^%NI^@;8[& 8!'?7I9\
M+[85<Y$]XSWI_]H?/O>GZ,_XM_[;;UFI7VMY\Q:,?T_M5DR,&DTQO(4;;A2A
M2<9]3&#\)65KIE@12N>,K$V5=**TY,_4/3A7ABCB1(\.3](*H:+;V7P8'#".
M_G7,-OH(/]II;<Q@!*< OMDFZ1@!+9EVC',PMJ=9"%656PTB-.$53UQ7G^C;
M8:;5AC AVQ,IXP37D"5\#)KI]D^E21OC_.*V<ZZ<:4[*LAUQ/K*&T/R(3./Z
M8&\G)N&4U(VB7@1C0Z+L<=3H:'YP,SYC*X>85AL!%!J6Q:'INYX^J+T?>2*-
M_2<S])>/IIZHLN3+*@J6HAW]_$QF52 #N_+!@?(0E@U\^WG_7C5^]R;\K/]^
M\"EU7T<HOW::D,%K>KNGO#V4ZZ3XZF#7PWX!W@(:ZZ5M&J1P-69:[40BO)P3
M@U;EX6T^UL#BN++4-1TUK3:LB1-P1)X00N6-E?Q*V-S^"T!JGWWXM5Z\"=D^
MW?'F@E).%2[73YJH#\S/"^_M-+RH'VYQ*[U._H$;Z?5!(XT_?KF;')&Y_Z(1
M-.; :<C":O?^Y>Z1AKX?V"O48]UM<RY0X<FJC1)*+;L*(V4<*5.]JTF%E'M#
M"D]6[7@O3*&(&G+P:]'G5R&=)Q L/2O^-[#P,Z9^DBJQ#7,U7Z;(&DDM1Q\\
M4BMIEX9(4%KT'GYRZ+J&(Q(G+DGGX17&VR7A%.R@ 8U991.499:)2%+SI;V^
M^2&'F<?(3K;OXW<AO "(A<E<9L-DQI/1TV Z'4U^;PU'L[[:,!@<^93[,%9>
MXEJ&MFC0Y-C&YPUBR6]IBF?NDK?"-"".@XY"6V':4ZG!5I@&]/,S*7DK3.Z@
M*MEKVEV%0V#D2,S?^6(EUXYQ&:RE_:W"\)63_GTA)&48$%L(:1@.$3XN,3:V
M&#/[W7E"2GTY%%WV\(*KH-WN)7"N:HV[-K9A9SB:']J!NN8E)V^.&(00BC1M
MXKKVIU-< ?PLWM__'U!+ P04    " "5.*Y28)O7VFB\ 0"\@P\ %    '!L
M>"TR,#(Q,#,S,7@Q,'$N:'1M['UI<^)*LO;W&W'_@U[/G3M](HQ;N\!]3M^0
MA=AW(19_40BI "$A@186__JW2H"-#5X;;($U$^T#4B%E9>63E9F5E?7W_RW&
M%C8#KF<X]C__(:[P_V# UAS=L ?__$=N9A+)__S?[__"X/_"/QCV]_]+)#"C
M<],H8;JC!6-@^YCF M4'.C8W_.$UUG0F$]7&RL!U#<O";EQ#'X#U3U)7[!7'
M$=05C=,,A242O[<?>Z-Z\"F.?;UN35P13YL(ZU>A1LQ/@OY)XB2!$<0U3ETS
M*8PO/_W!ZDDEH^>J[G+3TVOX:/R>$';G+:L?2<"=&1K "DX/RZ>O,<"D.%HG
MZ(2NJ52"3I)Z(D7AR02G,AH-")7$D]M=@O_Y>^A#]D(6V]YUX"4&JCKYYV+H
M^Y/KGS_[JM>[<MS!S_4-V!,BE<")!$5<K'\RL1;WS>?S^=7$=7S5,A97FC,.
M.XY3#XTMPS8?M5[T7"M\ 8GCU$]TNP?YNVFN.8'MN\O[7X2M/:!=#9S9S_5-
M1!+WF"343/<?_VK]#N;GZN:FJ;'P$_"!CVC:O,"P(3T <?FG[ZJVUW?<L>K#
MD4&O9!*0J0^O]%Q_EVGPXAZ&&8OG.$!06^_<-'=!_UF.L3_AW>U>&R\PU[ ]
M7[6U>^;JP-C/6'AC']F>0Y,$]](+5BW6/WC4<$Z%S8A4*O5S@>3MGN@=B7C4
M%-V];[KWD?#-Q,].N21I0S!6$T\["<=W/\6O#2Z9(-E'\F3LE2=V)4_&Q>^_
MAT#5?_\]!KZ*:8[M0YWSSX4/%O[/57_1CQ-@&ABS?R[6]Q/^<@(I_?G[;]_P
M+?#[[Y^;_ZZ>U7/TY>^_=6.&>?[2 O]<C%5W8-@)WYE<4_C$_P7?^A/>?M1&
M-[R)I2ZO;<<&J(&QN$9/ ^[JHZ'KP X_P@85J!I=0UO1N_ ;2-32@1OR02'@
M_Q%^E::C4 JU_M(H4D)[*G*F;.0R"4MADM5*HWZ!V>H8O1P8UZ(->[$48/]<
MU<K;.E@4P?(",_1_+IJ: GK94=I1W9K8'O&<ZJCU,5T:**1"7/S&X5A"EI))
MXN^?CP@\*KU"X+J0V(SA::K5!:HKVGH:ZN][DBU:NO5O2]Y8+@I:TK7X;*ZA
M\/ =D.1$@B A2#Z3WO1Z1GL@. .O>/?DXJ4>E2:D4LHL\BFS,^WVZ!*H*S0B
M%[WBZVBMP1<X^F-J*\UAT^)UB3"G.36S(*FL[ZMUA4'4UC^55AX2JH?$6NI@
M15]%=5V%4=DADZ<+ADQJE19? )[03=0O?O=5RP,[!/Y\##*HGP&4+@UXO_]&
MRNS:"_44I!@+E=LU4@'_7'C&>&(AI15>&X8Z'TZLB<W\>;7P= 3VQX]8O6W[
M%>%7SPG<\%LX(UROF11VZ!4FP0E+D7PH^X@-D@9L%0X8OS \93W_*YN+-4NU
MRV#< ^[#K:#G&;H!+1A)M4"U+_F.9H8_ACU1>+^LNB;P1:@!_66U#VF&YMOZ
M$?U< F2,=KLIMB>=IF?:LUE^/+_8] "$&F7SS=#1][X!7"SD!-@[>0OYXF.%
M\O3'F\=Y8(!ZN_JJPY<M)I:A&?Z*-$PWX-W0\+R W+G>RYV+WVL>7.^RY^^?
M>Y_[AM?=/_,YOE[\AHR]?HFQS[[\YY.^_]S'Z$D(UWL^^:KK([T8*A%D&^#W
M7'VX=S]B^E93*M20C^]LOF]>\O.1L.Z37=Y3JOTM8;V7N\V0K#@@..,)G/IL
MWWLDN TX+\,)7Q=5UX;\\=:25YE2%C$8&%F\777Y3CYP.FFO'C7)NQ>%E[KZ
M((7[^WI(85B96?Z>\=W<^>SQY77=0)H-SC*JH>=M09T8T ]9#W-C80PRXK@U
MEPVQMU26J:FH%$]]F%_L\FF,-D&NAQL_#)S375M)DF,GC6?OZAYWVP6W?I8_
M\7'^5#CC&X/VBP?X93PSK*Q5\CJABFVGT*.S!)[(C0<G/LY?@><##S=U6#CS
M:B+;LSFO@;=O.:;;FLS26?+4U?8GP_DHL_-AT=S+F3==M51)R-E>(Y,.DK-F
M*W7JP_PU:#[*[$RD#@-GA:]GLHY7J(J *L-YF1_GR<2I:^W/A#.1.L[L_.X!
M?AG/U7F1';<;LB0".97IM\2RV%C&>/[RX?ZH;P4OCQT[C#NL1YC FPQGY+LI
M7!I5[P;YVP%1D4_=SM[IYIG[4+O#VFL.!C>4.]5$4@AZ\K2S2-S1IZZ@/VM8
M(V)*[XYJT9K1S6J+DL0$G5AH"8N6ZL7(15<C.ZK1,*EVAU4T%&G0KG3F<I5*
M9R>WE8DRZYSZ+/M)PWJXF?4-*RHUU]$#S:^ZZUR-1^.ZOKD>TT<+,%G@#%QU
M,C0TU;I?1ZGUC3O@KINSDV*;Q'L>U-?%@+)S_4J9NXT<LM&ZR3X>/(SZ(R9\
M?,7DT0+-4^ZM5DNVV7=6JR.'E<-*TY.M9:N=PPU^6 VT1(%ONI$S! XE6-]Q
MO$OP@NT!WM;7=S<1],FRVTW9:147EHI-ZGZSVL]%SK)_?>2?Z=]9RP"^+0/X
MQV7@WN88JO8 Y&U>"W/M#'L@>KXQAL3>+)O+R>.'[38N W_HZ.OO0,\X+N]M
M6FT>].2-Z*G5/N^ZJ!4:B/MY3Q@:P#-DCQ^X8'7'UE?7Q,76U4W@N"7:Y<"^
M+8KD[7+D5.\*'9;Z!E+\9G/L+4.[997]P=C^.:U[A6(UG;]+*HZ&??SMV,>C
M@OT_LCN3[8(/TKG,# ]RPW1:Z@H=RCY;\^!D[,YSE\-UQK=RTU!R UFH,&Q6
MD(7>,,?HC>7(;\2>SS,2N&;<]4TCEKUG9<_U L$<\MI0+O9G?KE0YPJZ>;8B
M]1W'^SE[-U&K4>UYB1--EJ1!@LV,4H$0N4A:]'R>+Y4!2B%36X[OYLOKGD28
MYPWTU8S\U'%H#A?%P4W0)^4B:6?8:=]WR>@I@3=8QB_U\IA.,)4@4V]V@A^:
M'D @4EM*(:50^./%DX_*0[UAB"-Z5C:!0^B=I=T>Y2N1<R2C*@\0]:FW*XA4
M@L(/* ^D0G#W"N+A2Z!TBBS@Y)8H=2WIIIKNYY+4T97]!Y!$)@CNC4C:;OJG
M"?8'@P[@AGHVT'G!)"5%465].*E*D9M5(P2=QZN.VV@XVO+40=*ZBC-R<7LC
MIFTQ&-X4%DY&DMO]R.K(R*1U13U\?!#9\/M6?3JHI%TY.ZS9.6A=C?JI6#9.
MQ\Q^66^D0<_/0^7D!H_FA8KC P\U7$M!OEVA:"$K37$2])O5VTP^/:]'5@IV
M.[6:!Y[TZJQTP7,)@L\,L 1FP*XY!MK9.P,UX$+'TU<'0'#L&7!]HV>!D%M/
MEG<RJN&V5"L -\O[CSDX5JJK#9<E^$SKD4ZY;Y.W)X'OA0VH)X\L ]4+W!"T
M8:N==:FG#:2AZH*:^^#]WZBY9 F?,VEQJ2T,/\@MC70ELB[?<\+YOA'Y\T69
MMPWE@\Y\82S_G)CGA.#A]:])P9'LN*-OCCP_?#8,S\Q &SL/.^\"SV\\K!+?
ME%6IG+,*?5.:6P.QNYBVJT%D/8H8J0=!ZO/R$&,V*I@-%6G+L:#):$$6KQ]G
M,TD#GSEF769O@I0]*M+D-!/#];SANE<48J1&!:GB8@(T'^A-X([7SV(JY82?
M;:NRN9SUIW?]AA@4[-C^/6^8[LI!C-'/QB@B\^G-K@$L??T LB\UNA8CLZ;!
MWHGI865Q6X[N!H\8F.\")F+-"X/_/='X!#G2T'%]I*'04W<3CI\(4$U=JO#S
M)O!<L)>%0MF=F2Q=:M>54OEFUC]7\!Q*7/<R?'MSU@L<CR7VL--'F^M)?4Y6
M YF4M6)''%5)HGMR,?-/%N#/4/Z1DN>'O(8NP_"NTI'*N&#3%5/B[:JK'#TG
M^]V=WTY5.-P6:2.[Z*:=K-<SV5HJF16\8K)+'QTL[U[3/]).8J:9[BTH&3=,
M=BID9IJ8%$KC**2T?,&&VXUJS=N:,P;W"[HE1PM_];B8*; LPQYD@0TUA,7;
M.J^/#=N 6@RVG0'D(]G>O8LPF,[(=(4RBV(VE^$5#1]TBNW(6A0O]'^K7.E[
M&'!6ZYT'E*(&\ ":7R#[TFC^<"9A!L&*=VO9(=JS; 'O=YIXT*M+R:!I#(;&
M:<O.&[H=2\Q^B1$<SZ_V437?C6XI@^E T(=-VIQZ]2(S+?@5X)ZV?.QT\JRE
MX9G<J<//0O5!#J@)E\Z);6KL+U)5M:0=?Z[_!K-0%+*L_D"*WC(+51:UVVS#
M4'!SFNBV<D9U:0^B6P4Y\K/05TC,RO:'+A^%3/_DP3?.:_*LKX]F\ZZHIO+E
MS%BKII-V9$4DBCO#MWR>9 +G$B1U,(\/5PBTRPEZ_(<>]A&5D$EK,$N9:C?=
MG=C3A'#'Q</^L6'G$@2>(%)_/NP'3=[?4\117[J52D9T<6/2*B[&DW*Y[T0V
MPAB% F*1,SN?DXB/'\6B4S=N9VS<$C@HL3R5(@MR*GI'L=P+17PVRM[%#59.
MM5*^D%#DL9!I#_F!.$\</][PI9'PK3*H_?%(X()"SY0-9^"6YISFT,G(18,_
M-QYZB+K.G%H0R+)T,S1!JG,SK,D+=A'=*%;4ZCI_N9)XD!1\R]U\^'* V2.K
M^#W6RS9LD[TA.273JHUF<N0* T5Y]L"1\?A6I_)1T\-O_GG-N[@WIS?!*3(_
M'RJUVT59#AID3[FKYT>+4605Q*MNQ-/^17U)^ TU(1NHK^$PHF]EPS;&P281
M],U.I?34?52X07!C=]6LF:CEZI51KY--1<]]1 54[OM_\1M]?<2 /T\_>-TQ
M?<JZ,YU@CBI_T)/?D4#"NQ$I1VJ6<>#7K*[E,R4MB)PO&P$)W,.\;RZ#ZN(@
M.C!_F\ZGBVU<,XT%(]=+(\5<+B/G..^3P&T&Q#KP-.1OGPYT$]8TR29P7VY/
M"S?U2FN*&\=W>T]0 K^-#B21=[=5 @E_JWTOJ2Y:?--E3\W;VM5327-<%>]X
M-^6^69URB^[D]K::F4?.WGN#/+S<SV,*!0F=MS<*Q7;3B%1[V5U,R,MYM=&7
MAFVY&#@X1]3G=]GHG1@0V<6$K\T^6(6 "&8=#Z+6WW1@*"4P4"TQ[,9#+6C7
M\57+6-P83G,(7'4" M_0/+1@[TZ<U4/78O'F@KY_6&S,I?A<\3;A4KB0\?#,
MK9FJ6'>1L[X@0Z^?,'1='OK-'/WX]/CG-8(/H7&_H@XAP;PYJ+9J>E!T,0I!
MWT_"#U^VHZU@&B!=-(-_=K8Y/;E_ #M1:-6;XB*;F<K+NV&=+03S&\:/G)VX
M':3=PY^M]+%]##H_*Q(*)OU&@V&[Z9]&A:,@L$99:C3,2C8C3C.E1B-+\<T"
M'@MLQ 3V<41[6P8/%]'^(Z/UY<7-FZ3;-UPKY^ )3].XN^E\+$?OR)B36-R,
M8"KM8E(NU>_F0L=4^5DS 98)T1.BL#ONRQGWX8S2'34]%P=C4^G5.5R0"O,9
M,^O2K!,Y&SP:<<I(98GNFW/EVQY#=FM,UIPZY QD9-L:**<[F)\V]QTN^_/>
M_EI'[3B<[XVJMI/%J[P%VF5\Y%6/OT?H(Q/_\>M6-XJ4T)Z*G"D;N4S"4IAD
MM=*( B^^)/8;V,:*:S+\@(PA6U==7?%0C4M/4?1"NC3*^GDSZTI%5ZS.)PWB
MP; 9KXJ0_%[3&/YF\Y[-O<UW]*)77BI+:44>MV=LJ6,MS6!Y1TZGG""4T_6=
M-QJ>0Y,$=PU_\@<OG,#VRLWDUA3H:KYA2LE*X/#";8%^MH_H%W_P0G6C1A3-
M32_2-C_CQ'&6!UY;%L>:-]]Y*])"]S]Z_XO3Q@P*8<C8]8AV@RF7MY)V!R]:
M5,O.*/.R/7_HK1[^8/MAE6 ,()X<]X-#L/-[=#$-;&=LV/L>^U99>O2(GX^I
M?\078W'M BO4"-[0F&"JJ[F.]1C(J/V5XPY^DCA._5RW^-E7-3_1=QS?=GQP
M@?5=9]P ?>^?BZ:FI$!#G+29CBX'OG7'J\QL5A5YA578"\QW5LT4'6C]/L-H
M2H_M$PK=H_M*2J,UJ(=Z?8U4"9!*P><ZK@[<?RX(. @_GQ![+.J[<VJNM3-9
MR513.+>PV=*,F,\A]=0I4&_.;RE;MJR**;3&%M.Z(UL=? [MT&W>)QD*U]04
MK;!:DE;H/IU44DG8!4[3&)5,,2D:Q[^$^J2FC<NZ1CIBN\C@>(=8- P?44^=
M O5,4"0[@RZ1%X7\K-7/%Y+)@L$KR4>\9VF:8W2"4<A>GU%HP#%*#^B40M Z
MZ+$JE=(9YDNHKRMRZ\;1C*8L+9/=,C5I945F#JFG#DO]ZHKG!*X&O-77(5#U
MT!" 2NKWW_ /YOE+U*&QNDC,#=T?7D/SX=^_)BKTN^U!P@)]_YJY2B8?+KG&
M8'A_S?%"[WS]XAGX=?'DJ>[ L!.^,[DFB2MVXO^"RC(Q!.$C"/J*AE>VW@I_
M/-G\M \MA$1?'1O6\OH_36@P>U@%S+&&,U;M_URNKL#_>M"NZ/_G5]C:,^X
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M3BOC%-**&C;=X>NX4B^1;3TY$:<NSXJ]5,8*A#EJNL/7BIH:3PJD69/;U"#
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M.CHLTT[@Y"67>MM&YQC/,9YC/'_RQKD]@";G!;V%SQH"+J@MOU$8]AIJ88X
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MS\AM19%N;PBSG0]DOM@<%6IVB/VP!@!'Q*DQ9Q@\65MU]R*") T#XXGE+ '
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MOQ3!;0X!IFJ:,X8T+5%Q%72.-S3877C9Q@SXM($++?*)ZH86N@^;0^S##GE
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M'$"KGWO:,M,0I"+=R<ABMK8<. />2*L37B$5\FE+@6@'^4[3JN"2T*E/@\F
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MJ7A7+'WQ?5MR(FVQ_09 %IL:",C^J]O(!1F)GWVE\RMZ$ 07"'?JD=OI?G3
M*HB*2,"1_8M$-X= %LKD3AR$WP>\\A*#'V]0$.6_AJ ^:'H-X>!KF^U&EZF6
M!D2VU.@^LFVFR7+=4J[C)I^4ZKF' X'/->IYMMYA\_"'3J-:RC-=-M_IPG]K
M;+W;:11R3.>Q4&U\J>'ZT27M)DD<SI+83Y-H% @T40+.M-\YDS9!=C;WT'F
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M6Q1W%G=YMZRBV\R==;O88Y-ICJSHNKR)C2=05I._?L<#^XR$X9?["+_DP<*
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M>3OK3A*GOD: ;88E2V2AG2!SV_Y ,DFREZM@ 49]#,/4J9\1=U.T%= LW5!
M&%X+G>HPO'9]YMK+3G5I+[L!^"[/V$HILWA:D7U]DEAO1/OQ.=/B*5QC/QV+
MA5&U$ #"J-H-F'N?!8":RC3RY4&]PG6H+:</-/4IIC(( '"CZMBY(>"^K+];
M,O)VAZL+8;L[6<6U8"$7AH[Y3W?,+V^KW4ED[>WSCZ8C@(PF,4XIYNK^FDH
MA/> ,%P:I?J"+9;&=:[02Q;X!(1P7'H_D0KO,8;"?'UVUYU$V;Y<F#/QUK:_
MD>=QKKBH%<Q5O=IDI1829E2#/Y*DPLZ5]QMS.[R:X.2TJ;HV(2Q@S ^O*H8N
M^#E=\+%N2,"(.H/_H18;PM1512+^B\3_NU*-\,4QNDL3X;I<^',;AKA2=UW7
MW+M(QQKDQ;.;3&]2-7*@E6;G%3Z=*W>>,]$MM MQW7[:;Q:&H;T05\X=^KLT
M$:X+5\YMHWX.5Q2)801CE61(I6$; Z8<+5;Y%L(59*)F_%5DPX#A[0<,D_@5
M=6 1HF!.4<Z==%)5 ^[UZD7S] =JB[M3"O_]=6'$2R_SNF#_>\U)*+,Y*+)-
M0U\I$I"R6\Y$M<1W.4',3G!?O5?;T.7*6MO(,S!8;F8@+R>&]0F<,"Z6%DG'
MPK8 (1"$]M\UVW]? P3/^6)_VX@Q@(WV=.41%"9\.[]&0.#<QJ52X6W<.XQ0
M7IT3?0^:X7YRA:Z)&.<YJ;X1:H1B$HK))<^ ;X4:=V5>7+L5,3YZQ1H@RQO.
M4I70#4^F\T@4JHU^ARBT&S6B5.^QG6ZI7B287+?4*W5+;.>?__SO.,QB^?%9
M+)=/2;N"#0UY^*9Y^/*96%>QH?>D?6_/N7>KI3=M0YRB]"-=)L:"-B,DL-!-
M):RI]7,<E,#0[HUYYM<5T_V^\@S^\_PL%-J\*[-!B>)]2;0SC;K*T8WG=MNP
M!I.>M.;I&*Z-FHJD8V%24"C[-QUNN"[9_[[*#A^7_:@X$YO5/LDJSS6>+1=;
M!DDS2/:34/83$9+T%W,(\W9N/^+BF7:&#G=),@G9T.>[)M#F5#>L*$XO?\W4
M^X&H?G/@'?8RO-T;@0C0/0$M0/ETVCQWD'!VH6R^@NK% L<KR>:@.]O6:T\6
MU^[KV>2$IW&U^U0D$0#JH8"' GZ[)EL8FPIC4\3"0&G'UA97* !+6UG,07 7
MYM!1O4=']9J(<7DCZ%Y"6EZ:8E/8(G$VNSHC0MDV0-,5]Z8J:!:C2:PG\4'U
MK&+K'CTMVVNRR*Q;>?-YPW(R-(APG?A8.AG&MT+8N 9B7*%I=:/1L"^!#;#8
MMIBG;GPU:RRX0K[%IL5M>8U@(_GK=_+,J'%?%N?5&Y:!D;'WFY@_4"7\1.2_
M/;OP3H)C.WSW!<@^ O#:<I75Y]JH12X3TK;S5"[4N@H$>%R(/N&O<1A*>BCI
MMVO*A5&R'QHE.RP@90#3,A31 I)WN!>ZNC_%U?T1M=OOQ, )3N=H[Z37/?Y[
MM4N'R$DSCEJO9_/1H\0WS&8M_SCA:5S%G7I?FYT0"$(@N-%0UIW4$OT"()C$
MZJE<1J[UR0I/*\^T,!@M4FL$!*@TTWF!X+Y,PFNW_)BY4[Q=AOOFE&:"]M\"
MB+A#(I@O5'T+@-,ST23LA8[^;BD&0/YRA-! &-OZ X_WTE5,SGG=[M)KO:XS
MC?,<A19TXS#\A<OVH;8>IJ]LRZE"V*:->;6G:FT6B/6VR([J^C#&\#2N#4^G
MPYI-(0R$A9NNU2#\.AC(%VO-+I<R2"[YN%*Z^DK.6D,, SC[/ZS8=+\A05_)
M3L7CF#=*=H8!@9]8^?D<%T OO?[KTAT7J?X9K#9>C"L 8RP^+9HEF054??(T
M',RLE3+A:5Q*/D9&DNEWEO\,024$E>\)0%YZ_=<%*A>I)/I!4(DJ8KJ[!E.=
MK ">>RS'T\^#ZAJ!BGLE-166DK_CB.716IV1417(%IY"6#HIS-"YHUR\*Z!"
MR.P_8\V7/XZ]!BK<E2:_O=B3^XJ/U/DLE.I,/??..I^A&WF/R2K71(S[M!E"
MN0GEYL==;+PF\MR577+EY@<Z^5HX1Z<HM(7N],T5T]2-+:'I%@A]JMOTJ;ZP
M#=U5P=2-'S2U@2MK9D.N0_'R&M\')259C\WXRIJFV4I\ULYMV)98;DSX&(U.
MD^(1\KUE&D)IO7YI#2,@803D_!&0EZAR!5;)<;T!:(_8@B;BF@.B/I_KB&*Z
M.,-U!]:"80@04%_,SP[=N="=N_<PR!W=\CM,WBRY@M^0<UCL.TCJ&4WJNS(/
MG9>&[ W*Z69048-6SF8,.]GDV XI,).^$=5746A'>?7<D[0_LS.$D9\"(_=>
MSOV.;OU]-3 8^7FZV\E(.;8OLNMM--J+SA88&%!F33J2)/U->L.PUQ^&O6[?
MYD17!PW"F@("%=@Q"69B@/""8.B!W^%-P3NQ*H.*8P4JD* [02EN)+:+=(:S
MYU6^*=OU+3=E^!BN'9^.)%+O,QY#"+C]_.R+!>DN390PB!<&\3Y[M(@OU2W<
M%'ABO"5D18.X&UZL"^_ G-\=#RVNZ[A75_ PX-7KV"F3ACYZLQSG.A.KD&G+
MC2;;7O,Q7*4^3D<HRG^=+D22$$G.%]B[]/JO"DDN<IGN?4C"F;6E(>D3B:79
MQZQI/2E/]1Y&DC#2=_<);J_FU[.% IOK$HT"P0YRCTR]R!)MILL2SL\=HE$G
M< H^4\\[/[ MKM1CJFR]VWDI[?X'JI6?H3WNS]STK?O&T^M860:BU9#9C3@5
MM EH"Q9H:$AQ,)J$_H.JWZ^@=M"L5R]=3\%64FI3N<?:XV8TEA36*1TI#%P(
M/T:%B7<A#MR5L7A^'/A>:_&K<""_RA6D>8Z*<[GU9LH,V\VL\-1".( ,1[_1
M&%8$^Q&W,NMLERC5<VV6Z;#$7WG6^>EO^-G'K<4P.G&/:45A:X';,QZ17CC1
M#?NRXJ[N./[@8&034D^7_(7)1=5&FW*HB!SE%*!MQMJJ9H-Q;4+:Z<13I3F/
MLQ-YPL><!@611#),5 P1Y:ZS%>_-#CT[I+QHR69ZMJH_T56:RXVZJ<RCE=!3
M68PMR)*-).FP?></#8%FF2I3S[$H!OJB\4HP72++%DOU.BH] D<VV7:ID0\C
MH/<;^?A)'1&^W9!E3+XA\Q2]TS/R_"F7LLMC:+KJ$Z.Z3HEZ/,W\D9[Q1S88
M*R<8QA:2LB>H=M =X\6L4*]7T\/8+"K.:VFRTH_7:BT^AAL?4.D(_4Z3,Q3X
M4.!O*=YY9H&G,GRBFQ]O8ARIS)++7&$ELNE<=?YGONIG!%X7^?PRD6.SY+::
M7-7DXN/F<88%'IJ!5"J2RKRO_=6/MO;N,J;Y7C.0A9^_:0"&(8CSI%S%(*I*
MNCU6P56HD/-G;UZ  %>@5_8AT"27Z66L7!1^.5?H3YD)NXXJYU<KL5FSO6S'
MF2JG##;Q>#M1Z.IYAH_AS@=4)I*.D6'H,L2-Z\G5_-FX0?)*<3/,ZT5S/$LV
M,^EBSJRDA_'S^Y\Y/E?IR.32Y(J2(-:S::4RFJX1;B!S-!ZADOZP9!B5?-E.
M_5\+%1/[^GF>3NQ@X&[<SM-#C0O>.?/OGN>E9W8@\R*4"&"<[CV:TGNL\^X4
M$((HZG,X0210N#:C20@&_!@U*[/ Q!!48B$8N)4MNIT.Q1^N#K4S@S]AUUNP
MX"_N_2LXV+3@![@6W</.CO_N#7DO1TO*ZO=_X#_>]T05" 82W^D)M\702USA
M)<G_^1:X/MXZ.N[)[6[K$@>3QO_^W_]S.'D_.KDJYV!54V>[:8PY$Q =&T"8
M1049OO@?05T+6]-=93K]0,<]=?;/3FTA.A")AW3Z?XC]CX@:/E+.A4WT@& N
MPCE-19QO>1]A->5]AIIJ0_C]QP"J8"DK@)Y]]%2\*Y:^^+XM.9&=V'X#_B,0
M4P/IN?_J-G)!6/795SJ_H@=!10&5H?KOH7"Z'QVP"J(B$E<$PT@0<T@'0PG;
M,;?P'@8_WJ @RG\-07U \QI>P=<VVXTN4RT-B&RIT7UDVTR3Y;JE7"?BQ Y+
M]=S#%Z+(1V>7:]3S;+W#Y@GX4Z=1+>69+ORETX7_J>'PA1?;P 7USP3S<&)_
M<0^=!VANJJI@F*BYI#75;1-:<.;?9]4U>WGYB],$6X)&D/25,SA>-&)]1;/A
M*QSN0#!/4?\2])5K?@$;IWP\*23(F)SAQW H'X^EX[P *,"G,C%:%,48G1"2
MOQR!%G9IXX/G1G,=S2189:/E2^FG0;E?;:%$@].13Z ^3!8+K3:[5+*V8JU'
M>H:=\+1_Y' \K9*=Z6.!FZ^?YDPN'U6R10:.3)R.%#:3>GST/(^3PCBW;L>$
M/,/%H#'-DZ<CLU)!S2UR5)WM5U:-M"7(^F3;XN/^D:UFHINOZJ,4"V+%3=]^
MCLVG_ 2.],V3)@=/D_S +)'+N2FIT;BN\#0:Z9MGOU:0F<ZZV.*2:V&A5@%7
MSLAK/N%_.S.KU:>=5B<]JSPVJ+XR2\4+TPD<Z7L[-5B76AT!Y&;1OM428TIQ
M,0<,'.E[.]_1J_'VTY8C&PV]PU4RW<QVN>:3_K<+VPIHS@;,ENTDALO:/).M
M598,'.E[9JP^[RZMBKDF<].DH0Y7S7G2GO!I_S/KS=E6'JWH'MNA!M751FB5
MYJL)G_&/'/"%\D1<)\$L*8N):6N2+C<R:SC26SLV]7<FAN/=B@AC%B;XQ_OA
M4&"24 9<,P.I&-%139X]A?6_8%NZ]X&C_?$G1S;"@5ODCO'K>\OP)N:^D'(D
M]'T9$RGJ(?&J&W:@-P^>K\-GRJJ^]J3;^SV*'+Q_'(-J#>GTIBWC@@9^L3=4
M&$,3VK; .0R;EQW"8[_K0\:T^^\?GMO2KQYAA/MRF7VA'N+Q<%^N<%_(-W*T
MPXT)@2S<EQ#(KGU?,@^I5S/#PWVYE+R\>BLAW)8_VI8/)GJ_Z;9<C CI#Q#A
M6_7J12G@BR=^D"30IT8?_G^_$K\^2Y[X0R9^T<S(]'L"A>]/&NM.#0"(&OS#
MU"18#97X^Z([ 6\@V^TR4@@J5P<JZ;<(\)H(>,'MTW]]<K"##_JS\$%!\SAY
M3_!1$PQQZI K1KF'2"BM[<ON%86,XS$.?=G;!^=A'#)4/N=)9K\&K?0:?W2X
M9K.*#WV9]I HU0N-=HWIEAIU5-"M5.^QG2[NH5[/!W94)^H-5."CUZCVT!_V
M9\9G:+5^50;TI3-77X\&_2QBO!5+_E'4".4DE)//A2I_%#&NRY"Y5S<99Q?]
M^MVTH5$JF#CO;V'H"SC=+>Y0"I:VLD")MK?@TUSEW>FX+VIV"S=8/J?A+[[.
M'U#R"[43] KKE+2J(F >5H!9T(VF*[I-5= L1I-83WH#[J]TR5&VN2I.<Z00
M7VSJR_Y\LDHS/&X.!>?[/;430@"X4P!P3)>++_.JY/_[VHE^A?S;\Y@H%<S<
MG%7:ZCK7[R9S)0/)/[Z^]KZF C_9I+N]X)-KZ[618"!#SX;VGF":P#()?6P)
MB@8DE.$/W.)LB!4)#;X3\11D;&U"J(CI"'7/<Z&??%8_^>+X>KF;T*&!>>Z:
MLA@G&C)G @:!1,.%B)+F56^$"J?A04,5(8.GC+8!ZJ9:I09QI:.9Y#+>'K##
M9*I?7Z);#JC* OT^<S-$EA!9OBGH=O'U7Q6P?&]EV:\%EGJU:)'M88KF[&&O
M-$O33X(U1, "[5@Z%CMW#88;Q94;C%G6=0L0!A"!LL+7R61#GQ.*VQL;V;<B
M[HX-)Z*+,QS,7 N& 1TC$W>[1R-VHT7=#".<WY/W?I=K/L^!YI4WK_ZYW'YQ
M:R$,Y]V+483">4B3M7>*K #U6,E53 TYAY58!^DP1I/ZK@:K0[-)]@;EH/(*
M:@#UV%[2U<X@SR7)6+%+K9=1C4-WP)%A%$G%WE>>ZB=;0+<7XKLZ[_(N=,2=
M)KL<?.\C5XU^1H[851$GE*+KE:(P9>QJB'%7QL>UVQCOSV'/ESJY:J/#M=E=
M3W*WBMEM7)6Y6C?TAZTY#+J$W'ZA-7]9@YGSZ.L/\?#Q!;XP G#;$0#W<*2$
M+BD"TW(/2( 4NB?A>7J8J7-?F3I.*J@CZ&U7SNL@*!8\+Q:?Z^RBOV8[Z_9H
M2\8RG8[2XIT>)^^,!(=H<9?!C.]OSGR#-D\8D0A[<@3,\](SN]V>'))B+E1A
MBY2,6]CYW310%0U$W1IP[V4C\@,A^]OJUY$,^W6XNQ+VZWA?OXZPWX9_=O5&
ME^TX,^DVB!>Z;[CE59CJ01^."X'Y:=.+/^W!XI3J1U2@.J5BO50HY9AZE\GE
M&EP=E9=I0B+D2FP'M8R(>_7]'1^A;L_A<L2O<'>.TX*S@JF8#;D)O1E(#OP\
M1I,ZD#Z*#$TNS6*@PK)18XY)$ZH?40%F%TX@J^KBS'5TQKP-M.EB7A]UR*0R
MZE"#1$(9IB>.<X8[>C#6*^-X-(SZ10#H0"W@U"S#!E\&*3X>/=WN/<:@C7&X
MDW+^$R4.MHG8[Q/A;13FBF_:()RB)%BV 1JRFY<-+0"\!UO_#CR/AI/IN+=L
MLI5!D2W13"OQ9 3L0/"X%W;@?0TC=HKJUVD<SY&'6-)O@K\>[,0R"A7-*Q9^
M^KO,^A?X96=][M445H7.NX6'('?F>N97!!ID(/5,?L9>KA)Q1RL9N@5W=D-D
M%1W:P' ;@0WWVXP0)4U\(/Y"K 1$A)+JEE@KUI10+),P[;&I2(I@0,B)8&,8
MV9$T^6_.,:#Q;]2_?^,D<_2%]10^9QO5U^A*Y?&W=S.H6M(#_L)^3@^]DRD<
MO:QS\!SOC1%LLH\5?3$5H'T@XM5 6]RQ[.% 0M9%&QGMNH:?)0'X7!W?"<8O
M1SGRP$#VN_*,Y1I9$@: 'X^186^A+WE40I5!+*!H)C$6#AYY0 0J]:^)ZX?
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M]4;E#SSW"9B_EUN3K]?;S:/]T^ONQL?8;V]_?=_,-J3__0X^V]GO,2>_+YC
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M9!<ZP'CA8CIC/A*3L-1G@KCEE;"$<2RNP5B)0_@!,9I(.!%]4 ]PE8/9'5<
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M0"<6&-P8&U>I7+H36MQ-BC=()BEL/$PR,F6ME^Z8%*E>,@%).BJE%8@%:RP
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M<@"FCBF,.$VSK5=%P*X N^OQ\%GYH20Z##G!R9Z1>I&?]-*2+M7$U_E@KDA
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MI@.!+OZ*_!M8%-0=@4G)"SYVK=<8+5IL!X92VIS!'>4D@L>8/AJKSAM!B:Y
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M?RR-UIQS,"VNPMEX L:JN%^F%?B8:!PBGH5CDB,PHKP1) 4@7CSSH>-?(V'
M#HC>Q+.)/YKUJ6EVQ6@#Z31$A"D#3<7%XRS,,"67A):.WT45?YN:&X]<3/^G
MN_-_T25%Y-2L5H0A_W]JM4KC__*_A8LJY<2J;>+!MS:T)U[/BQ>*&DWV0\.D
MM$F4T!&FYB\M"Z]OJP+,G.J1NU]IL%G-LJ#@F)T*=BN)IE'MG<%IA .5* JP
M!/UUY&@&:E5&D1"<"@:$+1K%&(3SV42W/2IBF$=$$GXY:6U)*$8E!92R$F!^
M*@ +2,KJD!H ZE:PGKSLSYY83MIKAX<"OR75A%=::IGT/:K7OL8J3GU#4QHK
MWS"=/W,>F"AKP$5I, #"]DL!7E/3](JQ97+V/4>QQ<F7T<O'2=12=\KNG42R
MD=D1O&%)5%3.F=!;J7<E-2(/[0@T7U_T]@1AG?1TIU/H8IM:M"H%2L&A .7B
M B-# 3TA;8.<UENV%J0-(088ZB^^EL@KYT\"W^YGKU.KSKH,7^*E4"H79L($
ML*.D5)E"F7SQ1/YAPLGS1**%]+;:2N1J<&HR*S)B>![L[T6]5)'\&I5JXB*F
MB]*3 8-7M4T5W/8.7^/)?(*-Y ^ Y%_5ZY5Z0WU?@2.FQFF$LV5K8Y">B+J9
M,A%R4Y2'E"CE,MVG8-KI:<( Y5JEOHP P[+Y'!:$!S>V:%"O)6W$H=RXDR3C
M^0#KR#LGY=9.N75@$$ 44(:'54LEU2\ZJRE*80#;C2GE2;\XN/O^U). >8JZ
MT(FO:W9W73:572-.$2U]# 6+=]*1ONIV7@,_]P,&KES?J#2,5XU*C=&C-^J5
M&M!99?,ULAUUY/@5DB(,EXY@E+BND)"OX52YDU?%.%?;Q:T&J"G:5N#8P'XQ
M1(%,RT.>0IKBUO%^*;M]Z8*A]1;5.!1DTZ#%A9G66DX594A+TL7IX2X,;886
ME_%@7%[Z<NE%77+AKT4"NK:(XWUV90Y$DU\"L^,\X/LX0H467Y9XD,661)+>
M (N06/6J12'\="+3'1R/-/7B#'N!!H">2!@J-Y.'>M",I1:-^)A*!X>O9<NY
MU&'R<3EBFC/5[-\XE@H@1URX!&;L:!9BG:Y72N.E*V:8I(07&^9$]?/115ZJ
M_U;U2]X7+923+*QM24 ,&K3@UF[JJ'&+\VVF$12$;C9VBW>H?X="QB(Z2/>+
MOPO(A5M"IVSRD#N5YFB*E!H!KR6M:SCHE.J%Y"-<)&IN8(_'[-6RL*]$:6Y\
MW]3A;0C:3ZB OV0H<W,5RER%,G\K# ?*#S:]$&0[0V024DXNK5B8Y<P\!,?*
M@1ACF3P"_&+9ALI_0P\T<P"$J0(K$R2(J)%*L2)LQHVNYDAD09%\2IH+IYUF
M+U#.'"<8[DL/#BK<.2$,[L&HE_'D=+Q)H*I1,&WJ!VY_2JV/QM@4I\RL,1U;
M(]^9]'<],+BF^\9+N>A:MI8R;9=K):-I )!BCV[7N:5<>_JV9'CF?_ZGWM@$
MVRL;'7JUF50)K NO9=9-)T)U5!<B6N&0+,5PF-"3D/%/8 G5BN[7R10;D7M1
M^Z!B=/12$^7D*_07I?U#V=J0%&2:VC3V1I?!2&676^C<"H<CA2JFMGMCBP_8
M&D;_:3IM]6XE5)"7+%10BF72"D _*2]%06M5,726W; NRG2J)\IG*C8T3U(M
MXTNC(A5"#B?RH[ @6@6RY.AQ580/@C?4LS;2/1*6U^^ KX)PJ<.F627T0)9S
MQ)^$^^8D.V?925$$D3;RYS/E8$014^PY_B1T; V:E]U8/UOTG7)C2>2V;S&:
M6Q&C_&P=['>[!G"7D=\'$34$PW5+3H:59!4M9\]^,U,,*!UQ" C!  W"S*[^
ME4XO)!--F.=>3.6!/]W<S14\ OWP8BN/S[8S/BRX+(=TV=8$6 -</<*]X$.O
MU=BA;+Q:WZBL_?4Z=_4+RXAX[<+G(JU[[=5L#D@.(*N^:0_(NK%5,S8&?\,
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M:>XX3UJG1/6TH*=NMOV:E5/._5S?Z)1DSO+II%)!2=H2 : "4<"UP]/@OZT
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M= NF%XKIT::O53:*R.&A!%G*4N1FYGU$D:W->13YL$G6UBIK/S'+*F8'/GA
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M4OQ@$<1Z&X:(4#Q.PQ1,[CXW!@V:8!GXC$@3T2S$/6<Y.1W-R>I["9.R'6&
M?-/FR\^8KA397BVHXE9 MD33:D=PD6+L"$+PNZ3V/4M*SK@?>0 #[:V60,\6
M"L;]<PBL61]VLOH)M8QQ+CHSI?T%[B@OWYIL'V:K\M*Z;T/80]#*^&-4?JZD
MJ5EEG\P5@WMOZ:&JD7F)8;L+:+)3":%&=K;-I/0EM1=B<4=55P\&@QJ\A=#0
M+#2QO(%>V0;@.XNY//L8%'X0+=CII2,V!B/C-$>)\K\[<IW;"8&-.V*)"[+9
M>1NH%0;#4[^HJ$R3>E0>C(6&@Z^DW9FIR?K![* 7B2P_??+OT5=J4SCI6!>6
MB'E-KJ S56A#$?_AY4_D:NZ4PK=2WC%R:H.KIV;[3KT(7>\(0RX2MS7'TB*?
MZW/]RW;3W\R1X.!Z1\:(+BHA0J@K]=']<%$!B((?\;E1!L@S%!)&*0,DI_^2
M@;P@O0'4;O%.'P5F8_\:?H6X4?00-!UJ!VOVEDJ$I1'6G[E'_\XM2(FTZ]/,
M\4_F$;#@TS/"01)_[E"&3)_^"S6E^(?QR-?H-<G(42NI;_7/=\D*OT%XE-]*
MH4BQ2LDBV;(EH_8WS$5BM=1?L+&(WR0FY<,87)3/1//P&5N'7:/C4L)@B9"&
MP.,@ILG&OSSD\R<GGWWV[W:!!F%*8V69YU,&;^=W21=-?X:]\6<VOR_\,EUI
M^9IH</AHMFGKLN_<!S:#IR&?\4$*!%]/,(S;,HSWSBS[;"#YY-FR$7=A(YZ=
M//MBV8@[L!'+B;@C&_'LY/FR#W=@'Y8#<5<VXM')X\^7G;@+.[$<B?>Z$4CE
MI\45O\M]N+U9/[O!K#^HR/WN*3^[+(-RC4 IQQ_&_PVA4IV_=UQI4?Z??WOR
M;^^Z%L]//G]\IQ>#.7J^YUSK-\BUCM;A7UT./M E^-$7X+]<)@R+V/CW._M/
M8_<7??_Q=_KRE/F5BS#:^QNNRGN[!20NJ@7)A[<K\+:N-&%_AP]+6@5ROQ3%
M1Q:?WW5YW&.1&5'X+E)S7:E9+IV/O_]WW+CD(/P]5@]48'A?=,&=EX7G]UT4
M'BZB\#Y]SD48/B%AF+ &QC6_VZUSN]VP/>NCFPDO;!D7E>API=;4YMYT3A_7
M,DQFJ;OVX29U5<[]]LW=F4+:U1.O@)Y=8N<MV_SNB>2[M,N?/7RZ[/([3NJ#
M!X;?XSX_??KX7V.?[X'3_9INT:R32_2!JR8OTONW]!^L%.TN':0G3RY3F/]2
MFW9_+KG//UOV[-Y=68\??5J[EL!'W)&"_P_>33:$'J#&<U>=>F<2#2QG+C]%
M-PHU\V1;[L<A\ 1NJ:+&K@!S:RB)0Q/0U/<9YU;0PAGJH$4#1D)1BB9 AOA.
M^MZE5VBV%23I>LG0>-1I4PBZ2/Q+I0NJ7:_.Z@OG)76-"0#?.R=N1#0$'9JZ
MDRY_#"/R:.7^*ZWV[;26\;K8>]&65IY1U\^'[)B_;@.GXCG#QOF@C8M?,K5H
MV$I ZJ.7$_M=$)9"M4.SG2)BSS$),CP),<P0K@?1!( %%##_:]"LE4<A+A6>
M&P%$X38U)3(UU*&!D9 !LYO"#SJCMBR"[P;C#$3*X"-0\QHU)*4L@P28+=2,
M:X8KH18P$B3P]!7HK<P@\O2FO,DN_&O00R4,0.B$RW+BR[& VOX+;[R"K"PT
M,RW+6IC!QTOTLVD$K<$S1_U:TBP65\6RZA08V(& I!LF3A7H;[]N)1WJM\6>
MP1B91T%D1UB@+@24_]P9]IUD]?V,J877=+71UF,W^8.,+I-PRT;ZH"%?D "2
MAXF<-OZPAE$]V#@@6JWHP#?]/LA-QOUK=:NT#D$&VR%_$*N4ENF29++26!EA
M.6CGO!@2O@ZF'I26>3&]J/1KUR7BGSQ3EN)5W\3?<YLDJ2)IUU-M%YD6+.F(
M&2X^%$;"<_QPC9._ T#B\^S1X^SY]O&O6?[\BU^?YH\?_?I\^VC[:_8\?_;D
MLX=/MINGCZ73/;;'/Z4._*8N6R\!/Q+-04[:^]=GGW_V^/'GGT)?_-.3U4KG
M"#&/L[P;3>_?)*V<L4O_HX_Z%]O$[H4R[3F-W;7$5@%VC)V@45&[^3210QYG
MM[6S.X39":8+GHXV8-L=#5A1[2[U&O9_]UGCS[=7:*^](FL S_-MW8B\/'KX
MX']+<VL<.76@QEE%M*NV/Q!.4*M@I@$@G3&KB99$YN$7-6, &MO&3+,CQ*S=
MZINWP/KS^NL5>I@;)B''WR)YO?SMQ&[X[))<\C=>;6$_\#=!77DC^T@0;[T2
MUA8$*[CG\5NRA(W3_1!J0P 2'$!A0:CQ=GD"(,.+K9\V&%?HZKW>)JSI-J2>
M]"8G'A1A4Z%_MOV>;J1_0L!R>;O THGJ[8J][G^[(MBS8E?$OO:O"#X-D/:D
M%Q]]\:5_45]*#SE-N[WV"F=E6U]G.3%YNZ9^<MEVV^][1EYC*-S]OB<,VRZ:
M8--RHTAK-Y0;<"D#,,)?ZF#,J<EXJR^P7B5N.0@S+?QIUN!=8?/C,;P=N_DO
MVB_>)8=Q_:ZGAOTIOYDP/G/LR_H]:X[U=176A6N,)F2K#P@:48 <"U#&\!DW
M/)+VZ(7S^?X/E'3LQP.E%"; "13W+!UWF2DCMZ#@'4",)-@%Y%10RAYGH.TW
MWL,H +U!9IA?';;!83:^UX.1D R,$38NSARO*_]<;,.:DA+8.,"O L/5Y?>3
MM/+S!6UK0=OZ!$@KKQUW.7.@#ON.O$()97G]],W0.%5[^M8,Z%>SM_X[WGMK
M[RC[L2&0*."WI)ZO>5$)BCY<8F U\>>8\SYZN*P.:90 DCD HZIC[$T$[2A(
MY)JFYJ'23[LFZW/"I=%'ML?6NVUK@G#TMP7%+L^\:4+,?-'"B@X"75S;+"!/
M^<TKC^;R7'/T4'HNU\.[E'&-[7N#*1AB-:WB[JSVKF.?0-P4HIH<?'VU[RF0
MX'8EK[ #%U=X6:-\EH*D1?=<UQ"\51M9OS9>ZG:%Q)9T/_#<30RWN7REITB"
MG$6C1(;?]@V]:TU805G?ACALH=)>&FDOF. SG4:+Y4^=MC 4N]RZLL.%)3M
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M_5*B$_[8D\_Y;P/ _$M'/1SE %T?5IX?WR7X^L]&F/K__;\]__R+YU\.QS$
MWK?F:NHA? SC]2+CQA2N9FUC8_D(P'\1E7]Q4:&"X]9<5U[AN([* 0[.&RRD
ME1;I6:1G3GKZBF*0@%3VQJH-JRY2LTC-G-2D#<^V_2>4'EUN*,GGQ1+U\Q1L
M,938]6TL3)PL$ I)3K>>J/Y?!'<1W#G!C54^5 A),M>ZXI]>W2U"LPC-G- @
M22]M^4(Z8%H)ZQ&.Q2)+BRS-R9)$TI#+C2V%B\0L$C.O?7[K*Q$3<O/ND*@L
MDG*G)&7;H!, N;@62.;46#PO+].IXT<R-TZ/WF+ESZAO.*VN8;>BZO>NJ062
MA5B"LG:0WDIKV Z'\KA>;28#XK'$S+^Y;Z\7Y_Y]:!)4)2DL?<DX(W;)$@!>
MSK(?CDC08A@L(C(G(HD;L@C*(BAS@O*//D/SDX#O+Z*RB,J<J'B#Q96+.EED
MY!(90=U0A];D14P6,;DDU+ZOR:];A&01DME$(@$C%YO^"CFY9\T(3QXNS0A+
M,\*M-B,LFO1?7).ZM]3!O]RUBX3,24AD&#0P7J$359L!0G\%]9^" 4$IJU>&
M^7)0<;/DI1;!NR3G'3K[;8]S@@.C8KBO<W1[!YC]:30G:G;14 478&3%_JZG
MNK0Y^/VCIZ^OAD^_+<STP+I[6;M:@*!*>L:O-]WC.O+<!D@4,UL!(6'2W.RH
MC!K:%BV@"=;O6)M._AG8.G2--(W?)J L2%-/P.D&\>D;-Y;>,?"XZ:0:\YP@
M.VB0G@-C11A="GLHHV,:D=M /+ZE!LM14^DE,,^*V:!((OX,&>;=V -FVHC6
M2C92NM.BE=8B(#",F'KX#^:!A[HLML=AH]@5&&J1D-?/J*@9J*(QF.Y%H^#M
MHV0V=3&V@2 B78!;0C6X%*0L8GI'-3\)]S6$J)_83QSL*^C2%.. R=;6OT.8
M;PE+['TND!?XI3Y@L:FT C^! M8^XO44Z*'?"=(L0Y!#( BNIU3+XD@NLG>Y
M[*7=&0^T@LF/Q)N%1.UVR(Y<W.3_ 9'A=GI+@&%@[P@OX+1Q;)8NTK=(WWP8
MPZ+X*CPOP>MZ&R%",XRNTRDEYZVP.R1IBZ#=*4&#5WI1M,0GN6=J),9'W1]<
M5["+0&"UA.G=!FRSX(A=0_[N>,#B"KJ>&:<,1OQU7='W8LA_#."1KP9@YQ1#
M\5,\<@LMU22O =SR@+!E^KTRH.8% >82. 2,LA:>(M%)$<Q^P,%/J4-[(K%T
M+;&O 41\;0(#GP(MQ]_ M3!$CQ\OZ/46$+C"(,#;. 9D]\)[' ;=FN*T1AGY
M3%SL9/6C =9G)M:BL_#[P-[.AB2R@GRJS"T%KB1&?]VA-%^^+@SB DI"@3(.
M#PCD#_,$2) !3PYQ)U=MZY[RSW1VO*K8B^JQX//9QC^=0Q>-.Q N\@3?Q43C
M&N/!#J9DL)H0:TFE^F3U2K!-B"^#]&?9;[U@"0C5&O"3BG6(3X[!9@(>SQ2,
MU1I;ISC,,K1U,B'#*<$KYR?RRA+\"J'R/$I:$;3<OLASSM0>SOR?&?_[Y<N7
MI)\ZP8XOJ:5@Q-;,G&P9<-2(ZX- KK.2'Y#<;#.\FB#B"/@TCJ([*\LQ]J&/
MX5\+P@^=AO@*$%PFZKF^!CQM3#2MKZ1<$-*(AMT$7LSXN4#2,@Z*FD^1;"IU
M  =';Y=Q0;G (VZX]\^KK5,(/=E:0TLYG+\L,DXS@IDB1T371P1 YK@LD:#%
M3/7#:<OZ0A4PW95$\KAJ #Y&6HSQU>E,-SU#!:]Q/=(EFC7E!"UQ8&]I@-#-
M2("1ACH!"%P<]44PY\-$G) , (=Y#3HCSM MDK-(SCPH4?!XA&IDD9E%9J[J
M7-F^(243X,W)X=44Z_4!.NY;I?&CI=)XJ31>*HT737NK/1LA4T<>ZC2=XZ;F
M(-.Y8U;W$$SJ:C\%X1H!LM*A<5VT$8D2![&UZX6LV*N6L((6I]4(.2VH3(M(
MOY.K$FH4U7D^U =%H&;7F> RX<I4XQ"P(M5OF"#6?YC9YS9-G>42DB7CMNJX
MS Q4PBT9*X%,CP19#%\*6>+X>&%Q=B2+."_B/ \994I_]G55=!3X5C[(+'?_
MZ)G"*0\0=HR($Y@@%NE:I.MJZ4*PGO*]?JQPMP@<D;)=&?$0GE-Y^"G3UG,&
MS?_<]1*J%WZ.39TU.=(>#(6?!L6#N;!TF"PB>0WG/UZXJUW/)68D64AMNRF2
M\CM>@6%)7VQNZ?*\$JI4QF3LDYE/,2\X-3M!'7>=:H[?666P&K(_"A*TD&_P
MT&;X-LC8:ON64,LGIFT9=(C3I.C(6>$\JY3K4(J#6B<1F0[&'5V3DL+C!Q%
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M\!VC5[>?J2/4WN3Z_H:P#SEX=0TSU&IC4Z$?_S:I+N>J6Z@(#:\<W%6#FZQ
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M%V!4(AY>%A])"PSDC[GEU7<<$C2D;TI7'EM)T86-X$!W*_#B IIML$ME*V6
M].3^@##,16V#'T\>/MC[93N3#[93L 1$*Q* ^@- P8L(U,_(H9N20+64HHS7
MC84*,^T JQFV_.#\ZSMA[]K2&;UPAC=H3X,/L229#)WQ@COZ41U&1IDB0IE#
MRY5!#" 6H/;C^V+AS\69X^8T]$H'&KGMMA?<-'#:U!= 5"%@W .AI;5=FV#^
M65 (B](_5?-VQ:Q,X&E.,N_7&;R!0GH%D$FJ,COE:&1 Q<@ (%^TC-Y()\T+
M?VW@K@#-$2)T$\D9^F:)*J]3+K[\L:F_\D?QF[>K]MAV;B](:N2,3B"DG_@K
MT>!'AA$PCEYX,62RJJL')N/$JE5A6A. +@QS](A[M;WO<3?'Z;4#09!Y.ZR'
MH28EL#?=3*/JIO8UW 1D(Y@1A%Y3QE*0EE&2IHJ@DJ%P>2#%UE6MFP#;'PP_
M8./(R%QN#KMI'+6RP+B!D(:<XM-8%KD.&+9KT@T-J"T4[*::W35_TX\KKYLJ
M%E"^LG-B9#D&8'P#8$7N9TSY_B:*2,V-U5IVEJAG[=I)[(>ML*Z0I<N=[0$V
M8(8)AF'8U&LR&PAT%V^6UGSK?(4JC;)OI7M;2$" DQG0XO"J2B^@%>*7L3]^
MMG-R:@0O=T+8:7&5N9@:/<?,"Q-&M0'-@R7S<JD9$0A6WCBZT5E_))*;S!(7
MTT71VKNUDJ9XPGF,M[9>/J,G3F+>!K22C.!V#CT17VSJ?NJQ#"LI ",,#1OF
MULZ*/[+Q)>"U!2C8HCK; 2:H 0R^19_8N,KMBF@ F!5$_9/D@:RP*>;H;M74
M1[_U#,L\3@]IW<H^XE-^VC!H+,09,$L5E.&FAW&=LJ+ L2*,!UZ>4I$6WR_F
MY"7^#Y2<E[! LF=N++F>YJ>8H?Y^5Y=%K8"E0046$5@'&G/4J0VRK-:Y-WA'
M36ZFMK,(&BKIG#+B("<(IC+&8IL:0%$]#=2S'1LH$@?/I%X3J1&TG[6M*=KV
M;2UY-.?0S;8V<DKC VIBU-OKT-0"XZBS"'5#<'M3?QAI8OF:&J\%LPD5'7,D
M@5S4_VU?,"Z6+7L\U)3,*B9-@/7JZ+J@&X^%*_.IT0&.<:I+&:"7-"6OM]NT
MZWUI'ECB;Q.QWS%C5,%7W#8[:/Z5&=+XDUIA$0 =_M%G@@W,7 8VAKRMVXY=
M8SBG2Q9BD<2;2*+%7H)049OC,63$N.1;,7Y)))E>$1=/!/[G/-DB>XOLS7='
M1XBR?>0[3MTM032%4S)M4GHWHZV)<W&1M476+LOY!^MQ[TW1.N>>\IX PHW&
M2RITKVU ?NFUWQV2OD7X[I3PS5VRA('';*PK)D,B^5.(0400*'J(0B@"'>#8
M01MYV+?^S]F6(@RM7U?1E0*DYRA345 X)R+G;_09PK(4PT(!0GGOO",T@]@M
MM06_,R-\W^IC/UOJ8Y?ZV$\*5W:0D%2S:\!U[,:,!!.VUZ<:ZZ240>S\<H/8
M/L!@T9"0;0-"%,, O%5X,<[ T!J.H*.\_.S;E:M '^ :=J\X0:@),@U%4G*X
MT,3,O5GHR]=5NYI&_4PQQFB6GO%T_&?\)>=FNO8"F^$ECP83DC1=2:[/-%QQ
M9F%7-'O;*<A$\=0^Z+=&(643YI<A,OO$BT,W(2*^XSW6[6P'N^U'YP;3]5_^
M1Y\A1:5)NB!.1,UGH,EL^0@"QF?%01!*E:*3H&0ZH7V\0":'<U2A*J%P"1_E
M"(AYN%*R#J&P&RMGETO0?(BU@$!"1VNU3EF&0JXG606_T_6*@95M&BTT<)YE
M5)/2DEV?]7G1C;KI+)_G+(I^(20*?N2HL#$5,7@J/?0Z;7E7<G@H88Q98%LB
M,B=70[622&5@A!VNC60@P\]*'*0B.D3O$4H">UVT9GR?:%7<+T _%YPB6T!"
MZTK##!B20DDXSNZL+T=5FKM/-87HWGK+P+]0F'.-P'+1IF1_E835Y"+6DY"7
MLYA*XY%?.<:5 $<P^^^97U#[L;KM;IG;K*H'C&9<H%>AT*P,Y&:[QKE_$I;W
MD9%YW"$DA87[9G!+T_Y"94_+PB3M"KV(R5(LN"T-0T6<#IEA-$6Z;GH/YLLZ
M,&U7G69$#UR'C+H^[[+-PX0$/CUF<4/J+[UW_;?^$YM]*/U=)'5G]@-UDG;@
M"L&0=O"OB.R_AELWA%'29Q5MP-13K9.V/T_K5]3'1(=UO=KW;:<-& /SRS57
M3<DF[OK(3"IJDZGE@Q0,'KU'_66RK@HBZ@80H@;[SR:,:<[G==D+<Z=(I][X
MH=66KF!RTQ.NR_2$^WO4Y:'NA$5%R':\V>#'D"Z^D,&F&Z(W?P#X;K6<T]!4
M\_6H@Y]X.JUD2/=K<AK]N78^4@29S"CQ1\*$+%_-]&2&+,$(_?6E:YFGB#E1
M(]62K++*VO78B)0J%S8:%]^V;X23B[TFMG+LYV'3%1!MI:U5/MP)6VH<@^%J
MTF]0&+03"Q:W >I/&@>G+5\+>2=?#!,,RRES:ZQ=40\G',\A-.4D)L'<H;RJ
M2&KX<&QVRBL_=;,,HE;NT% HJV]3Q3+$)/Q(9L37\5;&Z@WS'>.L1LLE7X:F
M4G,;MJ@T</@QD\0M<-G>UGVNG+89\8MZ-;[KJ:J#2F%.&_!)S%:#PL79^UO'
M->:WAOHP%,D02  =,._*$3_FW!,)JS;+W;[8#GBPF>N3D2I/O<FA;Y<;M_=V
M]%;85(MS4OTA[9!TKG)!RR2_ O92W(# \ O..JDG:;*#OC7^Q'5[MBIE<QQ2
M_BHI<="J]8$JF"A_JQIJ0P/F@@/4WA5<H@?*ZL'3DLHH8;H<LTZ"ZY0,-%"K
MKKDF-0E#4\N;$+*-KD6E:XM[RH6P0VZ>"NP31)SJ79E3@5PT,,!SE3MT/X#J
M6^@"^8Z2D\7%;@@<4*&6%+_JK ?C_"FRV+;.**-(C!DY_#3J[T\I:7SN6["C
M2M9B  \LNY3$ZO*5%S'RU_TXG M\*WSCP1]_].7J*]4=MW6BOZ_;4%27$$]+
M&6A6"D-45Y]R=9B&$0I;)@]F(REE78NZ<GI^P^GB N(I1G- 4>MUK0&?8$>;
M<K;RR+SOKIE$S\6N$.MM+4799-6WMG?,/"!Q29:RKR4/Z(=C(,^A"Y:"A456
MYF3%X-RG>/:* QZ*;!=ZG$6HWB\0YW5<O$7,%C%[-^X<OOH6@(I%@N8EJ,SZ
M:GL&CA>CJ4 3PQ%]"-&_6"72YTLETE*)]$E5(@F_4H+HAG!+$OJ2)&C'L7ZD
M0Z@E##@,!#E:"J\43X!=^]_JHNI6Q [<>P=^&$+9Q1+*I'ON9/4BIN;&@0ON
M-MM3:I:2/)50#;I<@]-IE!5IHT%C(_=.<*Q,<W5I'NA>1G5OW$7J#[$VS<\1
M/$L&PP;\)U=ST.D('B0-EHZ?'3IT*W<*.2^QI219=V0M+UFZM*<4>=Z+*K2*
MED<#*S"UJE[&D'JF.:/S- W_@F_L@<4RD/CD#!EP"/'&9M005?,.1>\>;"D8
MEM;.HQ?VC>-'=P!OD(R0V<8WWJ9Y0+V<"'$' CA*_\GX!FC&PZ'1!J=QN:*B
MP;2<>17PXT%M$H+VE!:FRB@_)2K1JF*^<BA;1OU$J?H 0HO8-1+IO93"/3@0
MV[R?NR61.Q0'YTTC1X%Z!"F16>1< B7@0V%5G/P4J$)9SA.O7]G=K@?I_NJE
MM+O=OX(D5. 9O'%UP6 MTB%2'@4!@5.7F_NQ)I=<QV'&8'XS]UNR JRAJ<S"
MXG<75/T:"-S\3RC $*(%_TQ:E'6<:E8.YLJH+90<>'O0$J1!O-Z^KG';IB_X
M97Q6C3J8L!&X/A3/;BU35UQZD+^[C.L1#!X<W^V:>?'&E&LZ,Z\PY7#MV[,=
M#AGC0/G9*N8H:Q8%SQH\+\J>")U-ZH\0QA*CPVLPAMO(B[;I#]U@FEH3,BGH
M]%%Y8<C0 3@F-H7VHD(34D$JA0[X&0H.,E2*,VIO.L7%AZ@\ZC4D&O1NW=0W
MURY;+F\V6>:YS']8=)28: J<-IPK /D\0#+;MO9SI&,JZ3-4GEB+&#<UB]!]
M-'N"P!XHVU>%F2)TZ>]"2@<FIDQ8/%UP5"R]41[- &C#)?OT(R[&JW<EG)[A
M1DYN'[+YV#^IT^DKJ?T.*DT.*2_R:"/3C0^-!;%&+2_HV/6EK4BT7Y'B)K.3
MS*0@X\\C,^_@6^$#AGX7@[+5*FO6AE:?1AT6JL"]XT:V'S6[48"9;<F@KKPL
M^36II"PIVHEES3RRP&?QNU0?G9A"_N*I]Z@^%$@?'6IXIEQ 6=% T5";')4$
M>,-([K'4790B+$KEQN9/1MWR5M9I48DBTNMP4(5F]"OJL/G\P +M=U39H'60
MNJS\X@=PM*/OV!#P4--IG1173,B490(6@BO,FFKQJ],"L$EMZ[HQXF!BL(1B
MFN  7RGTH4[=GJB;]Z.LN/)N0KV<K+[E@@BJ#0EG5\M@O+3#/=@ #:IH6V\
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MY('EV5&:Z2Y9V@#@Z$_;>;&5B,OO/.^\&$A1FW#%1#M+O##6)M01VM*\.GI
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M:8HE4!'*&CL:18= #(19,6L:6D8HO[7&7!G_%D#R(D!1;FI)\H6,2PL<W6[
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M3$#+;/N&6U6I# G-A\TQ7KJ,.H]B,J:"&,BP+:@^]-W5B!CJ7FN C=O*8$D
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M$8S6R)ALZK#5+D3T Z2C:E\*N"-/H5UE"EWG;8,ZHJI,9AVF]>\235H$>$Z
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MH-3^4%D[!08)!\BB;*^9>!BQ/<)KU Y<-L5CY5SN=E0;I5%9D_ZP_N=T1S
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ML%XYOVKUGC@?2;S(G*1=HTR&&I=B*OS$Z-,[F<):D'H[T K\QD!18B:TKBH
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M?2GO ;HNG:+PPA%>*[\E-@MA /1^\'M+INM*H@G*FS$'Y":)%C-Y2 \S==L
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M0@$;1GK:-6T5YD+X+89K+[<L/$9BT([)6Z65G9VV;['_(GFU(KXB(ZH-;(F
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MH=@DDE6<++.A#VL]WQ.;K*X5 8B+K%99"TSLX\O/JE87<9NDGE,ULTRWQ46
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MF"HGQ$)U48C=)H8S$/AJDHEK,9P2);= /%X#O%5!H9+ B*1&!4'$)BTNT>!
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M7-YRUQ@=[&-C7!C! G*D=<QQ3F2Y4,"6DH&C>$)VBRTE[+NF%E.OQ^9-WK"
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M#_!L/&#'_0"O,?& SLCYHWW1/FEKL]WI]MW6?;;]R!W<;]M;SD.C#=8+L%Z
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M\U\ 7;VAKVZGJ$KONU)F*O.OME##:_U_(P#L9F1<Q5CG"ZJ3E&7F*WD>K%+
MNL -G$[81,39BI_0("$[EN1IWJBT\),1=]^RPTLJSLF[$$&2#U<@@.'/^ $5
M/U-TCG72"KZS==]/NB2P,VU<-=U49=B+37J 0\9*E^W^(*@AZT+3HW\_-1D+
M\E@M0;?E3M4\A8QDF5>Z20$KT''A;:L\QMD/3O J'#O*5*,S"'!47+YFK&/X
M]C1>=]50P94Z5F!CT#7ZGJ:8/XH66X+P0X=]B94-1M4P.1GZ1J)SM.<D(UQ.
M;C46*%<W]E3H0C<_A.D=1R%/TG3T3I *"AS^1ZU+GFZ'FH8VG?!9R;NU4G/S
M9D0#W"R';3R8'^HZV_U:>R.583@G^EVUI\.3ITM3<^G![6H5(I&(WWU98:!T
MK9K&;#N4?8M4'B-$V1B/++CO%QS?B7#Q"A];@V2TK0RJQF%$.>2+S2_5T]?7
MMF:JUNT36I%AXEP+N8S?5N<=3P#<>+19/+>('=$UEA7H&('[7.\/^.F^"E&T
MQXTV;G?I^\.R25U^MVG2I3-I3PJ>]IE&>&2!_ &$50KDI%7QC*THX+P3I?UN
M9:FJ)DE%X4-AZ]Z%+1I>/F9O3]=$,W?*-+J!'CPI?YN-&0+*P7CN6DHPFK 5
M3.ZOG);-R4@40B<+:$A<YXP@]6ULF7/<@"R:^KK,M+T9 H24RVVF"RUA@D$]
MQGCO:PQ)*\2N%KSX_@#RAO$ARC\]'6?EQ(V8>/SUSM46G3::FR _J$%<;/MH
MR0R"@@:A614 IQF#QI8MW9R0758VQTOT*%RCTI(88UJ6$)> Y@%5_FC6["Y[
MCPA9$#^V@@M=-+/@:7WC]2ULD! S"]5#R*IT^P!5TJFXU54M=]OB8:Q=05?4
MR5GE0*LTLQRU1<1F?G0DD?6#- &Y, AP4%QI-=6?Q)YITV7>-E]EQ >6:4+F
MRS;C<I%X1J*'O+"'KVF-*7=VC--X7$G%E&60G=$F'$J0D^-/&7@U(J]IK:BV
MMR&N&H"_,J*F[63VNX@RS3S4SO^*<;;UM$<./<4>XZI\JZH&,RPVA ?3)>.J
ML"TL#71G;4P:H,/^E?N.B]\65V"8L1_NY+.=\#F!2KKE]4"!88\W.HW-=I;U
M9-BV)T9<][4$N3*^T: M.ZM)NDXZ$P7'>+0D5<+I@,Z_.^ 0C-N9?VC^[?Y5
M*L,V-!8"BMQW)6M4)W^.)GEHDVA;VA]WB;LY-^)+[M?P[NDY@=@K_9S]<T?:
M3BXK!TA5U\GUQ5+6#))V<UG,GP;K @:<@,Z\O?TE=$6N\GG@Q\=%<=[E6BT]
M?';'! LR>*>[5G\[6B[%+QB)H1XP@P$IF8'<^4&4WQPWDJ 5RV]6.1B7#B$R
M]-S?+MZ!;LE=^WU2PF\2A4SJO8FP3;8!VO6'&F72NV=T527'!L#.-%A#WAU.
MJ20NAVL^TZ^/]Q437'+!/6S#VU2:3+J)/V;F9N<T0QEITSWLL_L9<T& ?X_2
M(WZKT4&%'W#-W9H,@,3/W+^FZ6>U+4M9,'5YRTAUSQ@@"VYOZIX3\#BKR3"+
M/C^7Y!EYAMJO3 $YKI:\OQ;YU)E3(6Y?[GRLB5N@Z:2;Z9 Q&]AB7-_44!+^
MFF/EAMNX%IXJ2$9V@Y3QR?FA=&;6VLLR1H.;AGQX4(:B)U8HMCEW7*Q&J>7U
M;U@XTG<(S?:ZFFMW<L2)XAG;(GRGS<]VXSZEA@=SZ_HQ521BFM4>M:$]/3W/
M&!@\G^SGP)'IG[0%"2,W6UZF0"AD4RS!C/:>ZC'Y&3B XW,-!E!%]#VV:/WP
MC.QLD"Z*28<7NF*6.<BO/#PJ]U:#_Z"<=DOB^_UA4]1N"I?%N]&8F3CQ(CVO
M2U1E=U<G)WO6B#<_!2QZ+,F1)^7FHS7JF,R8.MB!Z@:K8DPHY@[W?+7>4V_
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MV,X W$1'22*#62%^T9PSM@639)@)/['XYI/#ST0,S?&^K2AH2$9#*&A7D^K
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MD-?-<$TQH+GBYRP7%6(8,6"7S'4"Q- G VQJZ>'ME9Y9Z&0Z"IS&Y?,XKE*
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MOS6(CM06#L=_J;; +0LZ5;E+.4C^ZA=G]ZN,!A7FZ9!O>Q#[I?MS(E8!GH6
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MY,4T];9:N#O>X9<^Q"!#IJG\.:PSZWWI3'6@WB:_F\SVH;CF'[6!DRD&8F;
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M,0+?Q(&!E=7Q$JAAU?FQC#IFD!8EZ44[C@$^X8DG<F5X:0;YH9"-3DT/YOE
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M$XKGFH+Y&296H>].X/:0H8ZUCL7V=/8RN6[<*L'FT[N*BAKR*/10SD-=[R9
MSX)F:@F^"BPM JP]@L KN+PQ#$#[!<'O;( ^<>7E=S^XS8^^5J4M+2(6=VZ
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M+X8D;A#_1>D6'K*F(^%<:$]_\F#@;EZ6 KW3LNKXT@G#$MWEX_Y*:R,H*U,
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MJ1[?2RR+RS./[:H2X8T-4)'X_]5@=/YI%8#^@^XH0NIQ95,0VULU(S3)!OS
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M. V"+4<VI04_CKWF  \3D*F4>^9WC^-2_*$*US?2Z3/;XK;F69N"'&6QH?
MI\6CW&]:7),0A1^I$=L]*$NW]S?ZG]+1%P_A)=DO9G*]M_4>:ALR9O;Q2[R^
M\O>21*4R*_U$1.QPH>% B)\9+CBJZR=6,D>*X1F3;@$B>\86B[^13!=WZ+5R
MK%BT:*)2F@T/X</7?-1?=&$C'0'S6RUT,R_]C7LIO".Q:<8.BXURK\V5QZP"
M4"^H'J2S0%^V7MQHS +N# %HA7\RCB&RNM$Z?3LZ5!JR/8*DZHI!7S.Q?XA1
M6UY5Q<1Q8MY4UQR#J%4@V8(S*%-]3/YX/[T,V9W2W9<,+7=TRB*./Z0_ ?/U
M-Z02?JO75?C.3!'"X(\D#G,S+)^3=K?OQX<SRZA)NXU;&Q1AQ(N7Q7# '_K3
M&K^!A!I-]&)[%C)S=M.FG)5U5P&EVB]D>BLT+QNU8]!-0K[L4[,GSXI/#-11
M!NLN13Y+@KY!A^T(E[IJXO;<;-#:!:5*>//0@QML>"' 1C!/%&:M62P"LJ*C
MKYH&8P==WM%L.(2CTKT(60M($]B-3X,3C]X(&;?;1SI]T%_G+&[+= J[W/".
MN<B,656/AEA?3CR)#5L]A>;$4RT%A=W7T% +W.$?Y5C!FJST0IF*N#^L@!:F
M!X4_TG]>)PU=@4+D2G7&]O::HI?ZOE*%^(B]",ON5OUP81+6:HW1"I IF2L(
ML92^))"]@Q6F>SD^F^@L(WJ.1+'PM_":;PK1 :[61K>'DY.EO:G[&BVN$_T=
M3&65D X_(G:L4<SWT=5RT_$8*7:\<>:#S4%6<GI?XA,J@G[8=R)LZ4-V3BPU
M9H"MG0WHB;)UB*:K=7[IPT0_U6)6=R#4Z>76S0M7T*-H4_-=$8NXQEKS;[4P
M&J)$4L09@,-$D1G@W$1!ADO;^L=$%D6GDZ-<3^ 41]@/\PX%OF5;:C@9Z@EM
MTE_93K4G;?OEGY]0FUS+4KYL]=40L'6'D3OR\)SHID+'9W[SNNB91]L:4AH3
MFXO2(,3*PKIJ-UW^#+886WC2:)#O*C=72\!0R;J]+[?M$"S<$,!P*5D9FP+4
MILJ?P>8]D.EVMU_!0PH@MUH#*,,SV"D?X=ZS:.^ ]+-V[LJT^@G'<S+=J-:"
MQV+\OZ>;S4(!8X-$KK;\M:<>>>CC!=$%K!S6I@P-^<2FLSCAPL'.^:6K*Z#[
ME(6$40*%XVP87EZ"(QW--XJ%F1GGUOHD60,LE,Q,W":%,8> ]AB'N_T"D,L*
MFIJ.V8=UHR*6Z$N]'"T:IKWSW5CY&Q$2Q?1"T-,7EOJ&$#Q[@8%H>WU_5:%T
M4\HS=NC 3'U5<(RCCB=93YF[G5JJ:EWB&1[KN(!2XY7M)=\SA\W4*Q).HT(
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M$PO#5'YSWMI0LD$N+'%9^ZP>-W^Y+Y$ ]<<#>K(?3NH1<X'N[&IZ'GAQ\E^
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MU>;YWDMIRWY3_24\VU]35H[LK%TXWGI2E^HNDC6K.KP2@J/X/LWM/<'^>+G
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MC A$QQ$&^C"\/=/T3_D\^.=$$T:2[8*=5.E 4$MS%H.UH.;@7?VE;,!BY65
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MEU$6N#*+CN8=U:TRA'X#\ Z],D$Y^SL00-G7Z>XQ.^], X$Q@$*&@+W$P!#
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ME[RL_(RMA/$& ;N5OP$?38ZJN=[#(>ZTN6-)F5^2U0Q"_/UF7A:=BN,4^&_
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M=#<ICM8K+N[ZYURZ737OY6[5K,Z^&)ZQ2]X^(%]C[V@4=P0ENET9$^QN7PY
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MTKK@G/A HKS_5-;P_\(>_U[\%U!+ P04    " "5.*Y28GFOK+3A  #L @$
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M1< BI'M,;N,Y^8B"5?@GV\D_T/X%V?\]8*'_KY#]=V#_ ]<B@ @+XV'RL)X
M9 &7S7:<2@*CRCN-N84YWV;T!]UUM:3;<>@#_!_!8W"\51^NYX^[R^M,RIDG
M^!W\XCQ#3>A[:5/:93\P2*'/R>G(<!8XLE="/ST(*2MB_&\0$-\!M^.9&F2U
MXRAP+/\!&15B>&O\G^?E_X) J#^F$V'M_Y@%S-^)#]>5'WCS\X);61\4Z3SP
MEOS*Y1M\4$3VH/R%!.?_>0+\@<3_ =7:S?/_ WW\KQ3@@!LZ=O62T\KNXY )
M?MZ]J5#4'9]U?D$0D)I>5/8N_8N_12*8:,[AI81RDV=-7UKGF#AK>C+*,)U8
MH!+6"JN)9ST=T&M3"2##2LS11%CJ5\_\1#XSG-(EV.*_?@8<N<4">.*[]1@
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MR/.Q1JFYPZ5*6 .](7O4'5+_>+Y_>8.J3U*W,=RU8QQ3 1KH+L7SFV\]YYD
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M=&N6#N1JR'Y>5Y.AD;SB4N""_WP9+U6 U6Z'1&!<ZB3&W_+F["\@^.7^Z5]
MJ,(WES,0U!FB^DA(V371A(AAI8XN0TMVE7NZSE _?>4K*-#'W=[%'CUXX71
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M0@2;MW(.ANYF84DR&X6&TU)\\8KO6T)_#/L.ME!1HTLT<P2NHSD2-+R\]/1
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M>TX?Z]O].7V[SVFS_^;H(3;!6<EA3Q>IJ@'F'UF.15'7,9K?T\K>FHV2^9+
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M^VJ#^?K6^#LI)D8#H7M7'T3:W9$;G26IP_+<:3X9?LO89$RO=_Q5XS"_FZ%
M0Y;GN20W.L?32/Z#H&#"6RO2F]YL=[$.E#S]65:\HFIOF@16\#'#3(43EV<3
MOH58[E]+4NP_NLR+? :H9ZAHC8U9Q CQ(S%^GK[5-F)++SW+3=#[0!]Q3;Z.
M4CX"390QP%GRLU%Z[Y2 'OB5LY_,?&5;]#H_ORFBXT((6&)S76&M-B@4KFAQ
MEGPO67].QH_$%CR/3GVN2W)FM$=1%FOO4MB7K8@.T:I)Q7R-W8'B3SR)L+1U
MH>@%V6,5MKF9@3EI):V7+<.&O_@6/G091-[+O+]#WE698U^>RM98UIZ_$+1E
MLJP==QN,$BF)K9FSP7X''DS?R26,/^)!^+[:\97P>%LD]I3/$#>G2!<SQ>VO
M&BEDYYV0,5!N:/W'R@&U)"^O:P6#44[S5U@60C=9I3),:7RE*@"?B(G89>(^
M1=DZJY"/@V/_89!73=K"YO]T%M]__"!MEZ/?8#S*]T$9L&= ;\!_W" V8B)'
MKP"3U$R9KMD!S#;)@_G6VAY#S=TM;.S+Q\:6Q+'VIFL,]WRG4UK6^CE*%B/%
M?X@>5\!H*Y*B!,J@\92EQOK(HRE;ZV37SZ^CIR?P@_4?O&D:_E"RI#L(C&>9
M"\40)!,PIX58P@$K9H$)-V-Z8>]E3LU8W+^-L#\#JD-Z9V.R0LZ^I]:MDR]&
M+SCT\*AFD/>\!=XSJG)&%503,A=I_9)'DH0K@Z;)J(?Y6CB\OY2BY>"-ZFX?
MOJ6EOYU=WB+"3;-?/$P#:>6<7!398KW=Q(C5M#USATJYV[<9>H\T&=W-/[U<
M_O?3L_VU.(=T772J8BNIDJ==R@@J-VN6!XY4!XIIG,]$3K?3X_>^*5);7W;Q
MP2LLCA3SGA6>](9Y^,$Z<4;)SO2H#?_8[!!*/45'D_995.F'/I8PFE]&#K66
M3_BI/0&+Z>\Y#C-JHRH%O]]*!=G-5@O-U\<T'K]_:L.]>?W7^)V@*ZU3>K)&
M#7YUH]Y;8"OY(B0->FW0R:J\0+PMU,W]#.CZ+(L*Z])*'M671QV$Y11C#U,$
MGQ-X47=\#OX()6]+^7,P[&4J=KG13[_FHW1U4-RL^8(P#EU_6ZBP5)3B*EX7
M:-!;]]JM%2CS\K=SR#P9_:H,3Y#/R+'%J^GWUD_O6&Q1M_+9OSH>U#1!\ HU
M(_PR"ZF.3,%8ZR@>)80W R(L>@5M8^4P=K91AGO>5$QY2D') 2FZE?CX"4W/
M!UH06\H''S]\U_&Q8;,@;OX?"=[B&(>!\9<%!IY&ZI,$7K5B,G.*=7)KX9W(
M]%91S'U=0?*L\[(5!1.*=P_8?BQZPM&+D[E3I/P"6GME)AG6K-'II:\@(C3"
MD45>:PWV[&6R,QP,534)@TVM8(YD3%"<C >5F5D 2!=_MQ0*;)H4[7['5^KT
M\K2/>6@6\8!Y4>JSC&6D?'V5= =6L]8%Y^O]3'DQ%C2SA%\=0$G=2RZ8R^5J
M(/MYPO=+*>S/0J>YQ4<N&=]J<GKDAOBD!:F^P^!]U=VYR37/::WJU@8X] MD
MAAAYP&K4(-1G4P?ZK<G617D<._JJ0.)G:7T"?62F7WMEL?'=16FZ[!^(D6PA
M:@M>OYMW/=-> 5,JBD/;"<."!(5$WRLH[2E:#JMP]^2"-JEG0S3,/@OL(+<A
M.=#:T($"\<R=$+5T>4QF3?(VV_5S]$%MN3H:K93<,(V;5Y9J[UB!VBSEK,H[
MK$\D+>TQ=0^=*%$I?^^MX\6L;*=+%#P\U+!_P/=P-"V224Z2%YNXNL8/MX^4
MINR2ZEG8"(YI'*8]D9!DU?7\[9DSN37)^C;0_CBDML4G@;T+BQ$;?$V_8GRO
ML=Y3U_:5AY(EM@8VY(ZP <>LYJ);O*I4QQ&AB#G^PV/T-HOJFK\T88GAXO7A
M=<@/)BQJ^<[7O<HMH^C?\Q5UB.>5@C1^A^XF#0Q]H)DY/P,[RR,^OS\_>Y18
M">:KI;:SUJ7WCE[\L3<TFJ-7-A7_989=4)"><*Y0<>T&!G,P//_46M]8#Z'W
MT7ZE'T%IPQTG1Y?A/\D!9MMN'$EBL7^R;JE['2] W%7L83KB5EQ]8W)W:PE]
M>L+@R$M:.(HDJ,P%R;<PH20DP)6M<+Z/WQ3+D2?<$ZI"Y( $2_0^9'/!$*3;
MWZ:!:>S*S!6GWY)A-F^MJ*Q)KO 699V;E0\W5M:%1!H IH5")=XQ847RA8;Z
MUMY@_LJ]ET6N5>UF="'SC2^!Z%0NO<1:^QU1$AEVR4QUA+NG7ZI$?=(_??R[
M-<1/Z .F(*OL;R@YKHLP!ITI-C#4^.CX7D6GT[-_7R&>Z;(4)-N',.?#UO;W
M_=YZ!$NW!-V],T8C__.M)/Z$C'I>V?^()TYN6!@7+;GB=WVSL!DVB"R:4KE"
MQSVN(SAA(BVP5YFY&QX,LQ$V6-"^:VU>Z-\D0W$B#N6.(>/2WX#(BE[L2F(^
M S#HZJ%GKQU]W-P=1</MVI7F6_*<B38 F32*-&TA!)X]#)$+;U.]KQ/T:W-T
M =ERFQK+P0E@_!@7,-4X_<GP]5S^A/UQ9JR:@,46OU64[/G'RB9.N)/[-MT&
M2%WWQL*SW)ZCC$/=-J\%<K29Q%V\F7WV)Q,!P'++^F84]H#W# B^^ZL]^7C]
M-/E\!'Y*L;7$*XP,8\TL4I:K.LD="1'+S'?C+>BW8T=/N&MSW_)?EY$.QI])
MDL%7<' PR/@\%,<I5?RDH=)Q!DMB?0!3*^,<ZX<2]NE.CWBQ]-RY[^K66I\C
M,B.^OE'7@!0/IQD3SIBMQ70L^&>LS1QOUL!3O5!;%Z*QM GL9\:P'EJH_DY&
M1P^SGYYF2_7TA0^+CVP29EW"L),VF*/Q<.)>PWV)&H+-(ULC\%(YP^TJU+@
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M(S7LCXR\RV+K-J6\??R@^?)CO'S>=_U4WV*)7%AQK3T_:N@2GHYG&S@:SOW
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M5<H=T[N<:DO+4," *=1#G1J>AI[FX3J&I,A_3Q_BW^MQ/5DTGH @IR-:!N5
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MT5UN FF;O$-R"P/UKHE:3CBN">K*V!<,RQDL:' U\;Q7:S-EJ#R$3M=Y7"^
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M+$$=EQ%W3XML]OKC+K.GD..+MTV=3ZSLH?(GZ^WK":F_Q30P&<H>2J_GA<"
M_YD5V:]X8@][(C<Q-;M3$;"H\E\ Q ?/MSE3QXB VO]]K?K/BO^G5L2O+DG[
M,8:Y_Z^)AJJO0*##BHWJVEK/D84/@V3* %5"XXP9-3V,"=OL%=TEBY@>P5*Z
M.B8WZ^C)U@B+A239C_*,!=?GWI5W1%A8(ZMN7=:7Z7QG(*3VA1ZI3F)=5%1Y
M_H]@[YL0YNP99H8CCLJZ\B(UUPN_I_6,H+/"X4&W8?I*F\B2ED=TR*0JQ^+M
ME2#;RCV+*I7(&K>2K&WQ_/+P&7"YAR'D)IX0@U;ST*9$(F]JU7 &2PU%OG]?
M'8S49!PCW%:R%JU8T9POO#S-.#'4&8*P?)6O?QUU'(Y(EVH)]>C"/'('@(V"
MEYIZ2"S+/2L6>TQLG2V5=W@K,% &'U$&\!YI%\"JQ7TZG>QJX&SB8HS0@>:$
M=SF-B2-,E B$:.U_W/<4\!LR9D<<F$E9V \UN<.P+R?*L4GJ@ARVL=2()(<W
MWE,'[N. V<1;FCY]KXO:=^'&/K%'66)&]O&>Z4*ZRC>X&&BV ?O-GD.OF;EF
MW78B>9;"HU,R?A2DM/RUZ@'_E67&XD2[O2$Y 3-^7\OO? $H"J]@ M'B%.%+
M_OZ?1P^K<*;S\UYY974,/F*/6J1FD!>=5\Q'Q ?_MS\0<FP#@2 ]N#,1"W.2
M:\*8*B@*TKQYPDJWJMSC;I2ULBI:E.-G.L.71D(_B.PNT7++50!ASRE-,Y%6
MX\#[E=7 #!KR"-XKOMW&RG2MV%,C^#Y7M"C>#!O))L*6MT928'%]WY#N[,J8
MWWZ(L226G1=.B*WH&2V"8UYVX.TITXI#M:K4$ =\8[I *J1!)'-9,N56*1'1
M?[_/*+GB7!,\0C= 2H%L?W?Y: YK">Z+[/-@O@;%']Z'UZ$O9[D]#HF,>T3^
M.E-<N6WH7E5MFB)/P&X!#RY'LBD62?' 7:^9"<6]F?Y#4[97O\PV"W1C.CG*
M;DH7E88J)4P4EE.LD$(83X0&N/*MB,;/2.(@@,5@.&2/M<AQ7XZB(IN*\L/R
MC(T=XT!,/#.77[ '&GRK89=C[*)R\M =Z)YIO('_1WA)0\]&?;[8>44$&0D5
MOI]<]X:ZJ[(H;9Y8Z6'^AC'"[4O?6&_]I1.&F#\JUUN9^3":8*#D5Z>9S8$!
MD)S:6%V(<;7LS#0HO"RR^F])RZ90&WXE=_ 1,KYW7UBTKJB[2T.W]!8<DRCO
M(RO$E\N\+/A1W @[WM:S:$5SD:&W)%, DP*#Q^:*<Z<S;^\$4=>2ZS?'+]S>
M&)@FX@U?#O,RJC.YG_C+*YF> MC=Z&CQ%#$_=I)A>& 7L4R<F]25ILN/$<51
MXNREI_C7/JQW,ACZ<M*4S/*%9Q1:,S'8&#;]3$,(\4>>AM6!I,ALX@=4NV'6
ME>X@9R%84$\A@ &_<XI$RRT2^3Q7>WQL*7/,G$9(Z3I5OOKWXDL,EXH6 Z7Q
MHC'+?+<S^:6FUS;W1/"_J:EE5XB:<;#T*EMH'=-;* JSWJ7Y^:!:2LS5)4Y'
MI+6$5[?AC;X1[3S/0L&G1U X"PSW*5A:?6K +2_?=2/:B@*\HX"]W22'5HQ4
M6K L]+DRY5HGG/L9Q0UR-?#R<,#D2GR3D^^7_=8BVY2"8(\_B*M?S2]ROPN6
M/0(J3'%YMYP3>*_%7V@SV8ELGI%?9"'%J6+-.LV]WKAQ=N<2.0G.W^V1ME '
M(G&A222Y>/1E/Y"9Q0;9 ]DCY?5)2YB*#4^EV):[#6/T/A'R],C$M$IUB.)>
MERC>@KOTPRMM&=9B9(C0/Z_[&UPCDVBOH<^?B1!@JN+6IW-YBU[>5I:OG NW
M(PXBH75GZ6'\B=!F*C7_(FEBL!.!PS,!\>4T+[OC'*-CY.3$XT0RJ?%IY8VR
MMLW.:YJK2P6Z55!/@W(#39@)ZGP18(L1.K4 DSG53%ZJ^<"5/;7N?>KG*=,/
M?$U0$2+O<SNA@HJ% RV3I^F&AL3KBPFT^\'-*&R]HBRD:36!E$<6J\0$')A/
M@5 (?T+Z*BSR*,OW5!^M! 5T\]]+Y74MZ27RHQ\D(;Z]4>]P[]'O?K]-QY+<
MU9IB.#&J:>YL!._H-7\<A.7^_6W/'426(+-)1\&*07#;U;]:8?[&@Y[O1 ]B
M300Y46KX$<O_,P8F#*#P_%.8KRXQ :*)-+@;7@YV]U.UKEAIGL@'*$CH6SRS
M3E8ZT=2[MONM0*5HDXUAD5%9K_[XX,]9+9I46ZT*HM1D1PT3;$/?.F9^(?;5
MR&F6%2:V<!7K=XVA83@N)UX;8\AZMZ"I;G!SU_EEJ66V;H1 HZ*B\FC=S]K=
M0<"7?K< S0/0*2%V0\, W6&C$ F8+EX/9)]MEF/O@Z9W[S5R0S^S:%JBX ]0
MJ(M)*6_2Q__:G(-$-,!6Y]2HZ]7Z]0/;Q?8A4(JF&*)G-_KS:L),75ZB$OY*
MS#V7EHAX4QLCE^G0=SK:^KX\0G<\L"N^7$4E+%9\H)G'!!8]X) SR6J ,7SB
M/EWY:@C''] 52:T.<$E'X]>%8(LTMU=6&HE\'$RUA*D%WU%@-2[VG&+[KW!=
M#661,>(U5+1=6:%J^/3+,YTQ$#*Z!$&BNZ^^#MA7RB"*Q3.%. 4F7T*Q<?:R
MM977EO$*R9TQFT*&;A"Q0%#!,MMDHUWH^OF8(@.M1BP*LQG#KP9/%H#0H4X2
M#K!54J6>86#\/KF[W$.R$*\%.D9((,@62NXJ&WD!X)K/JKFH&U[CZ;<U =VV
M9&"T,PJ%_-M?E30GK>Z_SNF91BHUN-^ SF=%Y!TDA5FDUM7)FP,U\P-YE?)^
M_B#S'XYA8[]5A*O[#QC$_UO%L:6^_2JA@=.*7K)5AO%Y@D-ZW@YFT.3Q .F!
M0,,'S7*$3)>GZ;QC N[\+@:92R.CYP50KO.$]46-9W\M5UFNX:HCHV3B_M@.
M/_!'$;_E<,+Q&47T4Q3,-,>/59*O:JENIHP*O=#\OL>/[A026U4.V1UZJ85:
M!S2YR:'[F,T55W,O@)@7@/#_T]YW!D45+7\.220+DG,4% 8DYR!(!LDPPX H
MB QAR!E!0!TEQR$+.&1DR,P 0U#)("!#DB'G($FBDEQ\;VNK]K];6[55;[?>
MA_?AGCIUN\^O;W77[3KG].G3G^DK1;1/E"9DGJA34M&#%L28&89!X)D!>S21
MMDQ*U[.)M9WJ^]][!N+S<WUL_>BKFNHWM$R-7%_:?>C^[HSQMG&FC9.N&'K/
M)G*00R X$"NJLB^8E6#X;3U^ND,=PBY%IS?)\N!@70YX9@73M%(4!S$+NUZ&
MM%]$*QU ="M2=.-#)'K.'SN!=(B\<Y)B?UJIUE85P4,0M8&FR^9P7TR/4+06
M*&)4V;4F"T<1Q9L,0N 9YUGX=O-,S(Q+/'Z,7KP#D00$E%Q0A)5P^#B5=7 6
M[H/3#Z5Y!,7?>HA!?R=RD@V:Q6BUN9(]31YR:+>*]^;0%E]XEN-U7'D2K6=Y
MU:K:V_3DJ:#_O%WW'\":5\"9P/9>%:H530?>68U3V>JG)_QDGA47-X0JFKM,
MUPF1D>B\V+'*N;OB4,)1-X$E%UI[.7F\(AOYJ@T[C[&<OYKY2D/UO9[NL4V]
M55+FE,\),A]]0[)!FQ/1KDF?W32BEU5";7YM>3ZU_U&\\I\/8</I6<35?A'F
M'!DS])1KCYS['!DN\G<Y]6FCF0HW!]4Z^(R&#)1B?T??-#QP)#N+1X@B\O6=
M7!=Q4G\ ]R AOU<R7@.0]U,)C3[T7R%F1M0"E :^G-39.>,I;T%WR-#-LMXN
MQ$*6QL.)-*:#.;3& XN7IG/*$EN04*,!B#8&NITFD\3</]C?J'1+FV\TZV@:
MHB."2I[#"T33#XV9A,L/'Y>54F/D#!4[C$BV[TK'5E%:\T10=4^QV/3V/-=F
M^<RA:,;4$:!MB /NH,(&5$]$3G Z3![I?+P YK,5K@GLEE#P'\#C]C6NR=4K
M[?3-.:Y6F5-%E/2;7"J9$$<F3KUN< J;V1.2;FW2$@94T&)?RWL%-D42 RB&
ML1:F!O".:H#\O($M_^\@%$;7=D^XW]HPX2[BMA"CA8WB,@31:\!H4P*))7H'
M3YD^,!_?R<7+%&?YFKR7\$_SH J-K5;3,\B_0,W<3B0)=J2?;OU;7>\/( ,(
MO/3_ ^ ;]CB:_JY5!?5E:DNQB&*D"*>OL&LF:^A;5:_F#PUU=MJ?'3Z1C;;8
MCCU-"5(G(R?$I<+%$:I[1+\F\T<T3QG0\GOT8)M9$,B0H0S+F&XRH^\BGFE.
M>!.PK\-_2_EC;BCOR<5P6+,^OL.G#*R75ED0"/KND93J*:&J6:6.3&89_M6F
M.#&R?$Y2DFOIZT1!U[OQ2E5"V!,B=^9CPUW3WJ A<)+MO;1LB\Z2<V<@,E!"
M*M"D<BJ$2C[&& \[DXR\&Z;K6^D52/ \KU"@W>O[ /T#J/J1S^E3BA\^;]4R
MY$#"#T'H9&7E+W!84K6(53Y_?.Z7>F[<7J48WYB90?(06YPU65<=@(66[Q[N
M/CME3I@ZUGGG29,X"]+JH)!.NS%T@N/FZ<K8V"CF>/-*_>7D\I53#F@S'6]@
M;;$Z$2-]X>PD_7&:]Z/2(UP:5?W)T\_2$ CN&(,.8?8%\\0;*C^-5A1:3GJ
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M*<A@=)@;@%V@?A4. !" DWZ]Z"L9+)'L\S@)Z?!Q].$DL^VL[@Y>J"-4%BY
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M6(4#3U%<C7I=_(&0[9+6*J6%2Q<1%;O(!,<:QK4CS_XUQX+^6Y[]<NRW7T,
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M6JLK55)N>QWJ=AGVWVJ-C!(DJ+5ZDWFX+P\;U>5--PHJC.#1TG!&*^\4Q,*
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MY=>^7P,&K$BKZ-9R!U?+T<"VYV.^=*M/+DS<J/"FC09NK? R2<'J=I8^6)Z
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MC15PH1@>S<R:V<;R81.8-DP_-:R"WDRGH2AW'D-FQYA U4>A_ Z&\B#"%+8
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MP-YVY%8&Z@MF]=B@ <.4CI-RD7Q2+EA^C5XT.Q98SWFP?0+G=R7"%O@YFG;
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M G@UTW("F'R_I)W Z($:&4&H,:'E3_JZC..VV\"$W $9]# ,X*/X+ (E>:3
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M[C&=:;VJP+M,A1?X[4QND4F8ZV+RJ<7X)CCL;%%BP@AX [GS"//0:-S#NB&
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M?:]BX^3)O8/S",4?O=J!%CVW5H#7SCZ@_T!#I(&R[,K8A3Y"E %(L0<56=V
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M =JNM$U5$:C +A0!""X>50(P(89B.1TT8?C 0)[E2)82Y2>"_*WO%UJE&P*
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M"'Y'_ <-U]X?H#4![\D?X9;XC>28@B6*L6X=,WG)!MX)[%/'1!P3>9*)5"P
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M5)0B>A.5.I^Z 9GTLXP/L5\>NNCA4T&$,.3 U?*&9GFE$$*IHBM VQKOE,Q
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MUGZF8> 6_X>##*?'%G)NF4QI+1K*,D_R2K25%U+I1)46T/U@$(Z6<%&5LDC
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MQS1<Z]BE9XX<N<P1ESE2 _,=+PG/N]HV$<O \YX&!VO(;JU1V6XM".AMOUQ
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M<&0X,C:*C!6']%W$=OZ([8^&9^]2$<V*SN[WTF@,_PR*8?SF_P-02P,$%
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M@P/E>T[7\[WD 4["$&3<@_""7AB-PH@D&9\#W/F^<T]C:L>1(WT^?6&_[_6
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M$%$Y)*^8X#&6?V5E2KE>/ )[_Q.9005O"^5O#>&SLO2WT;%@I57ETZ]R3]I
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M"RHJGHSMZLG8WA&F_%$*!Q3R*) /L8IFB;Z4^1NY6]T=6$\J39";J,L^9PW
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M2IQ6XK1BHI4XK79")4X?+4YWMN8!U;NLXG3;B%.$5$PB*SQ=+E\O"1KP&!'
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M.D<"]4K3SM1#'-^U[<UUT<.8J>M$PG4>8KM4\W]:QS=T2+%4LV;<(PJ ENP
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MFQ<G]-@\D$RAF]Z8G^D1C5RJX[MDQW?KW1[?;RQG9QU;UM%-LX=[E$]PLN
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M.FYUZ)O&T7I..YJ6_C3%><R5#UZ$[6(<G, 8*A3UMRH6EV7:D8YM37B'DHM
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M_+]CBF;V0!O%7$F.V#$(WMH';R1==F35+ZP*E$B4' >MB4%XCWV9:H]Q8-=
M_4F,RXS[RP!-%>VHAVSFXIX@YWY0AV:8N2$!B>Q2&GA!46= >,L0QN CIKYC
M@].CTG,;DCR<OM(F8I$-=>8ZYP8.(YA"*EPL\[KL%;070$+>PBH%:A%G-V9\
MB;Z,"^:ASVMS\=;8[81&.>^ W8XK95HGFY"01WW;QX^2CGFA9C&5?8XKOZJJ
M.V-UV#$GB4*";O$?5%,=K@;GOEZZ2YP?LCK,J&>!;BA-'1J=?#<SJ_\;=00J
M#**F]2BM7N>TN^*(#1BB:7%&/O#AB,N.=8<N4-TLFF:*>JS4<>JT@)J==D\P
MIK9N7Q"S]8!8BP]$),XXZIO.LSP$2S".MT(KB3WK(6UMU@_?,!+W^T!>72TV
M.J%#T#M@H]>6TJ;-^1AT,.!J0X*%+O>TA=12%EXU0#<%9BVSV5_POI )29?%
MVB0O<XC$"3MEI7)-$!-36I'Q6IC.VF/#>5M5&J:"=!ZIIV\K*%HE8[PB#WM?
MR1BH"DV-9FK68NH7V0C5."J6WE+"WM8P=^MI]9WKKUZ^\4259:5'5N77+SR_
M?KO*KZ_RZQ^72S7-6GJZEF"1SWH1AH;[?GBO.9+^O('(4)]XZ>^!/C.7Q/SN
M=*EQI3S2B$GS/FV/36YI_$1RBWTLI^-H/5JOJ>C]<_0N,3.?KI55Q/\)XD_P
M?F^^ _?W.S!D)G3)>0?.F+SG&JM"5'U-T;:95%QC&CH70THU]KW C'R9N53*
M@TOP+44R*7W$1,7*K"3E[,&WW6%@+]%E&6,-HT^N;K[ (SYWKIOGQZWU.MIN
M[$:^"SU7=^ERP[2;U,A3?P<*=,R#1W\\/I:]T\8932-;W3Y7;^W43FC/\PY.
M[=,*KQ"OU82JE'T8JWXZ+LE2L""M0'!7/H24_(+!WLRKX05%YC#S2%2E":]3
MFC A%ONLTH3-^N8[*4TX44+I2%QY\7>4!F=A7%J3\%8<:F_+R*Y@(5]+-FZ_
M,UC(@CR,!]YH6N*%E5B&F;FV9",%$35 3LO-"[H)]>G<(R\6JCZXJ"'K5+KI
M&;JJT5R^<N%GAJ9CE9SI0+<[)F%$)0;"^_*Y@7;:QUA&Q!-G<GK<%)=1F,!Z
M_1#8>Q<F4!,]6+<0B$1N0TD-BW&91CB04>@%J(3'F- AVD$O9()N 9]^HY'6
M-XN'-Z>6)!53?@)3?E\HF@7FH0JV1 ^'W<?B#*DR-!S_(<;4?:HA4.P;8UCE
MJ:@50Z@R*%:&([POA,QK+V'XH+%#K3-GG3BV58G[@2I%&[\!5!]0;.#G+!=V
M0KV3P0Y"M5<XW?#N%8 K5IN'5.'4UX\P5>'4*IRZ,L0O=T/GL+ZKP,RK:37O
M-[?= DL<Z[O7PP@INCN\(;I$T-<Q]+"BT)>)KMWO@1[C%;TEY&OR O$Y<O[R
MN&L?5O-0&[\@QF=EE3VN%R>1UTWIBWS_#JJ?S!J:3*_(!KVI*[-@J*5:F;AH
M%?59TJC/A./US*A/8PG:E,\CZG,9>3UY)"Z=!_0Q'(EKYX=<6-#G!3IOO.>:
MCGICK]R@V#FLS\$G\;99R[:5+KPXWC*W+H.[]<,EB".WV;_ E?(38)!1FF.:
MD^K. 7)214ZP'ZX",/ 4J%",3Q)K^^OB 22WJG(O%@BK)B#D"@F[B0.R/0^3
MQ6@GE%%E'*'FQQPV+PKV412Z:0ZW2_^J.FL1:@*'5%0/$D[WH,)95\8]T!@P
M)(.N$;RB9B$-!?(>IL7SB%$+ 0WAFVA,Q*&A'*F_HQ[2@^T Z@5!.U&3DSBA
M'E^4=Y6;1&X4&.GB%KT2[!BQAGMN:R$E+BO8%@E[TT]@L3_CL\G5=&P?UC>G
MZ@HO;,E:?8/'C=JW:,Q.]-SDR+Y9/YS:M;6B^DM0?6NJ>E_1? %5=LNQ$:KC
M]QI4;^Q79*].8'4"7RV D3^-E3#\F6S=I=P&2SFH1\9W*H<S>86F<L$7\@I-
M -G<?TY(9[N^OX"I/+)%EG9[V)W*I^ 9FYHQ)U:MH.-/,^,EE<6]).RE4CB6
ME^J5Q<V/O1]XB=P -M&3GT:1I*G ->R ?7L2O3IRRTOURLJN3EVU_)5EO23T
MMZ'1EL2J?6=LX673)\ML%Q7^5%NM,?HA8']YKM!Y.PLU:*="\?TAG2@#U7N:
MN?Y3W/4%)OA\A\.82OYV%E!#;#(1-,ZF6=)%#T<E0:C17+6/6WIUNH9_5#LM
MKXF^G<U&H*U,!$)N?<5M]OYWUC,RR<>TK;>SQ3"5ZK6YU[)NZPF*3&/>=2 S
M/;!SI<LN)K^:9#-^PRFA-XSU(A5ID'B^" ,IUAHJ*9%[S8U?6Y]/!&(QO&"R
MV[Z,.G--Z5] 1O_/S>[9O'QU%F^F*ZM:OT6LWUQJOJ8[199@(5=0^E@I\:8=
MG6[8QZ)(MZQ%4117LJB212N[>)4L6HKUJV31ZLHBTW"ZDD:5-%KMQ:NDT5*L
M7R6-5E8:]<,T$FL[E3"JA-&J+UXEC)9B_2IAM+K"R+L#RVBW$D:5,%KUQ:N$
MT5*L7R6,5E88Q=X/L;97R:)*%JWZXE6R:"G6;Y5ET<YV?6?._2W?E##"GQ04
M8/OB7%]<@ANX4B>B$D>KN'B5.%J*]5LA<?02P)^/3S?GWM17TG5ZB71S;69Z
M8=#W$!;4(V1VZ20(W:K[[-:SDC$:N%5>21CO6( P.'*]>.0[#Y]HCFI8N@1A
MFT8*G[5)B&B@^>I+ZZ&Y)VWTI.]/KWB86_UF 3:U!S2049["C9WQJD/Z[R":
MO'M5V85%K/P/NEL5O %AP#65-DNIR%\17NJNA:*L %-S7V$7C&T^#[=R@ZMF
MR0#]Y/CWSD.LP6H.ZEL[IFI$,8_"FB!FJT7N'&PKOS,/W*J^FU&=:U&D^(*R
M.Y<-*O?M-S?*E<4^G?M6G42> #OUOOJCS:.]03NX"[V>9*1OU>2 NAL4 ;OC
MM#OT$N'IZZT6'^DH#$P7QLD-0J@AK>M&,HYU?UKX]:I]?7'UQT^TKJT7T-%'
MS@.U@72&"" >"S>E[B<W]4Y=G.!1C[A7)'S'XKBO;3=J>@O#M5J;,#8[3=%J
M^_NVT,3?#(O<WZNC-5?&).?45A;.Z1O&YMNKOP:/W)G/X/</WTT+F*SEB^BD
MW?_(7JY/Y&%]ESF'%XLF]LU&+E@$[WMQCG%8/WP$R^"K2GC&WE9][_!-,(T7
M;SP+EN7+6K8ORC,:];V]!3.-]IP":0=;]?TET*JH(0KU'5$MJ&-2+Q)D D+^
MZ$DX+G':&XC8\65<$W>.G\H-&"FV1 $E*@5%A2^^'WAP6=:EQ31I<5&W\)U[
M]@/X/G(4TDJ4OG%4<8\7;&!R^)(]HMX\^SA8P!',LX\Y\H_=!?"^6?R#> ,Q
M@)KPL%_]0PWL#T;WC>7( 25#^@\P%"?A]D6:0?SC;]N'1[$Q/Y"7Z/M&CN=:
M]@CR#7U73:2!CR:5Z67-G970H@-V)8<CZO24NP,?'6>:C&7_.,C./*O;8V3&
M8QE\RD0#>VU(SP*R!3+*<;>SYN]XAX-0QO:PX<'4XBFCDC8-@:QH/M(=W-")
MGG*$;ZCXX>+Y8:5/<4/.G44C%;7GQQ$;]<-7C=+P:PJ>).2#H8\\L-CS%ME
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M*$3FG\;20CLMH[AZL++2U/)$,NQ7'K/Y<>G=K?K^!"R;N:7AOFRCA1=ETZ
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M)./L]]Z#&'.@S&<&:6PV]Q+O!I;W$'11%*2W%28(&X48)(O\&[)4##Y=XGK
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M!?<OMW9%Y\LI*'K=IN1JPJQ3!L!6*/M9J$0!S8-ZGF*V))G$A$G$>*M49:9
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MT<J;<+'>-(Y#A2TPCL-A*L!&"\G:EG5 QF-+T[!9W9)"6^7?WL3Q4##9!3Y
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M*BBM<]\C5B!65^JO$DXRCXC>")-Y*+F::5OY$EN*Z"V8JCE"%:$!OQ26'P/
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M5:&6 KV+7/FHYG<<!( ^24;I[IBI3VC.C0M]-Q\M0'6N=[(HERGFQ #:<F^
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M[WU;S[W1YE][<^_1G?X?4$L#!!0    ( )4XKE*I4ZM&@ 4  % 7   7
M<&QX+3(P,C$P,S,Q>&5X,S)D,2YH=&WM6/MOVS80_E=N#M:F@&5)MI.YLAL@
M<5S40/-8JF#=C[1(641I4:6H..Y?OR,IN7*V8FU7+T51 W[Q<7??=P^>./G%
M\V9Y1O*$47@57[P&*I-JQ7(-B6)$X^B:ZPQB610DAPNF%!<"SA2G2P;PO!<&
MO: W&GG>R01%3>L],H_@R ^'?C_HAQ"&43"(AK_!Z04<WL;39W;U^=4T_O-Z
MYK1>WYZ]GD^AX_G^'X.I[Y_'YVYBV M"B!7)2ZZYS(GP_=EE!SJ9UD7D^^OU
MNK<>]*1:^O&-G^F5&/I"RI+UJ*:=DXD9P4]&Z,EDQ32!)".J9/I%YS9^Z8UP
MA>9:L).)WWR[M0M)-R<3RN^@U!O!7G161"UY[FE91(.@T&/<Z>/T@S7WWII3
MG45A$/PZ+@BE/%]Z@J4Z.D*2/@XIOLRV8])!BQ031/,[9F2WI":"$14MI,[&
M#Q7\T\ZBV9?*7'LI67&QB9[&?,5*N&1KN)$KDC_MNA'\+IGBZ=.Q75WR#PQ%
M(SS-[K5'!%^B<&/KV.&/< [,.ZQ_&(V+'8UK9K$MI* X.7O[:GXVCV'0[X43
M?X&D%7LP,<%X9>IK;;R^N8I/7\_?PMG\*GXUNSF]GMW&\^F;+LPOI[W'M+IJ
M5-I=E"52$>OP*J=,"9ZS\8,9+Y%"JN@@L"^4,9W=Q/.7\^EI/+^ZG/C5M\3R
M:<OG.20RSUEB;'(51&<,WE=$(62Q <4*J33(%*Z5U,C'/9QQ&6=,D8)5FB<E
MLI\G/3@T^YX<C/K]8#R5*RQ"&_LO'#_#*@,OI5JA8N]W2*6R.@HT55)@R!"%
M"Z*2[,E!>!R,!V$7;#4B):1<-(7-;'G#DDIA)B%XDE.8W6.1R+&\H;X5+TL#
MH6W&C;6]L0+M[,*Y0NUGI,1]743$2DY-"372IAEG*<I$'29%X2I-><*4@6YD
MUIBZ@-#98@,XI7FZ,5;6*RA65#LKTRZ44C"DSX M*H4%@-EUL2E>$(ZZJ(X4
M2#$<#[H&E^'?X0\'1T$C\C;GIDJ_T2BZ1!,HZ^(XT:"EG5^PTOIFM8%WN5PC
M64L6[3EP^L/>D8V=P_"9-<+1#&DE$'""- GCH*W3%'M?<<7,464I> #VD&!\
M* B/#BFZ"-DD!0I(R$(@UIJ&EM^W/C]-+/+P^6 X-O[;/^IA#;OO8/,<G;NR
MR6QR2!/,<HJC.YP0;I*HP$ S\+MFFN"QC-M0,Q%(3ED@'V77[DIYC@>\&4>!
MU!X9-C1Q524<>Q+3QNHL'P0FF*BHH]"EQVZBE:B;(J\83[V]<(74Q!G'*+6)
M8309\S/T:"XU1BK#C#-F8>XA VX,*,/ H-TF8VV^UPG[)6F_-T03,]F(O>,E
M7W#!]2;*.,7"@0N,L<%@//'-0E>S;;>A30 W&Q=2X3%@2KX@1<FBYD=;]3'J
MR]QQ9[H'$U$8,K4UKC4AE9;-@&M,[,A.^V+,WFU>[&%FK/$$V<BJWM3J3CI@
MCSEL8.PY9UHMU5A>6Q0Z,C3=4F&<G!!1GY#8]&BYJH4>H<P6B;4U#:&MAJDE
M7*+ 5,AU0VSSWUOC.1,ML%M]YZV1Q7]MPIPE3G&SE"RP&E>:[8#>?[BT%N+D
M9P:/ZU7K3TU_<OX8G/M:F23X-N3O ?(Y5O$(>Z9-?8@.7<?DP'RKH/E.JNGW
M[Q!HWOV_@VR7[^ +(O*G$RVP^N"L"TQ8W)N^FE-H'IL>S<E^Z;>?);[&:9_"
MILT=2D'4Q]/_QW6LN:5Y3*^:6OK?O/C#>NA_!?993^(_N'M\VZ0W?<CW8EZK
M-<JV3P4+DKQ;*EGE],$U5NL*='>B;CM-\32W85[]/]AYOG'7K#L/.#M#VSO=
M@BR9YQI4DN(C2T3N)*>UVT>C7G^XK3!N++#7P.ZNV%X^G_P%4$L#!!0    (
M )4XKE*SO%3:@@4  &H7   7    <&QX+3(P,C$P,S,Q>&5X,S)D,BYH=&WM
M6'MOVS80_RHW%VM3P+(DVRE<V0V0. YBH'G,5;;N3TJD+*(TJ5)4'/?3[TA)
MKIVMV-HU35'4@%\\\AZ_>XJ37SQO)G,B4T;A/+YX#52EU8I) ZEFQ.#JFIL<
M8E441,(%TYH+ 2>:TR4#>-D+@U[0&XT\[VB"K*;-&24C./3#H=\/^B&$810,
MHL, CB_@X":>/G>[3Z^F\9_7LUKJ]<W)Z_D4.I[O_S&8^OYI?%H3AKT@A%@3
M67+#E23"]V>7'>CDQA21[Z_7Z]YZT%-ZZ<<+/S<K,?2%4B7K44,[1Q.[@I^,
MT*/)BAD":4YTR<RKSDU\YHUPA^%&L*.)WW[7>Q-%-T<3RF^A-!O!7G561"^Y
M](PJHD%0F#&>])%\;\^=M^;4Y%$8!+^."T(IETM/L,Q$APC2QR7-E_EV3=6F
M19H)8O@ML[QWN*:"$1TERN3C^P+^Z631GLN4-%Y&5EQLHF<Q7[$2+MD:%FI%
MY+-NO8+?)=,\>S9VNTO^@2%K-,^P.^,1P9?(W.HZKNV/D ;V'38_K,1D3^*:
M.=L2)2@29V_/YR?S& ;]7G_B)PA:\0 JIABO3'^ICM>+J_CX]?PMG,ROXO/9
MXOAZ=A//IV^Z,+^<]AY3ZZH5Z4Y1EBI-G,,K29D67++Q/8J7*J%T]"1P+^0Q
MG2WB^=E\>AS/KRXG?O4U;?FTYG,)J9*2I5:GNH*8G,'[BF@T66Q LT)I RJ#
M:ZT,XG$')US%.=.D8)7A:8GHR[0'!_;<TR>C?C\83]4*B]#&_0O'S['*P)G2
M*Q3L_0:9TDY&@:HJ"@P1HG!!=)H_?1*^",:#L NN&I$2,B[:PF:/O&%II3&3
MT'@B*<SNL$A(+&\H;\7+TIJPJ\;"Z=YJ@7IV8;8A A95PF47N4F.NOS.4X;&
ML9)36TTMXVG.609G7&*YY7C@*LMPD[8H6/:->5U %%BR 209GFVLPLT.BL75
M4576A5()ADAN[:XTU@/F]L:VED$XZJ)(4B#B\&)@%7/NJ.$(!UB/&[8WDMNB
M_<8@^Q+5H*R+Z\2 48Z>L-*Y:K6!=U*M$;LEBQXXCOK#WO#0Q=)!^-QI4<,.
M6270ZA2Q$M9A6R=J]K[BFMG6Y3"X9^T!P7C1$!X>4'090DH*9)"21*"Q#0X[
M<;"-@>/4F1Z^' S'UHG?SNQ^;3:7Z.&52VZ;4X9@UE-<W<.$<)M4!4:;-;]K
MR03;-!Y#R1AI2"@0C[+K3F7;"$2&U+40%Y^XJQ(U>@K3R,DL[T4GV+!H0K%.
ME_W$*U$V15PQH'H/@A5"$^<<P]1EAY5DU<_1HU(9#%6&*6C5*G.+0+T&E&%@
MT&Z;P2[_FP3^G#+P8!9-++%E>\M+GG#!S2;*.<7J@1NLLL%@//'MQKJ&N^G#
MV !N#R9*8UNP+4"0HF11^V-7] N4E]?MSTX3-J(P9!IMZE&%5$:U"_6@XE;V
MQAFK]OXPXYJ;U<839*.JYM#.M-(!U_9PH'%]SXY>NM6\T2BLP3!T"X5U<DI$
MTS%Q"#)JU3 ]1)X[(#;:M(#N#% [S!4RS(1:M\"V_[TU]ITHP>GUG;=&%/]U
M**LUJ06W6TF");DR;,_HAP^7G8U(_(_!4\^NS:>A/S%_#,Q]HVT2?!WP'\#D
M4ZSB$<Y0FZ:)#NL)JC;F:P7-=U)-OW^'0/ON_]W(W?(=?$9$_G2B,ZQIG$V!
M"8L[.UQS"NUCU*,YV2_]G6>++_'9ITPS]DJE(/IC\_]Q_6HO;1[3J?8>Y'\Y
M\8=UT#<U[+,?S']P5_EN7&\GDN]%O9TA*=\^'R0D?;?4JI+TW@77SN7H/J$9
M0&T9M?=D7O,_V'O2J2]@]QYU]I:VM[T%63*O'E5)A@\O$;E5G#9N'XUZ_>&V
MV-1K@;L@KF^1W;7TT5]02P$"% ,4    " "5.*Y2 7G,HLT+   %8   $
M            @ $     <&QX+3(P,C$P,S,Q+GAS9%!+ 0(4 Q0    ( )4X
MKE) &C249 H   &'   4              "  ?L+  !P;'@M,C R,3 S,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( )4XKE)LS\XI0A4  %DS 0 4
M  "  9$6  !P;'@M,C R,3 S,S%?9&5F+GAM;%!+ 0(4 Q0    ( )4XKE)V
MS^#C,3@   WG @ 4              "  04L  !P;'@M,C R,3 S,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( )4XKE+CS3B1!2<  ()] @ 4              "
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M+FIP9U!+ 0(4 Q0    ( )4XKE+28Q!OL5P  +V!   7              "
M 2,2! !P;'@M,C R,3 S,S%X,3!Q,# W+FIP9U!+ 0(4 Q0    ( )4XKE(,
MF1FG^RT  +/; 0 7              "  0EO! !P;'@M,C R,3 S,S%X97@Q
M,&0Q+FAT;5!+ 0(4 Q0    ( )4XKE*XP/3L9\X  .- "  7
M  "  3F=! !P;'@M,C R,3 S,S%X97@Q,&0R+FAT;5!+ 0(4 Q0    ( )4X
MKE)'L4-R.PL  %YV   7              "  =5K!0!P;'@M,C R,3 S,S%X
M97@Q,&0S+FAT;5!+ 0(4 Q0    ( )4XKE)T8MIZ7P@  +,F   7
M      "  45W!0!P;'@M,C R,3 S,S%X97@S,60Q+FAT;5!+ 0(4 Q0    (
M )4XKE*$%[0$<P@  !LH   7              "  =E_!0!P;'@M,C R,3 S
M,S%X97@S,60R+FAT;5!+ 0(4 Q0    ( )4XKE*I4ZM&@ 4  % 7   7
M          "  8&(!0!P;'@M,C R,3 S,S%X97@S,F0Q+FAT;5!+ 0(4 Q0
M   ( )4XKE*SO%3:@@4  &H7   7              "  3:.!0!P;'@M,C R
F,3 S,S%X97@S,F0R+FAT;5!+!08     $  0 #H$  #MDP4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
